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Introduction
Aspergillus is a saprophytic fungus that plays an important role in carbon recycling from dead organic 
materials, therefore it can be found virtually everywhere. The fact that Aspergillus species are able to 
grow in such a wide variety of conditions and can utilize a wide range of organic molecules explains 
its success in being ubiquitously present in the environment. During the growth of Aspergillus, 
spores (also called conidia) are produced in conidiophores (see cover illustration of each chapter). 
In 1792, the Italian biologist Pier Antonio Micheli discovered that these conidiophores resemble the 
form of an aspergillum which is used to disperse holy water by priests, hence the name Aspergillus 1. 
Disturbance of the conidiophores allows them to effectively and abundantly disperse spores in the 
environment. This abundance is reflected by the fact that the spores of Aspergillus spp. are amongst 
the dominant fungal components found during air sampling 2,3, which includes the air in hospitals 
(especially in old buildings and during renovations 3-5). This results in the fact that humans, and more 
importantly hospitalized patients, are continuously exposed by inhalation of Aspergillus spores.
 The Aspergillus genus consists of over 870 species 6, which are predominantly saprophytes. Yet, 
Aspergillus fumigatus distinguishes itself together with A. favus, A. niger, A. tereus, A. clavatus and 
A. nidulans from the other Aspergillus species by being capable of causing infections and allergic 
disease in humans. Among the various Aspergillus species, A. fumigatus is the most common 
opportunistic pathogen and allergen 7. 
Aspergillus as an opportunistic pathogen
Hundreds of Aspergillus conidia enter the human body daily via the airways and, due to their small 
size of 2-3 µm 8, easily reach the alveoli in the lung. The cilia on epithelial cells in the airways and 
the innate immune system, such as alveolar macrophages, are capable of efficiently removing 
inhaled conidia from the airways. Thereby preventing the conidia from germinating into hyphae, 
without inducing an inflammatory reaction or pathology. Since Aspergillus is so efficiently cleared, it 
rarely causes infections or induces inflammation. Interestingly, a high burden of Aspergillus conidia 
in the environment could lead to abnormal high exposure and even colonization of Aspergillus in 
the lungs 9. Despite the fact that Aspergillus rarely causes infections within the general population 
there are several predisposing factors, primarily related to the immune status of the host, that can 
make individuals susceptible to opportunistic invasive infections and even allergic reactions 8, often 
collectively called aspergillosis (Figure 1). These diseases primarily manifest within the lungs due to 
inhalation of conidia, but Aspergillus is also known to cause infections of the sinuses, brain, wounds 
and eyes. The latter occurs primarily in trauma injuries, which are often associated with agriculture, 
due to fungal spores entering the cornea 10. 
 Before the Second World War, aspergillosis was considered to be of little importance since it 
only rarely occurred 11. However, advances in medical care have resulted in an increasing population 
of immunocompromised patients that are at risk to develop opportunistic infections with A. 
fumigatus 12. Especially patients who have a compromised immune status due to haematological 
malignancies, bone marrow transplantation (hematopoietic stem cell transplants) 13-15 or solid 
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organ transplantation 16-18, are at risk to develop lethal pneumonia and invasive aspergillosis (IA). 
The development of aspergillosis in these patients is primarily caused by their therapy, which 
suppresses the first line of the antifungal host defence in the lungs 14,15,19, that is required for clearing 
inhaled conidia from the lungs. Chemotherapy has a massive immunosuppressive side effect by 
being cytotoxic to fast proliferating immune cells leading to neutropenia. The myeloablative 
therapy before stem cell or organ transplantation results even in a more complete suppression 
of the immune system. Furthermore, additional risk factors are neutralization of immune effector 
functions by treatment with high dose corticosteroids, old age, chronic diseases like diabetes and 
development of graft versus host disease (GVHD) 15.
 Besides medically induced immunosuppression, congenital immunodeficiencies can also lead 
to a immunocompromised status of the host and an increased susceptibility to IA. A rare genetic 
defect in the NADPH oxidase complex leads to a disease called chronic granulomatous disease 
(CGD), which is characterized by an inability of immune cells to induce reactive oxygen species 
(ROS), which specifically predisposes these patients to develop invasive infection with A. fumigatus 
and A. nidulans 19,20. 
 On top of acute invasive disease in immunocompromised individuals, Aspergillus can also cause 
chronic pulmonary aspergillosis (CPA) in patients that do not necessarily have a known severely 
immunocompromised status. CPA was already described by John Hughes Bennet in 1842 21. Pre-
existing lung damage and pulmonary diseases, such as sarcoidosis, tuberculosis and chronic 
obstructive pulmonary disease (COPD) are primary risk factors for the development of CPA 22,23; 
primarily because damaged pulmonary tissue facilitates saprophytic fungal growth. Especially, 
Figure 1| Schematic overview of the infections caused by A. fumigatus 
(adapted from Soubani et al 2002 Chest). In the normal host efficient clearance leads to removal of conidia and no 
progression to infection, whereas in immunocompromised hosts (ICH) Aspergillus spores will not be cleared and 
invasive aspergillosis (IA) can develop. Patients with cavitary lung disease such as tuberculosis and sarcoidosis or 
chronic lung disease and mildly immunocompromised hosts can become infected and colonized by Aspergillus 
which can lead to the formation of an aspergilloma or chronic pulmonary aspergillosis. Individuals with asthma 
can present with severe asthmatic fungal sensitization (SAFS) but can also develop an infection characterized by 
hypersensitive allergic responses called allergic bronchopulmonary aspergillosis (ABPA).
Inhalation of Aspergillus spores 
Normal host Cavitary lung disease Chronic lung disease  Mild ICH ICH 
Efficient clearance 
No infection Aspergilloma CPA        CNPA Invasive Aspergillosis ABPA        SAFS 
Asthma 
Infection / colonization Infection 
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in cavitary lung diseases necrotic tissue in the lung allows a niche for saprophytic fungal growth. 
Moreover, Aspergillus can grow into a “fungus ball”, called an aspergilloma, filling the pre-existing 
cavities in the lung 22,24,25. In this disease, also called chronic cavitary pulmonary aspergillosis (CCPA), 
the growth of an aspergilloma is often limited by the physiological barriers, but in some cases it can 
gradually expand and destroy surrounding host tissues. 
 Due to the complicated status of patients who develop IA and CPA, the mortality as a result of 
aspergillosis in patients is 50%, despite improving treatment possibilities 26. Even a higher mortality 
rate is reported in patients infected with resistant strains, in mis-diagnosed cases and when diagnosis 
delayed. Recent estimates suggest that there are yearly over 200.000 life threatening infections with 
A. fumigatus with a mortality rate between 30 and 90% 26.
 In contrast to these invasive forms of aspergillosis, found in a host with a compromised immune 
status or pre-existing lung damage, fungal particles and also A. fumigatus itself can cause the 
development of pulmonary allergic responses in an individual with a hypersensitive immune status 
27-30. Asthma with severe asthmatic fungal sensitization, also known as SAFS 28, is characterised 
by positive Aspergillus-antigen skin tests 27,29 and high serum levels of Aspergillus-specific 
immunoglobulin E 29,31. Asthmatic patients and patients with cystic fibrosis (CF) are mainly effected, 
and the lungs of these patients can become colonized with Aspergillus leading to a continuous 
exposure to the fungus. The hyperreactive T-helper (Th)2 response in these patient groups, 
can progress to detrimental inflammatory pathologies also termed allergic bronchopulmonary 
aspergillosis (ABPA). ABPA was first described in asthmatic patients 30,32, but was later also associated 
with CF 30,33. Worldwide, ABPA is expected to affect around 4 million asthmatic and cystic fibrosis 
patients 26,34.
Host defence against Aspergillus
Individuals that are able to induce an effective innate antifungal host response will not develop 
invasive, chronic or allergic aspergillosis, therefore the reports of aspergillosis in immunocompetent 
patients are very rare. The first step in this protective immunity is the clearance of inhaled spores 
from the lungs. To efficiently clear conidia from the lungs, they need to be recognised by the hosts 
immune system but also by the pulmonary epithelium that is also able to recruits immune cells. 
The immune system employs various pattern recognition receptors (PRRs) that recognise distinct 
pathogen associated molecular patterns (PAMPs) that are present on and in the fungal cell wall 
but not in the host itself. The relevance of an effective pathogen recognition is highlighted by the 
observation that Drosophila fruitflies deficient for the pathogen recognition molecule Toll succumb 
to lethal Aspergillus infections 35. Of interest, this observation led to the discovery of the Toll-like 
receptors (TLRs), which now have been implicated in inducing host responses against bacterial, 
viral, parasitic and fungal pathogens. In contrast to the Drosophila immune recognition, evolution 
led to redundant system cosisting of numerous in PRRs and immune signalling pathways in the 
human immune system. To date 13 different TLRs are known in mammals of which TLR1 to 10 are 
expressed in humans 36. The progressing research on immune recognition of fungi like Aspergillus 
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also led to the discovery of another class of pattern recognition receptors, namely the C-type lectin 
receptors (CLRs) 37. CLRs are similar to TLRs, capable of recognising specific moieties on the fungal 
cell wall, and thereby activate immune cells and the subsequent antifungal host response. Another 
class of PRRs are the NACHT-LRR receptors (NLRs), to which the Nucleotide Oligomerization Domain 
(NOD)-receptors belong. Although these receptors have been described to primarily play a role in 
the recognition of bacterial peptidoglycan derivates, there is increasing evidence that they play a 
role in inducing host responses against A. fumigatus 38-40. 
 Downstream of the PRRs several signalling cascades of various kinases and adaptor molecules 
will eventually activate several mechanisms. The immune cell can be triggered to phagocytose 
the pathogen and transcription factors activate the immune cell by switching on transcription 
of inflammatory genes, such as those encoding cytokines. Cytokines regulate a large variety of 
processes within the immune system. Chemotactic cytokines (chemokines) released by infected 
epithelial cells or activated innate immune cells regulate the recruitment of additional immune cells 
to the site of the infection, other cytokines regulate immune cell activation and proliferation, while 
some of them also exert metabolic effects. 
 Responses by antigen specific T-helper responses also play a significant role in the host response 
against Aspergillus. These T-helper responses serve to amplify and strengthen the innate immune 
responses. The Th17 response, that plays a significant role in host defence against extracellular 
bacteria, fungi, parasites and viruses 41, is characterised by expression of the transcription factor 
RORγt and production of the cytokines interleukin(IL)-17 and IL-22. IL-17 facilitates neutrophil 
recruitment by inducing chemokine release in bronchial epithelial cells 42, whereas IL-22 promotes 
the antimicrobial defence of the epithelium by promoting release of anti microbial peptides (AMPs) 
43. The Th1 response is characterized by interferon(IFN)γ expression and plays a prominent role in 
fungal clearance 44,45 and protection against Aspergillus-induced detrimental Th2 responses 46. The 
Th2 response regulates allergic inflammation and humoral (antibody-mediated) adaptive immune 
responses. However, in the host defence against aspergillosis this response is primarily associated 
with development of allergic immune responses that contribute to the severity of the infection due 
to immunopathology 29,46.
 Due to the redundancy of the human immune system, individuals that are deficient in one of 
the immune systems components that are involved in the host defence against Aspergillus do not 
immediately develop invasive Aspergillus infections like the toll deficient Drosophila flies. However, 
in a patient with a severely compromised innate immune system, relatively small deficiencies in the 
receptors and cytokine signalling pathways, required for anti-Aspergillus host defence, could result 
in an increased susceptibility to aspergillosis. Knowledge on the pattern recognition and cytokine 
pathways that orchestrate the induction of the antifungal host defence against aspergillosis 
is therefore crucial for the design of genetic studies that can be used to predict susceptibility to 
aspergillosis, and for the development of targeted and personalized immunotherapy. 
Introduction| 15
 1
Figure 2| Schematic overview of the immune responses involved in the clearance of A. fumigatus
(1) The primary line of defence against Aspergillus, are the brush border pulmonary epithelium and alveolar 
macrophages that are capable of efficiently clearing inhaled conidia from the lungs. (2) When conidia are inefficiently 
cleared they can germinate into hyphae. These germinated conidia expose all kinds of pathogen associated 
molecular patterns (PAMPs) which can activate specific pattern recognition receptors (PRRs) leading to an induction 
of a cytokine and chemokine response. (3) Cytokines and chemokine released by the alveolar macrophages and 
pulmonary epithelium will induce recruitment and activation from polymorphonuclear cells (PMNs) or neutrophils 
and monocytes/macrophages. (4) After having recognized and phagocytosed fungal particles macrophages 
but also dendritic cells (DCs) can activate T-helper cells through antigen presentation, cytokine signalling and 
costimulatory molecules. (5) Depending on the cytokine profile different T-helper subtypes can be induced. (6) In 
particular the cytokines IL-17 and IL-22 released by Th17 cells can amplify the antifungal defence by the pulmonary 
epithelium by inducing the release of chemokines and antimicrobial peptides respectively.
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Outline of the thesis
The previous paragraphs illustrate the disease spectrum of A. fumigatus, and demonstrate the 
importance of the immune response in preventing aspergillosis. However, many aspects of the host 
response and in particular the human host response remains unknown. The aim of this thesis is to 
study the pattern recognition and cytokine signalling pathways that orchestrate the human host 
response to A. fumigatus and to provide insights that may contribute to the prevention of Aspergillus 
infections and development of novel therapies.
The first section of the thesis (chapter 2-6), entitled “Induction of immune responses against 
Aspergillus fumigatus by pattern recognition receptors”, addresses the recognition mechanisms that 
play a role in various aspects of the host defence against A. fumigatus. 
 A relatively large number of studies have been conducted to elucidate which PRRs on the 
host immune cells play a role in the induction of the antifungal host defence against A. fumigatus. 
Chapter 2 provides an overview of the literature on the PRRs that play a role in the recognition 
of A. fumigatus, and investigated how these receptors activate various antifungal host defence 
mechanisms to combat invasive Aspergillus infection.
 The initiation of T-cell-mediated immune responses is highly dependent on the processing 
and presentation of antigens in MHC complexes. Autophagy is a mechanism that is involved in the 
recycling of cell organelles during cellular stress. However, autophagy is also involved in the host 
defence against various pathogens by facilitating antigen presentation 47. During phagocytosis, 
a non-canonical autophagy pathway can be activated in which LC3 proteins are recruited to the 
phagosome (LC3-associated phagocytosis) which induces phagosome maturation and killing of 
phagocytosed pathogens 48. The aim of chapter 3 is to assess how this non-canonical autophagy 
pathway is induced by Aspergillus fumigatus. Numerous studies have demonstrated an increased 
immunogenicity of Aspergillus upon conidial swelling, through the increased exposure of β-glucan 
49. In this study we assessed the role of β-glucan exposure and its recognition by the dectin-1 and 
spleen tyrosine kinase (Syk) signalling pathway in LC3 recruitment to phagosomes containing 
Aspergillus. Moreover, we investigated whether corticosteroids, one of the immunosuppressive 
therapeutics that is highly associated with an increased susceptibility to aspergillosis 14,15,19, are able 
to interfere with induction of LC3-associated phagocytosis. 
 The PRRs that recognize A. fumigatus and orchestrate the induction of the immune response, will 
eventually lead to T-cell activation and induction of the adaptive immune responses. The cytokines 
IL-17, IL-22 and IFNγ, that have been primarily linked to Th17 and Th1 T-cell subsets, are known to play 
important roles in the host defence during invasive aspergillosis in mice. In chapter 4 we studied 
these responses in human PBMCs. More specifically, we investigated which human lymphocyte 
subsets are involved in the production of these cytokines in response to A. fumigatus, and which 
PRRs and innate cytokines regulate the induction of these cytokines.
 Besides Th1 and Th17 responses, T-cells can also become polarised towards the Th2 subset. The 
responses induced by this subset stand at the base of fungal sensitization and contribute to the 
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pathogenesis of ABPA, in individuals that mount a severe allergic Th2 responses, such as asthma 
and CF patients. To gain insight in the allergic response to Aspergillus, we investigated in chapter 5 
how A. fumigatus induces Th2 cytokine responses. We explore which pattern recognition pathways 
induce a Th2 bias, and investigated the ratio between protective Th1 responses and detrimental 
Th2 responses in patients with ABPA. Furthermore, we investigate how the Th2 response can be 
modulated by several immunomodulatory drugs that target the IL-1, tumour necrosis factor (TNF)α 
and IFNγ axis. 
 The NOD-like receptors are PRRs localised within the cytoplasm of innate immune cells. Thus 
far, they have been studied in the recognition of peptidoglycan moieties from the bacterial cell 
wall and are associated with Crohn’s disease. However, there is increasing evidence that the NOD2 
receptor is involved in recognition of Aspergillus. Chapter 6 investigates how deficiency in the NOD 
receptors influences the host response against A. fumigatus, and investigates the role of both NOD1 
and NOD2 in a mouse model for invasive aspergillosis in an immunosuppressed background. 
The second section of this thesis (chapter 7-12), entitled “Cytokines involved in orchestrating the 
antifungal immune response”, focuses on cytokines and modulation of cytokines that are involved in 
the antifungal immune response against A. fumigatus. 
 The IL-1 family cytokines are highly associated with host defence against bacterial and fungal 
pathogens by their capacity to induce neutrophil recruitment, regulate the induction of T-cell 
proliferation and skewing of the T-cell responses towards a Th17 response. A review of the current 
literature on the role of the IL-1 family cytokine response and in particular the cytokine IL-1β, in the 
host defence against A. fumigatus is presented in chapter 7. 
 Recently, the Aspergillus cell wall polysaccharide galactosaminogalactan has gained interest 
because of its immunomodulatory effects and its capacity to render mice susceptible to invasive 
aspergillosis 50. Chapter 8 describes the study that investigated how galactosaminogalactan 
modulates the host response against Aspergillus. Due to the previous observation that 
galactosaminogalactan inhibited neutrophil recruitment to the lungs of infected mice 50, we 
specifically investigated whether and how it modulates the IL-1 axis.
 Common genetic variations in cytokine genes can affect their expression or function, thereby 
influencing the capacity to mount an effective host response. In chapter 9 we investigated 
how polymorphisms within the genes encoding for IL-1β and IL-1Ra affected Aspergillus-induced 
cytokine responses. Furthermore, in a cohort of solid organ transplant patients we investigate 
whether polymorphisms in IL1B, IL1RN and the DEFB1 gene, encoding for the antimicrobial peptide 
β-defensin-1, affect the susceptibility to invasive fungal infections.
 For some of the members of the IL-1 cytokines the role in the immune system is still largely 
unknown. In chapter 10 we introduce the IL-36 family, which is a subclass of the IL-1 family. 
Although these cytokines belong to the intensively studied IL-1 family, their role was unknown 
until recently. In this chapter, we give an overview on the knowledge about the biology of these 
cytokines and their role in a wide spectrum of diseases. The IL-36 cytokines have been found to 
Chapter 1  18 | 
play an important role in recruitment of neutrophils to the lungs 51, therefore they gained our 
interest and we hypothesized that they could potentially play an important role in the host defence 
against Aspergillus. Therefore, we investigated in chapter 11 whether IL-36 cytokines are induced 
by Aspergillus. Since the IL-36R is highly expressed on naive T-cells 52, we also assessed the role of 
IL-36 in Aspergillus-induced T-cell responses, and in particular the Th17 response which is highly 
associated with neutrophil recruitment.
 Mortality due to fungal infections and especially aspergillosis is still very high, despite the 
introduction of azoles and echinocandins as novel therapeutic agents 53. It is believed that an 
important reason for this is the immunosuppression often encountered in the patients, and it has 
been suggested that adjunctive immunotherapy can provide a necessary complementary step 
for the improvement of the outcome in these patients 54.. chapter 12 describes a case series of 
patients with invasive fungal infection in whom we systematically addressed the immunological 
effects of IFNγ immunotherapy.
The findigs presented in this thesis that can potentially impact development of novel immunotherapy 
and genetic screening for susceptibility against aspergillosis are discussed in the general discussion 
in chapter 13.
A summary of the findings and conclusions of this thesis is presented in chapter 14.
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Abstract
Pattern recognition receptors (PRRs) are germline receptors that recognize conserved structures 
on microorganisms. Several PRRs have been identified in the recent years that are involved in the 
immune response against Aspergillus fumigatus. The role of PRRs in invasive pulmonary aspergillosis 
becomes especially apparent in the setting of an immunocompromised status of the host, because 
of the redundancy of many PRRs in the host defense against A. fumigatus. Studies that investigated 
the PRRs and their effector pathways in invasive aspergillosis have led to a better understanding of 
the pathogenesis of invasive aspergillosis in immunocompromised patients. This knowledge may 
pave the way for novel diagnostic and immunomodulatory treatment strategies that are needed to 
overcome the high mortality associated with invasive A. fumigatus infection in immunocompromised 
patients.
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 2Introduction
Aspergillus fumigatus can cause invasive pulmonary aspergillosis (IPA) in immunocompromised 
patients. The management of invasive aspergillosis still presents a major challenge, and knowledge 
of the host defence against A. fumigatus is essential to develop new treatment strategies. Here we 
review the literature on pattern recognition receptors (PRRs) that recognize A. fumigatus and focus 
on their role in the host defence against IPA.
Pattern recognition of A. fumigatus
The first step in the innate host defence against A. fumigatus is the recognition of fungal cell wall 
components by PRRs present on and in the cells of the innate immune system. Three of the four 
major families of PRRs have been implicated in recognition of Aspergillus spp: the Toll-like receptors 
(TLRs), the C-type lectin receptors (CLRs), and the nucleotide oligomerization domain (NOD)-like 
receptors (NLRs). RIG-I helicases are not currently known to be involved in A. fumigatus recognition 
(Figure 1).
Toll-like Receptors
Both TLR2 and TLR4 signalling are associated with NFκB translocation and production of pro-
inflammatory cytokines in response to A. fumigatus in vitro 1,2. Initial studies have shown that peritoneal 
macrophages deficient in TLR2 and MyD88 stimulated with A. fumigatus produce significantly lower 
tumour necrosis factor(TNF)α levels, whereas TLR4 deficient peritoneal macrophages produce 
normal levels of TNFα when stimulated with the fungus 3. Blocking TLR4, but not TLR2, resulted in 
decreased A. fumigatus-induced TNFα production by human adherent monocytes 4. Furthermore, 
conidia and hyphae of A. fumigatus stimulate cytokine production in macrophages through TLR2, 
whereas only conidia are able to stimulate macrophages by TLR4 5. These in vitro studies are the 
first reports that have demonstrated a role for TLRs in the recognition of A. fumigatus. Most of these 
studies controlled for the absence of bacterial LPS.
 In a murine model of IPA, TLR2 and TLR4 deficiency are both correlated with decreased cytokine 
levels, and TLR2-/-, TLR4-/- or MyD88-/- mice have a higher fungal burden than WT mice 6,7. TLR2 and 
TLR4 are important for the recruitment of PMNs to the lung during IPA, and the optimal killing of 
A. fumigatus in vivo requires both TLR2 and TLR4 7. TLR2 can form heterodimers with TLR1 or TLR6, 
and a recent study has reported that TLR1-/- and TLR6-/- mice have increased fungal burdens during 
A. fumigatus infection. In addition, it has been shown that TLR1-/- and TLR6-/- macrophages produce 
less pro-inflammatory cytokines compared to wild type mice 8. 
 The intracellular TLRs, TLR3 and TLR9, have also been reported to play a role in anti-Aspergillus 
host defence. Epithelial cells can contribute to the protection against A. fumigatus in a TLR3 
dependent pathway 9. TLR3 signals through the adaptor molecule TRIF, and TRIF-/- mice are highly 
susceptible to IPA. Furthermore, A. fumigatus RNA is recognized by TLR3, and dendritic cells (DCs) 
can promote protective cytotoxic T cell responses through a TLR3-mediated pathway 9. In line 
with these findings, TLR3-/- mice are highly susceptible to IPA 9. TLR9 can recognize A. fumigatus 
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DNA 10, and TLR9 is actively being recruited to phagosomes that contain A. fumigatus conidia 11. 
Interestingly, but still largely unexplained, is the finding that TLR9-/- mice are protected against lethal 
A. fumigatus infection 7.
 A. fumigatus itself can influence the immune response by modulating TLR signalling. A. fumigatus 
conidia can decrease TLR2 expression on the surface of monocytes by inducing TLR2 internalization, 
while A. fumigatus hyphae can selectively downregulate the TLR4-mediated immune response 12. 
Moreover, the Aspergillus cell wall components β-glucan and galactomannan can suppress TLR4-
induced responses, while α-glucan inhibits TLR2- and TLR4-induced interleukin(IL)-6 production 13. 
TLR5 is strongly upregulated by A. fumigatus conidia in human monocytes, and although there is 
no evidence for direct recognition of A. fumigatus by TLR5, activation of TLR5 results in decreased 
capacity of monocytes to inactivate viable A. fumigatus conidia 14. This suggests that the increased 
expression of TLR5 induced by A. fumigatus on the surface of human monocytes can help survival of 
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Figure 1|PRRs involved in recognition of Aspergillus fumigatus
Schematic overview of the pattern recognition receptors (PRRs) and the downstream signalling pathways 
involved in the recognition of A. fumigatus. Pathogen associated molecular patterns (PAMPs) of Aspergillus lead 
to various host responses such as cytokine production and phagocytosis through the activation of PRRs. TLR 
(Toll-like receptor), Syk (spleen tyrosine kinase), DC-SIGN (dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin), MR (Mannose Receptor), CR3 (complement receptor 3), C3 ( complement factor C3), 
SP-A/D (Surfactant Protein-A/D), PTX-3 (pentraxin-3), FCγR (FC gamma receptor), Af (Aspergillus fumigatus), TRIF 
(TIR-domain-containing adapter-inducing interferon-β), IRF (Interferon regulating factor), ERK (extracellular-
signal-regulated kinase), MYD88 (Myeloid differentiation primary response gene 88), CARD9 (Caspase 
recruitment domain-containing protein 9), RIP2 (receptor interacting protein 2), NFκB (nuclear factor kappa-
light-chain-enhancer of activated B-cells), NOD2 (Nucleotide-binding oligomerization domain-containing 
protein 2), NLRP3 (NACHT, LRR and PYD domains-containing protein 3), ROS (reactive oxygen species).
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 2the fungus when ligands are present that activate TLR5. However, all TLR5 ligands known to date are 
of bacterial origin, and TLR5 is most likely influencing host defence against Aspergillus in the context 
of co-colonization or co-infection with bacteria.
 In line with the in vitro and in vivo data demonstrating an important role for TLRs in anti-Aspergillus 
host responses, several studies have reported polymorphisms in TLRs that are associated with 
invasive aspergillosis in patients. A single nucleotide polymorphisms (SNP) in TLR4 that influences 
TLR4 function is associated with invasive aspergillosis in patients that received heamatological stem 
cell transplantation (HSCT) 15,16. Although, functional studies have demonstrated involvement of 
TLR2 in the recognition of A. fumigatus, to date no polymorphisms in TLR2 have been associated 
with increased susceptibility to A. fumigatus infection. However, SNPs in TLR1 and TLR6, co-receptors 
that form heterodimers with TLR2, are associated with the development of invasive aspergillosis 17. 
A TLR3 SNP has been reported to be associated with increased risk of IPA in a cohort of patients with 
HSCT 9.
C-type lectin receptors
The extracellular portion of CLRs consists of several carbohydrate recognition domains, which 
enable binding to sugar moieties present on microorganisms. Dectin-1 recognizes β-1,3-glucans 
and is involved in the recognition of A. fumigatus 18. Dectin-1-binding to germ tubes augments 
TLR2-mediated production of pro-inflammatory cytokines 19. Alveolar macrophages induce strong 
inflammatory responses to swollen and germinating conidia, which correlates with the increased 
surface expression of β-glucan during germination 20. The importance of dectin-1 for anti-Aspergillus 
host defence has been demonstrated by the fact that dectin-1 deficient mice are more susceptible 
to IPA 18,21. A. fumigatus induces the cytokines IL-17 and IL-22, important for neutrophil recruitment 
and the production of defensins by epithelial cells respectively, in a dectin-1 dependent way 22-24. 
It must, however, be noted that the current literature describes both protective and detrimental 
effects of IL-17 in the host, depending on the host conditions in which the Aspergillus infection 
occurs 21,24,25. Human airway epithelium and DCs also express dectin-1, which enables them to 
recognize A. fumigatus 26. Human monocytes with the dectin-1 Tyr238X polymorphism that results 
in an early stop codon produce less pro-inflammatory cytokines in response to A. fumigatus 
stimulation. Importantly, this polymorphism correlates with an increased susceptibility to develop 
IPA in patients receiving HSCT 26,27. Recently, a study demonstrated increased susceptibility to 
invasive aspergillosis in haematological patients that carried SNPs in dectin-1 intronic regions 28. 
 Dendritic cell-specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) is a 
CLR that is expressed on DCs and macrophages, and has been shown to be involved in binding and 
internalization of A. fumigatus 29. Co-stimulation of neutrophils with Aspergillus-stimulated DCs results 
in the upregulation of co-stimulatory molecules on DCs, a process that is dependent on DC-SIGN 30. 
Notably, SNPs in intronic regions or in the 3’-untranslated region(UTR) of the DC-SIGN gene have 
been associated with increased susceptibility to invasive aspergillosis 28. Another CLR, the mannose 
receptor (MR) has been suggested to be involved in the induction of pro-inflammatory cytokine 
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production induced by A. fumigatus conidia that are deficient in melanin 31. Dectin-2 mediates the 
release of cysteinyl leukotrienes from murine bone marrow derived DCs that are stimulated with 
extracts from A. fumigatus, suggesting that dectin-2 recognizes A. fumigatus 32. However, the function 
and the importance of the MR and dectin-2, as well as the role of other CLRs in anti-Aspergillus host 
defence such as mincle or macrophage galactose lectin (MGL), remains to be determined.
NOD-like receptors
In addition to the TLRs and CLRs, NOD-like receptors (NLRs) that are localised intracellular and 
recognize intracellular PAMPs have been reported to be involved in the recognition of Aspergillus. 
NLRs are generally subdivided in two categories: firstly, NOD1 and NOD2 are the main intracellular 
receptors for peptidoglycans, whereas the function of the members of the NLRP subfamily is mainly 
in the formation of the inflammasome. NOD2 is upregulated after exposure to A. fumigatus, and 
recently it has been reported that NOD2 recognizes A. fumigatus, which subsequently results in the 
activation of NFκB 33. However, individuals completely deficient in NOD2 and suffering from Crohn’s 
disease 34 do not show an increased susceptibility to invasive aspergillosis.
 Nlrp3 is an NLR that has been extensively studied over recent years. Nlrp3 is involved in the 
activation of the inflammasome, which is a protein complex that can activate caspase-1. Caspase-1 is 
an enzyme that can cleave the inactive protein pro-IL-1β into the active cytokine IL-1β. A. fumigatus 
hyphae, but not conidia, can activate the NLRP3 inflammasome through the induction of reactive 
oxygen species (ROS) and potassium efflux 35. This in turn results in the release of active IL-1β. This 
process is spleen tyrosine kinase(Syk)-dependent, which is an adaptor molecule downstream of 
dectin-1, suggesting that dectin-1 is involved in the induction of ROS, the activation of the NLRP3 
inflammasome, and release of IL-1β induced by A. fumigatus.
Soluble pattern recognition receptors 
Collectins are soluble C-type lectins that bind to glycoconjugated structures. Surfactant proteins A 
(SP-A) and D (SP-D) are collectins that are produced by pneumocytes and can bind to A. fumigatus 
conidia. The survival of immunosuppressed mice infected with A. fumigatus is significantly increased 
when mice are treated with SP-D 36. In line with this, SP-D-/- mice die earlier then WT mice, and 
treatment of SP-D-/- mice with SP-D decreases mortality from 50% to 33% 37. Interestingly, SP-A-/- mice 
are less susceptible to invasive aspergillosis and SP-A treatment increases mortality in SP-A-/- mice 37. 
 Mannose-binding lectin (MBL) can bind to A. fumigatus, but this does not necessarily result in 
enhanced killing of A. fumigatus 38. Immunocompetent mice deficient in MBL are protected against 
invasive aspergillosis 39. In sharp contrast, immunosuppressed mice with invasive aspergillosis that 
are treated with recombinant MBL have a clear survival benefit 38. Thus, MBL could have different 
effects depending on the status of the immune system. In addition, low MBL concentrations in 
serum are associated with higher susceptibility to invasive aspergillosis 40.
  Pentraxin 3 (PTX3) is a soluble pattern recognition receptor that can bind to Aspergillus conidia, 
but not to hyphae 41. PTX3 deficient neutrophils display impaired phagocytosis of Aspergillus 41. 
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 2Dendritic cells (DCs) and alveolar macrophages can recognize A. fumigatus through a PTX3-
dependent pathway and genetic deletion of PTX3 in mice results in impaired recognition of A. 
fumigatus and increased susceptibility to A. fumigatus infection 41. The complement receptor 3 
(CR3) and the FCγR are required for recognition of PTX3-opsonized Aspergillus 42. Notably, NADPH-
dependent ROS deficient mice 43, and corticosteroid immunosuppressed rats 44, which are both 
highly susceptible to Aspergillus infection, can be rescued by PTX3 treatment. Therefore, PTX3 
treatment can prove to be an important immunotherapeutic strategy in invasive aspergillosis.
Pattern recognition receptors orchestrate the immune response 
When A. fumigatus conidia are inhaled and reach the alveolus, PRRs present on alveolar macrophages 
and epithelial cells, and the soluble PRRs from the alveolar fluid will recognize the fungus and 
induce the activation of the immune response (Figure 2). Alveolar macrophages and epithelial cells 
will release cytokines and chemokines in response to A. fumigatus recruiting innate immune cells, 
a process dependent on TLR2, TLR4 and dectin-1 1-7. Both neutrophils and macrophages recognize 
and phagocytose A. fumigatus conidia, a process that can be enhanced by soluble PRRs such as 
PTX3 and possibly SP-D and MBL 36,38,42, and kill conidia by NADPH-dependent ROS production 45,46. 
A. fumigatus-induced ROS production can also trigger the NLRP3 inflammasome through dectin-1/
Syk signalling, resulting in the release of active IL-1β and recruitment of neutrophils 35. Neutrophils 
will release neutrophil entrapment traps (NETs) that in turn might help to kill and inhibit growth 
of A. fumigatus hyphae that will be too large to be phagocytized 47,48. Notably, restoration of 
NADPH oxidase activity by gene therapy in patients with chronic granulomatous disease provides 
protection against invasive aspergillosis 49,50. The restoration of the NADPH oxidase activity restores 
NET formation and calprotein release, which is associated with more efficient killing of Aspergillus 
ex vivo 49,50. Recently, plasmacytoid DCs have been reported to have the ability to kill hyphae 
extracellularly 51. However, the PRRs involved in this process, and the PRRs that trigger the formation 
of NETs in response to Aspergillus have not yet been elucidated. If the innate immune system fails 
to control the infection, antigen-presenting cells such as dendritic cells will activate the adaptive 
immune response, a process where dectin-1 and TLR3 play an important role 9,52. 
 The interplay between other CLRs and TLR-MyD88 pathways are also important for the induction 
of the adaptive immune response. Especially dectin-1, which can regulate the balance between Th1 
and Th17 responses 53. Although TLR-MyD88 signalling is crucial for interferon(IFN)γ production in 
Aspergillus-specific CD4 T-cells, it is not required for the recruitment or proliferation of these cells in 
response to A. fumigatus 54. The TLR-MyD88 pathway plays a less important role in the induction of 
Th2 responses by A. fumigatus 54, in contrast to the induction of Th2 cells by OVA, which is MyD88 
dependent 55.
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Figure 2|Effector functions of PRRs in anti-Aspergillus host defence
Overview of the PRR-mediated effector functions of innate immune cells that play a role in the pulmonary 
antifungal host defence against A. fumigatus. Inhaled conidia are recognized and opsonized by soluble PRRs like 
pentraxin 3 (PTX3), and mannose-binding lectin (MBL), and surfactant Protein-A/D (SP-A and SP-D). Epithelial 
cells and macrophages produce cytokines through Toll-like receptors (TLRs) that mediate recruitment of innate 
immune cells like neutrophils (PMNs) and dendritic cells (DCs). Following internalization by dectin-1 phagocytes 
induce reactive oxygen species (ROS) to mediate eradication of the internalized conidia. Neutrophils generate 
neutrophil extracellular traps (NETs) by releasing their intracellular contents and DNA. DC-SIGN (dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin), CR3 (complement receptor 3), FCγR (FC 
gamma receptor), NLRP3 (NACHT, LRR and PYD domains-containing protein 3).
Concluding remarks
Although PRRs play an important role in the host defence against A. fumigatus, it has to be noted 
that invasive A. fumigatus infections only occurs in immunosuppressed patients. MyD88-/- mice 
only develop invasive aspergillosis when they are immunosuppressed, and non-immunosuppressed 
patients with MyD88 deficiency are not prone to develop invasive pulmonary aspergillosis 56,57. 
Furthermore, humans that lack surface expression of dectin-1, which is involved in many 
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 2fundamental anti-Aspergillus host responses, do not suffer from invasive aspergillosis when they are 
not immunosuppressed. These findings suggest that the TLR and dectin-1 pathways are redundant 
in anti-Aspergillus host defence. On the one hand, this suggests that only concomitant deficiencies in 
more recognition pathways at the same time will likely result in an increased susceptibility, and this 
hypothesis is supported by the increased susceptibility to infections in CARD9-deficient patients, 
who display defects in several CLR pathways, and possible also NOD2-dependent signalling 58. On 
the other hand, invasive aspergillosis especially develops in patients that are immunosuppressed, 
and it is in this particular setting that polymorphisms and deficiencies in TLR-, dectin-1- and other 
PRR-signalling pathways become highly relevant for the antifungal host defence. 
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Abstract
Aspergillus fumigatus is the predominant airborne fungal pathogen in immunocompromised 
patients. Genetic defects in NADPH oxidase, such as chronic granulomatous disease (CGD), and 
corticosteroid-induced immunosuppression lead to impaired killing of A. fumigatus and unique 
susceptibility to invasive aspergillosis (IA) via incompletely characterized mechanisms. Recent 
studies link Toll-like receptor activation with phagosome maturation via the engagement of 
autophagy proteins. In this study, we found that infection of human monocytes with A. fumigatus 
spores triggered selective recruitment of the autophagy protein LC3II in phagosomes upon fungal 
cell wall swelling. This response was induced by surface exposure of β-glucan and was mediated by 
activation of the dectin-1. LC3II recruitment in A. fumigatus phagosomes required spleen tyrosine 
kinase (Syk)–dependent production of reactive oxygen species and was nearly absent in monocytes 
of patients with CGD. This pathway was important for control of intracellular fungal growth, as 
silencing of ATG5 resulted in impaired phagosome maturation and killing of A. fumigatus. In vivo and 
ex vivo administration of corticosteroids blocked LC3II recruitment in A. fumigatus phagosomes via 
rapid inhibition of phosphorylation of Src and Syk kinases and downstream production of reactive 
oxygen species. Our studies link dectin-1/Syk signalling with autophagy-dependent maturation of 
A. fumigatus phagosomes and uncover a potential mechanism for development of IA in the setting 
of CGD and corticosteroid-induced immunosuppression.
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Introduction
Aspergillus fumigatus, a ubiquitous saprophytic fungus, is a leading cause of morbidity and mortality 
in immunocompromised patients 1. Acquired quantitative and qualitative innate immune defects, 
typically encountered in haematological malignancy patients with severe chemotherapy-induced 
neutropenia and recipients of transplants following treatment with high doses of corticosteroids, 
are major predisposing factors for development of invasive aspergillosis (IA)1-3. A. fumigatus is 
currently regarded as an emerging fungal pathogen in a broad range of non-neutropenic hosts 
who receive prolonged courses of corticosteroid therapy 4, including patients with autoimmune 
and inflammatory diseases, and prolonged stay in intensive care units 1,4-6. Moreover, patients with 
chronic granulomatous disease (CGD), a rare primary immunodeficiency characterized by genetic 
defects in NADPH oxidase complex, are uniquely susceptible to development of IA 1,2. 
 Although risk factors for development of IA are well characterized, the immunopathogenesis 
of this frequently lethal opportunistic mycosis is incompletely understood. In immunocompetent 
individuals, professional phagocytes, including resident alveolar macrophages, circulating 
monocytes, and neutrophils, efficiently eliminate A. fumigatus spores, which are inhaled in a daily 
basis, to prevent germination of spores to hyphae and development of invasive fungal disease 1,2,7,8. 
A. fumigatus spores are degraded within acidified lysosomal compartments of human phagocytes 
via the complex process of phagolysosomal fusion 9,10. Genetic defects in NADPH oxidase-
derived reactive oxygen species (ROS) generation and corticosteroid therapy are associated with 
impaired maturation of A. fumigatus phagosomes and attenuated fungal killing, via incompletely 
characterized mechanisms 11-13. 
 The past few years have witnessed major advances in understanding innate sensing of fungi. 
Initial studies demonstrated that A. fumigatus preferentially activates TLR2 and TLR4 and results in 
NFκB-mediated immune responses 14,15. Recent evidence suggests an emerging role for dectin-1 
and other C-type lectin receptors (CLRs) in antifungal immunity 16-21. Dectin-1 recognizes β-glucan 
carbohydrates in the fungal cell walls and triggers intracellular signalling via a cytoplasmic ITAM-like 
motif via recruitment of spleen tyrosine kinase (Syk) and Raf-1 kinase 16,22. 
 In contrast to the well-characterized role of pattern recognition receptors (PRRs) in activating 
signalling pathways for induction of cytokine release, their contribution in phagosome maturation 
is less well defined. Recently, the recruitment of proteins of the autophagy machinery, including 
LC3II, ATG5, and ATG7, in phagosomes containing microbial ligands in response to TLR activation 
was found to be important for phagolysosomal fusion and pathogen elimination by murine 
macrophages 23. Although the signalling regulating autophagy protein recruitment in TLR-
containing phagosomes has not been characterized, this response was shown to be dependent on 
NADPH-derived ROS production 24. At present, there is no clear evidence on whether and how innate 
sensing of A. fumigatus is linked to phagosome maturation and killing by professional phagocytes. 
 In this study, we found that A. fumigatus infection of human monocytes triggered a selective 
recruitment of LC3II autophagy protein in phagosomes upon fungal cell wall swelling. This response 
was induced by surface exposure of β-glucan, required activation of dectin-1/Syk/ROS signalling, 
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and it was nearly absent in monocytes of patients with CGD. This pathway was important for fungal 
clearance because conditional inactivation of ATG5 resulted in attenuated phagolysosomal fusion 
and killing of A. fumigatus spores. Importantly, in vivo or ex vivo treatment of human monocytes 
with hydrocortisone blocked LC3II recruitment in Aspergillus-containing phagosomes via rapid 
inhibition of phosphorylation of Src and Syk kinases and subsequent blockade in ROS production. 
Overall, our studies link dectin-1/Syk signalling with autophagy-dependent maturation of fungal 
phagosomes and uncover a potential target for development of novel immunotherapies against 
invasive Aspergillus infections.
Experimental procedures
Reagents | Highly purified Escherichia coli LPS (catalog number 437627) was purchased from 
Calbiochem; Laminarin from Laminaria digitata (catalog number L9634), β-1,3-D-glucanase 
from Aspergillus niger (catalog number 49101), and 2’,7’-dichlorofluorescin diacetate (DCFH-
DA; catalog number D6883) were all obtained from Sigma Aldrich. Purified particulate β-glucan 
(curdlan) was from Waiko (Tokyo, Japan). Yeast whole glucan particles (WGP) were from Biothera. 
For immunofluorescence imaging studies, WGP was labelled with fluorescein dichlorotriazine 
(Molecular Probes-Invitrogen). Anti-β-(1,3)-Glucan mAb (catalogue number 400-2) was from 
Biosupplies (Parkville, Australia). Blocking mAb for dectin-1 (GE2) (catalogue number ab82888; 10 
mg/mL) was from Abcam. TLR2 (10 mg/mL), TLR4 (10 mg/mL), and appropriate isotype control Abs 
were from eBioscience. In some experiments, highly purified Bartonella quintana LPS was used as 
a potent TLR4 inhibitor. A Syk inhibitor (1 mM; catalogue number 574711), piceatannol (40 mM; 
catalog number 527948), and raf-1 inhibitor (40 mM; catalog number 553008, GW5074) were from 
Calbiochem. Hydrocortisone (Lyocortin) was from Vianex. Anti-LC3 Ab used for immunofluorescence 
was from Nanotools (0231-100/LC3-5F10). FITC-conjugated dectin-1 Ab (MCAA4661FT) was from 
AbD Serotec. Latex beads of 3 µm diameter were purchased from Sigma Aldrich. Coating of latex 
beads with IgG or BSA was performed by overnight rotating incubation at 4°C with human IgG (1 
mg/mL) or BSA (1 mg/mL) followed by three washes with PBS.
Isolation and stimulation of human primary cells from patients and controls | Healthy volunteers 
without any known infectious or inflammatory disorders donated blood as a control group for the 
assessment of LC3II recruitment in fungal phagosomes. In addition, PBMCs were isolated from 
three patients with CGD harbouring homozygous mutations in the NCF1 gene (p47phox) in which 
the complete absence of ROS production has been demonstrated, and three homozygous patients 
with the early stop codon mutation Tyr238X in dectin-1 (dectin-1-/-). After informed consent, blood 
was collected by venipuncture from these patients and volunteers into 10 mL EDTA tubes. Six 
consecutive patients with various rheumatologic diseases receiving treatment with a standard 
dose of corticosteroids (Table I) were recruited from the Rheumatology Department, University 
Hospital of Heraklion. Monocytes from healthy controls and patients were isolated from PBMCs 
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using magnetic bead separation with anti-CD14-coated beads (MACS; Miltenyi Biotec) according 
to the protocol supplemented by the manufacturer. The monocytes were resuspended in RPMI 
1640 culture medium supplemented with 1% gentamicin, 1% L-glutamine, and 1% pyruvate. The 
cells were counted in a Bürker counting chamber, and their number was adjusted to 1x106/mL. A 
total of 23105 monocytes per condition in a final volume of 200 mL were allowed to adhere to 
glass coverslips (Ø12 mm) for 1 hour, after which they were exposed to A. fumigatus spores at a 
multiplicity of infection (MOI) of 3:1 at 37°C for 1 hour. After stimulation, the coverslips were washed 
twice with PBS to remove medium, and nonphagocytosed spores and cells were fixed on the 
coverslips for 15 minutes in 4% paraformaldehyde (PFA). Subsequently, the coverslips were washed 
with PBS followed by a fixation in ice-cold methanol for 10 minutes in -20°C, after which coverslips 
were stored in PBS at 4°C until immunofluorescence staining was performed.
Microorganisms and culture conditions | The A. fumigatus strains Af293 (ATCC 46645) and the 
GFP-A. fumigatus strain (kind gift of K. A. Marr) were used in this study. All isolates were grown on 
YAG agar plates for 3 days at 37°C. Fungal spores in the presence of sterile 0.1% Tween-20 in PBS were 
harvested by gentle shaking, washed twice with PBS, filtered through a 40 µm pore size cell strainer 
(Falcon) to separate conidia from contaminating mycelium, counted by a haematocytometer, 
and suspended at a concentration of 108 spores/mL. Swollen A. fumigatus spores were obtained 
following growth in liquid RPMI 1640 media for 4-6 hours at 37°C. Typically, 90% of fungal spores 
were visibly swollen. The conidia were labelled with FITC as previously described 9. Briefly, freshly 
harvested conidia 5x107/mL 50 mM Na carbonate buffer (pH 10.2) were incubated with FITC at a 
final concentration of 0,1 mg/mL at 37°C for 1 hour and washed by centrifugation three times in 
PBS- 0,1% Tween 20. 
 Enzymatic digestion of β-glucan in swollen A. fumigatus spores was performed by using β-1,3-
D-glucanase (Sigma Aldrich). A. fumigatus spores were incubated overnight in a water bath with 100 
U/mL β-glucanase at a temperature of 55°C and pH 5. Inactivation of enzyme was achieved by 10 
minutes incubation at 100°C followed by three washes in PBS. Verification of β-glucan digestion was 
performed by immunostaining with an anti-β-glucan mAb. Inactivation of fungi was done by heat 
exposure (30 minutes, 65°C) or exposure to 1% PFA (4°C, overnight) following by treatment with 
glycine (100 mM/PBS) and three washes in PBS. PFA inactivation of A. fumigatus spores had no effect 
on β-glucan surface exposure as evidenced by immunostaining.
Immunofluorescence staining | For immunofluorescence imaging, cells were seeded in coverslips 
pretreated with polylysine, fixed with 4% PFA for 15 minutes in room temperature following by 10 
minutes of fixation with ice-cold methanol at 220°C, washed twice with PBS, permeabilized by using 
0,1% saponin (Sigma Aldrich), blocked for 30 minutes in PBS plus 2% BSA, incubated for 1 hour with 
a mouse mAb to LC3 (1:50; Nanotools), washed twice in PBS plus 2% BSA, and stained by a secondary 
Alexa555 goat anti-mouse Ab (1:500; Molecular Probes), followed by DNA staining with 10 mM TO-
PRO-3 iodide (642/661; Invitrogen). After the washing steps, slides were mounted in Prolong Gold 
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antifade media (Molecular Probes). Images were acquired using a laser-scanning spectral confocal 
microscope (TCS SP2; Leica Microsystems), LCS Lite software (Leica Microsystems), and a 403 
Apochromat 1.25 NA oil objective using identical gain settings. A low fluorescence immersion oil 
(11513859; Leica Microsystems) was used, and imaging was performed at room temperature. Unless 
otherwise stated, mean projections of image stacks were obtained using the LCS Lite software and 
processed with Adobe Photoshop CS2 (Adobe Systems). 
 Phagosome acidification was assessed by use of the acidotropic dye LysoTracker Red DND-99 
according to the manufacturer’s instructions (Invitrogen) and immunostaining with a mouse mAb 
to CD63 (catalogue number 556019; BD Pharmingen) in primary human monocytes and THP- 1 cells. 
THP-1 cells (American Type Culture Collection) were maintained in complete medium containing 
RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 100 U/mL 
penicillin, 100 mg/mL streptomycin, 0.05 mM 2-ME, 4.5 g/L glucose, and 10% FCS v/v) at 37°C (5% 
CO2), with passage every 3 days. Briefly, for LysoTracker staining, THP-1 cells were seeded on coverslips 
in 24-well flat-bottom plates and differentiated to macrophages following 48-h exposure to PMA 
(100 mg/mL; Sigma Aldrich) in RPMI 1640-10% FCS media. Cells were preloaded with LysoTracker, 
diluted 1:20,000 (v/v) in RPMI 1640 complete medium, for 2 hours and were subsequently infected 
at 4°C with FITC-labelled A. fumigatus conidia (MOI 5:1) in fresh medium without LysoTracker. After 
removal of nonphagocytosed conidia by washing with warm RPMI 1640 media, medium with 
LysoTracker was added to each well, and conidia internalization was initiated at 37°C. Infection was 
stopped after 2 hours, and the cells were washed with PBS, mounted on microscope slides, and 
examined immediately under the confocal microscope. 
 For β-glucan immunostaining of A. fumigatus, live or PFA-inactivated spores (2x107/ condition) 
were pelleted in propylene tubes, washed twice with PBS, blocked for 30 minutes in PBS plus 2% 
BSA, incubated for 1 hour with a mouse mAb to linear)-β-1,3-glucan (Biosupplies; 1 mg/mL) at room 
temperature, washed twice in PBS plus 2% BSA, stained by a secondary Alexa Fluor555 goat anti-
mouse Ab (Molecular Probes), and images were acquired by confocal microscopy. 
Immunoelectron LC3 microscopy in monocytes | Immunoelectron microscopy was performed 
using mouse monoclonal LC3 Ab (Nanotools), applying the pre-embedding gold enhancement 
method as described previously 25. Primary human monocytes cultured on polylysine pretreated 
coverslips were fixed with 4% PFA (Nacalai Tesque) for 15 minutes at room temperature. After 
washing with the same buffer three times for 5 minutes, the fixed cells were permeabilized using 
0,25% saponin in PBS. The cells were washed with PBS, blocked by incubating for 30 minutes in 
PBS containing 0,1% saponin, 10% BSA, 10% normal goat serum, and then exposed overnight to 
0,01 mg/mL anti-LC3 mouse mAb or 0,01 mg/mL rat serum in the blocking solution. After washing 
with PBS containing 0.005% saponin, the cells were incubated with colloidal gold (1,4 nm diameter; 
Nanoprobes)-conjugated goat anti-mouse IgG in the blocking solution for 2 hour. The cells were then 
washed with PBS and fixed with 1% glutaraldehyde in PBS for 10 minutes. After washing with 50 mM 
glycine in PBS, 1% BSA in PBS, and finally with milliQ water (Millipore), gold labelling was intensified 
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with a gold enhancement kit (GoldEnhance EM; Nanoprobes) for 3 minutes at room temperature 
according to the manufacturer’s instructions. After washing with distilled water, the cells were fixed 
in 1% OsO4 containing 1,5% potassium ferrocyanide in PBS for 60 minutes at room temperature and 
washed with distilled water. The cells were dehydrated in a series of graded ethanol solutions and 
embedded in epoxy resin. After the epoxy resin hardened, the plastic coverslip was removed from 
it. Ultrathin sections were cut horizontally to the cell layer and double stained with uranyl acetate 
and lead citrate. Samples were analysed with an electron microscope. Serial sections were collected 
on pioloform-coated copper grids and samples analysed in a Philips CM100 electron microscope 
(Philips, Eindhoven, The Netherlands).
Western blot analysis | Human monocytes were stimulated with A. fumigatus conidia for the 
indicated time points at an MOI of 10:1. Where appropriate, cells were pre-incubated with DMSO 
or the indicated concentrations of inhibitors for 30 minutes prior to stimulation. Cells were washed 
once in PBS prior to lysis in 1% Nonidet P-40 containing RIPA buffer: 50 mM Tris (pH 7.4), 150 mM 
NaCl, 1 mM EDTA, 0,25% sodium deoxycholate, 1 mM NaF, 1 mM Na3VO4, and 1 mM PMSF plus a 
mixture of protease inhibitors (Roche Molecular Biochemicals). Cell lysis was performed on ice for 20 
minutes, and samples were centrifuged. After protein estimation of supernatants, addition of SDS 
sample buffer, and boiling, samples were separated on SDS-PAGE and transferred to polyvinylidene 
difluoride membranes. Western blotting was performed according to the instructions of the 
manufacturer using the following primary Abs: rabbit anti-LC3 (NB100-2220; Novus), mouse anti-
actin (mAb 1501; Millipore), mouse anti-tubulin (T5168; Sigma Aldrich), rabbit anti-Syk (sc-1077), 
rabbit anti-phospho-Syk (Tyr525/526, 2710; Cell Signalling Technology), rabbit anti-phospho Src 
(Tyr416; 2101; Cell Signalling Technology), and goat anti-ATG5 (sc-8666; Santa Cruz Biotechnology). 
Secondary Abs used in Western blotting were purchased from Cell Signalling Technology (anti-
rabbit HRP and anti-goat HRP) as well as Millipore (anti-mouse HRP). The blots were developed 
using chemiluminescence (ECL; Thermo Scientific).
Measurement of ROS production in human monocytes | ROS measurements were performed by 
means of a DCFH assay 26. Stock solution of DCFH-DA was dissolved in DMSO to a final concentration 
of 100 mM. Human monocytes (2x105/well) were plated on 96-well round-bottom plates, incubated 
at 37°C for the indicated time (2 hour) with or without hydrocortisone, and accordingly stimulated 
for 1 hour with A. fumigatus spores in the presence of DCFH-DA added to a final concentration of 
10 mM. After 30 minutes of exposure, the content of the wells were transferred to vials and the 
fluorescence of the cells from each well measured by flowcytometry. Cells were acquired on a FACS-
Calibur (BD Biosciences) and analysed using FlowJo software (Tree Star). 
Killing of A. fumigatus spores by THP-1 cells | THP-1 cells were plated onto 12-well plates and 
allowed to differentiate to macrophages in the presence of PMA (100 mg/mL). Cells that were 
adherent after 48 hour were used in phagocytosis and killing experiments. To measure macrophage 
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killing of conidia, PMA was removed by adding fresh media, and THP-1 cells were allowed to 
ingest A. fumigatus conidia at an MOI of 1:10 for 1 hour at 37°C. Medium containing nonadherent, 
nonphagocytosed conidia was removed, and wells were washed three times using warm PBS. 
Macrophages were then allowed to kill conidia for 2 and 6 hour before intracellular conidia were 
harvested. Macrophages were removed by scraping, placed in propylene tubes, snap frozen with 
the use of liquid nitrogen, and rapidly thawed at 37°C to lyse the THP-1 cells and harvest conidia. 
The process of cellular lysis was performed twice and confirmed by light microscopy. Lysates left 
overnight at 4°C in RPMI 1640. The percentage of killing (number of nongerminated spores per 
100 counted conidia) in the culture well after 6-8 hour of incubation at 37°C was assessed under 
a microscope. Control wells containing only A. fumigatus conidia showed that the percentage of 
germination of the conidia used was always 90%. 
Figure 1 | LC3II is recruited to phagosomes of human monocytes during cell wall swelling of A. fumigatus
Monocytes (2x105 cells/condition) were infected with live (A, B) or PFA-killed (B) GFP A. fumigatus (GFP Af ) 
at an MOI of 5:1. Cells were, stained for LC3II and the percentages of LC3-associated A. fumigatus-containing 
phagosomes (LC3+ Aspergillus ; n=150/group) were quantified by measuring the number of LC3+ Aspergillus-
containing phagosomes out of the total number of engulfed Aspergillus spores, data are presented as mean ± 
SEM of three independent experiments. *p<0.0001, paired Student t test. (C) Monocytes (2x106 cells/condition) 
were infected with live or PFA-killed GFP A. fumigatus as in (A) and (B), and levels of LC3II and tubilin (as a loading 
control) protein were determined. (D and E) Monocytes were stimulated for 1 hour with PFA-killed dormant 
or swollen spores of GFP A. fumigatus as in (A). The percentages of LC3+ A. fumigatus-containing phagosomes 
(LC3+ Aspergillus ; n=150/group) were quantified, and data are presented as mean ± SEM of five independent 
experiments. *p<0.0001, paired Student t test. (F) Monocytes (2x106 cells/condition) were left untreated (Unstim) 
or stimulated with either PFA killed dormant (Resting sp) or swollen spores (Swollen sp) of A. fumigatus. Cell 
lysates were prepared, and LC3II and tubulin protein levels were determined. (G) Representative immunoelectron 
micrograph in which LC3II was labelled in monocytes stimulated for 1 hour with PFA-killed A. fumigatus swollen 
spores with 1.4-nm gold particles. Scale bars in (A) and (D) represent 5 µm. 
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Silencing of ATG5 expression by specific short interfering RNA | Short interfering RNA (siRNA) 
targeting was used to knockdown ATG5 expression in human THP-1 monocytes. A human 
monocyte nucleofector kit (Amaxa, Gaithenberg, MD) and Nucleofector device (Amaxa) were used 
for delivering siRNA into monocytes by following the instructions provided by the manufacturer. In 
brief, 1.5x106 THP-1 cells were suspended in 100 mL human monocyte nucleofector solution (Amaxa) 
and transfected with siRNA at a final concentration of 100 nM using the V-001 program. Transfected 
cells were immediately diluted with prewarmed growth media and cultured in 12-well plates for 24 
hour. THP-1 cells were allowed to differentiate for an additional 48 hours in the presence of PMA (25 
mg/mL) and then used for experiments. The following siRNA pool of oligonucleotide sequences 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA): ATG5 RNA interference (RNAi; sc-
41445) and control RNAi (C RNAi) oligonucleotide sequences (sc-37003). Specific gene knockdowns 
were assessed by immunoblotting. 
Statistical analysis | The data were expressed as means ± SEM. Statistical significance of differences 
was determined by Student t test and Bonferroni t test (p<0.05 was considered statistically 
significant). Analysis was done in GraphPad Prism software (version 5.0). All experiments were 
performed at least in triplicate and replicated at least twice.
Results
LC3II is recruited in A. fumigatus phagosomes upon fungal cell wall swelling
To evaluate whether autophagy proteins participate in immune responses against A. fumigatus, we 
monitored the kinetics of LC3II recruitment to phagosomes of primary human monocytes infected 
with live spores of GFP- or FITC-labelled A. fumigatus by immunostaining with the use of an anti-
LC3 Ab. In contrast to the previously reported rapid LC3+ phagosome formation, within minutes 
of the uptake of beads coated with TLR ligands 24, we noticed a delayed LC3II recruitment in A. 
fumigatus-containing phagosomes that was pronounced only after 2 hours of infection (Figure 
1A). Subsequently, we investigated whether the formation of LC3+ phagosomes is elicited by 
fungal molecules that are either released or exposed during intracellular fungal cell wall swelling 
of A. fumigatus spores 9. Thus, we infected human monocytes with PFA-killed resting (dormant) or 
swollen A. fumigatus spores and assessed LC3II recruitment. Surprisingly, we noticed minimal LC3II 
recruitment in phagosomes even at late (4 hour) time points of infection of human monocytes with 
resting A. fumigatus spores (Figure 1B). Similarly, although monocyte infection with live A. fumigatus 
spores triggered high levels of LC3II protein expression, there was no evidence of significant LC3II 
protein expression in monocytes infected with PFA-killed A. fumigatus resting spores (Figure 1C). In 
contrast to resting A. fumigatus spores, swollen spores triggered robust LC3+ phagosome formation 
(Figure 1D, 1E) and pronounced LC3II protein expression (Figure 1F). Collectively, these data reveal 
that LC3II protein recruitment in A. fumigatus phagosomes is not dependent on release of soluble 
factors and occurs upon fungal cell wall swelling.
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 In agreement with previous studies that reported lack of classic double membrane autophagosome 
formation in LC3+ phagosomes containing TLR ligands 23, we found that A. fumigatus swollen spores 
were contained within single membrane phagosomes, which was also suggested by the presence of 
gold-conjugated Ab against LC3 only in the outer part of the phagosome membrane (Figure 1G).
Figure 2 | β-glucan exposure in swollen A. fumigatus spores triggers LC3II recruitment in phagosomes
(A) Primary human monocytes (2x105 cells/condition) were infected with GFP A. fumigatus swollen spores with or 
without laminarin (500 mg/mL) or swollen spores (Swollen sp.) following overnight enzymatic digestion of β-glucan 
(β-glucanase) at an MOI of 5:1 for 1 hour. Cells were stained for LC3II, (B) the percentages of LC3+ A. fumigatus-
phagosomes (LC3+ Aspergillus; n=150/group) were quantified, and data are presented as mean ± SEM of three 
independent experiments. *p<0.0001, paired Student t test. Monocytes (2x106 cells/condition) were stimulated 
with A. fumigatus swollen spores or in the presence of laminarin (C) or IgG coated 3 µm latex beads alone or in 
the presence of laminarin (D) for 1 hour. Protein levels of LC3II and tubulin (as a loading control) were determined 
in cell lysates. (E and F) Monocytes (2x105 cells/condition) were left untreated (Unstim.), stimulated with purified 
β-glucan (curdlan, 100 mg/mL) or LPS (100 ng/mL) with or without pretreatment with laminarin (500 mg/mL). 
The percentages of monocytes containing autophagosomes LC3 staining (LC3+ monocytes; n=150/group) were 
quantified, and data are presented as mean ± SEM of two independent experiments. *p<0.0001, paired Student 
t test. (G) Monocytes (2x105 cells/condition) stimulated with FITC-labelled BSA beads or DTFA-labelled WGP at an 
MOI of 5:1 for 1 hour. (H) Monocytes (1x106 cells/condition) were left untreated (Unstim.), stimulated with BSA-
coated beads, IgG-coated beads, or WGP with or without pretreatment with laminarin at an MOI of 10:1 for 1 hour. 
Protein levels of LC3II and tubulin were determined in the cell lysates. Scale bars in (A,E and G) represent 5 µm. 
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β-glucan exposure triggers LC3II recruitment in A. fumigatus-containing phagosomes
Recent studies demonstrated that resting A. fumigatus spores are immunologically inert because 
of concealing of pathogen associated molecular patterns by a surface layer of hydrophobin 27. 
Importantly, swelling of A. fumigatus spores leads to surface exposure of the fungal polysaccharide 
β-1,3-D-glucan (β-glucan) and induction of robust inflammatory responses 28. Therefore, we 
assessed whether stage-specific surface exposure of β-glucan in swollen A. fumigatus spores 
accounts for selective LC3II protein recruitment in A. fumigatus phagosomes. Accordingly, we 
performed enzymatic digestion of β-glucan in PFA-swollen A. fumigatus spores by using a β-1,3-
D-glucanase and assessed the effect on LC3II protein recruitment in fungal phagosomes. Efficient 
digestion of β-glucan layer in A. fumigatus swollen spores was confirmed by immunofluorescence 
microscopy with the use of anti-β-glucan Ab. We found that enzymatic digestion of β-glucan 
resulted in significant reduction in LC3+ A. fumigatus phagosome formation (Figure 2A, 2B) following 
infection of human monocytes with swollen A. fumigatus spores. Furthermore, laminarin, a non-
immunostimulatory soluble β-glucan that acts as competitive inhibitor of β-glucan receptors 28, 
almost completely abolished LC3+ A. fumigatus phagosome formation (Figure 2A, 2B) and LC3II 
protein induction in human monocytes stimulated with swollen A. fumigatus spores (Figure 2C). 
Notably, laminarin treatment had no effect in LC3II protein conversion in human monocytes 
stimulated with IgG-coated latex beads (Figure 2D). 
 The cell wall of A. fumigatus also contains Galactomannan moieties 29, and previous studies 
have implicated mannose- or mannan-specific receptors, including dendritic cell-specific ICAM-
3-grabbing non-integrin and the long pentraxin PTX3, in the recognition of A. fumigatus 30,31. 
To address the possible role of a mannose- or mannan-specific receptor in LC3+ phagosome 
formation by swollen A. fumigatus spores, we pretreated human monocytes with Saccharomyces 
cerevisiae-derived mannan 31 prior to their addition to swollen spores and observed no effect on 
LC3II recruitment by immunofluorescence imaging or LC3II expression by Western blot analysis, in 
contrast to the effect of laminarin (Figure S1).
 To confirm the ability of β-glucan to trigger LC3+ phagosome formation, we stimulated human 
monocytes with different forms of purified insoluble β-glucan, including curdlan and yeast-
derived WGP of ~3 µm size. Stimulation of human monocytes with curdlan particles elicited robust 
autophagosome formation that was blocked by pretreatment with laminarin (Figure 2E, 2F); in 
contrast, laminarin had no measurable effect in autophagy induction by LPS in human monocytes 
(Figure 2F). In addition, stimulation of human monocytes with fluorescein dichlorotriazine-labelled 
WGP resulted in a high degree of LC3+ phagosome formation, comparable to that induced by 
stimulation with IgG-coated latex beads (Figure 2G). Similarly, we noticed high levels of LC3II 
conversion following stimulation of human monocytes with WGP, a response completely inhibited 
by laminarin (Figure 2H). Collectively, these studies demonstrate that β-glucan surface exposure 
in A. fumigatus fungal cell wall activates the recruitment of the autophagy protein LC3II in fungal 
phagosomes.
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LC3II recruitment in A. fumigatus phagosomes depends on dectin-1/Syk signalling 
Sensing of β-glucan by human myeloid cells predominantly occurs via engagement of the C-type lectin 
receptor dectin-1 16,17. Patients with the homozygous early stop-codon mutation Tyr238X in dectin-1 
display lack of surface receptor expression, defective cytokine release, and hyper susceptibility to 
mucocutaneous fungal infections 20. We tested whether dectin-1 is involved in β-glucan-induced 
LC3+ phagosome formation by infecting monocytes of three patients having homozygous dectin-1 
Tyr238X mutation (dectin-1-/-) with PFA-killed resting and swollen A. fumigatus spores. We found that 
monocytes of dectin-1-/- patients had significant reduction in formation of LC3+ phagosomes following 
infection with swollen A. fumigatus spores when compared with monocytes of dectin-1+/+ controls 
(Figure 3A). In addition, blocking of dectin-1 in monocytes from healthy individuals with the use of 
a specific Ab resulted in significant reduction in LC3+ phagosome formation following infection with 
swollen A. fumigatus spores (Figure 3B). Because TLR2 and TLR4 receptors are the main TLRs involved 
in sensing of A. fumigatus 2,14,15, we tested whether they also regulate autophagy protein recruitment 
in the phagosome. There was no evidence of significant reduction in LC3II recruitment in phagosomes 
containing swollen A. fumigatus spores following blockade of either TLR2 receptor using an anti-TLR2 
Ab or TLR4 receptor using either an anti-TLR4 Ab or the TLR4 antagonist B. quintana LPS (Figure 3B). 
Because β-glucan has been reported to activate complement receptor 3 (CR3) in human phagocytes 
17, we blocked this receptor by using competitive inhibition with N-acetyl-D-glucosamine 32,33 and 
assessed the effect in LC3+ A. fumigatus phagosome formation. We did not find significant reduction 
in LC3II recruitment and LC3II protein conversion in human monocytes pre-exposed to N-acetyl-D-
glucosamine and subsequently infected with swollen A. fumigatus spores (Figure S1). These studies 
suggest that LC3II recruitment in A. fumigatus phagosomes depends mainly on activation of dectin-1. 
 Coupling of Syk with dectin-1 and other CLRs activates multiple downstream pathways 16,17,34. 
However, the role of Syk in phagosome maturation has not been earlier evaluated. In agreement 
with a stage-specific pattern of β-glucan exposure in the cell wall surface of A. fumigatus, we 
found selective activation of Syk following monocyte infection with swollen and not with resting 
A. fumigatus spores (Figure 3C). Importantly, treatment of human monocytes with two different 
Syk inhibitors almost completely abolished LC3 ΙΙ recruitment in phagosomes containing swollen 
A. fumigatus spores and blocked LC3II protein conversion by Western blot analysis (Figure 3D, 3E). 
Similarly, treatment with Syk inhibitor blocked LC3 ΙΙ recruitment in phagosomes containing purified 
β-glucan particles (WGP; Figure S2). Of interest, Syk inhibitors also blocked LC3II recruitment 
in phagosomes containing IgG-coated latex beads (Figure S2), implying that Syk controls LC3+ 
phagosome formation upon activation of a broad range of PRRs that contain ITAM motifs. 
 Raf-1 kinase has been implicated in dectin-1 signalling via a Syk independent alternative 
noncanonical pathway of activation of NFκB 22. Thus, we tested whether signalling mediated by raf-1 
kinase is involved in LC3 recruitment in A. fumigatus phagosomes. Blocking of raf-1 kinase did not cause 
significant reduction in LC3+ phagosome formation (Figure 3E, 3F) and LC3II protein expression (Figure 
3G) in monocytes stimulated with swollen Aspergillus spores. Collectively, these studies demonstrate 
that dectin-1/Syk regulates the formation of LC3+ A. fumigatus phagosomes. 
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Figure 3 | Dectin-1/Syk signalling regulates LC3II recruitment in A. fumigatus phagosomes
(A) Monocytes (2x105 cells/ condition) isolated from homozygous patients with the stop-codon mutation 238X 
(dectin-1-/-) and healthy controls (dectin-1+/+) were infected with FITC-labelled resting or swollen A. fumigatus 
spores at an MOI of 5:1 for 1 hour at 37°C. Cells were stained for LC3II and the percentages of LC3+ A. fumigatus-
containing phagosomes (LC3+ Aspergillus ; n=100/group) were quantified, data are presented as mean ± SD for 
each patient. *p<0.0001, paired Student t test. (B) Monocytes were stimulated with FITC-labelled A. fumigatus 
swollen spores following 30 minutes pre-incubation with blocking Abs for dectin-1 (10 mg/mL), TLR2 (10 mg/
mL), or TLR4 (10 mg/mL) or the indicated isotype control Abs (10 mg/mL) at an MOI of 5:1 for 1 hour at 37°C. 
Cells were processed for immunofluorescence microscopy as in Fig. 1A. (C) Monocytes (2x106 cells/condition) were 
either left untreated (Unstim) or stimulated with resting or swollen A. fumigatus spores with or without 30 minutes 
pretreatment with Syk inhibitor (1 mM) at an MOI of 10:1 for 10 minutes at 37°C. Protein levels of phospho-Syk 
activity, total Syk and tubulin (as loading controls) were determined. (D) Monocytes (2x106 cells/condition) were 
stimulated as in (C) for 1 hour at 37°C, and levels of LC3II and tubulin were determined in cell lysates. (E and F) 
Monocytes (2x105 cells/condition) were stimulated with FITC-labelled swollen A. fumigatus spores with or without 
30 minutes pretreatment with Syk inhibitor (574711; Calbiochem; 1 mM) or raf-1 inhibitor (GW5074; 40 mM) at an 
MOI of 5:1 for 1 hour and processed for immunostaining as in (A). The percentages of LC3+ A. fumigatus-containing 
phagosomes (LC3+ Aspergillus ; n=150/group) were quantified, and data are presented as mean ± SEM of four 
independent experiments. *p<0.0001, paired Student t test. Scale bar, 5 µm. (G) Monocytes (2x106 cells/condition) 
stimulated as in (E), and levels of LC3II and tubulin were determined in cell lysates.
Syk-dependent ROS production regulates formation of LC3+ Aspergillus-phagosomes 
Recent studies implicate NOX2-dependent ROS production in regulation of LC3II recruitment in 
phagosomes of murine macrophages containing TLR and FcγR ligands 24. Since Syk regulates ROS 
production in response to β-glucan 16,17,34,35, we tested whether Syk-mediated LC3II recruitment in A. 
fumigatus-containing phagosomes was dependent on ROS production. We initially confirmed that 
similar to murine macrophages 35, treatment with Syk inhibitor in human monocytes resulted in 
complete inhibition of ROS production in human monocytes stimulated with swollen A. fumigatus 
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spores (Figure 4A). 
 Importantly, patients with GCD have mutations in various components of NADPH oxidase and 
unique susceptibility to invasive A. fumigatus infection via incompletely characterized mechanisms 1,2,11. 
Thus, we tested whether abolished ROS production in monocytes of CGD patients results in defective 
LC3II recruitment in A. fumigatus-containing phagosomes. When compared with monocytes of 
control healthy individuals, monocytes of three CGD patients displayed almost complete abolishment 
of LC3+ phagosome formation following infection with A. fumigatus (Figure 4B, and 4C). In addition, 
we noticed decreased LC3II protein expression in lysates of monocytes from CGD patients infected 
with A. fumigatus in comparison with lysates of monocytes from healthy control patients infected with 
the fungus (Figure 4D). Therefore, NADPH-derived ROS production regulates LC3II recruitment in A. 
fumigatus-containing phagosomes, and this pathway is defective in patients with CGD.
Figure 4 | Syk-dependent ROS regulates formation of LC3+ Aspergillus-phagosomes.
(A) Primary human monocytes (2x105 cells/condition) were left unstimulated (Unstim) or infected with 
resting spores or swollen A. fumigatus spores at an MOI of 5:1 or stimulated with PMA (100 ng/mL) with or 
without 30-min pretreatment with Syk inhibitor (574711; Calbiochem; 1 mM). DCFH-DA was added during 
the last 30 minutes of stimulation, and intracellular ROS production was determined by measurement of 
mean fluorescence intensity (MFI). Data are presented as mean ± SEM from four independent experiments. 
Representative histograms from human monocytes left untreated (gray solid line), stimulated with either 
swollen A. fumigatus spores alone or PMA alone (black solid line), or in the presence of Syk inhibitor (black 
dashed line) are shown. *p<0.005, paired Student t test. (B and C) Monocytes (2x105 cells/condition) isolated 
from CGD patients and healthy controls were infected with FITC-labelled resting or swollen A. fumigatus 
spores at an MOI of 5:1 for 1 hour at 37°C. Cells were stained for LC3II and the percentages of LC3+ A. 
fumigatus-containing phagosomes (LC3+ Aspergillus; n=100/group) were quantified, and data are presented 
as mean ± SD for each patient. Representative immunofluorescence image of LC3+ phagosomes containing 
FITC-labelled swollen A. fumigatus spores in monocytes obtained from healthy control and CGD patient. 
*p<0.0001, paired Student t test. (D) Monocytes (1x106 cells/condition) from a representative CGD patient 
and the corresponding healthy control were left untreated (Unstim) or stimulated with resting spores 
(Resting sp) or swollen spores (Swollen sp) of A. fumigatus at an MOI of 10:1 for 1 hour at 37°C, and levels of 
LC3II and tubulin were determined in cellular lysates.
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ATG5 silencing attenuates phagosome maturation and killing of A. fumigatus
Recent studies demonstrated that silencing or knockdown of autophagy related genes ATG5 and 
ATG7 in murine macrophages resulted in impaired fusion of zymosan-containing phagosomes 
with lysosomes 2 3 and defective killing of S. cerevisiae 23 and C. albicans 36. To evaluate the role of 
autophagy in human macrophage effector function against A. fumigatus, we performed silencing 
of ATG5 in THP-1-differentiated macrophages (Figure 5A), a human cell line previously shown to 
efficiently internalize and kill A. fumigatus 37. Silencing of ATG5 in THP-1 macrophages resulted 
in significant reduction of the percentage of A. fumigatus spores within acidified lysosomes, as 
evidenced by LysoTracker staining (Figure 5B, 5C).
 We next assessed the effect of ATG5 silencing in killing of A. fumigatus by THP-1 macrophages. 
Previous studies demonstrated that elimination of A. fumigatus occurs following an initial 2 hour 
lag phase and reaches maximum levels at approximately 6 hours of infection 9,10,37. In agreement 
with previous studies 35, we found that THP-1 cells prevented germination of approximately 60% 
Figure 5 | Inactivation of ATG5 in THP-1 cells attenuates phagolysosomal 
fusion and killing of A. fumigatus 
(A) THP-1 cells (1x106 cells/condition) were transfected with RNAi sequences 
targeting ATG5 versus scramble C RNAi by Amaxa electroporation. Cell 
lysates were prepared 48 hour following transfection, and protein levels of 
LC3II, ATG5, ATG5-ATG12 and actin (as loading contol) were determined. (B 
and C) LysoTracker staining in THP-1 cells transfected with ATG5 RNAi or C 
RNAi and differentiated to macrophages with addition of PMA (25 ng/mL) 
following 2 hour of infection with FITC-labelled A. fumigatus spores. Data are 
presented as mean ± SEM of three independent experiments. *p<0.0001, 
paired Student t test. Scale bars, 5 µm. (D) Degree of association (uptake) 
of GFP A. fumigatus spores with THP-1 cells transfected with ATG5 RNAi or C 
RNAi and differentiated to macrophages in the presence of PMA (25 ng/mL) 
at different time points of infection (1, 2, and 6 h) assessed by FACS analysis. 
Results are representative of two independent experiments. (E) THP-1 cells 
transfected by Amaxa nucleofection with ATG5 RNAi or C RNAi were seeded 
in 12-well plates (5x105 cells/condition), differentiated with PMA (25 ng/mL) 
for 48 h, and infected with A. fumigatus spores at an MOI of 1:10 at 37°C. 
Medium containing nonadherent, nonphagocytosed conidia was removed at 
1 h, and wells were washed three times using warm PBS. Macrophages were 
then allowed to kill conidia for 2 and 6 hours before intracellular conidia were 
harvested. The percentage of germinating spores after 6-8 hours of incubation 
at 37°C was assessed. The germination rate (number of germinated spores per 
100 counted conidia) of A. fumigatus spores following different time points of 
infection (1, 2, and 6 h) was calculated, and data are expressed as mean ± SEM 
of three independent experiments; *p = 0.0003, paired Student t test.
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of A. fumigatus spores at 6 hours of infection, whereas there was little evidence of inhibition of A. 
fumigatus growth at earlier (2 hour) time points of infection (Figure 5E). Silencing of ATG5 in THP-
1 human macrophages had no significant effect on the uptake of fungal spores (Figure 5D), but 
resulted in attenuated killing of A. fumigatus (Figure 5E). Collectively, these studies demonstrate that 
autophagy proteins regulate phagosome maturation and intracellular killing of A. fumigatus. 
Corticosteroids block LC3II recruitment in A. fumigatus-containing phagosomes 
Seminal studies in the 1970s demonstrated that corticosteroids block the fusion of lysosomes 
with Aspergillus-containing phagosomes in murine macrophages, leading to impaired killing 
of A. fumigatus 12,13; however, a mechanistic explanation of the immunosuppressive action of 
corticosteroids on fungal phagosomes is lacking.
 Since we found that components of autophagy regulate maturation of A. fumigatus phagosomes, 
we evaluated whether corticosteroids target this pathway. Therefore, we assessed LC3+ phagosome 
formation in monocytes of patients with rheumatologic diseases before and 2 hours after i.v. 
administration of corticosteroids (Table I). Notably, we found a significant reduction in LC3+ A. 
fumigatus-containing phagosomes following corticosteroid treatment in monocytes of all patients 
tested (Figure 6A, 6C). In addition, ex vivo administration of corticosteroids resulted in significant 
reduction in recruitment of LC3II protein in A. fumigatus phagosomes when compared with control 
untreated monocytes (Figure 6B). 
Table 1 | Clinical and demographic characteristics of patients who received i.v. corticosteroids
No SexAge (y)
Underlying 
Disease Disease Status Comorbidities
Other Immunosuppressive 
Agents
1 F62 RA Active disease Multiple sclerosis
Methotrexate, rituximab (anti-
CD20)
2 F68 RA
Active disease, 
rheumatoid lung Hepatitis B
Leflunomide, rituximab (anti-
CD20), receipt of anti-TNFα 
mAb in the past 12 mo
3 F63 SLE In remission
Cirrhosis
(autoimmune 
hepatitis)
Azathioprine, 
hydroxychloroquine, rituximab 
(anti-CD20)
4 F46 Polymyositis In remission
Parkinson disease, 
pulmonary 
embolism
Methotrexate, low-dose 
prednisone (5 mg daily) in the 
past 6 mo
5 F56 RA
Active disease, 
extra-articular 
manifestations 
(pericarditis)
NA
Methotrexate, rituximab (anti-
CD20), receipt of anti-IL-6 mAb 
in the past 6 mo
6 F61 RA In remission
Chronic 
obstructive 
pulmonary 
disease
Methotrexate, low-dose 
prednisone (2.5 mg daily) in 
the past 6 mo
All patients received corticosteroids (methylprednisone or hydrocortisone) at a standard dose of 250 mg 
hydrocortisone equivalent as premedication for prevention of infusion reactions associated with the use of 
rituximab (anti-CD20 mAb). Blood was drawn before (0 h) and after (2 h) i.v. treatment with corticosteroids. F, 
Female; NA, not applicable; SLE, Systemic lupus erythematosus; RA, Rheumatoid arthritis.
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Figure 6 | Corticosteroids block LC3II recruitment in A. fumigatus phagosomes 
(A) Monocytes (2x105 cells/condition) from six consecutive patients with rheumatologic diseases were collected 
before and 2 hour after i.v. administration of corticosteroids (250 mg hydrocortisone) and stimulated with 
swollen A. fumigatus spores at an MOI of 5:1 at 37°C. Cells were fixed, permeabilized, stained for LC3II and the 
percentages of LC3+ A. fumigatus-containing phagosomes (LC3+ Aspergillus ; n=150/group) before (0 h) and after 
(2 h) corticosteroid treatment, were quantified, and data are presented as mean ± SD for each patient. *p<0.05, 
paired Student t test. (B) Representative immunofluorescence image of LC3+ phagosomes containing FITC-
labelled swollen A. fumigatus spores (FITC Af ) in monocytes obtained before (0 h) and after (2 h) administration 
of corticosteroids. Scale bar, 5 µm. (C) Monocytes (2x105 cells/condition) from healthy individuals (n=4) were 
stimulated before (0 h) and after (2 h) ex vivo exposure to hydrocortisone (20 mg/mL), fixed, and processed 
as in (A); data are presented as mean ± SEM of four independent experiments. *p<0.05, paired Student t test. 
Monocytes (2x106 cells/condition) from healthy individuals were either left untreated (Unstim) with or without 
1 hour exposure to hydrocortisone (20 mg/mL) or stimulated with swollen A. fumigatus spores with or without 
1 hour pre-exposure to hydrocortisone (20 mg/mL) at an MOI of 10:1 for 5 (D) or 10 minutes (E) at 37°C. Cell 
lysates were prepared, and levels of phospho-Src and phospho-Syk activity were determined, in the same 
lysates levels of tubulin and total Syk were determined as loading controls. (F) Monocytes (2x105 cells/condition) 
were left unstimulated or infected with swollen A. fumigatus spores at an MOI of 5:1 for 1 hour with or without 
pre-exposure (2 h) to increasing concentrations of hydrocortisone at 37°C. DCFH-DA was added during the 
last 30 minutes of stimulation, and intracellular ROS production was determined by measurement log mean 
fluorescence intensity (MFI). Representative histograms from monocytes left untreated (gray area) or stimulated 
with swollen A. fumigatus spores (black solid line) with or without pre-exposure to hydrocortisone (20 mg/mL) 
are shown. Differences in ROS production between experimental groups were quantified, and data are presented 
as mean ± SEM from four independent experiments. *p<0.0001, paired Student t test.
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 We subsequently assessed whether dectin-1/Syk signalling regulating antifungal autophagy 
responses is also targeted by corticosteroids. Of interest, we found no difference in the uptake of 
A. fumigatus spores and dectin-1 expression following administration of corticosteroids (Figure 
S3). Because corticosteroids block TCR signalling by inhibiting phosphorylation of ITAM motifs of 
TCR-mediated by tyrosine kinases 38,39, we reasoned that they might as well inhibit phosphorylation 
of Src and Syk tyrosine kinases in human monocytes. Importantly, we found that hydrocortisone 
administration caused a rapid block in phosphorylation of Src and Syk kinases within 5 and 10 
minutes of A. fumigatus infection, respectively (Figure 6D, 6E). 
Corticosteroids inhibit ROS production in murine macrophages following infection with A. 
fumigatus 10. Because we found that ROS production in response to A. fumigatus infection in human 
monocytes is dependent on Syk signalling, we reasoned that corticosteroid-mediated blockade in 
Syk activation would result in defective ROS production. Indeed, human monocytes treated with 
corticosteroids displayed a significant reduction in the levels of ROS production following infection 
with A. fumigatus (Figure 6E). These studies demonstrate that corticosteroids target autophagy 
protein recruitment in A. fumigatus phagosomes via inhibiting Src/Syk-dependent ROS production 
and provide a potential mechanism for their direct immunosuppressive properties in phagosome 
maturation and killing of Aspergillus spp.
Discussion
In the present work, we shed light on the signalling regulating A. fumigatus phagosome maturation 
and uncover a potential mechanism for development of invasive fungal disease in patients with CGD 
and corticosteroid-induced immunosuppression. In particular, we found that activation of dectin-1/
Syk/ROS signalling upon exposure of β-glucan in A. fumigatus spores triggers the recruitment of 
autophagy protein LC3II in fungal phagosomes, a response that is abolished in monocytes of patients 
with CGD. Furthermore, by silencing ATG5 in human phagocytes, we demonstrated that autophagy 
protein assembly is important for maturation of A. fumigatus phagosomes and fungal clearance. 
Very important from a clinical point of view, we also discovered that corticosteroids target the 
pathway of LC3+ A. fumigatus phagosome formation by causing an early block in phosphorylation 
of Src and Syk kinases and downstream production of ROS. 
 Autophagy is a lysosomal degradation pathway that, among other immune-related actions, 
mediates clearance of intracellular pathogens via their engulfment upon escape to the cytosol 40. 
Little is known about the role of autophagy pathway in immunity against extracellular pathogens, 
including fungi. Recent studies implicating autophagy proteins in regulation of maturation of 
phagosomes containing TLR ligands prompted us to study the physiologic relevance of this 
pathway in immunity against A. fumigatus 23,24. Our initial experiments identified that fungal cell 
wall swelling is the trigger for LC3II recruitment in A. fumigatus phagosomes. Of interest, these 
studies provide a mechanistic explanation of previous observations by electron microscopy on the 
intracellular lifecycle of A. fumigatus, suggesting that fungal cell wall swelling is a prerequisite for 
efficient phagosome maturation and killing of A. fumigatus by murine macrophages 9.
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 Since β-glucan is selectively exposed at the surface of the fungal cell wall surface upon swelling 
of A. fumigatus spores 28, we tested whether this could be the trigger for LC3II recruitment in fungal 
phagosomes. By using different assays, including β-glucan enzymatic digestion, competitive 
inhibition with laminarin, and stimulation with purified β-glucan particles, we found that LC3+ 
A. fumigatus phagosome formation was dependent on cell wall β-glucan. Previous studies in 
the murine RAW macrophage cell line using zymosan, a crude fungal cell wall extract rich in 
β-glucan, reported robust LC3+ phagosome formation around zymosan particles mediated by 
TLR2 engagement 23,24. However, because RAW macrophages express low levels of the β-glucan-
sensing receptor dectin-1 41 and because zymosan is a mixture of β-glucan and TLR ligands, it was 
difficult to dissect the contribution of β-glucan sensing in LC3II recruitment. Overall, our study 
identified β-glucan as the key molecule activating recruitment of autophagy proteins in fungal 
phagosomes. 
 In a following set of experiments, we tested whether LC3+ Aspergillus phagosome formation 
was defective in monocytes of patients with the homozygous early stop-codon mutation Tyr238X 
in dectin-1 (dectin-1-/-). Indeed, we found a significant reduction in recruitment of LC3 protein in 
monocytes of dectin-1-/- patients when compared with control dectin-1+/+ monocytes infected 
with A. fumigatus. Similarly, blocking dectin-1 in monocytes of healthy individuals with the use of 
a specific Ab resulted in significant reduction in LC3+ A. fumigatus phagosomes, whereas blocking 
TLR2 and TLR4 did not affect LC3 recruitment. Our findings corroborate a recent study reporting 
that in murine dendritic cells dectin-1 activation was required for LC3II recruitment in C. albicans 
phagosomes 42. Importantly, dectin-1-/- patients are not at risk for IA in the absence of additional 
immunosuppression 20,21. In our studies, we noticed residual LC3II recruitment in A. fumigatus 
phagosomes of dectin-1-/- patients, which is suggestive of redundancy in upstream innate receptors 
implicated in antifungal autophagy responses. Although blocking of other known fungal PRRs, 
including mannose, mannan receptors, and CR3, had no significant effect on LC3+ A. fumigatus 
phagosome formation, we cannot preclude that cooperative activation of other CLRs (e.g., dectin-2, 
Mincle) may play an important role in LC3II recruitment in fungal phagosomes.
 In addition, we assessed the role of Syk in LC3II recruitment in A. fumigatus phagosomes. 
Pharmacologic inhibition of Syk almost completely abolished LC3 protein recruitment in Aspergillus 
phagosomes. Notably, inhibition of raf-1 kinase that also activates an alternative signalling pathway 
downstream of dectin-1 had no impact on LC3+ phagosome formation. Because Syk is downstream 
of many different signalling receptors 34, our finding could have broad spectrum implications on 
regulation of autophagy responses following sensing of endogenous or pathogen-related ligands. 
Importantly, a recent study in Syk-/- bone marrow chimeric mice found an indispensable role of Syk 
in intracellular killing of A. fumigatus by neutrophils and alveolar macrophages 43. An important role 
of dectin-1/Syk signalling in acidification of phagosomes containing β-glucan-coated particles has 
also recently been reported 44. In agreement, we found that inhibition of Syk impaired acidification, 
as evidenced by defective CD63 protein recruitment 45 in A. fumigatus phagosomes upon infection 
of primary monocytes and THP-1-differentiated macrophages (Figure S4).
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 NADPH oxidase-derived ROS production was recently shown to regulate recruitment of autophagy 
proteins in phagosomes of murine macrophages containing TLR or FcγR ligands 24. In agreement with 
previous studies in murine and human phagocytes demonstrating that ROS production in response to 
zymosan is dependent on activation of Syk 35, we found that ROS production was selectively induced 
in response to swollen A. fumigatus spores in a Syk-dependent fashion. Studies in monocytes of CGD 
patients also revealed a block in LC3+ A. fumigatus phagosome formation, confirming that NADPH-
derived ROS also regulate recruitment of autophagy proteins in fungal phagosomes. Because patients 
with CGD have increased susceptibility to IA 1,2,11, and macrophages of mice with mutations in NADPH 
oxidase display defective phagolysosomal fusion and killing following the uptake of A. fumigatus 
spores 10, our studies suggest that defective autophagy protein recruitment could play an important 
role for development of invasive fungal infections in CGD.
 Previous studies in murine macrophages demonstrated an important role of ATG7 and ATG5 
proteins in phagosome maturation and clearance of yeast, including S. cerevisiae and C. albicans 
23,37. We also found that silencing of ATG5 in human THP-1 macrophages did not affect the uptake 
of fungal spores, but resulted in impaired maturation of A. fumigatus phagosomes and attenuated 
killing of the fungus. In humans, there are no previous studies to suggest a link between defective 
autophagy protein function and invasive fungal disease. Because full disruption of ATG5 is lethal in 
mice 46 and human patients with homozygous loss-of-function mutations in ATG5 have not been 
described, it has been difficult to assess the direct in vivo role of autophagy in Aspergillus immunity. 
Future studies in conditional ATG5 knockout mice should define the in vivo role of autophagy in A. 
fumigatus host defence and allow studying this pathway in neutrophils and other immune cell types 
with important role in antifungal immunity. An important future direction of research is represented 
by genetic association studies of polymorphisms in autophagy genes with susceptibility to fungal 
infection, studies that could validate the present in vitro data in a clinical setting. 
 Finally, we assessed whether corticosteroids, the major risk factor for development of IA, 
target autophagy protein recruitment in A. fumigatus phagosomes. Surprisingly, we found that 
administration of a relatively low dose of corticosteroids blocked LC3 recruitment in A. fumigatus 
phagosomes within 2 hours of exposure. Because of the rapid inhibition of LC3+ A. fumigatus 
phagosome formation by hydrocortisone, we reasoned that this effect is mediated by nongenomic 
action of corticosteroids on dectin-1/Syk signalling. Notably, corticosteroids had no effect on A. 
fumigatus uptake and expression of dectin-1. Because corticosteroids have been shown to block 
tyrosine kinase phosphorylation within minutes of exposure in T-cells 39,40 and B-cells 47, we focused 
on their effects in phosphorylation of Src and Syk kinases in monocytes. Notably, we found that 
hydrocortisone almost completely inhibited phosphorylation of both Src and Syk kinases within 
minutes of exposure. Because Syk regulates ROS production in response to A. fumigatus infection, 
and corticosteroids have been shown to block ROS in macrophages during fungal infection10, we 
tested whether hydrocortisone blocked ROS production in monocytes infected with A. fumigatus. 
Indeed, hydrocortisone caused a significant reduction in ROS production following infection 
with A. fumigatus. Of interest, recent studies on T-cells demonstrate that glucocorticoids induce 
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macroautophagy prior to the induction of apoptosis, because of their ability to inhibit Src kinases 
and downstream inositol 1,4,5-triphosphate-mediated calcium signalling 48. We also found 
evidence of increased macroautophagy in monocytes pretreated with corticosteroids, an effect 
that precluded the assessment of blockade in LC3+ phagosome formation by Western blot analysis. 
Thus, our studies reveal a selective property of corticosteroids to inhibit LC3II recruitment in fungal 
phagosomes, which is regarded as a specialized form of autophagy.
 Collectively, our studies demonstrate an important physiologic role of autophagy pathway 
in restriction of intracellular growth of A. fumigatus within human phagocytes. Furthermore, our 
findings on defective antifungal autophagy as a result of impaired dectin- 1/Syk/ROS signalling 
could provide a mechanistic explanation for the defective phagocyte function in two distinct 
groups of patients with increased susceptibility for IA. Future studies are warranted to explore the 
therapeutic potential of autophagy induction in these patients and better define the in vivo role of 
autophagy in antifungal immunity.
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Figure S1 | Effect of N-acetyl-D-glucosamine (NADG) or yeast mannan pre exposure in LC3II recruitment 
in A. fumigatus phagosomes 
(A) Monocytes (2x105 cells/condition) were infected with FITC-labeled A. fumigatus swollen spores with or 
without mannan (500 μg/mL) or NADG (500 μg/mL) at a MOI 5: 1 for 1h. Cells were stained for LC3II and the 
percentages of LC3+ A. fumigatus-containing phagosomes (LC3+ Aspergillus; n > 150 per group) were quantified 
and data are presented as mean ± SEM of 2 independent experiments. (B) Monocytes (2×106 cells/condition) 
were stimulated as in (A) and levels of LC3II protein were determined.
Figure S2 | Effect of Syk and raf-1 inhibitor in LC3II phagosome recruitment in monocytes stimulated with 
purified β-glucan particles (WGP) or IgG coated latex beads
Monocytes (2×105 cells/condition) were stimulated with IgG coated beads with or without pretreatment with 
a specific Syk inhibitor (574711, Calbiochem, 1 μM) or yeast derived whole glucan particles (WGP) both at 
MOI 5: 1 for 1h. Cells were stained for LC3II and the percentages of LC3+ A. fumigatus-containing phagosomes 
(LC3+ Aspergillus; n > 150 per group) were quantified and data are presented as mean ± SEM of 3 independent 
experiments. *, P < 0.0001, paired Student’s t test.
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Figure S3 | Effect of hydrocortisone on dectin-1 expression and the uptake of FITC-labelled A. fumigatus 
spores by monocytesh
(A) Monocytes (2×105 cells/condition) from healthy individuals (n = 2) were stimulated before (0h) and after (2h) 
ex vivo exposure to hydrocortisone (20 μg/mL),infected with FITC-labelled swollen spores of A. fumigatus for 1h, 
washed three times with PBS to removed unbound spores, and the degree of internalization of FITC-labelled 
A. fumigatus spores with monocytes was immediately assessed by FACS analysis. (B) Monocytes stimulated as 
in A were stained with the use of a FITC-conjugated dectin-1 mAb or appropriate isotype control and levels of 
dectin-1 surface expression were analyzed by flowcytometry.
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Figure S4 | Syk signalling regulates acidification of A. fumigatus phagosomes
Monocytes (2×105 cells/condition) isolated from healthy individuals and THP-1 PMA-differentiated macrophages 
(105 cells/condition) were stimulated with FITC-labelled resting or swollen spores of A.fumigatus with or without 
30 min pretreatment with Chloroquine (Sigma, 100 μM) or a specific Syk inhibitor (574711, Calbiochem, 1 μM) at 
MOI 5: 1 for 1h. Cells were stained for CD63 and the percentages of CD63+ A. fumigatus-containing phagosomes 
(> 150 per group) were quantified and data are presented as mean ± SEM of 3 independent experiments. *, P < 
0.0001, paired Student’s t test.
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Aspergillus fumigatus-induced interleukin-22 is 
not restricted to a specific T-helper subset and 
is dependent on complement receptor 3
Chapter 4
Chapter 4  60 | 
Abstract
T-helper cell responses induced by Aspergillus fumigatus have been extensively investigated in 
mouse models. However, the requirements for differentiation and the characteristics of A. fumigatus-
induced human T-helper (Th) cell subsets remain poorly defined. We demonstrate that A. fumigatus 
induces Th1 and Th17 subsets in human PBMCs. Moreover, we show that the cytokine IL-22 is not 
restricted to a specific T-helper subset, in contrast to IL-17A. The pattern recognition and cytokine 
pathways that skew these Aspergillus-induced T-helper responses are TLR4- and IL-1-, IL-23-, and 
TNFα- dependent. These pathways are of specific importance for production of the cytokines IL-17A 
and IL-22. Additionally, our data reveals that the dectin-1/ spleen tyrosine kinase (Syk) pathway is 
redundant, and TLR2 has an inhibitory effect on Aspergillus-induced IL-17A and IL-22 production. 
Notably, blocking complement receptor 3 (CR3) significantly reduced Aspergillus-induced Th1 
and Th17 responses, and this was independent on the activation of the complement system. CR3 
is a known receptor for β-1,3-glucan, however blocking CR3 had significant effects on T-helper 
responses induced by heat-killed Aspergillus conidia, which have minimal β-glucan expression 
on their cell surface. Collectively, these data characterize the human T-helper subsets induced by 
Aspergillus, demonstrate that the capability to produce IL-22 is not restricted to a specific T-cell 
subset, and provide evidence that CR3 might play a significant role in the adaptive host defence 
against Aspergillus, although the ligand and its action remains to be elucidated.
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Introduction
The primary line of defence against Aspergillus fumigatus is mediated by neutrophils and other cells 
of the innate immune system 1. In addition to the innate immune response, adaptive T-helper (Th) 
responses also play a crucial role during invasive aspergillosis (IA). The Th1 response is associated 
with a protection in IA 2. However, conflicting data are reported regarding the role of Th17 responses 
in the host defence against A. fumigatus. A protective role for IL-17 is described by Werner et al. 
who showed that dectin-1-/- mice have decreased IL-17 production, and subsequently reduced 
A. fumigatus clearance 3,4. In contrast, other studies show that IL-17 promotes inflammation and 
reduces resistance to the fungal infection 5,6. Although these studies have investigated the role of IL-
17 in mice, our group has previously reported that the human host response against A. fumigatus is 
mainly driven by the Th1 response, rather than the Th17 response 7. In addition, human mononuclear 
cells have been shown to express a primarily Th1 biased cytokine profile in response to stimulation 
with Aspergillus 8, and when Th2 responses are being suppressed enhanced protective Th1 response 
develop in mice 9. Furthermore, mice are resistant to A. fumigatus when proper IL-12 dependent Th1 
responses are induced 9,10.
 Even though various reports have focused on Th1 and Th17 responses against A. fumigatus, a 
role for the cytokine IL-22, which is a characteristic cytokine of the Th17 response, has not been 
addressed in human host responses. Recently, a protective role for IL-22 was demonstrated in the 
early host defence against A. fumigatus in a murine model of invasive pulmonary aspergillosis 11. 
Furthermore, the induction of IL-22 contributes to lung pathology in a murine model of allergic 
bronchopulmonary aspergillosis (ABPA) 12. In the host defence IL-22 is primarily responsible for 
the induction of anti-microbial peptides 13 and is mainly produced by CD4+ T-cells, Natural Killer 
(NK) cells and NKT-cells 13-19. Within the CD4+ population, IL-22 is mainly produced by cells of the 
Th17 lineage 13, but also T-cells that are specialized in the production of IL-22 and TNFα; named 
Th22 cells 19.
 Still, little is known about which cells mainly produce IL-17 (IL-17A), IFNγ and/or IL-22, and which 
recognition pathways and cytokines play a role in the induction of these cytokines in response to A. 
fumigatus in humans. In the present study we investigated the A. fumigatus-induced characteristic 
T-helper cytokines IL-17, IL-22, and IFNγ in PBMCs to elucidate which human cells primarily produce 
these cytokines, and which pattern recognition receptors and cytokines are involved in the induction 
of these cytokines in response to A. fumigatus.
Experimental procedures
Healthy volunteers and patients | Blood samples from healthy controls and patients were obtained 
after written informed consent. Three patients with homozygous Y238X mutations in exon 6 of 
CLEC7A gene (the gene encoding dectin-1) provided blood samples. In these patients diminished 
dectin-1 expression and failure to induce a cytokine response to β-glucan was demonstrated 
previously 20. 
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Aspergillus | A clinical isolate of Aspergillus fumigatus V05-27, which was previously characterized 
21, was used for all stimulations. Conidia and hyphae were prepared and heat-inactivated (HI) as 
described previously 22. A concentration of 1x107/mL was used in the experiments.
β-1,3-glucan immunofluorescence of heat inactivated Aspergillus | To determine β-1,3-glucan 
expression after heat inactivation of Aspergillus. The HI conidia and hyphae were incubated for 
30 minutes with mouse anti-β-1,3-glucan (Biosupplies, Bundoora, Australia). Subsequently the 
Aspergillus was washed and antibodies directed to β-glucan that were bound to Aspergillus were 
secondarily stained by goat anti-mouse alexa488 (Invivogen) according to the protocol supplied 
by the manufacturer. Immunofluorescence was observed at 400x magnification using a Zeiss 
Axio imager M1 fluorescence microscope, equipped with MRm camera (Carl Zeiss, Sliedrecht, The 
Netherlands).
PBMC isolation | Venous blood was drawn into 10 mL EDTA tubes, and PBMCs were isolated as 
described previously 21. In brief, blood was diluted in phosphate buffered saline (PBS) (1:1) and 
fractions were separated by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) density 
gradient centrifugation. Cells were washed twice with PBS and resuspended in RPMI-1640 culture 
medium (Gibco, Invitrogen, Breda, The Netherlands) supplemented with 10 µg/mL gentamicin, 
10mM L-glutamine and 10mM pyruvate (Gibco). The cells were counted using a particle counter 
(Beckmann Coulter, Woerden, The Netherlands) and the cell concentration was adjusted to 5x106/
mL.
CD4/CD56 cell depletion | To deplete the CD56 or CD4 cells from isolated PBMCs, cells were labelled 
using magnetic beads coated with anti-CD56 or anti-CD4 (MACS Miltenyi, Bergisch Gladbach, 
Germany). Subsequently, the cells were depleted over a depletion column according to the protocol 
supplied by the manufacturer. As control for the isolation procedure PBMCs were also runned over 
the columns without labelling with magnetic beads.
PBMC stimulation | PBMCs were plated in 96-well round-bottom plates (Corning, NY, USA) at a 
concentration of 2.5x106/mL in a volume of 200 µL. They were either not stimulated or stimulated 
with 1x107/mL HI conidia or hyphae for 24 hours or 7 days at 37°C and 5% CO2. All stimulations were 
performed in medium containing 10% human serum, which was obtained from a serum pool of 
healthy volunteers.
 Pattern recognition receptors were inhibited in PBMCs by pre-incubation for 1 hour with specific 
inhibitors. LPS derived from Bartonella quitana was used to block TLR4 at a final concentration of 20 
ng/mL 23. B. quitana LPS was extracted and purified as described previously 24. Mouse anti-humanTLR2 
(eBioscience, Halle-Zoersel, Belgium) and control mouse IgG1 (eBioscience), anti-human integrin β2 
(αCR3) and control goat IgG (R&D systems Minneapolis, MN, USA) were used in a final concentration 
of 10 μg/mL. Laminarin was kindly provided by Professor David Williams of Tennessee University 
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and was used in a final concentration of 50 ng/mL to inhibit dectin-1. Spleen tyrosine kinase (Syk) 
kinase inhibitor was purchased from Calbiochem (Merck, Darmstadt, Germany) and was used in a 
concentration of 50 nM. In order to check the blockade of the PRRs, PBMCs were stimulated with 
the TLR4 ligand LPS (10 ng/mL) from Escherichia coli serotype O55:B5 (Sigma Chemical Co, St Louis, 
MO, USA); or with the TLR2 ligand Pam3Cys (1 μg/mL) (EMC microcollections, Tübingen, Germany). 
Inhibition of dectin-1 and Syk was validated by stimulation with HI C. albicans (1x106/mL). After 24 
hours of stimulation at 37°C and 5% CO2 IL-1β was measured by ELISA. All blockades resulted in a 
significant reduction of cytokine production (Figure S1A, B).
 The cytokine pathways of IL-1, IL-23 and TNFα were investigated using supplementation of 
the cultures with recombinant human (rh) IL-23 (50 ng/mL) and rhTNFα (10 and 100 ng/mL) (R&D 
Systems). IL-1 receptor signalling was blocked by its natural receptor antagonist (Ra) IL-1Ra (10 μg/
mL) (Amgen, Inc., Thousand Oaks, CA, USA), and IL-23 was blocked with mouse anti-human IL-23p19 
(10 μg/mL) (R&D systems). sTNFRII (Enbrel) and human anti-human TNFα (Humira) were kindly 
provided by Dr. Renoud Marijnissen and Dr. Marije Koenders of the department of Rheumatology 
Radboud University Nijmegen Medical Centre the Netherlands, and were used to block TNFα in a 
final concentration of 100 μg/mL.
Cytokine measurements | IL-17A, IL-22, IFNγ, IL-1β and IL-23 were measured using commercially 
available ELISAs (R&D systems or eBioscience) according to the protocol supplied by the 
manufacturers.
Intracellular IL-17, IL-22, and IFNγ flowcytometry | Following 7 days stimulation, PBMCs were 
stimulated 4-6 hours with PMA (50 ng/mL) (Sigma-Aldrich), ionomycin (1 μg/mL) (Sigma-Aldrich) 
and Golgiplug (BD Biosciences, Breda, the Netherlands) according to the protocol supplied by the 
manufacturer. Cells were stained extracellular using PeCy7-conjugated anti-CD4 (BD Biosciences), 
PeCy7-conjugated anti-CD8 (Biolegend, San Diego, CA, USA) or PeCy7-conjugated anti-CD56 
(Beckman Coulter) antibody. Subsequently the cells were fixed and permeabilized with Cytofix/
Cytoperm solution (eBioscience) according to the protocol supplied by the manufacturer. Following 
permeabilization the cells were stained intracellular with alexa647-conjugated anti-IL-17 (BD 
Biosciences), PE-conjugated anti-IL-22 (R&D systems) and FITC-conjugated anti-IFNγ (eBioscience) 
according to the protocol supplied by the manufacturers. The cells were measured on a FC500 
flowcytometer (Beckman Coulter) and the data were analysed using CXP analysis software v2.2 
(Beckman Coulter).
Statistical Analysis | Differences in IL-17, IL-22, and IFNγ production and the percentage of CD4+ cells 
between the medium and Aspergillus stimulated samples were analysed with the Mann-Whitney-U 
test. Data of stimulations with and without inhibitors of PRRs, cytokines, or cytokine inhibitors 
were subjected to statistical analysis with the Wilcoxon signed rank test. A p-value of <0.05 was 
considered statistically significant, with p<0.05 = *, p<0.01 = **, and p<0.001 = ***. All experiments 
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were performed at least twice and data represent cumulative results of all experiments performed 
and are presented as mean ± standard error of the mean (SEM) unless indicated otherwise. Data 
were analysed using GraphPad Prism v5.0. The proportional Venn diagram was drawn using the 
eulerAPE application v2.0.3. 25,26.
Results
The pro-inflammatory adaptive cytokine response to A. fumigatus
We investigated the capacity of A. fumigatus conidia and hyphae to induce the cytokines IL-17A, 
IL-22 and IFNγ. Stimulation with conidia and hyphae induced a significant production of the Th1 
cytokine IFNγ in human PBMCs, whereas IL-17A was induced in low amounts. Both conidia and 
hyphae also induced IL-22 in human PBMCs (Figure 1A). 
 To determine which cell populations expand after stimulation with Aspergillus, we performed 
flowcytometry analysis. We initially focused on CD4+ cells, since T-helper cells are generally 
considered to be the main producers of IL-17A, IL-22 and IFNγ. PBMCs that were not stimulated 
with conidia showed relatively small populations of IL-17A+ and IL-22+ CD4 cells (1.2% SD 0.7 and 
1.7% SD 0.9 respectively), whereas the IFNγ+ CD4 cell population was 10.7% (SD 3.9). Stimulation 
with conidia induced a significant expansion of the IL-17A+, IL-22+ and IFNγ+ CD4 T-cell population 
(Figure 1B). By gating on the Aspergillus-induced IL-17A+, IL-22+ and IFNγ+ cells we observed that 
the majority of IL-17A+ and IL-22+ cells were CD4+ cells. However, approximately half of the IFNγ+ 
cells were negative for CD4 (Figure 1C). Subsequently, extracellular staining with the NK-cell marker 
CD56 and the cytotoxic T-cell marker CD8 revealed that a significant proportion of to the IFNγ+ 
population was CD56+ and CD8+ (figure 1D). The remainder of the IL-17A+ cells was positive for CD8+ 
only. No CD56+ IL-17A+ cells were found (figure 1D). However, despite the fact that a fraction of the 
IL-22+ cells was positive for CD8 or CD56, still approximately 9% of the IL-22+ was negative for all the 
investigated surface markers (figure 1D). Interestingly, we found that the populations of CD8+ and 
CD56+ cells that were IFNγ+ were already present in unstimulated PBMCs, and did not expand upon 
stimulation with A. fumigatus (figure 1E). 
CD4 cells are the primary cellular source of Aspergillus-induced IL-17A, IL-22 and IFNγ
To demonstrate that CD4+ cells are the major contributors to Aspergillus-induced IL-17A, IL-22 and 
IFNγ, we depleted CD4+cells from PBMCs and compared this with normal PBMCs. Depletion of CD4+ 
cells resulted in a complete loss of IL-17A production. Furthermore, IL-22 and IFNγ production were 
also significantly reduced, in most donors, to undetectable levels (figure 1F). Since several reports 
indicate that NK-cells can produce IL-22 14,16-18, we also investigated the contribution of CD56+ cells. 
Depletion of CD56+ cells had no significant effect on IL-17A, IL-22 and IFNγ production (Figure 1G).
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Figure 1 | Induction of IL-17A, IL-22, and IFNγ by A. fumigatus, and the cellular source of these cytokines
(A) IL-17A, IL-22 and IFNγ concentrations in culture supernatants of PBMCs (2.5x106/mL) (n=6 donors) that were 
stimulated with 107/mL HI A. fumigatus conidia or hyphae in the presence of 10% human serum. (B) Intracellular 
IL-17A, IL-22 and IFNγ in CD4 T-cells in the PBMCs of the experiments shown in panel A. (C) The percentage of 
CD4- and CD4+ cells within the IL-17, IL-22 and IFNγ positive populations in Aspergillus-stimulated PBMCs of the 
experiments shown in panel a. (D) Assessment of surface markers CD56 and CD8 to elucidate the contribution of 
different cell types to the population of IL-17A+, IL-22+ and IFNγ+ cells. (E) The expansion of CD8+ IFNγ+ and CD56+ 
IFNγ+ determined by comparing unstimulated to A. fumigatus stimulated PBMCs (n=4 for CD8 and n=5 for CD56). (F, 
G) IL-17A, IL-22 and IFNγ concentrations in culture supernatants of PBMCs, (F) PBMCs depleted of CD4+ cells (n=10 
donors for IL-17, n=12 donors for IL-22 and n=11 for IFNγ), (G) PBMCs depleted of CD56+ cells (n=6 donors) that 
were stimulated with 107/mL HI A. fumigatus conidia or hyphae in the presence of 10% human serum. The Wilcoxon 
signed rank test was used to determine whether the means were significantly different. 
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IL-22 is not restricted to a specific T-helper subset
Since CD4+ cells were the major population that were IL-17A+, IL-22+ and IFNγ+ we investigated 
the phenotypic diversity of these CD4+ T-cells by focusing on the expression of single or multiple 
cytokines. Stimulation with HI conidia resulted in the induction of IL-17/IL-22 and IL-22/IFNγ 
double positive CD4 cells (Figure 2A). Whereas we found a relatively small percentage of IL-17/
IFNγ double positive CD4+ T-cells. Strikingly, the cytokine IL-22 was not specifically expressed in a 
certain subset, but could be found in both the IL-17 and IFNγ positive T-cell populations. Moreover, 
Aspergillus induces IL-17/IL-22/IFNγ triple positive CD4+ T-cells (Figure 2A). To determine whether 
the IL-22+ cells in our experiments match the phenotype of previously-described Th22 cells we 
assessed whether these cells co-expressed TNFα, a characteristic of Th22 cells 15,19,27. Indeed, the 
majority of IL-22+ cells co-expressed TNFα (Figure 2B). Additionally, we investigated how IL-1 and 
TNFα signalling can influence the IL-17 and IL-22 populations. Blocking IL-1 resulted in significantly 
decreased IL-17+ and IL-22+ populations and a trend towards decreased IL-17/IL-22+ cells, whereas 
blocking TNFα with sTNFRII only significantly decreased the number of IL-22+ cells (Figure 2C).
Figure 2 | Phenotypic diversity of IL-17A, IL-22 and IFNγ positive CD4 T-cells
Proportional Venn diagrams of IL-17A, IL-22, and IFNγ positive CD4 cell populations of (A) medium- and (B) 
Aspergillus conidia-stimulated PBMCs. Overlap between the ellipses represent double and triple positive CD4 
cells. (C) Expression of TNFα within the IL-22+ cell population of Aspergillus-stimulated PBMCs. (D) IL-17+, IL-17/
IL-22+ and IL-22+ CD4 cell populations of Aspergillus conidia- stimulated PBMCs (n=6 donors) in the presence or 
absence of IL-1Ra or sTNFRII (Enbrel) (Data represented as fold change from stimulation in absence of inhibitor).
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Differential roles for TLR2 and TLR4 in Aspergillus-induced T-cell responses
We investigated the role of the Toll-like receptors in the induction of the IL-17, IL-22, and IFNγ 
responses to A. fumigatus, as TLR2 and TLR4 have been associated with the recognition of A. fumigatus 
28-32. PBMCs were pre-incubated with B. quintana LPS to block TLR4, and afterwards stimulated with 
conidia or hyphae. Pre-incubation with B. quintana LPS alone did not result in any cytokine induction 
in PBMCs (Figure S1C). Blockade of TLR4 resulted in a significantly reduced IL-22 production in 
conidia-stimulated PBMCs and reduced IL-17 and IL-22 production in hyphae-stimulated PBMCs, 
whereas IFNγ production was not affected by TLR4 blockade (Figure 3A). Blocking TLR2 resulted 
in an upregulation of IL-17 and IL-22 production by conidia stimulated PBMCs and a trend towards 
upregulation of IL-22 in hyphae-stimulated PBMCs (Figure 3B). 
Redundant role for dectin-1/Syk signalling in Aspergillus-induced T-cell responses
Dectin-1 has been associated with the defence against Aspergillus in numerous reports 3,4,33-38. 
Gessner and co-workers described that dectin-1 deficient mice lack the ability to induce IL-22 
early in infection, which causes a decreased ability to induce antimicrobial peptides, resulting in 
an increased fungal burden and mortality 11. To see whether the dectin-1/Syk signalling pathway is 
involved in the induction of IL-22 production by human T-cells, PBMCs were stimulated with conidia 
or hyphae in the presence of laminarin, a dectin-1 inhibitor. Blocking dectin-1 with laminarin did 
not result in any significant effect on hyphae or conidia-induced IL-17A, IL-22, or IFNγ (Figure 4A). 
Figure 3 | Differential roles for TLR4 and TLR2 in Aspergillus induced T-cell responses
(A) IL-17, IL-22 and IFNγ were measured in culture supernatants of PBMCs (2.5x106/mL) stimulated with 107/mL 
A. fumigatus conidia (n=7 for IL-17, n=8 for IL-22, and N=9 for IFNγ) or hyphae (n=7 for IL-17, n=7 for IL-22, and 
n=11for IFNγ) for 7 days, that were pre-incubated with B. quintana LPS to block TLR4 and were compared to 
pre-incubation with culture medium. (B) Similarly, TLR2 was blocked by 1 hour pre-incubation using mouse anti-
human TLRf2 monoclonal antibody which was compared to the isotype control (n=6).
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However, there was one donor with unusual high IL-17 production in response to hyphae, which 
we excluded from analysis. It should be noted that the IL-17 production in this donor was almost 
completely blocked with laminarin. 
 We investigated whether Aspergillus conidia and hyphae expressed β-1,3-glucan on the surface 
by immunofluorescence staining. We found that β-1,3-glucan was only minimally present on a few 
conidia, which is in line with reports demonstrating that resting conidia do not express β-glucan 
34. In contrast, hyphae abundantly exposed beta-glucan (figure 4B). To confirm that dectin-1/Syk 
signalling does not play a significant role in the induction of IL-17A, IL-22 or IFNγ by Aspergillus, 
PBMCs of three patients with the homozygous mutation Y238X in dectin-1 (lacking dectin-1 
expression on the membrane of the cell 20) were stimulated with conidia and hyphae. PBMCs from 
these patients demonstrated either a similar or higher cytokine response to Aspergillus compared to 
PBMCs from a healthy control (Figure 4C).
 Syk is the downstream signalling kinase of dectin-1 and other C-type lectin receptors (CLRs) 
34. Although, hyphae-induced IL-17 production tended to decrease upon blocking of dectin-1, 
inhibition of Syk demonstrated no difference in IL-17A, IL-22, or IFNγ production by Aspergillus 
stimulated PBMCs (Figure 4D). 
The role for complement receptor 3 (CR3) for Aspergillus-induced T-cell responses
Recently, CR3 was demonstrated to recognize β-glucan, which leads to downstream signalling 
and activation of granulocytes 39. Moreover, CR3 has also been associated with phagocytosis of 
pentraxin3 opsonised Aspergillus 40. We investigated whether CR3 was involved in the induction 
of IL-17A, IL-22, and IFNγ by A. fumigatus. Blockade of CR3 resulted in a significant reduction of IL-
17A, IL-22 and IFNγ responses induced by conidia. In response to hyphal stimulation, only IL-17A 
and IL-22 were significantly inhibited by blocking of CR3 (Figure 4E). Since the primary role of CR3 
is recognition of C3 opsonised structures, we investigated whether active serum complement was 
required for Aspergillus-induced IL-17A, IL-22 and IFNγ. When human serum was heat-inactivated 
prior to stimulation, no differences in IL-17A, IL-22 and IFNγ induction were observed (Figure 4F). 
Figure 4 | Redundant role of dectin-1 and Syk signalling in Aspergillus-induced IL-17A, IL-22, and IFNγ
(A) IL-17A, IL-22 and IFNγ in culture supernatants of PBMCs (2.5x106/mL) with 107/mL A. fumigatus conidia or 
hyphae for 7 days, that were pre-incubated with laminarin to block dectin-1, (n=8 for conidia and n=5 for hyphae). 
(B) Bright field (BF) and Immunofluorescence images after staining with mouse anti-β-1,3-glucan conjugated 
with goat anti-mouse IgG alexa488. HI Aspergillus conidia (left panels) and HI Aspergillus hyphae (right panels) at 
400x magnification and an exposure time of 900ms for fluorescence pictures. (C) IL-17A, IL-22 and IFNγ in culture 
supernatants of PBMCs (2.5x106/mL) from three patients with a homozygous dectin-1 Y238X polymorphism and 
two healthy controls without the polymorphism were stimulated with A. fumigatus conidia or hyphae for 7 days 
and IL-17, IL-22, and IFNγ were measured in the culture supernatant. IL-17, IL-22 and IFNγ in culture supernatants 
of PBMCs (2.5x106/mL) stimulated with 107/mL A. fumigatus conidia or hyphae in presence or absence of (D) Syk 
inhibitor (n=11 for conidia and n=6 for hyphae), or (E) goat anti-CR3 monoclonal antibody or an isotype control 
(conidia n=11 or hyphae n=6 for IL-17 and IL-22, n=8 for IFNγ). (F) IL-17, IL-22 and IFNγ in culture supernatants 
of PBMCs (2.5x106/mL) (n=6 donors) with 107/mL A. fumigatus conidia for 7 days in the presence of 10% human 
serum or 10% human serum that was heat inactivated for 30 minutes at 56°C. Differences of the means were 
analysed for significance using the Wilcoxon Signed Rank test.
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The role of IL-1 and IL-23 in A. fumigatus-induced IL-17 and IL-22
The predominant cytokine produced by human PBMCs in response to Aspergillus was IL-22, while the 
IL-17A production was relatively low (Figure 1A). To elucidate the reason for the low IL-17A release 
by Aspergillus stimulated PBMCs we focused on the cytokines that regulate the Th17 response. Both 
IL-1β and IL-23 have been associated with the induction and maintenance of the Th17 response in 
humans 41. Additionally, a critical role for IL-23 in the induction of IL-22 was observed in the early 
response against A. fumigatus 11. Interestingly, IL-23 induction by PBMCs stimulated with conidia and 
hyphae was below the detection limit of the ELISA, while IL-1β production was detectable (Figure 
5A). To investigate whether the absence of IL-23 production is responsible for the low production of 
IL-17 in response to Aspergillus, IL-23 was blocked with an anti-human IL-23p19 antibody. Compared 
to stimulation with the isotype control, IL-17A production was reduced to undetectable levels 
although this was not statistically significant, while IL-22 production was not affected (Figure 5B). 
Addition of IL-23 significantly increased IL-17A production but did not increase IL-22 production 
(Figure 5C). Blocking IL-1 signalling with IL-1 receptor antagonist (IL-1Ra) reduced IL-17A and IL-22 
induction significantly (Figure 5D). These results suggest that IL-17A production requires both IL-1β 
and IL-23, whereas IL-22 production requires only IL-1β. 
Role of TNFα in A. fumigatus-induced IL-17 and IL-22
Although IL-1β and IL-23 play key roles in the induction of T-helper responses by A. fumigatus, it 
cannot be excluded that other cytokines also play a role in the induction of the cytokines IL-17 and 
IL-22. To investigate the role of TNFα in A. fumigatus-induced IL-17 and IL-22 we stimulated PBMCs 
with HI conidia in the presence of 10 or 100 ng/mL TNFα. Both IL-17 and IL-22 production were 
dose dependently increased in the presence of TNFα when compared to stimulation with Aspergillus 
alone (Figure 6A). To further investigate the role of TNFα we stimulated PBMCs with HI conidia in the 
presence of sTNFRII (Enbrel) or human anti human TNFα (Humira), two drugs that are used to block 
TNFα signalling in IL-17 related diseases like rheumatoid arthritis (RA) 42. Both blockers significantly 
reduced the IL-17 and IL-22 response (Figure 6B).
Figure 5 | Role of IL-23 and IL-1 in A. fumigatus-induced IL-17A and IL-22
IL-1β and IL-23 concentrations in PBMCs (2.5x106/mL) (n=7) that were stimulated with HI A. fumigatus conidia or 
hyphae 37°C and 5% CO2 for 24 hours (A). IL-17 and IL-22 were measured in the culture supernatants of PBMCs 
(2.5x106/mL) stimulated with HI A. fumigatus conidia in the presence or absence of 10 μg/mL IL-1Ra (C) (n=7 for 
IL-17 n=12 for IL-22), IL-23 (D) (n=12), or anti-IL-23p19 (E) (n=5 for IL-17 n=6 for IL-22). Differences of the means 
were analysed for significance using the Wilcoxon Signed Rank test.
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Discussion
In the present study we demonstrate that CD4+ T-cells are the main producers of IL-17, IL-22 and 
IFNγ in human PBMCs upon Aspergillus stimulation. Interestingly, CD4 T-helper cells that are capable 
of producing IL-22 after Aspergillus stimulation are not a distinct characteristic subset, but can have 
a Th1, Th17, or Th22 signature. Similar to IL-17, the production of IL-22 induced by Aspergillus is 
dependent on TLR pathways. While the TLR4 pathway contributing to the production of these 
cytokines, the TLR2 has an inhibitory effect on Aspergillus-induced IL-17 and IL-22 production. In 
contrast, the TLR2 and TLR4 pathway do not modulate IFNγ production by human PBMCs that are 
stimulated with conidia. Rather unanticipated, the blockade of the dectin-1/Syk pathway or absence 
of the dectin-1 receptor did not significantly affect IL-17, IL-22 or IFNγ production induced by 
Aspergillus. In the current study, CR3 is the only receptor that is important for induction of all three 
cytokines IL-17, IL-22 and IFNγ, and therefore the CR3 pathway could specifically play an important 
role in the host defence against Aspergillus. Furthermore, we provided evidence that IL-17 and IL-22 
responses induced by Aspergillus are dependent on the IL-1 and TNF pathway. 
 Using flowcytometric analysis of PBMCs and depletion of CD4 or CD56 cell subsets, we 
determined that the cytokines IL-17, IL-22 and IFNγ are primarily produced by CD4+ T-cells. Within 
the CD4+ T-cell populations diverse intracellular cytokine expression was detected. We detected IL-
17 single positive and IL-17/IL-22 double positive CD4 cells that match the classically described Th17 
cells 13 and IFNγ positive CD4 cells that match the classical Th1 type. Half of the IFNγ+ cells were 
CD4+ cells, whereas the rest of the IFNγ+ cells were negative for this T-helper-cell marker. We were 
able to demonstrate that a significant number of natural killer (NK) cells express IFNγ, which is in 
line with a previous report that demonstrated that NK cells play an important role in the antifungal 
response to A. fumigatus by releasing IFNγ 43. However, depletion of CD56+ cells did not alter IFNγ 
responses, suggesting that NK cells are not important for the production of IL-22 upon stimulation 
with Aspergillus. Furthermore, the IFNγ+ CD56+ cells did not expand upon stimulation with 
Figure 6 | Role of TNFα in A. fumigatus-induced IL-17A and IL-22
(A) IL-17A and IL-22 were measured in the culture supernatants of PBMCs (2.5x106/mL) (n=10 donors) stimulated 
for 7 days with 107/mL HI A. fumigatus conidia with or without recombinant human TNFα. (B) TNFα was blocked 
by pre-incubation of PBMCs (n=11) for 1 hour with sTNFRII (Enbrel) or human anti-TNFα (Humira). Subsequently 
the capacity to induce IL-17A and IL-22 was investigated by 7 days stimulation with HI A. fumigatus conidia. 
Differences of the means were analysed for significance using the Wilcoxon Signed Rank test.
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Aspergillus. These data suggest that, in the setting of PBMCs, NK cells do not contribute to the IFNγ 
response to Aspergillus. We found that after stimulation with Aspergillus IL-17/IFNγ double positive 
CD4+ cells were present in low numbers. Therefore, our results demonstrate that the polarization of 
T-helper responses induced by Aspergillus in vitro is different from that induced by the commensal 
fungus Candida albicans 44. It was demonstrated that C. albicans induces a T-cell polarization with 
high numbers of IL-17/IFNγ double positive T-helper cells. Here we demonstrate that Aspergillus 
stimulation leads to low numbers of this T-cell subset. This is of interest, since these double positive 
cells have been linked to autoimmunity 44.
 We also observed IL-22 single positive cells that might fit the description of Th22 cells 15, as these 
cells co-expressed TNFα. In addition, large numbers of IFNγ/IL-22 double positive CD4 cells and 
even IL-17/IL-22/IFNγ triple positive CD4 cells are present. This is to our knowledge the first study 
that demonstrates that Aspergillus can induce single IL-22+ and IFNγ/IL-22 double positive cells. It 
remains to be elucidated whether these specific subsets contribute to pathology or protection. A 
study in mice revealed an important role for IL-22 in the early defence against Aspergillus 11, while 
another study demonstrates contribution to pathology in an allergic aspergillosis model 12. In the 
current study, we observed that the pro-inflammatory adaptive cytokine response to A. fumigatus 
is dominated by IL-22, and the primary cellular sources were CD4+ cells. In contrast to the study 
performed by Gessner and co-workers, our model revealed that IL-22 production by Aspergillus-
stimulated PBMCs was independent of IL-23. We found that the innate cytokines IL-1 and TNFα 
played a crucial role in the induction of IL-22, which is in agreement with earlier studies 45. Previously, 
it was demonstrated that the IL-22 response also dominated over the IL-17 response in patients 
with pulmonary tuberculosis 46. Moreover, IL-22 was shown to be important in the defence against 
multiple pulmonary pathogens including Mycobacterium tuberculosis 14,46,47, Klebsiella pneumonia 48, 
and influenza A virus 16. Since the host defence against all these pulmonary pathogens strongly relies 
on IL-22, we hypothesize that IL-22 plays a pivotal role in the human anti-Aspergillus pulmonary host 
defence. 
 Although TLR2 and TLR4 play an important role in innate immune responses against A. fumigatus 
28-32, the role of these receptors in the induction of the adaptive immune responses such as the IL-
22 response against Aspergillus remains to be established. Here we demonstrate that TLR4 plays 
a role in the induction of IL-17 and IL-22 in response to Aspergillus. In contrast, blockade of TLR2 
resulted in higher IL-17 and IL-22 production. Therefore, this might indicate that TLR2 plays a role 
in an inhibitory pathway for the induction of IL-17 and IL-22. These findings are in line with several 
studies that report an anti-inflammatory role for TLR2 through Th2 skewing 49,50, the induction of 
anti-inflammatory cytokines by TLR2, and the TLR2-dependent induction of regulatory T-cells 51. 
Interestingly, TLR2 is a negative regulator of the Th17 response in a murine pulmonary infection 
model with Paracoccidioides brasiliensis 52, supporting a general role of TLR2 as a negative regulator 
of Th17 polarization of fungal infections.
 The fact that the β-glucan receptor dectin-1 and its downstream kinase Syk play a redundant 
role in the induction of IL-17, IL-22, and IFNγ by hyphae, which abundantly express β-1,3-glucan, is 
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rather unanticipated, since the dectin-1 pathway plays an important role in the host defence against 
invasive aspergillosis 35,53. In line with our results, it has been demonstrated that IL-17 production 
by PBMCs with the dectin-1 Tyr238X polymorphism is not different from PBMCs that do not have 
this SNP 35. Notably, this SNP influences innate pro-inflammatory cytokines produced by PBMCs in 
response to A. fumigatus 35,53. In mice, dectin-1 deficiency results in an increased susceptibility to A. 
fumigatus 3, that has been linked to disability to induce protective cytokines like IL-17 3 and IL-22 11. 
Although it is evident that dectin-1 plays a role in the induction of IL-17 and IL-22 in mice and that it 
plays a role in the innate host defence against invasive aspergillosis in humans, our studies suggest 
that IL-17, IL-22 and IFNγ production by CD4+ T-cells in the human host response to Aspergillus 
conidia is not predominantly mediated by dectin-1. 
 CR3 is a β2-integrin (CD11b/CD18) that is expressed by monocytes and neutrophils 54,55. This 
receptor can recognize self-molecules such as complement, but it can also recognize PAMPs from 
pathogens such as LPS from E. coli 56. CR3 plays a role in phagocytosis and induction of cytokine 
responses 57. Here we show that CR3 is involved in modulating T-helper cytokine responses induced 
by A. fumigatus. To date, the modulation of Th17 and Th1 responses induced by fungi has not been 
linked to CR3 and future studies are required to further characterize its role in fungal infection. 
Interestingly, CR3 has been shown to bind β-glucan, which can have modulatory effects on the 
immune response, suggesting that fungal components can modulate pro-inflammatory T-helper 
responses (Th1 and Th17) through CR3 58. Immunofluorescent staining of β-glucan revealed a very 
low expression on Aspergillus conidia, therefore β-glucan seems to be unlikely the main CR3 ligand 
in the recognition of Aspergillus. 
 In the present study we compared the IL-1β and IL-23 cytokine profiles produced by PBMCs 
stimulated with A. fumigatus and related this to the induction of IL-17 and IL-22. Aspergillus induced 
relatively low IL-17 levels, which was rather surprising since A. fumigatus induced a significant number 
of IL-17 positive CD4 cells. These observations are in line with a previous report, which demonstrates 
that A. fumigatus is a poor inducer of IL-17 and is even capable of inhibiting the IL-17 response by 
interfering with the tryptophan metabolism 7. One possible explanation for the low IL-17 production 
could be that Aspergillus does not induce a significant IL-23 response, since IL-23 production was 
undetectable in A. fumigatus stimulations. Interestingly, supplementation of IL-23 to the Aspergillus 
stimulated PBMCs boosted the IL-17 response, which is in line with an earlier report which showed 
that IL-23 can augment IL-17 responses in Aspergillus-infected mice 3. Although, Aspergillus did not 
induce IL-23 in PBMCs, it was found earlier that DCs induce high levels of IL-23 upon stimulation 
with Aspergillus and that these DCs can polarize towards both Th1 and Th17 responses 37,59. However, 
when we used monocyte-derived DCs instead of PBMCs in our experimental setup we were not able 
to detect any IL-23 or IL-1β in response to Aspergillus (data not shown). We further demonstrate that 
Aspergillus-induced IL-17 and IL-22 responses were dependent on IL-1. Notably, although IL-1β was 
present and the Th17 response was almost completely dependent on the IL-1 pathway, Aspergillus 
did not abundantly induce IL-17/IFNγ+cells. This is in contrast with a previous study that suggests 
that IL-1β is responsible for the development of IL-17+IFNγ+ T-helper cells in response to the fungal 
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pathogen C. albicans 44. These data provide evidence that next to IL-1, another pathway, such as the 
IL-23 pathway, must be triggered in order to induce IL-17+IFNγ+ cells. 
 Another striking observation is the role of TNF in modulating pro-inflammatory Th17 responses 
induced by A. fumigatus. Blocking TNF lowered the IL-17 production in response to A. fumigatus, 
moreover the effects were most prominent on IL-22 production. These observations are in line with 
previous reports, which demonstrated that IL-22 production can be triggered by TNFα 15,60,61, and is 
in line with the observation that anti-TNFα treatment can reduce IL-17 levels in patients 42. So far, 
the role of TNFα in pathogen-induced IL-22 production has not been described. This observation 
could be highly relevant given the widespread use of anti-TNF therapy. Notably, the use of anti-TNF 
62-64 and polymorphisms in TNFR1 or decreased TNFR1 mRNA expression 64,65 have been linked to 
increased susceptibility to invasive aspergillosis, underlining the importance to identify the impact 
of TNF blockade on anti-Aspergillus host responses, such as lowering IL-22 production in response 
to A. fumigatus as described in the present study. 
 In conclusion, we demonstrate that the T-helper cytokines IL-17, IL-22, and IFNγ in response to 
A. fumigatus are primarily produced by CD4 T-cells, and that these cytokines are not limited to a 
specific subset but can be produced by a variety of polarized T-helper subsets. TLR4 and CR3 and 
the cytokines IL-1, IL-23, and TNFα are of specific importance for Aspergillus-induced IL-17 and IL-22, 
whereas we observed that the dectin-1/Syk pathway is redundant for this response. Collectively, 
these findings contribute to a better understanding of the human adaptive host defence against A. 
fumigatus, and provide new knowledge that contributes to the development of targeted adjunctive 
immunotherapeutic regiments in patients with invasive aspergillosis.
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Figure S1 | 
(A,B) IL-1β levels in culture supernatants of PBMCs (2.5x106/mL) (n=6) stimulated with 1μg/mL Pam3Cys, 10ng/
mL LPS or 1x106/mL heat-killed Candida albicans in the presence or absence of TLR2 neutralizing antibodies 
(10 μg/mL), isotype control, Bartonella quintana LPS (20ng/mL), Laminarin (50 ng/mL) or Syk inhibitor (50mM) 
respectively (C) IL-17, IL-22 and IFNγ levels in culture supernatants of PBMCs (2.5x106/mL)(n=8 donors) stimulated 
with 20 ng/mL LPS from Bartonella quintana. Data were analysed using the Wilcoxon signed rank test and are 
presented as mean ± SEM (*=p<0.05).
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Abstract
Background | Allergic bronchopulmonary aspergillosis (ABPA) is characterized by an exaggerated 
T-helper (Th)2 response to Aspergillus fumigatus, but the immunological pathways responsible for 
this effect are unknown. 
Objective | The aim of this study was to decipher the pattern recognition receptors (PRRs) and 
cytokines involved in the Aspergillus-specific Th2 response, and to study Aspergillus-induced 
responses in healthy controls and ABPA patients. 
Experimental procedures | Peripheral blood mononuclear cells (PBMCs) were stimulated with 
heat-killed Aspergillus conidia, various other pathogens, or PRR ligands. PRRs and cytokine pathways 
were blocked with PRR blocking reagents, sTNFRII (Etanercept) or anti-TNFα (Adalimumab), IL-1Ra 
(anakinra), or recombinant human IFNγ (Immukine). ELISA and flowcytometry were used to analyze 
cytokine responses.
Results | Aspergillus was the only pathogen that stimulated the Th2 cytokines IL-5 and IL-13, 
while Gram-negative bacteria, Gram-positive bacteria, Candida albicans, chitin, β-glucan, or Toll-
like receptors (TLR) ligands did not. Depletion of CD4+ cells abolished IL-13 production. Blocking 
complement receptor 3 (CR3) significantly reduced IL-5 and IL-13, while blocking TLR2, TLR4 or 
dectin-1 had no effect. ABPA patients displayed increased Aspergillus-induced IL-5 and IL-13, and 
decreased IFNγ production compared to healthy controls. All biological agents tested showed the 
capability to inhibit Th2 responses, but also decreased Aspergillus-induced IFNγ.
Conclusions | Aspergillus conidia are unique in triggering Th2 responses in human PBMCs, through 
a CR3-dependent pathway. ABPA patients display a significantly increased Aspergillus-induced Th2/
Th1-ratio that can be modulated by biologicals. These data provide a rationale to explore IFNγ 
therapy in ABPA as a corticosteroid-sparing treatment option, by dampening Th2 responses and 
supplementing the IFNγ-deficiency at the same time.
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Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction against the ubiquitous 
fungus Aspergillus fumigatus 1. Innate immune cells, such as lung epithelia cells or alveolar 
macrophages initiate this inflammatory reaction 2. These innate immune cells sense fungi through 
pattern recognition receptors (PRRs), like Toll-like receptors (TLRs), C-type-lectin receptors (CLRs) 
or NACHT-LRR-receptors (NLRs) 3. Activation of these receptors by Aspergillus leads to induction of 
cytokines, recruitment of other immune cells, and can eventually trigger adaptive immune responses 
such as T-helper (Th) responses. A robust induction of the Th1 response during Aspergillus infection 
is associated with protection and successful clearance 4-6, while elevated Th2 responses impairs 
fungal clearance 7, 8. Exaggerated Th2 responses are being held responsible for the detrimental 
inflammatory reaction observed in ABPA, namely eosinophilia, increased mucus production and 
immunoglobulin class switching to IgE. This inflammatory reaction subsequently results in airway 
hyper-responsiveness with typical asthmatic symptoms like bronchial obstruction, coughing and 
wheezing 9, 10. The current treatment for ABPA is the administration of oral corticosteroids during 
exacerbations and control of the underlying asthma with β2-agonists. Furthermore, antifungal 
treatment with azoles in ABPA patients could spare the use of corticosteroids 1, 11. However, due 
to the potential severe side effects of azoles and the long-term consequences of corticosteroid 
treatment, new approaches for ABPA therapy are needed. 
 While most Aspergillus-related PRRs have been studied in the context of invasive aspergillosis, 
limited data exists of the Aspergillus-associated molecular patterns and their PRRs responsible for 
triggering the Th2 response in ABPA. In murine studies, TLR2 and TLR9 have been described to 
skew the Aspergillus induced Th response towards a Th2 profile 12, 13, and chitin exposure has been 
associated with pulmonary eosinophilia14. The current study aims to identify the immunological 
pathways through which Aspergillus induces a Th2 response in humans. Furthermore, the cytokine 
profile of a cohort of ABPA patients was investigated for assessing the Th1/Th2 balance. The 
capacity of treatment with biological therapy to modulate Aspergillus-induced T-helper responses 
was tested in vitro, with the goal to find innovative corticosteroid-sparing treatment options for 
ABPA patients.
Experimental procedures
Volunteers and patients | Blood was collected from healthy volunteers or patients by venous 
blood puncture after informed consent. Three dectin-1 deficient patients with a homozygous Y238X 
mutation in exon 6 of CLEC7A gene (the gene encoding dectin-1) donated blood, two of them twice 
at two different time points. In these patients diminished expression of dectin-1 and failure to induce 
a cytokine response to β-glucan was demonstrated previously 15. Seven asthma patients and nine 
patients diagnosed with ABPA according to the ABPA diagnostic criteria as described elsewhere 3 
were asked for blood donations, two of whom had cystic fibrosis with a homozygous mutation in 
the CFTR gene (Table 1).
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PRR ligands, blockers and other stimuli | Escherichia coli LPS (10 ng/mL) (TLR4 ligand, E. coli serotype 
O55:B5, Sigma-Aldrich St. Louis, MO USA), Pam3Cys (10 μg/mL) (TLR2 ligand, EMC microcollections, 
Tübingen, Germany), Poly I:C (10 μg/mL) (TLR3 ligand, Cayla-Invivogen, Toulouse, France), flagellin (10 
μg/mL) (TLR5 ligand, Cayla-Invivogen, Toulouse, France), N-acetylmuramyl-ananyl-D-isoglutamine 
(MDP) (10 μg/mL) (NOD2 ligand, Sigma-Aldrich), phytohemagglutinin (PHA) (10 μg/mL) (Sigma-
Aldrich). Escherichia coli ATCC 35218 (E. coli) (1x107/mL); Staphylococcus aureus clinical isolate (S. 
aureus) (1x107/mL); Mycobacterium tuberculosis sonicate H37Rv bub DL 6122005 (M. tuberculosis) (10 
μg/mL); Borrelia burgdorferi ATCC 35210 (B. burgdorferi) (1x106/mL); Candida albicans ATCC MYA-3573 
(UC820) (C. albicans) (1x106/mL); Aspergillus fumigatus clinical isolate V05-27 (A. fumigatus), resting 
conidia and hyphae (1x107/mL,) were cultured and isolated as described in a previous study 16.
 Fungal cell wall components: β-1,3-D-glucan (β-glucan) (10 μg/mL) was kindly provided by Prof. 
David Williams (Tennessee University), and α-1,3-glucan, α-1,3-1,4-glucan (either dissolved in PBS or 
DMSO), chitin (Aspergillus niger) (all 10 μg/mL) and galactosaminogalactan (GAG) (7,5 μg/mL) were 
a gift from Prof. Jean-Paul Latgé (Pasteur Institute, Paris).
 Bartonella quintana LPS was prepared and purified as described elsewhere 18 and used as a TLR4 
inhibitor (20 ng/mL) 19; isotype control mouse IgG1 (10 μg/mL) (eBioscience, Halle-Zoersel, Belgium); 
anti-TLR2 (10 μg/mL) (eBioscience); laminarin (50 ng/mL) 17; a spleen tyrosine kinase (Syk) inhibitor 
(50 nM, Merck, Darmstadt, Germany); isotype control goat IgG (10 μg/mL) (R&D Systems Minneapolis, 
MN, USA); anti-human β2-integrin (anti-CR3) (10 μg/mL) (R&D Systems); anti-human OX40ligand 
(anti-OX40L) (10 μg/mL) (R&D Systems); cytochalasine D (1 μg/mL, dissolved in DMSO) (Enzo life 
sciences, Antwerpen, Belgium); IL-1 receptor antagonist (IL-1Ra) (10 μg/mL) (Amgen, Inc., Thousand 
Oaks, CA, USA); soluble TNFRII (Etanercept) (100 μg/mL), human anti-human TNFα (Adalimumab), 
(100 μg/mL), both kindly provided by Dr. Marije Koenders (Department of Rheumatology Radboud 
University Nijmegen Medical Centre the Netherlands); Interferon-gamma 1b (Immukine) (50 ng/
mL) (Boehringer-Ingelheim, Alkmaar, The Netherlands). 
PBMCs isolation | Venous blood was drawn in 10 mL EDTA tubes. The blood was diluted 1:1 with 
Phosphate Buffered Saline (PBS). Subsequently PBMCs were isolated using Ficoll-paque (GE healthcare, 
Zeist, The Netherlands) density gradient centrifugation. The PBMCs layer was collected and washed 
twice in cold PBS. Cells were reconstituted in RPMI-1640 culture medium (Dutch modification, Gibco, 
Invitrogen, Breda, The Netherlands) supplemented with 10 µg/mL gentamicin, 10 mM L-glutamine 
and 10 mM pyruvate (Gibco). The cells were counted with a particle counter (Beckmann Coulter, 
Woerden, The Netherlands) and the concentration was adjusted to 1x107 cells/mL.
Cell depletion | PBMCs were incubated with magnetic anti-CD4, anti-CD56 and anti-CD19 beads and 
purified using MACS depletion columns (LD, Miltenyi Biotec, Bergisch Gladbach, Germany) according 
to the instructions supplied by the manufacturer to generate CD4- (T-cells depleted), CD56- (NK-cells 
depleted) or CD19- (B-cells depleted) PBMC fractions. Next to the labelled cells, also an unlabelled 
PBMC fraction was run over the depletion column and used as a mock treatment control. 
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PBMCs stimulation | PBMCs were plated in a 96-well round-bottom plate (Corning, NY, USA) at a final 
concentration of 2.5x106/mL in an end volume of 200 µL per well. All stimulations were performed in 
the presence of 10% human serum. Serum was either complement active if not otherwise indicated 
or heat-inactivated by incubation for 30 minutes at 56°C in a water bath according to a commonly 
used protocol 18. Mannose-binding lectin (MBL) deficient serum was obtained from a patient with 
MBL level of 0.09 μg/mL. After 1 hour pre-incubation with inhibitor or medium, stimuli or medium 
were added. Cells were incubated at 37°C with 5% CO2, after 7 days supernatants were collected and 
stored at -20°C. 
Cytokine measurements | IL-5, IL-13, IFNγ and IL-10 were measured in the cell culture supernatants 
using a commercial ELISA kit (IL-5 and IL-13: R&D Systems; IFNγ and IL-10: Sanquin) according to the 
instructions supplied by the manufacturer. 
Intracellular staining and flowcytometric analysis | After 7 days incubation, cells were re-
stimulated for 4-6 hours with 200 µL of RPMI supplemented with gentamicin, L-glutamine and 
pyruvate and PMA (50 ng/mL) (Sigma-Aldrich), ionomycin (1 μg/mL) (Sigma-Aldrich), Golgiplug (BD 
Biosciences, Breda, the Netherlands) and 10% human serum. Cells were stained extracellular using 
PECy7–conjugated anti-CD4 (BD Biosciences), PECy7–conjugated anti-CD8 (BioLegend, San Diego), 
or PECy7–conjugated anti-CD56 (Beckman Coulter) and ECD-conjugated monoclonal anti-CD3 
antibody (Beckman Coulter, Krefeld, Germany). Fixation and permeabilization was performed with 
Cytofix/Cytoperm solution (eBioscience) according to the instructions supplied by the manufacturer. 
Cells were stained intracellular with anti-IL-4 (FITC-conjugated), anti-IL-5 (PE-conjugated) and anti-
IL-13 (APC-conjugated) (BD Bioscience). Fixated cells were measured with a FC500 flowcytometer 
(Beckman Coulter) and the data were analysed using CXP analysis software v2.2 (Beckman Coulter).
OX40L expression | RNA was isolated from 1x106 PBMCs after stimulation for 48 hours with Aspergillus 
conidia either in the presence of medium or Adalimumab or IL-1Ra using Trizol Reagent (Invitrogen) 
according to a protocol supplied by the manufacturer. RNA (500 ng) was reverse transcribed into cDNA 
using the iScript cDNA synthesis kit (Hercules, Bio-Rad Laboratories, CA). Quantitative PCR (qPCR) 
analysis was performed using SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA) and the Applied 
Biosystems 7300 real-time PCR system. As PCR protocol the following conditions were used: 2 min 50°C, 
10 min 95°C followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. For the amplification 
of hOX40L the primers 5’-TCCCCTCTCTTAGGTGCTCA-3’ and 5’-GGCTGGTGCATAGCAGAAAT-3’ were 
used. To correct for differences in loading concentrations of RNA between the different conditions, 
qPCR results were corrected with the housekeeping gene β2 microglobulin (β2m) amplified using 
the primers 5’- ATGAGTATGCCTGCCGTGTG-3’ and 5’-CCAAATGCGGCATCTTCAAAC-3’. Primer efficacy 
was evaluated using a standard curve. OX40L Ct values were compared with the β2m Ct using the 
formula 2-ΔCt and the foldchange was calculated by setting the Aspergillus-stimulated samples as 1 to 
determine the effect of anti-TNFα (Adalimumab) and IL-1Ra on OX40L expression. 
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Genotyping | Genomic DNA from healthy Caucasian controls was isolated using the Gentra 
Pure Gene blood kit (Qiagen, Hilden, Germany) according to the instructions supplied by the 
manufacturer. The specific SNP identifiers (rs numbers) were extracted from a recent publication 
describing SNPs associated with ABPA 19. Genotypes of the different SNPs were obtained from the 
Illumina immunochip which has previously been run according to the manufactures protocol 20. 
Beforehand, a quality filter was applied which automatically excluded SNPs with either a low call 
rate (<99%), SNPs that were not in Hardy-Weinberg equilibrium (p<0.01) or that had a reported 
minor allele frequency of less than 0.01.
Statistical analysis | The Mann-Whitney-U test was used to detect differences between healthy 
controls and patients or between different genotypes. The Wilcoxon signed rank test was used 
to determine differences between stimulation with and without inhibitors of PRRs, cytokines or 
cytokine inhibitors. A p-value of <0.05 was considered Statistically significant (*=p<0.05, **=p<0.01 
and ***=p<0.001). Graphs represent cumulative results of all performed experiments and are 
presented as mean ± standard error of the mean (SEM). Data were analysed with GraphPad Prism 
v 5.0.
Figure 1 | Aspergillus conidia induce a Th2 response, in contrast to other pathogens or PRR ligands
IL-5 and IL-13 concentrations were measured in cell culture supernatants of PBMCs of healthy controls (2.5x106/
mL, n=6 donors) by ELISA (IL-5 detection level 24 pg/mL, IL-13 detection level 71 pg/mL) after stimulation with 
(A) TLR4 ligand (LPS), TLR2 ligand (Pam3Cys), TLR3 ligand (Poly I:C), TLR5 ligand (flaggelin), NOD2 ligand (MDP) 
or dectin-1 ligand (β-glucan) (B) Various pathogens like E. coli, S. aureus, M. tuberculosis sonicate (H37Rv), B. 
burgdorferi, C. albicans yeast and A. fumigatus conidia (C) A. fumigatus conidia and hyphae as well as differenT-
cell wall components like α-1,3-glucan, α-1,3-1,4-glucan, β-1,3-glucan, galactosaminogalactan, chitin PHA.
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Results
Aspergillus conidia induce a Th2 response, in contrast to other pathogens or PRR ligands
We investigated which PRRs are involved in the initiation of a Th2 response by stimulating PBMCs 
with different specific ligands for TLR4, TLR2, TLR5, NOD2 or dectin-1, and measuring IL-5 and IL-
13 (Figure 1A). None of these ligands or combinations of TLR2 with ligands for dectin-1 or NOD2 
was able to induce IL-5 or IL-13. We thereafter screened a panel of pathogens consisting of extra- 
and intracellular bacteria, as well as two types of fungi for their capacity to induce Th2 cytokines 
(Figure 1B). The whole bacteria E. coli, S. aureus or B. burgdorferi, as well as sonicated M. tuberculosis 
were unable to induce IL-5 and IL-13, while these pathogens induce other immune responses 
such as IL-17 and IFNγ in these conditions (data not shown). Among the fungal pathogens, the 
Th2 response was restricted to the stimulation with A. fumigatus conidia, while C. albicans yeast 
did not induce IL-5 and IL-13. Moreover, Aspergillus hyphae induced relatively low IL-5 production 
(76.4 pg/mL hyphae vs. 296 pg/mL conidia) and IL-13 (310 pg/mL hyphae vs. 568 pg/mL conidia). 
Stimulation with the fungal cell wall components α-1,3-glucan and α-1,3-1,4-glucan, β-1,3-glucan, 
galactosaminagalactan (GAG) or chitin did not induce IL-5, while IL-13 production was slightly 
induced by α-1,3-1,4-glucan or chitin (Figure 1C). PHA was used as a mitogenic stimulus to detect 
T-cell memory activation, and induced low levels of Th2 cytokines. 
Aspergillus-induced IL-5 and IL-13 are dose and time dependently produced by CD4+ T-cells 
To study the kinetics and dose dependency of IL-5 and IL-13 induced by Aspergillus conidia, we 
performed a time course of 7 days with 3 different concentrations ranging from 1x105 to 1x107 
conidia/mL (Figure 2A). IL-4 was undetectable in all stimulations (data not shown). In contrast, IL-5 
and IL-13 were detectable from day 4 onwards and increased steadily. Only the highest dosage 
of 1x107 conidia/mL induced IL-5 and IL-13, while dosages below this threshold induced cytokine 
values barely detectable above the detection limit. 
 To investigate which cells are responsible for the production of IL-4, IL-5 and IL-13 induced by 
Aspergillus, flowcytometric analyses with intracellular staining for IL-4, IL-5 and IL-13 were performed 
on PBMCs that were cultured for 7 days in the presence of Aspergillus conidia. Within the Th2 cytokine 
positive population, CD4+ cells were the main representatives (72.9% of IL-4+, 61.7% of IL-5+ and 
68.5% of IL-13+ cells) (Figure 2B). Surface staining for CD8, CD56 and CD19 revealed the CD8+ cells 
as the second biggest subpopulation contributing to the IL-5 and IL-13 production (Figure 2C). To 
determine which cell populations within PBMCs contribute to the IL-5 and IL-13 secretion induced 
by Aspergillus stimulation, PBMCs were depleted of CD4+, CD56+ or CD19+ cells (Figure 2D). Mock-
treated PBMCs lost their capacity to produce IL-5, which made it impossible to evaluate the effect of 
depleting a special subpopulation on IL-5 production (Figure S1). Depletion of the CD4+ cells led to 
a reduction of Aspergillus-induced IL-13 production to undetectable levels, while depleting CD56+ 
or CD19+ cells did not affect IL-13 production. These data suggest that CD4+ T-lymphocytes are the 
main producers of Th2 cytokines induced by Aspergillus conidia. 
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Aspergillus-induced IL-5 and IL-13 response is dependent on CR3 and phagocytosis
Since most PRRs have been studied in the context of invasive aspergillosis 3,21 only little is known 
about the PRRs and pathways involved in the pathogenesis of ABPA. We investigated the role of TLR2, 
TLR4, Dectin-1 and CR3 pathways in Aspergillus-induced Th2 responses in human PBMCs. PBMCs 
were stimulated with Aspergillus conidia in the absence or presence of specific inhibitors for the PRR 
pathways. Inhibition of TLR4 did not alter IL-5 production, while IL-13 was slightly reduced (mean 
15.7% reduction, Figure 3A). Although TLR2 has been described to polarize Aspergillus-specific T-cell 
responses towards Th2 22,23, neither IL-5 nor IL-13 was affected when TLR2 was blocked (Figure 3B). 
Dectin-1 is known to recognize the fungal cell wall component β-glucan 24 and is known to promote 
immunopathology in the lung during fungal allergy 25. However, blocking dectin-1 with laminarin 
(Figure 3C), or inhibition of Syk, the downstream signalling kinase of the dectin-1 receptor, did not 
alter the Th2 response induced by Aspergillus (Figure 3D). Additionally, PBMCs isolated from three 
dectin-1 deficient patients produced IL-5 and IL-13 levels comparable to healthy controls (Figure 
3E). Subsequently, we investigated CR3 (CD11b/CD18), a β2-integrin expressed on neutrophils and 
monocytes, since it has been described that CR3 is also able to recognize β-glucan 26. Blockade of CR3 
inhibited the Aspergillus-induced Th2 response completely (Figure 3F). We did not observe different 
cytokine production when the serum was de-complemented by heat-inactivation (Figure 3G). 
Figure 2 | Aspergillus-induced Th2 cytokines are dose and time dependently produced by CD4+ cells
(A) PBMCs (2.5x106/mL, n=4 donors) were stimulated with increasing concentrations of Aspergillus conidia 
(1x105/mL, 1x106/mL, 1x107/mL) for 1-7 days and IL-5 and IL-13 was measured in the cell culture supernatant 
by ELISA. (B-C) Cells were stained extracellular for CD4, CD8, CD56 and CD19 and intracellular for IL-4, IL-5 and 
IL-13. (B) CD4+ and CD4− cells (n=10) within the IL-4, IL-5 or IL-13 positive cells. (C) CD4+-, CD8+-, CD56+ and CD19+-
cells within the Aspergillus-specific IL-4+-, IL-5+- and IL-13+-populations (normalized to 100%, one representative 
donor) (D) PMBCs were depleted either for CD4+, CD56+ or CD19+ cells (white bars) or run over the depletion 
columns unlabelled (black bars) and stimulated with Aspergillus conidia. IL-13 was measured in the cell culture 
supernatant by ELISA (n=6 donors). Statistical analysis was performed with the Wilcoxon Signed Rank test.
Aspergillus-induced Th2 responses in ABPA patients| 87
 5
Figure 3 | Aspergillus-induced IL-5 and IL-13 response is dependent on CR3 and phagocytosis
PBMCs were pre-incubated for 1h with different blockers and stimulated with Aspergillus conidia. IL-5 and IL-
13 were measured in the cell culture supernatant (black bars: Aspergillus conidia stimulation with medium or 
control, grey bar: Aspergillus conidia stimulation after blocking). (A) TLR4 blocking with B. quintana LPS (IL-5 n=9 
donors, IL-13 n=8 donors). (B) TLR2 blocking with αTLR2 antibody (IL-5 n=6 donors, IL-13 n=7 donors). (C) PBMCs 
of three dectin-1 deficient patients compared with four healthy controls. (D) Dectin-1 blocking with laminarin 
(n=10 donors). (E) Syk inhibition (IL-5 n=9 donors, IL-13 n=7 donors). (F) CR3 blocking with αCR3 antibody (IL-5 
n=7 donors, IL-13 n=9 donors). (G) PBMC stimulation with 10% active human serum compared with 10% heat-
inactivated human serum (IL-5 n=5 donors, IL-13 n=6 donors). (H) Blocking phagocytosis with cytochalasine D 
(n=6 donors). (I) CR3 blocking with αCR3 antibody (IL-5 and IL-13 n=4 donors) in the presence of MBL deficient 
serum. Statistical analysis was performed with the Wilcoxon Signed Rank test.
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 Since CR3 is involved in phagocytosis 27, we blocked phagocytosis by inhibiting actin 
polymerisation by cytochalasine D, which significantly reduced IL-5 and IL-13 production (Figure 3H). 
High plasma levels of MBL are associated with bronchial asthma with allergic rhinitis and ABPA 28, 
therefore we wanted to investigate whether the recognition of Aspergillus conidia with subsequent 
Th2 induction via CR3 is MBL dependent. Aspergillus-specific Th2 cytokines in the presence of MBL 
deficient serum were significantly decreased after blocking CR3, suggesting that signalling via CR3 
leading to Th2 responses is independent of MBL (Figure 3I). These data demonstrate that the IL-13 
response induced by Aspergillus in human PBMCs is partially dependent on TLR4, while both IL-5 
and IL-13 are dependent on CR3 and phagocytosis.
ABPA patients have an Aspergillus-specific increased Th2/Th1 ratio 
PBMCs isolated from nine ABPA patients were stimulated with Aspergillus conidia and IL-5, IL-13 and 
IFNγ production was measured. Compared to non-allergic healthy controls, ex vivo Aspergillus-induced 
Th2 cytokines was stronger in ABPA patients, which was Statistically significant for IL-5 but not for IL-
13 (Figure 4A). In contrast, Aspergillus-induced IFNγ production by PBMCs was significantly lower in 
ABPA patients when compared to healthy controls (Figure 4A). Interestingly, IFNγ was significantly 
lower after stimulation with both Aspergillus conidia and hyphae (data only shown for conidia). When 
we compared the IL-5/IFNγ and IL-13/IFNγ ratios in ABPA patients and controls, we observed that 
they were significantly different and discriminated ABPA patients from healthy controls (Figure 4B, C). 
Table 1 | Demographic table of ABPA patients
No. SexAge (y) asthma/CF
total IgE
Asp-IgE 
 (U/mL)
Asp-IgG 
(mg/
mL)
Eo Be steroids use azole use
ABPA 1 F22
dF508del
/dF508del
60
1.5 48.60 1.06 yes
yes: 
ciclosenide, inh 160 mg yes
ABPA 2 M21
dF508del
/dF508del
229
13.9 40 0.79 yes no yes
ABPA 3 M63 asthma
1406
25.1 353 2.44 yes
yes: 
prednisone, 5mg/d no
ABPA 4
F
78
asthma 451567.7 n.d. 0.17 n/a no  yes
ABPA 5 F77 asthma
1263
46.4 120 0.88 yes no no
ABPA 6 M67 asthma
2710
29 128 0.88 discrete no yes
ABPA 7 M66 asthma
2508
15.1 187 n/a yes
yes: 
prednisone, 10mg/d no
ABPA 8 F70 asthma
3202
40.7 196 0.02 discrete
yes:
prednisone, 15mg/d no
ABPA 9 M77 asthma
3343
46.4 51 1.49 yes
yes: 
prednisone, 10mg/d no
Age, sex, underlying disease (asthma or cystic fibrosis), bronchiectasis (Be), eosinophil count (Eo), total IgE 
(U/mL), Aspergillus-specific IgE (Asp-IgE)(U/mL), Aspergillus-specific IgG (Asp-IgG)(mg/mL) and concomitant 
medication (corticosteroids and azoles) of the ABPA patients enrolled in this study are listed.
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Figure 4 | The Th2/Th1 balance in ABPA patients is shifted towards Th2 
(A) PBMCs of 9 ABPA patients were stimulated with Aspergillus conidia and compared with PBMCs of healthy 
controls. IL-5, IL-13 and IFNγ levels were measured in the cell culture supernatant (black bars controls, white bars 
patients). (B) The Th2/Th1-ratio between IL-5 vs. IFNγ and IL-13 vs. IFNγ was generated by dividing the individual 
IL-5 or IL-13 level by the individual IFNγ level. (C) The triangle diagram shows the mean of IL-5, IL-13 or IFNγ of 
every group on the corresponding cytokine axis (continuous line: controls, dotted line: patients). (C) PBMCs 
isolated from 3 asthma patients with an elevated Aspergillus-specific IgE and 4 without elevated Aspergillus-
specific IgE were stimulated with Aspergillus conidia and compared with healthy controls. IL-5, IL-13 and IFNγ 
levels were measured in the cell culture supernatant. (D) The Th2/Th1-ratio between IL-5 vs. IFNγ and IL-13 vs. 
IFNγ was generated by dividing the individual IL-5 or IL-13 level by the individual IFNγ level. Statistical analysis 
was performed with the Mann-Whitney-U test.
 To determine whether the elevated Th2/Th1 ratio in ABPA is due to the underlying asthma itself 
or due to Aspergillus sensitization, we investigated Aspergillus-specific ratios in asthma patients with 
and without an elevated Aspergillus-specific IgE (Table S1). PBMCs isolated from asthma patients 
with Aspergillus-sensitization that were stimulated with Aspergillus conidia showed a higher 
Aspergillus-specific Th2 response than the asthma group without Aspergillus-sensitization and the 
control group (Figure 4D). This resulted in an elevated Th2/Th1 ratio comparable to ABPA patients 
(Figure E). In addition, we investigated whether the anti-inflammatory cytokine IL-10 is involved in 
the elevated ratios observed in ABPA. Neither in the control, nor in the patient group did we detect 
IL-10 concentrations (Figure S2). 
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Etanercept, Adalimumab, anakinra and IFNγ modulate the Aspergillus-induced Th2/Th1 ratio 
Since we observed significantly different Th2/Th1 ratios in ABPA patients we wanted to investigate 
whether available biologicals for treatment of inflammatory disease are capable of modulating the 
Aspergillus-specific Th2/Th1 ratio. We used Etanercept (soluble TNFα receptor II-Fc), Adalimumab 
(human anti-human TNFα), anakinra (IL-1 receptor antagonist) and Immukine (recombinant human 
IFNγ) and stimulated PBMCs either with Aspergillus conidia in the presence of medium or one of the 
biologicals. All biologicals significantly suppressed Aspergillus-induced IL-5 and IL-13 production in 
human PBMCs. However, Etanercept, Adalimumab and anakinra also suppressed IFNγ production 
in response to Aspergillus and hence did not correct the IL-5/IFNγ-ratios (Medium: 0.65, Etanercept 
l: 0.61, Adalimumab: 0.92, anakinra: 1.82) and IL-13/IFNγ-ratios (Medium: 1.49, Etanercept: 1.41, 
Adalimumab: 1.89, anakinra: 2.77). Therefore, it was only recombinant IFNγ that was able to restore 
the increased Th1/Th2 ratio by down-regulating IL-5 and IL-13, but not IFNγ. 
 The co-stimulatory molecule OX40L is known to be involved in inflammatory Th2 responses 
triggered by thymic stromal lymphopoetin (TSLP)-activated dendritic cells in ABPA patients 29. We 
therefore investigated whether OX40L is also involved in the Th2 responses induced by Aspergillus 
Figure 5 | Etanercept, Adalimumab, Anakinra and IFNγ modulate the Aspergillus-induced Th2/Th1 ratio 
PBMCs of healthy controls were stimulated with Aspergillus conidia either the presence of medium (black bars) 
or one of the biological drugs (grey bars) like Etanercept (soluble TNFα receptor type II), Adalimumab (human 
TNFα antibody), anakinra (IL-1Ra) or recombinant IFNγ. (A) IL-5, (B) IL-13 and (C) IFNγ were measured with ELISA 
in the cell culture supernatant. (D) IL-5 and IL-13 measurement after blocking OX40L with αOX40L antibody (IL-5 
and IL-13, n=9 donors). (E) OX40L expression in PBMCs of healthy controls stimulated with Aspergillus conidia 
either in the presence of adalimumab or anakinra (n=6). Statistical analysis was performed with the Wilcoxon 
Signed Rank test.
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in human PBMCs. Blocking OX40L resulted in significantly decreased Aspergillus-induced IL-13 
production (Figure 5D). Since TNFα and IL-1 can modulate the expression of OX40L 30,31, we analysed 
whether blocking TNFα or IL-1 would result in a different expression of OX40L in PBMCs. We 
observed no significant modulation of the Aspergillus-induced OX40L expression in the presence of 
adalimumab or anakinra (Figure 5E).
Polymorphisms influencing Aspergillus-specific Th2/Th1 ratios
Single nucleotide polymorphisms (SNPs) in the IL10, IL4Rα, MBL, and SFTPA2, gene have been 
associated with an increased susceptibility to ABPA 19. We took a systematic approach to investigate 
whether reported polymorphisms that are associated with ABPA could influence Aspergillus-specific 
Th2/Th1 ratios (table 2). PBMCs isolated from 35 healthy controls were stimulated with Aspergillus 
conidia and IL-5 and IFNγ was measured. The homozygote GG genotype of IL4Rα (rs1805010) 
showed a trend towards higher IL-5 production and an increased IL-5/ IFNγ ratio (Figure 6A). The 
GG genotype in the IL10 SNP (rs1800896) showed a trend towards higher IFNγ production, however 
no association was observed with Aspergillus-specific IL-5 or IL-5/ IFNγ ratio (Figure 6E). The other 
polymorphisms in SFTPA2 (rs17886395 and rs17880349) and MBL (rs5030737) did not show an 
association with IL-5 or IFNγ production (Figure 6B, C and D). 
Discussion 
In the present study, we investigated the general and Aspergillus-specific features of the Th2 
response in primary human PBMCs of healthy controls and ABPA patients. Th2 cytokine responses in 
vitro could only be detected when PBMCs were stimulated with A. fumigatus, while Candida, specific 
PRR ligands, Gram-positive and Gram-negative bacteria did not induce IL-5 or IL-13 production. 
Furthermore, no single fungal component induced IL-5 or IL-13 in the same amount as Aspergillus 
conidia, suggesting that a complex of fungal PAMPs present on the cell wall of Aspergillus conidia is 
needed to induce a Th2 response in human PBMCs. The Aspergillus-specific IL-5 and IL-13 production 
was dependent on CD4+ cells, the pattern recognition receptor CR3, and phagocytosis. Moreover, we 
identified that ABPA patients, in contrast to non-allergic controls, had a significantly elevated Th2/
Th1 ratio induced by Aspergillus. Interestingly, not the asthma itself but the Aspergillus sensitization 
Table 2 | SNPs associated with ABPA 
Gene rs number SNP position MAF function
IL-4Rα (16p12.1- p11.2) rs1805010 4679 A/G 0.466 missense
SFTPA2 (10q22.3) rs17886395 1649 C/G 0.206 missense
SFTPA2 rs17880349 1492 C/T 0.461 Intronvariant
IL-10 (1q31-q32) rs1800896 min 1082 A/G 0.303 near-Gene5
MBL (10q11.2-q21) rs5030737 868 C/T 0.028 missense
Gene, rs number, SNP position, minor allele frequency (MAF) and resulting defect of gene function of SNPs 
associated with ABPA are listed
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Figure 6 | The role of polymorphisms associated with ABPA on Aspergillus-specific Th2/Th1 ratios.
PBMCs isolated from healthy volunteers (n=35) were stimulated with Aspergillus conidia and IL-5 and IFNγ 
were measured in the cell culture supernatant. SNPs were analysed for association with cytokine production. 
Statistical analysis was performed with the Mann-Whitney-U test.
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in asthma patients appears to be responsible for the increased Th2/Th1 ratios observed in ABPA. We 
suggest that treatment strategies restoring this Th2/Th1 imbalance triggered by Aspergillus might 
be beneficial in the treatment of ABPA. Although anti-TNFα and IL-1Ra had the capacity to decrease 
Aspergillus-induced IL-5 and IL-13 production they also lowered IFNγ production. Therefore, the 
capacity of recombinant IFNγ to lower IL-5 and IL-13 and to supplement the IFNγ deficiency in ABPA, 
provides a rationale to use IFNγ as a corticosteroid-sparing treatment option in ABPA.
 The observation that the induction of Th2 cytokines in human PBMCs was restricted to 
Aspergillus was striking. In the context of diseases caused by bacteria such as E. coli, S. aureus, M. 
tuberculosis, B. burgdorferi it can be anticipated that they do not induce strong Th2 responses in 
human PBMCs. However, the observation that no single TLR ligand, NOD2 ligand, or fungal cell 
wall component, specifically chitin, did not induce IL-5 and IL-13 was unexpected. Chitin has been 
associated with allergic inflammation in the lung 32,33. Therefore, it is most likely that chitin in the 
setting of an inflammatory environment is able to polarize towards Th2 responses, while as a single 
ligand it is not able to induce a Th2 response. 
 This study revealed a non-predominant role of TLRs in the induction of Aspergillus-specific Th2 
cytokines. Blocking of TLR2 did not have a significant impact on IL-5 and IL-13 production induced 
by Aspergillus. In contrast, it has been shown that there is an association between increased TLR2 
expression in fatal asthma 34, and polymorphisms in TLR2 are associated with a higher prevalence 
of asthma 35. Furthermore, TLR2-/- mice show a deficient Th2 production in a chronic fungal asthma 
model 13. The minor but significant contribution of TLR4 in the Aspergillus-induced IL-13 induction 
found in the present study is in line with former studies describing TLR4 in allergic responses against 
house dust mite in which an endotoxin containing extract signalling via TLR4 36. In addition, we 
identified a redundant role of dectin-1 in the Aspergillus-induced Th2 response. Blocking dectin-1 or 
Syk did not alter IL-5 and IL-13 production, and dectin-1 deficient patients produced Th2 cytokine 
responses comparable to healthy controls. The dectin-1 ligand β-glucan 17, however has recently 
been described to play an important role in Aspergillus-triggered asthma immunopathology in mice 
25. The role of dectin-1 in the immunopathology of asthma is not clear. It has been suggested that 
dectin-1 promotes the immunopathology in fungal asthma 25, while another study demonstrated 
that dectin-1 plays a role in suppressing asthmatic inflammation 37. Our findings suggest that TLR2 
and dectin-1 are not the main pathways driving the Aspergillus-specific Th2 response in human 
mononuclear cells. Whether TLR2 and dectin-1 play a role in Aspergillus-induced Th2 responses that 
are dependent on epithelial cells remains to be elucidated.
 Th2 induction by Aspergillus was dependent on CR3 (CD11b/CD18). CR3 is a β2-integrin that 
contains a lectin-like domain and is expressed on neutrophils and monocytes 27. CR3 contributes 
to antifungal host defence by interacting with pentraxin-3 opsonized particles, and by recognizing 
β-glucan 26. Furthermore, CR3 is involved in complement driven host responses 38, however the 
induction of IL-5 and IL-13 was still present in de-complemented serum, suggesting a complement 
independent contribution of CR3 to the Th2 response. Activation of the complement via the 
MBL pathway is an alternative route of the complement pathway, and increased MBL serum 
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concentrations have been associated with ABPA 28. However, Th2 induction by Aspergillus via CR3 
signalling was independent of serum MBL, suggesting that MBL is not crucial for CR3-mediated Th2 
responses induced by Aspergillus. Phagocytosis of non-opsonised particles via signalling together 
with FcR is also dependent on CR3 27. In line with blocking CR3, blocking phagocytosis led to a 
complete abolishment of Th2 production induced by Aspergillus. These data collectively suggest 
that CR3 is involved in phagocytosis of Aspergillus conidia, and that this process is essential for 
Th2 cytokine production by human PBMCs. Recently, CR3 was described in the induction of the 
Aspergillus-specific pro-inflammatory T-helper cytokines 39, suggesting a more general role for CR3 
in modulating T-helper responses. 
 An important issue to address was the cellular source of the Th2 cytokine in human mononuclear 
cells induced by Aspergillus. We could demonstrate that CD4+, but not CD19+ and CD56+ cells were 
the predominant source for the Aspergillus-induced IL-13 in human PBMCs. This is in line with 
previous studies showing that CD4+ cells are responsible effector cells in allergic reactions 10, and 
that CD19+ and CD56+ play a redundant role in an asthmatic mouse model 40. Although increased 
levels of CD8+ and IL-13+ cells have been associated with asthma and bronchial obstruction 41, IL-
13 production in human PBMCs was completely dependent on CD4+ cells, suggesting that CD8+ 
T-cells are not involved in the production of Aspergillus-induced IL-13 in human mononuclear cells. 
We could not demonstrate the cellular source of IL-5 in our setting since IL-5 was not measurable 
in depletion experiments. Since FACS analysis demonstrated a significant CD8+ population that 
stained positive for IL-5, we cannot exclude that CD8+ T-cells play a role in Aspergillus-induced IL-5 
production in human PBMCs.
 Several studies have shown an exaggerated Th2 response in ABPA 42-44. We investigated the 
Aspergillus-specific Th2 response in the context of Aspergillus-induced T-helper responses in human 
PBMCs isolated from ABPA patients. Interestingly, ABPA patients not only show an increased IL-5 
and IL-13 production after stimulation with Aspergillus conidia, which is in line with previous studies 
45, they also have an Aspergillus-specific decreased IFNγ production. Since we also observed an 
increased Th2/Th1 ratio in asthma patients with Aspergillus-sensitization, but not in patients with 
asthma that did not have Aspergillus-sensitization, it is most likely that the increased Th2/Th1 ratios 
in ABPA are due to an Aspergillus-specific host response and not due to the underlying host response 
associated with asthma itself. These observations strengthen the hypothesis that ABPA and asthma 
with Aspergillus sensitization share underlying pathophysiological mechanisms that are distinct 
from asthma itself, and support the concept that similar treatment approaches could be beneficial 
in both asthma-sensitized patients and ABPA, such as the treatment with azoles 11.
 Aspergillus hyphae have been found in tissue biopsies in ABPA and have been suggested to play 
a significant role in inflammation in ABPA 46,47. Furthermore, IgE antibodies directed against Aspf4 
and Aspf6 can be observed in ABPA in patients with CF 48,49. Aspf6 has been shown to be a hyphae-
specific protein. Therefore, ABPA patients are exposed to Aspergillus hyphae, which contributes to a 
Th2 response in vivo. We observed however that Aspergillus hyphae induced much lower amounts 
of Th2 cytokines in ABPA patients compared to Aspergillus conidia, suggesting that fungal cell wall 
Aspergillus-induced Th2 responses in ABPA patients| 95
 5
structures specific for Aspergillus conidia, or phagocytosis might play a more prominent role in the 
induction of Th2 responses in ABPA than previously thought. 
 Regulatory T-cells (Tregs) are important for controlling allergic immune responses 50. A recent 
study has shown, that Aspergillus-sensitized asthma patients with high Aspergillus-specific Th2 
induction had significant decreased levels of Aspergillus-specific Tregs, while they were strongly 
induced in the healthy control group 51. Also in CF patients with ABPA, Tregs were less frequent 
than in non-ABPA CF patients 29 suggesting that a deficient Treg response could contribute to the 
excessive and unbalanced inflammatory response observed in ABPA patients. It is tempting to 
speculate that the increased Aspergillus-specific Th2/Th1 response that we observed in the ABPA 
patients is due to a deficient Treg response, and that a deficient Tregs response, accompanied by a 
high Th2 and low Th1 response plays a significant role in the pathophysiology of ABPA. 
  The characterization of this immunological profile of ABPA patients with an elevated Th2/Th1 
ratio provides a read-out for testing potential immunomodulatory treatment options in ABPA. TNFα 
and IL-1 are interesting targets. TNFα has been shown to be the key cytokine inducing increased IL-17 
levels and neutrophilia in the lung in a murine ABPA model 52. The involvement of the inflammasome 
and epithelial derived IL-1 cytokines are also described in bronchial asthma in several studies 53,54. 
Therefore we tested the TNFα neutralizing biologicals, Etanercept and Adalimumab, and the IL-1 
pathway blocking biological IL-1Ra (anakinra). All biologicals decreased IL-5 and IL-13 production, 
but also IFNγ production, therefore resulting in unaltered IL-13/IFNγ and IL-5/IFNγ ratios. In addition 
we investigated recombinant IFNγ, which decreased Aspergillus-specific IL-5 and IL-13 production. 
The co-stimulatory molecule OX40L is involved in the initiation and maintenance of allergic 
responses, mainly driven by TSLP activated dendritic cells 55. Clinical studies that have been 
performed to elucidate the role of OX40L as a possible therapeutic target in asthma and have showed 
that blocking OX40L results in a decrease of serum IgE and eosinophils in asthma 56. OX40L was also 
involved in the Aspergillus-induced Th2 response, which is in line with former studies showing OX40L 
expressed on a variety of cells like activated T-cells, NK cells, B-cells and monocytes 57. We observed a 
low expression of OX40L in PBMCs that was not significantly modulated by TNFα or IL-1. Although it 
is reported that TNFα can increase OX40L expression in smooth muscle cells, significantly higher in 
asthmatic than non-asthmatic patients 30 and TNFα can up-regulate OX40L promoter-activity 31, this 
mechanism appears to play a more prominent role in DC-driven Th2 responses 58. 
 Taking the shifted Aspergillus-induced Th1/Th2 ratio into account, restoring the increased Th1/
Th2-ratio might be an interesting alternative for target-specific immunomodulatory therapy in 
ABPA. Previous studies have shown that neutralizing IL-13 has beneficial effects in an asthmatic 
mouse model 59 by dampening the IL-13 driven allergic airway inflammation. Similarly, blocking IL-4 
has been tried to attenuate allergic airway responsiveness, however the effect was not as strong 
and long-lasting as blocking IL-13 59. Biologicals targeting IL-4, IL-5 and IL-13 have been shown 
to have some efficacy in patients with high Th2 cytokine levels, however optimal biomarkers to 
identify responders and non-responders are still lacking 60. There is only little clinical evidence for 
immunomodulatory treatment with biologicals in ABPA. Omalizumab has been successfully used 
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in a few cases of ABPA with and without CF resulting in a corticosteroid-sparing treatment 61-63. The 
data of this study suggests that IFNγ might be an adequate immunomodulatory therapeutic option 
for ABPA, since it has the capacity to restore the increased Th1/Th2-ratio. Next to lowering the Th2 
response it also supplements the relative Aspergillus-specific IFNγ deficiency. Recombinant IFNγ 
has been used with success in patients with chronic granulomatous disease to prevent Aspergillus 
infection 64 and there are several case reports that describe the beneficial effect of IFNγ treatment in 
Aspergillus infection 65. Thus, IFNγ might contribute to disease control in ABPA by having a beneficial 
effect on clearing the fungal burden thereby decreasing the trigger of the allergic inflammatory 
reaction, and by restoring the increased Th2/Th1 ratio.
 Single nucleotide polymorphisms (SNPs) in the IL10, IL4Rα, MBL, and SFTPA2 genes have been 
associated with an increased susceptibility to ABPA 19. We therefore investigated whether these 
genetic variants could modulate the Aspergillus-induced Th1 or Th2 response. Variants in the MBL 66 
and SFTPA2 67 genes did not lead to different Aspergillus-specific Th2 and Th1 responses. In contrast, 
we could identify a trend between the IL4Rα 68 GG genotype with higher Aspergillus-specific IL-5 
production and Aspergillus-specific Th2/Th1 ratio. We observed a trend in the IL10 (rs1800896) GG 
genotype towards higher IFNγ production. Previous studies have identified this genotype to be 
associated with Aspergillus colonization and ABPA in CF patients 69.
 In conclusion, Aspergillus conidia are unique in triggering Th2 responses in human PBMCs, and 
we provide evidence that CR3 and phagocytosis play a predominant role in Aspergillus-induced Th2 
responses. Moreover, we identified that patients with ABPA have an increased Aspergillus-specific 
Th2/Th1 ratio, and the data in this study together with the clinical experience and safety of IFNγ 
treatment provide a rationale for exploring IFNγ in a clinical trial in patients with ABPA.
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Table S1 | Demographic table of asthma patients
No. age Sex Asp-IgE (U/mL) Asp-IgG (mg/mL) total IgE (U/mL)
Asp-asthma 1 61 M >5 neg 1913
Asp-asthma 2 76 M 11,2 62,1 570
Asp-asthma 3 44 M >5 3,76 52
asthma 1 44 F <0,35 n.a. 79
asthma 2 23 F <0,35 36,2 212
asthma 3 47 F <0,35 4,11 182
asthma 4 47 F <0,35 43,1 95
Age, sex, total IgE (U/mL), Aspergillus-specific IgE (Asp IgE)(U/mL) and Aspergillus-specific 
IgG (Asp-IgG) (mg/mL) of the asthmatic control groups enrolled in this study are listed.
Figure S1 | Th2 response against Aspergillus conidia 
before and after depletion column.
PBMCs were either directly stimulated or mock treated by 
running unlabelled cells of a cell depletion column. PBMCs 
(2.5x106/mL, n=4 donors) were stimulated with Aspergillus 
conidia and IL-5 and IL-13 were measured in the cell culture 
supernatant by ELISA.
Figure S2 | Aspergillus-induced IL-10 in PBMCs 
of ABPA patients and healthy controls
PBMCs (n=9 ABPA patients or healthy controls) 
were stimulated with Aspergillus conidia for 7 
days and IL-10 was measured in the cell culture 
supernatant by ELISA.
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Abstract
Invasive aspergillosis remains one of the most severe complications in immunocompromised 
patients. Recognition of Aspergillus by pattern recognition receptors (PRRs) is crucial for initiating 
host defence to protect against invasive aspergillosis. The intracellular pattern recognition receptors 
nucleotide-binding oligomerization domain (NOD)1 and NOD2 are an important class of PRRs that 
are unexplored in invasive aspergillosis. Studies have suggested a role for NOD2 in the recognition 
of Aspergillus, while nothing is known about NOD1. Here we systematically explored the role of 
NOD1 and NOD2 in the host defence against invasive aspergillosis. Strikingly, immunosuppressed 
(cyclophosphamide) NOD1 and NOD2 deficient mice were protected against invasive aspergillosis, 
which was reflected by significant decreased mortality. NOD2 deficient mice however were clinically 
more ill compared to wild type mice and had increased inflammatory responses, while NOD1 
deficient mice rapidly cleared the infection. In contrast to NOD2 deficient cells, NOD1 deficient 
cells are more efficient at inducing cytokines in response to Aspergillus and at killing A. fumigatus. 
In healthy volunteers, SNPs in NOD1 were associated with an increased Th17 response while SNPs 
in NOD2, like NOD2 deficiency in patients with Crohn’s disease were associated with decreased 
cytokine responses to A. fumigatus, suggesting that NOD1 and NOD2 indeed modulate human host 
defence against Aspergillus. Collectively, our data demonstrates that the NOD receptors are involved 
in the host defence against Aspergillus. In particular we have identified that NOD1 deficiency can be 
protective in an immunosuppressed host with invasive aspergillosis, which makes NOD1 a potential 
treatment target to explore in invasive aspergillosis.
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Introduction
Humans are ubiquitously exposed to Aspergillus, but only the immunocompromised host is at risk 
of developing potentially life-threatening infections. Invasive aspergillosis (IA) is one of the most 
severe complications in immunocompromised patients with high mortality 1. Knowledge of the 
antifungal host response that is required for clearance of the infection is crucial for the development 
of new immunomodulatory therapies. Although the pattern recognition receptor (PRR) pathways 
that play a role in recognition of Aspergillus and activation of the immune system are generally 
known 2,3, still new pathways are being discovered to be involved in Aspergillus recognition. 
An interesting observation is that a patient with Crohn’s disease, deficient for the intracellular 
nucleotide-binding oligomerization domain (NOD)2 receptor developed invasive aspergillosis 
following anti-TNFα treatment 4. Recently, the nucleotide-binding oligomerization domain (NOD)2 
receptor was suggested to play a role in the recognition of Aspergillus-derived chitin 5. Furthermore, 
exposure to Aspergillus was found to increase NOD2 expression in the lungs of mice, THP1 cells and 
A549 cells. In addition, co-stimulation of these cell lines with A. fumigatus and the NOD2 ligand 
GlcNAc-MurNAc dipeptide (MDP) synergistically induced tumour necrosis factor (TNF)α production 
6, and NFκB activation in RAW macrophages was found to be dependent on NOD2 7. An additional 
role for NOD2 has been suggested in the host defence against fungal keratitis. Stimulation of the 
human corneal epithelial cell line (THCE) with Aspergillus was shown to increase NOD2 expression, 
besides IL-8 and TNFα production was found to be partly NOD2 dependent 8. NOD2 belongs to the 
NACHT-LRR receptor (NLR) family and is closely related to NOD1. Both receptors are involved in the 
recognition of peptidoglycan-derived moieties and in the induction of pro-inflammatory 9-13. After 
activation by their ligands, NOD1 and NOD2 recruit their downstream signalling adaptor RICK which 
subsequently activates NFκB 14. Although, previous studies have focused on the role of NOD2 in the 
host response to Aspergillus, the role of NOD1 has not been thoroughly investigated. Furthermore, 
the effect of NOD receptor deficiency on susceptibility to IA remains unexplored. Therefore, in the 
present study we investigated whether deficiency of NOD1 and NOD2 influences susceptibility to 
invasive aspergillosis and whether it affects the immune response to Aspergillus.
Experimental procedures
In vivo experiments | Mice for in vivo experiments were supplied by the breeding center R. Janvier 
(Le Genest Saint-Isle, France). Mice were cared for in accordance with Institut Pasteur guidelines, in 
compliance with European animal welfare regulation. Upon arrival, animals were placed in isolated 
ventilated cages.
 For the survival experiment in an immunosuppressed background C57/BL6 wild-type(5m/6f ), 
NOD1-/- (6m/6f ) and NOD2-/- (7m/2f ) mice (28 to 31g, 10 weeks old) were used. Mice were 
immunosuppressed at day 4 and day 1 before infection by intraperitoneal injection of 200µL 
cyclophosphamide (Sigma Aldrich) at 4 mg/mL. At the day of infection mice were anaesthetized by 
intramuscular injection (150µL) of ketamine (10mg/mL) and xylasine (10mg/mL) hair was shaved 
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from the ventral lung area and subsequently mice were inoculated intranasally with 5x104 luciferase 
expressing A. fumigatus 2/7/1 conidia 15 in 25 µL PBS. 
 In all experiments survival and weight was monitored during the course of infection. 
Bioluminescence imaging was acquired at day 1 post infection (pi) and was continued on day 2, 3, 6 
and 8 pi. Images were acquired using an IVIS 100 system (PerkinElmer, Waltham, MA) as previously 
described 16.
 For immunological assessment female C57/BL6 mice (19 to 22g, 8 weeks old) were used. They 
received similar immunosuppression regimen and were similarly infected as the mice for survival. 
Weight and bioluminescence were monitored daily during the course of infection. At day 3 the mice 
were euthanized. Serum and BAL were collected and lung homogenates were obtained following 
disruption in saline using the Retsch Mixer Mill 301 homogenizer. Cytokines concentrations in lung 
supernatants, BAL, and plasma were determined by ELISA as specified by the manufacturer (DuoSet; 
R&D Systems)
Histology | Sinuses and lungs were removed and immediately fixed in 10% neutral-buffered 
formalin. After fixation, sinuses were decalcified for 1 month, using a chelating agent 
(ethylenediaminetetracetic acid – EDTA) in order to allow routine processing to paraffin while 
preserving high quality morphology. Sinus and lung samples were then embedded in paraffin, 
and cut into 4 µm thick sections. Serial sections were stained with hematoxylin and eosin (HE) for 
description or histological lesions and Grocott’s methenamine silver for fungal detection.
Ex vivo stimulation of WT, NOD1-/- and NOD2-/- murine splenocytes | Wild-type, NOD1-/- and 
NOD2-/- C57Bl/6 mice were bred and maintained in the St. Jude Children’s Research Hospital, 
Memphis, TN, USA. Animal studies were conducted under protocols approved by St. Jude Children’s 
Research Hospital Committee on Use and Care of Animals. Spleens were homogenized in 0,4μM cell 
strainer (BD) and the cell number was adjusted to 1x107/mL. The cell suspensions (500µL /well) were 
placed in a 24 well plates (corning) and incubated with culture medium or Aspergillus conidia for 2 
or 5 days at 37°C and 5% CO2. After stimulation culture supernatants were collected and stored at 
-20°C until cytokine measurement.
Killing of Aspergillus by bonemarrow derived macrophages | Bone marrow from mice (age 
between 8–20 weeks) was flushed out after dissecting mouse legs. Differentiation into macrophages 
(BMDMs) occurred in 5 days at 37°C (5% CO2) in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 30% of L929 supernatant containing 10% foetal bovine serum (heat-inactivated, 
Invitrogen), 100 U / mL penicillin and 100 mg/mL streptomycin. Following differentiation the BMDMs 
(1x105) were exposed to Aspergillus conidia (2x106) in a final volume of 200µL. After 24 hours at 37ºC 
the cells were washed in water and plated in serial dilution on sabouroud agar plates. CFUs were 
counted after 24 hours at 37ºC. 
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ROS induction | The induction of reactive oxygen species were measured by oxidation luminol 
(5-amino-2,3,dihydro-1,4-phtalazinedione). PBMCs (5x105) or BMDMs (1x105) were resuspended in 
HBSS and put in dark 96 well plates. Cells were exposed to HBSS, A. fumigatus conidia (1x107/mL), 
A. fumigatus germs (1x107/mL) or Zymosan (150µg/mL) and immediately 20µL of 1mM luminol was 
added. Chemiluminescence was measured in BioTek Synergy HTreader at 37°C for every minute 
during one hour.
Healthy controls and patients | Venous blood samples from healthy controls and patients were 
obtained after written informed consent and were analysed for polymorphisms in the NOD1 
and NOD2 genes. Six patients with Crohn’s disease that were homozygous for the Leu1007fsinsC 
polymorphism were included for studying NOD2 deficiency after informed consent was obtained.
Aspergillus fumigatus | A clinical isolate of Aspergillus fumigatus V05-27, which has been 
characterized previously 17 was used for all ex vivo and in vitro stimulations. Conidia and Hyphae 
were prepared and heat-inactivated (HI) as previously described.18 A concentration of 1x107/mL 
was used in the experiments, unless otherwise indicated. Aspergillus conidia were FITC labelled as 
previously described 19.
PBMC isolation and stimulation | Venous blood was drawn into 10 ml EDTA tubes. PBMCs were 
isolated as previously described (23). Briefly, blood was diluted in PBS (1:1) and fractions were 
separated by Ficoll (Ficoll-Paque Plus, GE healthcare, Zeist, The Netherlands) density gradient 
centrifugation. Cells were washed twice with PBS and resuspended in RPMI-1640+ (RPMI1640 dutch 
modification supplemented with 10 µg/mL gentamycin, 10 mM L-glutamine and 10 mM pyruvate; 
Gibco, Invitrogen, Breda, The Netherlands).
PBMCs were plated in 96 well roundbottom plates (Corning, NY, USA) at a final concentration 
of 2,5x106 cells/mL and in a total volume of 200 µL. The individuals in the NOD1 and NOD2 
polymorphism cohort were stimulated with medium (negative control) or live Aspergillus at a final 
concentration of 1x107/mL. The NOD2 deficient patients were stimulated in the presence of 10% 
serum with medium, live A. fumigatus conidia (1x107/mL) , HI conidia (1x107/mL) or HI hyphae 
(derived from 1x107/mL conidia). After stimulation culture supernatants were collected and stored 
at -20°C until cytokine measurement. 
Intracellular IL-17, IL-22, and IFNγ flowcytometry | Following 7 days stimulation with A. fumigatus 
conidia, PBMCs were stimulated 4-6 hours with PMA (50 ng/mL) (Sigma-Aldrich), ionomycin (1 
μg/mL) (Sigma-Aldrich) and Golgiplug (BD Biosciences, Breda, the Netherlands) according to the 
protocol supplied by the manufacturer. Cells were stained extracellular using PeCy7-conjugated 
anti-CD4 (BD Biosciences) antibody. Subsequently the cells were fixed and permeabilized with 
Cytofix/Cytoperm solution (eBioscience) according to the protocol supplied by the manufacturer. 
Following permeabilization the cells were stained intracellular with Alexa647-conjugated anti-
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IL-17 (BD Biosciences), PE-conjugated anti-IL-22 (R&D systems) and FITC-conjugated anti-IFNγ 
(eBioscience) according to the protocol supplied by the manufacturers. The cells were measured on 
a FC500 flowcytometer (Beckman Coulter) and the data were analyzed using CXP analysis software 
v2.2 (Beckman Coulter).
Cytokine measurements | The cytokine levels were measured using commercially available ELISA 
assays according to the protocol supplied by the manufacturer. IL-1β, TNFα, IL-17 and IL-22 assays 
were from R&D systems (Minneapolis MN) and Interferon(IFN)γ was from Sanquin (Amsterdam, The 
Netherlands). Mouse IL-1β, TNFα, IL-6, KC, IL-17, IL-22, and IFNγ in splenocyte stimulations were 
measured using the luminex multiplex platform (Millipore, Billerica, MA). For the in vivo experiments 
mouse IL-1β, TNFα, IL-6, KC and G-CSF were measured using commercially available ELISA assays 
from R&D systems according to the protocol supplied by the manufacturer.
Statistical analysis | Data are presented as mean ± standard error of the mean (SEM), unless 
otherwise indicated. Unless otherwise indicated the Mann-Withney U test was used to determine 
statistical significant differences between experimental groups with p<0.05 = *, p<0.01 = ** and 
p<0.001 = ***. All data were analysed using Graphpad Prism v5.0.
Results
NOD1 deficient immunosuppressed mice are protected against invasive aspergillosis
We investigated whether NOD1 and NOD2 deficiency influences the susceptibility of mice to 
lethal Aspergillus infection in imunnocompromised mice. Several survival experiment were 
performed where wild-type C57Bl6 with NOD1-/- and NOD2-/- mice were immunosuppressed with 
cyclophosphamide and subsequently infected with the bioluminescent Aspergillus strain 2/7/1 15. 
In contrast, to wild-type, NOD1 and NOD2 deficient mice were protected against lethal infection 
(Figure 1A). from the NOD1-/- mice 9 out of 12 mice survived and started to recover their weight 
from day 4 post infection, whereas wild-type and NOD2-/- continued to decline in weight (Figure 1B). 
Wild-type mice continued to decline in weight and 10 out of 11 mice did not survive the infection 
whereas 8 out of 9 NOD2-/- mice survived the infection and slowly started to recover from day 6 
pi onwards. Strikingly, there was a significant difference in weight loss between NOD1-/- mice and 
NOD2 -/- mice (Figure 1B), which decreased in weight up to day six but eventually recover from 
the infection. In addition, the NOD2-/- mice demonstrated severe symptoms such as head tilting 
and circling, symptoms that have been described in the in vivo aspergillosis mouse model 20. 
Bioluminescence imaging of the luciferase expressing Aspergillus in the mice revealed that NOD1-
/- and NOD2-/- mice rapidly cleared the infection whereas wild-type developed much higher fungal 
burdens as indicated by the luminescence signal (Figure 1C). 
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NOD1-/- mice do not develop inflammation following Aspergillus infection
To evaluate differences in tissue damage and inflammation in the mice another experiment was 
performed where mice were sacrificed at the peak of infection at day three post infection. All groups 
demonstrated similar weight loss until day 3 post infection (Figure 2A). However, bioluminescence 
imaging of the luciferase expressing Aspergillus revealed that wild-type mice develop high fungal 
burden within the lungs and the sinuses whereas NOD1-/- mice rapidly clear the fungus from the 
lungs. In contrast, NOD2-/- mice keep a stable fungal burden in the lungs following the course of 
Figure 1 | NOD1-/- and NOD2-/- survive lethal A. fumigatus challenge
(A) Kaplan-Meier survival curve of cyclophosphamide immunosuppressed WT (n=11), NOD1-/- (n=12) and 
NOD2-/- (n=9) mice infected intranassaly with 5x104 conidia. P values of the Kaplan-Meier curve were determined 
with the use of the log-rank test. Data represent the cumulative data of four separate experiments (5vs.6vs.4; 
3vs.6vs.0; 3vs.0vs.2; 3vs.0vs.3) . (B) Representative graph of percentage weight loss of surviving mice in one of the 
experiments where survival of WT (n=5; 4 died; n=1 shown), NOD1-/- (n=6; 1 died; n=5 shown) and NOD2-/- (n=4; 
1 died; n=3 shown) mice was compared. Timepoints were compared for significance by two-way ANOVA. (C) 
Bioluminescence signal of luciferase positive A. fumigatus within the mice at day 1, 2, 3, 4, 6 and 8 post infection 
measured (nd = bioluminescence imaging was not performed; † = mouse died). The graphs represent the signal 
of the thoracic and sinus area (each mouse is shown individually).
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infection that is higher than in NOD1-/- mice (Figure 2B and C). To assess systemic inflammation, 
cytokines were measured in the plasma. No difference in IL-1β concentration was observed between 
wild-type and NOD1-/- mice, whereas NOD2-/- mice demonstrate a trend towards elevated IL-1β 
levels. IL-6 levels were lower in the plasma of NOD1 and NOD2 deficient mice but this difference 
was not significant. Interestingly, NOD2-/- mice demonstrate significantly higher KC plasma levels 
than NOD1-/- mice, but no significant difference compared to wild-type was observed (Figure 2D). 
Broncheoalveolar lavages (BALs) and lung homogenates at day 3 post infection were obtained 
to investigate inflammation in the lung. NOD1-/- mice demonstrated no induction of KC and IL-6 
whereas NOD2-/- mice demonstrated increased IL-6 and KC responses compared to NOD1-/- mice 
(Figure 2E). No significant differences were observed in the lung homogenates except a trend 
towards increased TNFα levels when comparing WT and NOD1-/- mice (Figure 2F). 
Figure 2 | Inflammation during Aspergillus challenge in WT, NOD1-/- and NOD2-/- mice
(A) Percentage weightloss following cyclophosphamide immunosuppression and intranasal Aspergillus infection 
(5x104/mouse) in WT (n=4; f ), NOD1-/- (n=4; f ), and NOD2-/- (n=4; f ) mice. (B, C) Luminescence signal at day 1 to 
3 post infection from the luminescent Aspergillus within the mice. (D, E, F) IL-1β, IL-6, KC, G-CSF and TNFα levels 
in (D) serum, (E) broncheo alveolar lavage (BAL), and (F) lung homogenates, measured at day 3 post infection.
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Figure 3 | histolology of sinuses and lungs
(A-I) Histology of Nasal Sinuses of wild-type, NOD1-/- and NOD2-/- mice at day 3 post infection, stained by HE 
staining at (A,D,G) 2x and (B,E,H) 10x magnification and (C,F,I) Grocott’s Methenamine Silver staining at 20x 
magnification. (A-C) Wild-type mice: (A) Unilateral extensive sinusitis (arrowheads), characterised by (B) 
destruction of the mucosa, and (C) a high density of hyphae (arrow), multifocally invading bone (arrowhead). 
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Histology of lungs and nasal sinuses
Histopathological analysis was carried out at day 3 post infection to asses inflammation and 
pathological damage lungs and sinuses. In nasal sinuses, wild-type mice displayed invasive, 
unilateral, subacute sinusitis, characterised by destruction of the mucosa in three out of four mice, 
secondarily extending to bone in two out of four mice, with a high number of hyphae (Figure 3A-C). 
NOD1 deficient mice displayed less severe lesions with bone invasion only in one out of four mice 
(Figure 3D-F). In contrast, NOD2 deficient mice did not display any nasal sinus lesions (Figure 3G-
I). In the lung, lesions were only observed in the wild-type group. Multifocal necrotic lesions were 
identified, centred on bronchi/bronchioles, but secondarily extending to blood vessels and alveoli, 
characterised by destruction of the mucosa and marked necrosis of epithelial cells, destruction of 
blood vessel walls with multifocal thrombi, and high density of hyphae. (Figure 3J-L). In contrast, no 
histological lesions were observed in the lungs of NOD1 and NOD2 deficient mice (Figure 3M-R), 
except for a very small focus of infection in one out of four NOD2-deficient mice, containing only a 
few hyphae (data not shown). 
NOD receptor deficiency differentially modulates ex vivo cytokine responses in murine cells
To explain the observed protection of NOD1 and NOD2 deficiency it was investigated how NOD1 
and NOD2 influence the cytokine response against A. fumigatus. Splenocytes were isolated from 
naive NOD1-/-, NOD2-/-, and WT C57Bl/6 mice, and stimulated with Aspergillus and cytokine responses 
were compared (Figure 4A and B). Although the cytokine responses induced were generally 
low, a trend towards decreased TNFα, IL-6 (Figure 4A) responses could be observed with NOD2-
/- splenocytes, whereas IL-17, IL-22 and IFNγ were undetectable (ud) in the culture supernatants 
(Figure 4B). In contrast, splenocytes of NOD1-/- mice induced significantly more TNFα and KC in 
response to Aspergillus (Figure 4A). The T-cell cytokines IL-17 and IFNγ were undetectable (ud) and 
IL-22 was very poorly induced in the culture supernatants by wild-type mice, but these cytokines 
were significantly elevated in NOD1-/- splenocytes (Figure 4B). In addition to cytokine responses of 
splenocytes we investigated cytokine responses in bone marrow derived macrophages (BMDMs). 
Similar to splenocytes, BMDMs from NOD1-/- mice demonstrated significantly increased cytokine 
responses, with high production of IL-6 and KC, while the responses of NOD2-/- BMDMs were similar 
to wild-type (Figure 4C).
(Figure 3 continued) (D-F) NOD1 deficient mice: (D) Focal unilateral sinusitis (arrowhead), with (E) destruction 
of the mucosa, less severe than lesions observed in sinuses of wildtype mice, and (F) hyphae, focally invading 
bone (in only 1/4 mouse) (arrowhead). (G-I) NOD2 deficient mice: (G,H) No histological lesions and (I) no hyphae 
detected in the tissue (only 1/4 mouse displayed a minimal lesion with very few hyphae; data not shown).
(J-R) Histology of Lungs of wild-type, NOD1-/- and NOD2-/- mice at day 3 post infection, stained by HE staining at 
(J,M,P) 2x and (K,N,Q) 10x magnification and (L,O,R) Grocott’s Methenamine Silver staining at 10x magnification. 
(J-L) Wild-type mice: (J) Multifocal lesions (arrowheads), (K) centred on bronchi/bronchioles and secondary 
extending to blood vessels (arrow) and alveoli, characterised by necrosis of lung parenchyma and (L) marked 
invasion by a high density of hyphae (arrow: blood vessel infiltrated by hyphae). (M-N, P-Q) NOD1 and NOD2 
deficient mice: No histological lesion and (O,R) no hyphae detected in the pulmonary tissue.
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 In addition to cytokine responses, the capacity to kill A. fumigatus conidia by wild-type, NOD1-
/- and NOD2-/- BMDMs was investigated. NOD1-/- BMDMs where more efficient in killing Aspergillus 
conidia than wild-type BMDMs (Figure 4D) reflected by reduced outgrowth of hyphae (Figure 
4E). NOD2-/- BMDMs did not demonstrate a difference in killing Aspergillus compared to wild-type 
BMDMs. In addition, the capacity to generate an oxidative burst was investigated. Within the 
timeframe that luminescence was measured, the area under the curve was calculated to illustrate 
the quantitative difference in ROS release (Figure 4G and H). with zymosan (Figure 4G) or Aspergillus 
(Figure 4H). Zymosan-induced ROS release by BMDMs was significantly higher in NOD1-/- BMDMs 
compared to wild-type BMDMs (Figure 4F and G). Although serum opsonised Aspergillus dormant 
conidia and germinated conidia induced ROS at much lower levels than zymosan, NOD1-/-. BMDMs 
again induced more ROS. By contrast, zymosan and Aspergillus-induced ROS induction by NOD2-/- 
BMDMs was significantly lower than wild-type BMDMs.
Figure 4 | in vitro responses of murine NOD1 and NOD2 deficient splenocytes and fungal killing by BMDMs
(A) IL-6, TNFα, KC, (B) IL-17, IL-22 and IFNγ levels in culture supernatants of splenocytes from WT, NOD1-/- and 
NOD2-/- mice (n=5 mice per group) that were stimulated for either (A) 24 hours or (B) 5 days with heat inactivated 
Aspergillus conidia. (C) CFU remaining of A. fumigatus (2x106) following exposure for 24 hours to WT, NOD1-/- 
and NOD2-/- BMDMs (1x105) (D) ROS release by wild-type, NOD1-/- and NOD2-/- BMDMs following exposure to 
zymosan. Timepoints were compared for significance by two-way ANOVA. (E) area under the curve of the ROS 
luminescence data. Data in bar plots is represented as mean ± SEM and means were compared using the Mann 
Whitney U test. ud = undetectable.
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Human NOD2 deficiency results in reduced innate and adaptive cytokine responses to A. fumigatus
Since we observed an interesting phenotype of protection with NOD receptor deficiency in mice, we 
decided to further investigate these receptors in human cells. We first investigated the host response 
against Aspergillus within a background of human NOD2 deficiency. The 1007 frame shift mutation is 
highly associated with Crohn’s disease and results in a defective NOD2 receptor 21. PBMCs from patients 
with Crohn’s disease that were deficient for the NOD2 receptor due to homozygous carriage of a 
frameshift due to a insertion of cystein at position 1007 (1007finsC) were obtained, and were stimulated 
with different morphotypes of A. fumigatus. Compared to wild-type controls, NOD2 deficient PBMCs 
demonstrated lower IL-1β and TNFα responses to the different morphological forms of A. fumigatus 
(Figure 5A). Healthy volunteers demonstrated synergism upon co-stimulation with MDP whereas the 
NOD2 deficient patients demonstrated no change from the stimulation with Aspergillus alone, which 
conforms the complete NOD2 deficiency of these human cells (Figure 5B). Moreover, NOD2 deficient 
PBMCs showed a significant reduction in the ability to generate T-cell cytokines IL-17, IL-22 and IFNγ 
(Figure 5C). These reduced cytokine responses correlated with a reduced induction of IL-17+, IL-22+ and 
IFNγ+ CD4 T-cells within the PBMC population of NOD2 deficient individuals (Figure 5D). 
 We next investigated polymorphisms in NOD2. Individuals with a heterozygous genotype for 
the 1007fins polymorphism (rs2066847) demonstrated significant lower IL-1β and a trend towards 
lower TNFα and IL-6 in response to live Aspergillus (Figure 6A). The decreased IL-1β induction in 
these individuals also correlated to significantly lower IL-17 responses in individuals carrying the 
Figure 5 | Human NOD2 deficiency results in reduced innate and adaptive cytokine responses to A. fumigatus 
(A) IL-1β and TNFα levels in culture supernatants of PBMCs from healthy controls (black bars) and NOD2 deficient 
patients (grey bars) that were either stimulated for 24 hours with Aspergillus fumigatus live conidia, HI conidia or 
HI hyphae for induction of IL-1β and TNFα (n=6 donors) or (B) stimulated with HI conidia, MDP or a combination 
of HI conidia and MDP (n=9 donors). (C) IL-17, IL-22 and IFNγ levels after 7 days of stimulation with HI conidia or 
HI hyphae (n=6 donors). (D) IL-17+, IL-22+ and IFNγ+ CD4 T-cell populations (n=5 donors) after 7 days stimulation 
with HI conidia shown as percentage from total CD4 cells.. The bars represent Means ± SEM and the means 
of both groups were compared for significance using the Mann Withney U test p-values of statistical tests are 
shown within the graphs.
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Figure 6 | NOD1 and NOD2 genetic 
variants
(A-F) IL-1β, TNFα, IL-6, IL-17, IL-22 
and IFNγ levels measured in culture 
supernatants of PBMCs simulated with 
live (A, C and E) Aspergillus conidia for 
24 hours or (B, D and F) heat killed 
Aspergillus conidia for 7 days. The 
PBMCs of individuals with various 
genotypes of the NOD2 receptor 
were compared. These genotypes 
included (A and B) the 1007finsC 
mutation (ancesteral;Wt n=62 and 
heterozygous;insC n=4) and (C and 
D) the P268S mutation (ancesteral;CC 
n=36, heterozygous;CT n=28 and 
homozygous;TT n=4). (E,F) The PBMCs 
of individuals with various genotypes in 
the NOD1 ND1+32656 T/GG insertion/
deletion allele were compared 
(ancesteral;T/T n=36, heterozygous;T/
GG n=23 and homozygous;GG/GG n=5) 
Data is represented as mean ±SEM and 
means were compared using the Mann 
Whitney U test, p-values of statistical 
tests are shown within the graphs.
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C insertion on one allele (Figure 6B). Interestingly Aspergillus-induced IFNγ production was not 
affected by this genotype. In addition to the 1007fins polymorphism, we investigated other common 
genetic variants within the NOD2 gene namely: P268S (rs2066842), G908R (rs2066845) and R702W 
(rs2066844) polymorphisms. Individuals carrying the T allele for the P268S polymorphism induced 
significantly lower IL-1β and a trend towards lower TNFα responses in response to Aspergillus 
stimulation (Figure 6C). Additionally, the TT genotype was associated with a significantly lower IL-
17 production when comparing the response of these individuals with the GG and GT genotypes 
(Figure 6D). Individuals that were heterozygous for the G908R and R702W polymorphisms did not 
demonstrate altered cytokine responses to Aspergillus (data not shown). Homozygous G908R and 
R702W polymorphisms were not represented within our cohort.
 The ND1+32656 T/GG mutation in NOD1 has been associated with inflammatory bowel 
disease 22 and asthma 23 previously. Since it involvement in inflammatory disease we investigate 
using this polymorphism whether this genetic variant could reveal a role for NOD1 in the human 
host response to Aspergillus. We stimulated PBMCs of individuals carrying the ND1+32656 GG 
insertion and compared the cytokine response to carriers of the ND1+32656 T deletion (wild-type). 
Individuals that were heterozygous or homozygous for the ND1+32656 GG insertion variant had 
IL-1β, TNFα and IL-6 responses compared to wildtype (Figure 6E). However, IL-17 was significantly 
higher in individuals having the GG/GG genotype, but IL-22 and IFNγ were not significantly affected 
by the presence of this polymorphism (Figure 6F).
Discussion
PRRs are key players in inducing antifungal host responses during invasive aspergillosis by inducing 
cytokine responses and facilitating phagocytosis. Extracellular PRRs, such as Toll-like receptors and 
C-type lectin receptors, have been extensively described in inducing these responses in response to 
Aspergillus 2. However, there is only limited evidence for a role of the intracellular NACHT-LRR receptors 
(NLRs) in the host defence against A. fumigatus 6-8. In the current report we investigated the role the 
NOD receptors in the host response against A. fumigatus and susceptibility to invasive aspergillosis. 
 Immunosuppression that is needed for the treatment of cancer and autoimmune disorders, 
makes patients highly susceptible to invasive fungal infections such as invasive aspergillosis. 
Cyclophosphamide is an immunosuppressive drug used to suppress the immune system in 
mice and render them highly susceptible to develop infections with Aspergillus fumigatus. This 
immunosuppression allows a low dose of intranasally administered Aspergillus conidia, which in 
immunocompetent mice would have been quickly cleared, to induce an invasive infection that is 
lethal in days 20. In the current study we observed that NOD1 and NOD2 deficient mice were protected 
against aspergillosis while being immunosuppressed by cyclophosphamide. That a deficiency in 
pattern recognition receptors can protect against lethal aspergillosis is a striking observation. Especially 
when bearing in mind that it is challenging to protect immunosuppressed mice even with available 
potent antifungal therapies , which often requires combinational therapies to achieve survival of the 
mice 24,25. Although NOD1 and NOD2 deficient mice are both protected against Aspergillus infection, 
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there is a big contrast between these mice. NOD1-/- mice quickly resolve the infection, whereas NOD2-
/- mice developed severe symptoms and recovered significantly slower. This is in line with a previous 
study that demonstrated that Staphylococcus aureus pneumonia in NOD2 deficient mice was recovery 
than controlled the pneumonia then in wild-type animals 26. However, such a protective effect during 
an infection has, to our knowledge, not been described for NOD1 deficiency. In contrast to NOD2 
deficient mice, the NOD1 deficient mice demonstrated rapid fungal clearance following the infection, 
which was associated with no histological damage and fungal outgrowth in the lungs following lethal 
Aspergillus infection. Moreover, NOD1-/- cells demonstrated an increased capacity to produce pro-
inflammatory cytokines. In line with these data a previous study demonstrated that NOD1 deficient 
mice are more prone to develop inflammation in a model for arthritis 27, and the ND1+32656 GG 
insertion polymorphism is associated with increased pro-inflammatory capacity of human cells and an 
increased clinical severity in patients with arthritis 28. However, the NOD1 receptor was found to play an 
important role in host defence against bacterial pathogens such as Pseusomonas aeruginosa 29, Shigella 
flexineri 30 and Helicobacter pylori 31 where NOD1 was required for an effective cytokine response 29,30 
and killing of the pathogen 29,31. In contrast to these studies, our data shows that NOD1 deficiency 
results in an increased pro-inflammatory cytokine response and increased fungal killing, suggesting 
that NOD1 exerts an inhibitory effect on the antifungal host response against Aspergillus. How NOD1 
deficiency enhances these mechanisms remains to be determined. We observed that NOD1 deficient 
macrophages demonstrate an enhanced oxidative burst upon stimulation with Zymosan. Although 
zymosan is recognised by dectin-1 and TLR2 32, the NOD receptors are known to have interplay with 
TLRs via their downstream kinase RICK, and in particular with TLR2 27,33-35. Deficiency of NOD1 could 
therefore very well impact ROS release induced via dectin-1 and TLR2. ROS is crucial for the host 
defence against Aspergillus, which is illustrated by patients with chronic granulomatous disease with 
a defect in NADPH dependent ROS production are highly susceptible to infections with Aspergillus36,37. 
In addition, ROS has been shown to be involved in activation of the inflammasome by Aspergillus 38 
which could explain the enhanced cytokine release by NOD1-/- cells. This potent protective effect of 
NOD1 deficiency makes it tempting to suggest blockade of NOD1 as a novel treatment strategy for 
invasive aspergillosis. Currently, no pharmacological inhibitors are available to block NOD1 in vivo, but 
recently small molecule inhibitors have been identified that could potentially be used for therapy 39.
 We also found that NOD2 deficient mice were protected against invasive aspergillosis. However, 
these mice demonstrated a different phenotype than NOD1 deficient mice. We did not observe an 
enhanced oxidative burst as in the NOD1-/- cells. Moreover, cytokine responses in human and murine 
NOD2 deficient cells were decreased. This decreased inflammatory response could potentially 
explain why NOD2-/- mice are protected against IA. It has repeatedly been described that excessive 
inflammation and Th17-mediated inflammation can result in detrimental immunopathology during 
Aspergillus infections in mice 40-42. NOD2 activation was previously demonstrated to play a significant 
role in activating the Th17 response 43. In line with this we found that human NOD2 deficiency 
results in decreased Aspergillus-induced cytokine responses and T-cell proliferation, including IL-17+ 
cells. In addition, NOD2 deficient mice demonstrated less inflammation than wild-type mice. These 
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data suggest that, compared to wild-type, NOD2-/- mice are better able to cope with the Aspergillus 
infection due to their reduced inflammatory responses. 
 It is interesting that deficiency of NOD1 and NOD2 have different phenotypes in terms of 
disease, cytokine production, phagocytic capacity and ROS release, when considering that these 
receptors interact with each other through their shared downstream co-receptor RICK. A potential 
explanation for the differential phenotype is that both NOD1 and NOD2 compete for RICK as was 
previously proposed to explain differential regulation of inflammation by NOD1 and NOD2 in 
streptococcal cell wall fragments induced arthritis 27. Another explanation for differential regulation 
by NOD1 and NOD2 is that one, or both, of these receptors can, in addition to RICK, bind an 
alternative signalling cascade. In line with this it has previously been demonstrated that NOD2 can 
additionally signal through the intracellular adaptor CARD9 44, which has previously been associated 
with host response against fungi 45,46. 
 An important question that remains to be answered is how NOD1 and NOD2 are involved in the 
host defence against Aspergillus. It could be hypothesised that these receptors directly sense fungal 
PAMPs or that they modulate responses of other PRRs that are involved in recognition of Aspergillus. 
The NOD receptors have been discovered as receptors for derivates of bacterial peptidoglycan. NOD2 
recognizes MDP which is present in the peptidoglycan of both gram positive and negative bacteria 
9,11,12, and NOD1 recognizes diaminopimelate-containing GlcNAc-MurNAc-tripeptide muropeptide 
(GM-TriDAP) which is present in the peptidoglycan of gram negative bacteria 10,12,13. However, fungi 
such as Aspergillus fumigatus have neither of these peptidoglycan derived molecules, but their cell 
wall is rich in PAMPs 47 that might serve as potential ligands for NOD receptors. Although it has 
previously been shown that other fungi such as Candida albicans are not recognised by NOD2 48,49, 
the cell wall structure chitin that is present in both Aspergillus and Candida is being suggested to 
target NACHT-LRR receptors (NLRs) 5,50. Chitosan, a deacitylated form of chitin was found to activate 
the NLR, NOD-like receptor family, pyrin domain containing 3 (NLRP3) and thereby activate the 
inflammasome and induce IL-1β production, whereas chitin did not activate NLRP3 50. However, 
chitin was also found to induce IL-10 via TLR9, mannose receptor and NOD2 dependent mechanisms 
5. Suggesting that NLRs, such as NLRP3 and NOD2 play a role in recognition of fungal molecules 
such as chitin. However, further studies are required to further identify the PAMPs in Aspergillus 
that are recognised by NOD1 and NOD2. It is also possible that the NOD receptors are not directly 
involved in recognising Aspergillus, but rather coordinate the responses that are induced by other 
(membrane bound) PRRs. Both NOD1 and NOD2 have extensively described to synergise with TLRs 
51-55. By selectively modulating signals from PRRs that recognise Aspergillus it is possible that the 
NOD receptors differentially regulate the host response against A. fumigatus.
 Collectively, we conclude that the absence of NOD1 enhances the protective host response 
against Aspergillus in an immunocompromised setting, by enhancing oxidative burst and fungal 
killing. In contrast NOD2 seems to be involved in mounting innate and adaptive cytokine responses 
against Aspergillus. This paves the way for the development of new treatment strategies for invasive 
aspergillosis that target NOD1.
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Part 2
Cytokines involved in orchestrating the 
antifungal immune response
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Abstract
The IL-1 family consists of 11 members, which all play significant roles in regulating inflammatory 
responses in the host. IL-1α and IL-1β exert potent pro-inflammatory effects and are key players in 
the recruitment of neutrophils to the site of inflammation. Protective anti-Aspergillus host responses 
during the early stages of invasive aspergillosis are critically dependent on neutrophil recruitment, 
and several lines of evidence support that there is an important role for IL-1 in this process. However, 
IL-1-mediated inflammation needs to be tightly regulated, since uncontrolled inflammation can 
result in inflammatory pathology and thereby be detrimental for the host. Aspergillus-induced 
IL-1-mediated inflammation could therefore be amendable for IL-1 blockade under specific 
circumstances. This review describes the current understanding of the role of IL-1 family members 
in the host response against Aspergillus fumigatus and highlights the importance of balanced IL-1 
responses in aspergillosis.
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Introduction 
Since its discovery, interleukin (IL)-1 has been found to be a crucial cytokine in the host defence 
against a broad range of pathogens, ranging from bacteria to parasites and fungi. Initially, IL-1 was 
described as a single cytokine, but to date the IL-1 cytokine family consists of 11 members 1. In this 
family, the classical IL-1 cytokines are IL-1α and IL-1β, which are often described together as IL-1. 
IL-1β is primarily produced by innate immune cells such as monocytes, macrophages and dendritic 
cells upon activation. IL-1α also is induced by cells of the innate immune system, but also more 
widely expressed in different cell types, including pulmonary epithelial cells where it is released 
upon cell death 2. Over the last years, the cytokines from the IL-1 family, and in particular IL-1β, 
have been studied for their role in antifungal host response against Aspergillus fumigatus. This 
review summarizes the findings reported on the role of the IL-1 family members in the antifungal 
host response against A. fumigatus. 
IL-1 expression, processing and secretion induced by A. fumigatus 
IL-1β is a potent pro-inflammatory cytokine; therefore, its release by immune cells is tightly 
regulated. Transcriptional analysis of monocytes exposed to A. fumigatus demonstrated that resting 
conidia could induce IL1A and IL1B expression; however, swollen conidia, germinated conidia and 
hyphae were more potent in inducing IL1A and IL1B expression 3. Additional studies have shown 
that hyphal fragments 4 or live conidia 5 but not (inactive) resting conidia induce IL1B transcription. 
These data suggest that pathogen associated molecular patterns (PAMPs) that are being exposed 
on the Aspergillus cell wall following germination are different and are more potent in inducing IL-1. 
 An important aspect of IL-1β is that its mRNA translates into an inactive precursor, namely pro-
IL-1β, which requires processing to become fully bioactive IL-1β. This processing can be performed 
by a protein complex called the inflammasome that induces activation of caspase-1, which 
proteolytically removes the pro- part 6. Aspergillus induces inflammasome activation dependent 
on reactive oxygen species (ROS) and potassium influx 4. PAMPs in the Aspergillus cell wall are 
recognized by pattern recognition receptors (PRRs), such as C-type lectin receptors (CLRs) or Toll-
like receptors (TLRs) 7. Both MyD88 (downstream adaptor of TLRs and the IL-1 receptor) and spleen 
tyrosine kinase (Syk) (downstream adaptor molecule of CLRs, like dectin-1) were found to play a 
significant role in pro-IL-1β induction and secretion of mature IL-1β in response to Aspergillus 4. 
However, neutralization of Syk, but not MyD88, was found to prevent inflammasome activation 4. 
This suggests that MyD88 only regulates IL1B transcription, while Syk regulates both its transcription 
and processing. Interestingly, when pro-IL-1β is released extracellularly, it can also be processed 
by inflammasome-independent mechanisms, such as cleavage by neutrophil serine proteases 
like proteinase-3 8. Several reports have demonstrated that the dectin-1/Syk 9,10 and dectin-2-Syk 
5 pathways play a prominent role in the induction of IL-1 responses by A. fumigatus. Blockade of 
dectin-1 decreases Aspergillus-induced IL-1α and IL-1β 9 and dectin-1-/- mice fail to induce strong IL-
1α and IL-1β responses 10. Furthermore, dectin-2 regulates the induction of IL1B expression as well as 
IL-1β protein secretion 5. Macrophages isolated from TLR4- and TLR2-deficient mice have impaired 
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IL-1α and IL-1β production in response to A. fumigatus conidia 11. Interestingly, after interaction with 
germinated Aspergillus conidia, TLR4-/-macrophages showed no impaired IL-1 response, suggesting 
that the ligand for TLR4 on the hyphal cell wall that mediates induction of the IL-1 response is either 
absent or masked. Figure 1 visualizes the mechanism of IL-1 induction, processing and release of 
innate immune cells in response to A. fumigatus.
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Figure 1 | IL-1 processing and secretion induced by A. fumigatus
Schematic overview of IL1 transcription induction by Aspergillus fumigatus through MyD88 and Syk-dependent 
pathways. Subsequently IL1B mRNA is translated into the inactive precursor pro-IL-1β which can subsequently 
be processed into its active form by the protein complex the inflammasome. Upon cell damage, pro-IL-1β can be 
released which can be processed extracellular by serine proteases such as proteinase-3.
Effects of IL-1 signalling in host defence against Aspergillus
After its release, IL-1 can bind to the IL-1 type1 receptor (IL-1R1), which is followed by the recruitment of 
IL-1 receptor accessory protein (IL-1RAcP) 12. Recruitment of IL-1RAcP to IL-1R1 results in activation of 
signal transduction pathways, leading to activation of MyD88, thereby exerting potent inflammatory 
activities. The recruitment of inflammatory cells, particularly neutrophils, is driven by IL-1 signalling 
12,13. During Aspergillus infection, IL-1β can be detected in the lung 14, where it can directly induce 
chemokine release by pulmonary epithelial cells, which results in neutrophil recruitment 13. In 
addition to the induction of innate immune responses, IL-1 plays a key role in induction of T-helper 
cell responses by A. fumigatus 15,16. The Aspergillus-induced T-helper cytokines IL-17 and IL-22 are 
tightly regulated by IL-1, since IL-1R neutralization by recombinant IL-1Ra completely abolishes 
these responses 15. These responses amplify the pro-inflammatory effects of IL-1, as IL-17 plays a 
crucial role in neutrophil recruitment, and IL-22 regulates production of antimicrobial peptides by 
pulmonary epithelial cells 17,18. Additionally, IL-1R blockade demonstrated that IL-1 also regulates 
Aspergillus-induced Th1 (IFNγ) 16,19 and Th2 (IL-5 and IL-13) responses in humans 20.
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Pro-inflammatory effects of IL-1 in aspergillosis
Monocyte-derived macrophages from patients with chronic cavitary pulmonary aspergillosis 
(CCPA) persistently express IL1A and IL1B upon stimulation with Aspergillus, compared to healthy 
controls who did not demonstrate this phenomenon 21. This suggests that constant IL-1 expression 
could play an important role in the pathogenesis of CCPA due to continuous activation of the pro-
inflammatory immune response. 
 Although IL-1 signalling is generally associated with protection against infection 22, a previous 
report showed that IL-1R1-/- mice have no attenuated survival upon challenge with A. fumigatus; these 
mice demonstrated even a slightly increased survival and a significantly reduced fungal burden 23. In 
contrast to this observation, IL-1R1-/- mice have recently been described to be highly susceptible to 
Aspergillus infection, showing increased fungal growth, dissemination and pulmonary pathology 24. 
These conflicting observations could be explained by the different aspergillosis models used in these 
studies. Since IL-1 can promote immunopathology in the lung, it would be beneficial to have no 
IL-1 signalling in a model where the Aspergillus infection induces inflammatory pathology. However, 
when the model is highly dependent on IL-1-induced neutrophil recruitment, it will be detrimental 
for the host to have no IL-1 signalling, which is required to promote early fungal clearance (figure 
2). This differential role of the IL-1 axis is particularly illustrated within dectin-1-/- mice. As previously 
mentioned, dectin-1-/- mice fail to induce strong IL-1α and IL-1β responses, which results in a failure 
to induce an adequate IL-17 response and increased mortality in a model of invasive aspergillosis 
(IA) 10. However, in an allergic model , with chronic exposure to A. fumigatus, the dectin-1-/- mice have 
decreased IL-1β levels, which is associated with reduced IL-22-associated immunopathology 25.
Anti-inflammatory effects of IL-1Ra
IL-1 receptor antagonist (IL-1Ra) is a potent endogenous anti-inflammatory cytokine that regulates 
IL-1 bioactivity by competing with pro-inflammatory IL-1 molecules (IL-1α and IL-1β). Upon binding 
of IL-1Ra to the IL-1R1, there will be no recruitment of IL-1RAcP and no IL-1 signal transduction 
12,26. The A. fumigatus cell wall polysaccharide galactosaminogalactan (GAG) exerts potent anti-
inflammatory effects by diminishing neutrophil recruitment and favouring fungal infection 27. Recent 
studies exploring these anti-inflammatory effects have shown that GAG is a crucial adherence factor 
28 and could specifically induce IL-1Ra, thereby inhibiting the IL-1 axis and induction of T-helper 
responses, resulting in an increased susceptibility against aspergillosis 16. This supports the concept 
that in early stages of Aspergillus infection deficient IL-1 signalling can be detrimental, because in 
these stages it is crucial to control fungal growth by neutrophils, which is dependent on IL-1.
 A group of patients that are specifically prone to develop severe infections with Aspergillus are 
patients with chronic granulomatous disease (CGD) 29,30. These patients have a defect in NADPH 
oxidase-dependent ROS production and fail to induce a form of non-canonical autophagy, namely 
LC3-associated phagocytosis (LAP) 31,32. LAP is an important mechanism that is required for effective 
microbial killing and antigen presentation 33,34. Despite the fact that these patients are unable to 
induce NADPH-dependent ROS, these patients demonstrate increased inflammasome activation, 
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which correlates with increased IL-1β production 35. The blockade of IL-1 signalling by IL-1Ra in 
these patients resulted in reduced inflammation 36. This is in line with the concept that uncontrolled 
increased IL-1-mediated inflammation is detrimental for the host and can be a target in CGD.
 Monocytes from CGD patients that are stimulated in the presence of IL-1Ra demonstrate a 
restored Aspergillus-induced LAP. Moreover, IL-1Ra administration reduces fungal burden and 
rescues p47phox-/-  (CGD) mice in a model of IA 
32. Thus, IL-1Ra could contribute to increased fungal 
clearance in the setting of a defect in LC3-associated phagocytosis, such as in patients with CGD, by 
inducing autophagy 32. The mechanism by which IL-1Ra induces non-canonical autophagy remains 
to be identified.
IL-1 polymorphisms as genetic susceptibility markers for aspergillosis
Polymorphisms within genes of the immune system that are common in the general population 
can influence the ability to mount an effective antifungal host response. Analysis of polymorphisms 
within the IL-1 gene cluster consisting of IL1A, IL1B and IL1RN revealed that the IL1B -511T allele 
(rs1143627) correlates with incidence of IA in haematological patients 37. Although, IL1A and IL1RN 
polymorphisms were not directly associated with IA, a haplotype consisting of the IL1RN VNTR2 
(rs380092), IL1A -889C (rs1800587) and IL1B -511T alleles was highly associated with the development 
of IA. In CCPA, an intronic insertion deletion in IL1B (rs3917354) and a 3’UTR polymorphism in IL1RN 
(rs4252041) were found to be associated with the development of CCPA when comparing CCPA 
patients with healthy controls 21.
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Figure 2 | Beneficial and detrimental effects of IL-1 depending on the type and stage of Aspergillus disease
When the host response is dependent on neutrophils to clear Aspergillus infection, such as during the early 
stages of invasive pulmonary aspergillosis, IL-1 is crucial for an optimal protective host defence. However, in the 
setting of an exaggerated inflammatory response mediated by Aspergillus, IL-1 can play a detrimental role by 
maintaining neutrophil influx, increased Th17 responses leading to tissue damage.
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Novel IL-1 family members 
The IL-1 family not only consists of IL-1α, IL-1β and IL-1Ra but also other IL-1 family cytokines, such 
as IL-33 and IL-18. A subset of the new IL-1 family members has recently been renamed according 
to new insights in their biological function, namely IL-36, IL-37 and IL-38 38. IL-36 consists of three 
agonistic cytokines, namely IL-36α (IL-1F6), IL-36β (IL-1F8) and IL-36γ (IL-1F9) and one antagonistic 
cytokine IL-36Ra (IL-1F5)38. IL-1 and IL-36 are quite similar in their biological function. IL-36 cytokines 
are agonists of the IL-1 receptor related protein 2 (IL-1Rrp2), now also known as the IL-36R, that 
requires, like the IL-1R1, IL-1RAcP as a co-receptor for signal transduction 39. Furthermore, IL-36Ra 
inhibits signalling by binding to IL-36R competitively with the IL-36R agonists and preventing IL-
1RAcP recruitment , which is similar to how IL-1Ra inhibits IL-1R1 signalling 40. 
 The IL-36 receptor signalling pathway plays a role in the host response against A. fumigatus by 
regulating the induction of T-cell cytokines such as IL-17 and IFNγ, but not the Th2 response 41. IL-38 
(IL-1F10) was shown to exhibit similar receptor-antagonizing functions as IL-36Ra in the induction of 
T-cell cytokine responses by Candida albicans 42. However, it remains to be elucidated whether IL-38 
also plays a role in the host response against A. fumigatus. IL-37 (IL-1F7) is a novel anti-inflammatory 
cytokine the IL-1 family. It binds the IL-18 receptor, but does not compete with IL-18 43, and intracellularly 
it can form a functional complex together with Smad3 to suppress innate immune responses 44. The 
role of IL-37 in antifungal host defence against Aspergillus is currently under investigation. 
Future perspectives
The present data demonstrate the importance of IL-1 in controlling fungal clearance in Aspergillus 
infections, as well as a role for IL-1 in the inflammatory pathology of Aspergillus-associated diseases. 
Therefore, blocking IL-1 with the available biological anakinra, which is recombinant IL-1Ra, can 
be explored in Aspergillus-related diseases, such as IA in CGD or fungal asthma, but the timing and 
at what stage anakinra treatment should be given will be crucial. Predicting which patients are at 
high risk of developing IA could provide a powerful tool to stratify patients in need for intensive 
monitoring or prophylactic antifungal therapy. Based on the current literature and ongoing studies 
that demonstrate an association between IL-1 polymorphisms and susceptibility to aspergillosis, we 
suggest that IL-1 is a suitable candidate for predicting genetic susceptibility to aspergillosis.
 The novel IL-1 family cytokines IL-36 and IL-38 could play a significant role in the host defence 
against A. fumigatus. These cytokines are differentially expressed within tissues and cell types, and 
therefore, they could be of specific interest in targeting them during inflammation. Although IL-
36 cytokines were primarily found to play a role in the pathogenesis of psoriasis 45, they were also 
found to play a prominent role in inflammation and neutrophil influx in the lungs independent of 
IL-1α and IL-1β 46,47. Furthermore, they play a role in allergen-induced inflammation in the lung 48 
and were differentially regulated in patients with chronic obstructive pulmonary disease (COPD) 
exacerbations 49. With this knowledge in hindsight, we suggest that these cytokines could potentially 
play an important role in fungal sensitization and allergic bronchopulmonary aspergillosis (ABPA), 
and might be promising targets in Aspergillus-related allergic diseases.
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Abstract
The galactosaminogalactan (GAG) is a cell wall component of Aspergillus fumigatus that has potent 
anti-inflammatory effects in mice. However, the mechanisms responsible for the anti-inflammatory 
property of GAG remain to be elucidated. In the present study we used in vitro PBMC stimulation 
assays to demonstrate, that GAG inhibits pro-inflammatory T-helper (Th)1 and Th17 cytokine 
production in human PBMCs by inducing Interleukin-1 receptor antagonist (IL-1Ra), a potent anti-
inflammatory cytokine that blocks IL-1 signalling. GAG cannot suppress human T-helper cytokine 
production in the presence of neutralizing antibodies against IL-1Ra. In a mouse model of invasive 
aspergillosis, GAG induces IL-1Ra in vivo, and the increased susceptibility to invasive aspergillosis 
in the presence of GAG in wild type mice is not observed in mice deficient for IL-1Ra. Additionally, 
we demonstrate that the capacity of GAG to induce IL-1Ra could also be used for treatment of 
inflammatory diseases, as GAG was able to reduce severity of an experimental model of allergic 
aspergillosis, and in a murine DSS-induced colitis model. In the setting of invasive aspergillosis GAG 
has a significant immunomodulatory function by inducing IL-1Ra and notably IL-1Ra knockout mice 
are completely protected to invasive pulmonary aspergillosis. This opens new treatment strategies 
that target IL-1Ra in the setting of acute invasive fungal infection. However, the observation that 
GAG can also protect mice from allergy and colitis makes GAG or a derivative structure of GAG a 
potential treatment compound for IL-1 driven inflammatory diseases.
Author summary
Aspergillus fumigatus is an opportunistic pathogenic fungus that primarily causes infections in 
the immunocompromised host. It is known that Aspergillus employs various strategies to evade 
immune recognition by the hosts immune system. Recently, galactosaminogalactan (GAG), a new 
component of the Aspergillus cell wall, was discovered to have potent anti-inflammatory effects in 
mice making them more susceptible to Aspergillosis. In the current study we found that this anti-
inflammatory property of GAG was due to its capacity to induce the potent anti-inflammatory 
cytokine interleukin-1 Receptor antagonist. This cytokine interferes with IL-1 signalling and 
thereby can reduce IL-1–induced immune responses such as T-cell responses. We also found that 
the induction of this anti-inflammatory cytokine by GAG correlates with increased fungal burden, 
and mice deficient for this cytokine were protected against aspergillosis. Additionally, we show 
that the capacity of GAG to induce the natural regulator of IL-1 signalling could be used in the 
treatment of IL-1–mediated disease such as allergy and colitis. Our study provides new insights on 
the immunoregulatory activity of GAG and opens up possibilities to exploit the anti-inflammatory 
potential of GAG as a therapy for inflammatory diseases.
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Introduction
Aspergillus fumigatus is an opportunistic fungus that causes infections under specific conditions, 
of which secondary immunodeficiency is by far the largest risk factor for the development of 
invasive infections 1. In order to initiate an effective host response against Aspergillus, recognition 
of conserved pathogen associated molecular patterns (PAMPs) by specific pattern recognition 
receptors (PRRs) is required. 
 A. fumigatus has a complex cell wall consisting of polysaccharides that play essential biological 
functions in fungal cell biology and host-pathogen interactions. Some of these polysaccharides are 
recognized by various PRRs expressed on human immune cells 2. However, A. fumigatus employs 
various strategies to evade immune recognition. Aspergillus expresses surface molecules that shield 
PAMPs or can modulate TLR responses 3. Several surface molecules and PAMPs of A. fumigatus have 
been characterized as being capable of modulating or suppressing the immune response. Rodlets 
and melanin, that are present on the conidial surface, shield PAMPs that elicit pro-inflammatory 
host responses 4,5. In addition, β-glucan, α-glucan and galactomannan (GM) have been shown to 
modulate the host immune response 6. 
 Another cell wall component of A. fumigatus that is capable of modulating the immune response 
is galactosaminogalactan (GAG) 7. GAG is not expressed on Aspergillus conidia, but is exposed 
when conidia start to germinate and was found to be present in the extracellular matrix that 
surrounds Aspergillus hyphae in aspergilloma isolated from patients and in experimental murine 
invasive aspergillosis 8. Furthermore, GAG has been shown to serve as an adhesin of Aspergillus 9,10 
and to shield β-glucan moieties on the cell wall 9. This polysaccharide that is shed into the host 
environment during Aspergillus vegetative growth induces immunosuppressive effects that results 
in diminished neutrophil recruitment, which predisposes mice to A. fumigatus infection 7. However, 
the mechanism through which GAG induces immunosuppressive effects as well as its capacity 
to induce similar immunosuppressive effects on the human immune response were unknown. 
Therefore, we investigated whether GAG can be immunosuppressive in the human host response 
against A. fumigatus, and we have systematically addressed the possible mechanisms responsible 
for the anti-inflammatory property of GAG.
Experimental procedures
Ethics Statement | All studies with human blood samples were conducted in the Radboud University 
Nijmegen Medical Centre and the use of healthy volunteers was approved by the institutional ethics 
review board. Peripheral venous blood samples from healthy volunteers were obtained after written 
informed consent was provided. All animal studies were conducted within the University of Perugia 
and were performed according to the Italian Approved Animal Welfare Assurance A–3143–01. 
Legislative decree 245/2011-B regarding the animal license was obtained by the Italian Ministry of 
Health lasting for three years (2011–2014). Infections were performed under avertin anesthesia and 
all efforts were made to minimize suffering.
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Galactosaminogalactan | Galactosaminogalactan (GAG) was isolated from A. fumigatus culture 
supernatant and purified from the urea-soluble fraction as previously described 7. Lyophilized GAG 
was resuspended in 10 mM HCl at 2 mg/mL and used in a final concentration of 10 μg/mL. Before 
using GAG in stimulation experiments it was incubated with polymixin B to neutralize potential 
contamination of lipopolysaccharide.
Stimuli and reagents | A clinical isolate of Aspergillus fumigatus V05-27, which has been previously 
characterized was used for stimulations 11. Conidia and hyphae were prepared and heat-killed as 
previously described 6. A concentration of 1x107/mL was used in the experiments, unless otherwise 
indicated. Recombinant human IL-1β, IL-23, IL-12 and IL-18 were purchased from R&D Systems 
(Minneapolis, MN, USA) and were used in end concentrations of 100 ng/mL, 50 ng/mL, 10 ng/mL and 
50 ng/mL respectively. Recombinant human (rh) IL-1Ra (Amgen, Inc., Thousand Oaks, CA, USA) was 
used to antagonize IL-1β signalling at a final concentration of 10 ng/mL. Anti-human IL-1Ra (R&D) 
was used to block IL-1Ra in a final concentration of 10 μg/mL, and was compared to isotype control. 
PBMC isolation and stimulation | PBMCs were isolated as described previously 12. The cells were 
counted using a particle counter (Beckmann Coulter, Woerden, The Netherlands) and the cell 
number was adjusted to 5x106/mL. PBMCs were plated in 96-well round-bottom plates (Corning, NY, 
USA) at a final concentration of 2,5x106/mL and in a total volume of 200 µL. Cells were pre-stimulated 
for 1 hour with medium or 10 μg/mL GAG. Following prestimulation, the PBMCs were stimulated 
with culture medium, heat killed A. fumigatus conidia (1x107/mL), IL-1β/IL-23 (100 and 50 ng/mL 
respectively) or IL-12/IL-18 (10 and 50 ng/mL respectively). These experiments were also performed 
in the presence of 10 µg/mL anti-IL-1Ra antibody or isotype control. Plates were incubated at 37°C, 
5% CO2 for 24 hours, 48 hours or 7 days. 7 day cultures were supplemented with 10% human serum. 
In this serum we detected anti-GAG antibodies as described previously 7. After incubation, culture 
supernatants were collected and stored at -20°C until cytokine measurements were performed. 
IL-1 bioassay | The murine cell line NOB-1 responds to both human or mouse IL-1 by production of 
IL-2, furthermore these cells are unresponsive to other cytokines like tumour necrosis factor (TNF), 
colony stimulating factors (CSFS), IL-3, IL-5, IL-6 and IFNγ 13. NOB-1 cells were plated in 96-well flat-
bottom plates at a final density of 1x106 cells/mL and were stimulated for 24 hour using culture 
supernatants of unstimulated PBMCs or PBMCs stimulated in presence of GAG (GAG conditioned 
medium). After 24 hours of incubation at 37°C, 5% CO2 the culture supernatants of the NOB-1 cells 
were collected and IL-2 production by the NOB-1 cells was measured by ELISA (R&D systems).
Cytokine measurement | Cytokines were measured using commercially available ELISAs (R&D 
Systems)(Biolegend, San Diego, CA, USA) (Sanquin, Amsterdam, The Netherlands) according to the 
protocols supplied by the manufacturer. IL-1α, IL-1β, TNFα, IL-6, IL-8, IL-1Ra and IL-10 were measured 
after 24 hours, and IL-5, IL-9, IL-13, IL-17, IL-22 and IFNγ were measured after 7 day stimulation.
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Mice | Female, 8- to 10-weeks old, BALB/c (wild-type, WT) mice were purchased from Charles River 
(Calco, Italy). Breeding pairs of homozygous IL1RN–/– mice on the BALB/c background, were kept 
under specific-pathogen free conditions at the breeding facilities of the University of Perugia, 
Perugia, Italy. Experiments were performed according to the Italian Approved Animal Welfare 
Assurance 229-2011-B.
Fungal infection, allergy and treatment | Viable conidia from the A. fumigatus Af293 strain were 
obtained as described 14. For infection mice were anesthetized in a small plastic cage, containing 
3% Isofluoran (Isofluran Forene Abbot Scandinavia AB, Solna) before intranasal (i.n.) instillation of a 
suspension of 2x107 resting conidia/20 µL saline. Mice were treated with 250 µg/kg i.n. of GAG the 
day of infection and on days 1 to 3 post infection. Mice were monitored for survival, fungal growth 
(colony forming unit/organ, mean ± SEM), as described 15, histopathology, myeloperoxidase (Mpo) 
and IL1RN mRNA expression in lung cells and IL-1Ra production. For histology, sections (3–4 μm) of 
paraffin-embedded tissues were stained with periodic acid-Schiff (PAS) reagent. For allergy, mice 
received an i.p. and s.c. injection of 100 µg of A. fumigatus culture filtrate extract (CCFA) dissolved 
in incomplete Freund’s adjuvant (Sigma) followed by two consecutive intranasal injections (a 
week apart) of 20 µg CCFA. A week after the last intranasal challenge, mice received 107 Aspergillus 
resting conidia and evaluated a week later (16424201). GAG (250 µg/kg i.n.) or vehicle alone was 
administered daily, for a week, in concomitance with the Aspergillus infection.
Collection of broncho-alveolar lavage (BAL) fluid | Lungs were filled thoroughly with 1 mL 
aliquots of pyrogen-free saline through a 22-gauge bead-tipped feeding needle introduced into 
the trachea. The lavage fluid was collected in a plastic tube on ice and centrifuged at 400 g, 4°C, 
for 5 minutes. For differential BAL cell counts, cytospin preparations were made and stained with 
May-Grünwald Giemsa reagents (Sigma-Aldrich). At least 200 cells per cytospin preparation were 
counted and the absolute number of each cell type was calculated. Photographs were observed 
using a BX51 microscope (Olympus, Milan, Italy) and images were captured using a high-resolution 
DP71 camera (Olympus).
Dextran sulfate sodium–induced colitis | Mice received either regular drinking water (control) 
or 2.5% dextran sulfate sodium (DSS) in drinking water for 7 days and then allowed to recover by 
drinking water alone for an additional 7 days. GAG was given intraperitoneally (1 mg/kg) daily for a 
week. Weight changes were recorded daily, and the day after the 7-days of rest mice were killed and 
tissues were collected for histology and cytokine analysis. Colonic sections were stained with H&E 16. 
To assess colitis severity, stool and histological scores were used that recently were introduced and 
proven sensitive to experimental therapy 17.
Cell purification and cell cultures | Purified peritoneal CD11b+ Gr-1+ polymorphonuclear 
neutrophils (PMNs) (>98% pure on FACS analysis) were obtained as described 18. Lung epithelial 
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cells were isolated as described 19. Murine macrophages were isolated from total lung cells after 
2 hours plastic adherence at 37°C. PMNs, epithelial cells and macrophages were exposed to non-
opsonized Aspergillus conidia at the ratio of 1:1 or LPS (10 ng/mL) at 37°C for 1 hour in the presence 
of different concentrations (1 or 20 µg/mL) of GAG for 18 hours before the assessment of IL1RN 
mRNA expression.
Statistical analysis | The differences between the various stimulations were analysed with the 
Wilcoxon signed rank test (p-value of <0.05 was considered statistically significant). All experiments 
were performed at least twice and data represent cumulative results of all experiments performed 
and are presented as mean ± standard error of the mean (SEM) unless otherwise indicated. Data was 
analysed using GraphPad Prism v5.0.
Results
Galactosaminogalactan modulates human T-helper cytokine responses
To investigate whether GAG can exert immunomodulatory effects in humans, we tested whether 
GAG induces the production of pro- and/or anti-inflammatory cytokines in human PBMCs. GAG 
did not induce the pro-inflammatory cytokines TNFα, IL-6, IL-8, IFNγ, IL-17, IL-5 and IL-9 (Figure 1A), 
neither did it induce the anti-inflammatory cytokine IL-10 (Figure 1A). To determine whether GAG 
modulates Aspergillus-induced innate monocyte-derived cytokines, PBMCs were stimulated for 24 
Figure 1 | GAG inhibits Aspergillus-induced human T-helper cell cytokine production
(A) TNFα, IL-6, IL-8 and IL-10 concentrations in culture supernatants of human PBMCs stimulated for 24hours 
with 10 μg/mL GAG and IFNγ, IL-17, IL-5 and IL-9 concentrations after 7 days of stimulation. (B) TNFα, IL-6 and 
IL-10 concentrations in culture supernatants of human PBMCs (n=6 donors) stimulated for 24 hours with heat 
inactivated A. fumigatus conidia (1x107/mL) in the presence or absence of 10 μg/mL GAG. (C,D) IL-17, IL-22 and 
IFNγ concentrations in culture supernatants of human PBMCs stimulated for 7 days with heat inactivated A. 
fumigatus conidia (1x107/mL) (n=10 donors for IL-17 and IL-22, n=6 donors for IFNγ) (c), IL-1β/IL-23 (50/100 ng/
mL) (n=14 donors) or IL-12/IL-18 (50/100 ng/mL) (n=10 donors) in the presence or absence of GAG (10 μg/mL). 
Data are represented as mean ± SEM.
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hours with Aspergillus conidia (these morphotypes of A. fumigatus were selected because they do 
not contain GAG that would interfere with the study of the immunological function of GAG) in the 
presence or absence of GAG. The presence of GAG did not have a significant effect on the production 
of the innate cytokines TNFα and IL-6, or the anti-inflammatory cytokine IL-10 (Figure 1B). However, 
when the production of the characteristic T-helper cytokines IL-17, IL-22 and IFNγ induced by A. 
fumigatus was investigated, the IL-17 and IL-22 responses were significantly reduced in the presence 
of GAG (Figure 1C). To determine whether the effects of GAG are specific for Aspergillus-driven 
T-helper (Th) responses, or whether GAG has a general ability to modulate human Th responses, 
the effects of GAG on cytokine-driven Th responses were studied. GAG significantly decreased the 
pro-inflammatory Th cytokine production induced by the cytokine combinations IL-1β/IL-23 and 
IL-12/IL-18 that induce IL-17/IL-22 and IFNγ, respectively (Figure 1E). Thus, GAG can inhibit human 
pro-inflammatory Th cytokine production induced by Aspergillus and cytokine cocktails. 
Galactosaminogalactan induces IL-1 receptor antagonist
Human T-helper cytokine responses such as IL-17 and IL-22 production are highly dependent on the 
IL-1 receptor pathway 20,21. To investigate whether the observed modulation of T-helper cytokines by 
GAG was due to an interaction of GAG with the IL-1 pathway, we determined the capacity of GAG 
conditioned medium (culture supernatants of PBMCs that were exposed to 10 μg/mL GAG for 24 
hours) to reduce IL-1β bioactivity. Indeed it was shown that GAG significantly reduced the bioactivity 
of IL-1β while culture supernatants of unstimulated PBMCs did not (Figure 2A). Bioactivity of the 
IL-1 signalling pathway is dependent on IL-1 receptor agonists (IL-1α and IL-1β) and IL-1 receptor 
antagonists 22. One of the natural inhibitors of the IL-1 signalling is the interleukin-1 receptor 
antagonist (IL-1Ra); therefore the ability of GAG to induce IL-1Ra was tested. IL-1Ra concentrations in 
the supernatant of the cells stimulated with GAG were significantly increased, whereas GAG induced 
none of the IL-1 receptor agonists, IL-1α or IL-1β (Figure 2B), showing that GAG has the capacity to 
modulate immune responses by blocking the IL-1 receptor pathway. 
Figure 2 | GAG induces interleukin 1 receptor antagonist
(A) IL-1 bioactivity measured as IL-2 production by NOB-1 cells stimulated with 50 ng/mL IL-1β in the presence 
of culture supernatant of unstimulated PBMCs (medium) or culture supernatants of PBMCs that were exposed to 
10 μg/mL GAG for 24 hours (GAG conditioned medium) (n=6 donors). (B) IL-1Ra, IL-1β and IL-1α concentrations 
in culture supernatants of human PBMCs stimulated with for 24 hours with 10 μg/mL GAG. Data are represented 
as mean ± SEM.
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Suppression of IL-17 and IL-22 by galactosaminogalactan is dependent on IL-1Ra
To demonstrate that IL-17, IL-22, and IFNγ production by human PBMCs is indeed dependent on the 
IL-1 receptor pathway and that IL-1Ra can inhibit the production of these Th cytokines, Th1 and Th17 
inducing stimuli were studied in the presence or absence of IL-1Ra. Addition of IL-1Ra reduced IL-
17, IL-22, and IFNγ induction by both Aspergillus conidia and by IL-1/IL-23 and IL-12/IL-18 cytokine 
combinations (Figure 3A). To determine whether the immunosuppressive effect of GAG was mediated 
through the induction of IL-1Ra, PBMCs were stimulated with IL-1β/IL-23 and GAG in the presence 
or absence of neutralizing anti-IL-1Ra antibodies. GAG reduced IL-17 and IL-22 levels significantly, 
which was not observed in the presence of neutralizing anti-IL-1Ra antibodies, demonstrating that 
the inhibitory effects of GAG on Th cytokine production are dependent on IL-1Ra (Figure 3B).
Figure 3 | Suppression of IL-17 and IL-22 by GAG is dependent on IL-1Ra 
(A) IL-17, IL-22 and IFNγ concentrations in culture supernatants of PBMCs stimulated for 7 days with heat 
inactivated A. fumigatus conidia 1x107/mL, IL-1β/IL-23 (50/100 ng/mL) or IL-12/IL-18 (50/100 ng/mL) in the 
presence or absence of recombinant human IL-1Ra (10 ng/mL). Data are represented as mean ± SEM. (B) 
Inhibition of IL-1β/IL-23 (50/100 ng/mL) induced IL-17 and IL-22 by GAG (10 μg/mL) in human PBMCs in the 
presence of isotype control (10 μg/mL) or anti-IL-1Ra (10 μg/mL). The IL-17 and IL-22 production by IL-1β/IL-23 
in absence of GAG was set at 100% and mean percentage changes relative to the control are represented ± SEM.
Galactosaminogalactan induces IL-1Ra in vivo and IL-1Ra increases susceptibility to aspergillosis
The in vitro stimulations described above suggest that the immunomodulatory effects of GAG are due 
to inhibition of IL-1 bioactivity by inducing IL-1Ra. To assess whether this has relevant consequences 
in vivo, we measured IL-1Ra transcription in the lungs of mice infected with Aspergillus with or 
without the administration of GAG. Induction of IL1RN was increased in the presence of GAG (Figure 
4A). To determine which cells are responsible for the induction of IL1RN, we isolated macrophages, 
neutrophils and epithelial cells from the lungs of naïve mice. Macrophages and neutrophils, but not 
epithelial cells, expressed IL1RN after stimulation with Aspergillus in the presence of GAG (Figure 4B). 
Interestingly, not all microbiological stimuli can prime for increased GAG-induced IL1RN, since pre-
stimulation with LPS did not increase IL1RN induction by GAG (Figure 4B).
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Figure 4 | GAG induces IL-1Ra in vivo and IL-1Ra increases susceptibility to aspergillosis
BALB/c and IL1RN-/- mice were intranasally infected with Aspergillus conidia and treated with GAG (250 µg/
kg intranasally) the day of infection, and 1, 2 and 3 days post-infection. (A) IL1RN mRNA expression in lung 
homogenates of mice with invasive aspergillosis, (B) IL1RN mRNA expression in purified cells from lungs of naive 
mice pre-stimulated with Aspergillus conidia or LPS for 1 hour, and exposed to different GAG concentrations for 
an additional 18 hours. (C) Survival, (D) fungal growth (CFU/lung, mean ± SEM), (E) protein levels of IL-1Ra, 
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 To investigate the significance of IL-1Ra in vivo and to determine whether the effects induced 
by GAG are dependent on IL-1Ra, we studied the effects of GAG in wild type (WT) and IL1RN-/- mice 
with invasive aspergillosis. IL1RN-/- mice were highly resistant to invasive aspergillosis, as indicated 
by long-term survival (Figure 4C) and reduced fungal burden (Figure 4D). Administration of GAG 
resulted in increased protein levels of IL-1Ra in the lungs of wild-type mice during infection (Figure 
4E). In line with previous observations, GAG increased the susceptibility to invasive aspergillosis in 
WT mice but not in IL1RN-/- mice (Figure 4D). IL1RN-/- mice had increased Mpo expression (Figure 4F) 
and PMN influx in their respiratory tract (Figure 4G). As expected, administration of GAG reduced 
inflammatory PMN recruitment in WT but not in IL1RN-/- mice (Figure 4G). These data demonstrate 
that IL-1Ra has an important role in invasive aspergillosis, and support the concept that the induction 
of IL-1Ra by GAG may have important clinical consequences. 
(figure 4 continued) (F) Mpo expression in lung homogenates, and (G) BAL morphometry [% polymorphonuclear 
(PMNs) cells and lung histology (PAS stained sections, bars indicate 20× magnification) of Aspergillus-infected 
mice with or without GAG treatment. Assays were done a day after the last GAG treatment. (H) BAL morphometry 
[% PMNs or eosinophils (Eo)] and lung histology (PAS stained sections, bars indicate 20× magnification), and (I) 
expression of Th transcription factors and cytokines in total cells from the draining lymph nodes in mice with 
ABPA and treated with or without GAG. Naïve means uninfected mice, and none means untreated mice and/or 
unstimulated cells. (J) IL-5, IL-13 and IL-17 concentrations in culture supernatants of PBMCs pre-incubated 1h 
either with medium or GAG (10 µg/mL). After washing, the cells were stimulated for 7 days with heat inactivated 
1x107/mL A. fumigatus conidia (n = 4 donors). Data are represented as mean ± SEM. *, p<0.05; **, p<0.01.
Figure 5 | GAG protects mice from experimental DSS-induced colitis
(A) Body weight losses, (B) stool and histological score, (C) histology of colonic sections and (D) cytokine 
concentrations present in total colonic cells a day after the 7-day of DSS rest in C57BL/6 and p47phox-/- (CGD) mice 
with or without GAG treatment. *p<0.05, GAG treated vs untreated mice.
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 In ABPA, GAG administration decreased PMN recruitment, but not eosinophilic infiltration in 
the BAL and lung of allergic mice (Figure 4H), a finding consistent with decreased Th17 but not Th2 
cell responses in the draining lymph nodes (Figure 4I). To address whether GAG would have similar 
effects on human Th2 responses, PBMCs isolated form healthy subjects were pre-incubated for 1h 
with GAG and subsequently stimulated with Aspergillus conidia for 7 days. Similar to mice, IL-17 
production decreased in the presence of GAG, but not Th2 cytokines such as IL-5 and IL-13 (Figure 
4J). Thus, GAG has the potential to ameliorate Th17-dependent immunopathology in ABPA. 
Galactosaminogalactan-induced IL-1Ra can be exploited as a therapy for IL-1-mediated 
inflammatory diseases
Since IL-1Ra treatment can be beneficial for autoinflammatory diseases such as chronic 
granulomatous disease CGD colitis in humans 23, we investigated whether GAG could be beneficial 
in experimental DSS-induced colitis in mice with chronic granulomatous disease (CGD). The 
administration of GAG resulted in the amelioration of clinical signs of colitis (weight loss and stool 
consistency) (Figure 5A-B) and of inflammatory lesions (Figure 5C) in both wild-type and CGD mice. 
However the protective effects of GAG were most apparent in CGD mice. GAG induced IL-1Ra and, 
consistently, reduced IL-1β and IL-17 (Figure 5D). Concomitantly, there was an increased production 
of IL-10, an anti-inflammatory cytokine that plays an important role in the protection of colitis 24,25. 
The effects of GAG on CGD colitis were similar to those of IL-1Ra administration (unpublished data). 
Discussion
In the original report describing GAG 7, it was shown that GAG has anti-inflammatory effects in mice. 
However, the mechanism through which GAG elicits its immunomodulatory effects remained a 
question at that time. In the present study, we demonstrate that GAG induces its anti-inflammatory 
effects by inducing the potent anti-inflammatory cytokine IL-1 receptor antagonist.
  IL-1Ra can inhibit the activation of the IL-1 pathway by binding to the IL-1R type 1 receptor 
and prevents recruitment of the IL-1R accessory protein that is required for signalling. It has been 
repeatedly shown that IL-1 is an essential pro-inflammatory cytokine of the innate immunity. A 
deficient IL-1 pathway is also detrimental for the host, since it is an important protective pathway 
required to fight infection 26. Thus the IL-1 axis is a potent pro-inflammatory pathway that needs to be 
tightly regulated, and IL-1Ra is a crucial player in this regulation. Therefore, it is rather surprising that 
the role of IL-1Ra in invasive fungal infection has not been studied in detail to date. We observed that 
the absence of IL-1Ra completely protects mice from developing invasive pulmonary aspergillosis, 
underscoring the importance of the IL-1 pathway in clearance of an acute invasive Aspergillus 
infection. The observation that GAG induces IL-1Ra in vivo identifies GAG as a potent anti-inflammatory 
molecule that suppresses the IL-1 pathway, subsequently resulting in increased susceptibility to 
invasive aspergillosis. The relevance of the IL-1 pathway in aspergillosis is underscored by the fact 
that polymorphisms IL-1 gene cluster polymorphisms are associated with susceptibility to develop in 
invasive pulmonary aspergillosis 27, and that dectin-1 knockout mice display increased fungal burden 
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and mortality during invasive aspergillosis, which is dependent on IL-1 28. 
 One of the major risk factors that increases susceptibility to invasive aspergillosis is neutropenia 29, 
and neutrophils are crucial for clearing invasive germinating and hyphal forms of Aspergillus infection 
30. GAG has been shown to inhibit neutrophil recruitment to the lung, which is at least partly due to 
neutrophil apoptosis 7. We observed that in the presence of GAG, IL-1Ra increased during invasive 
aspergillosis, which correlated with decreased PMN recruitment, and therefore increased fungal 
burden. In contrast, IL1RN-/- mice displayed increased neutrophil influx when exposed to Aspergillus, 
which could explain the resistance of IL1RN-/- mice to invasive aspergillosis, since they can rapidly 
and efficiently clear Aspergillus conidia due to their increased neutrophil response. In addition to the 
induction of IL-1Ra by GAG in vitro and in vivo, we observed that the inhibitory effects of GAG on 
the pro-inflammatory Th cytokine response in human PBMCs could be restored in the presence of 
a neutralizing antibody against human IL-1Ra. Furthermore, the increased susceptibility to invasive 
aspergillosis induced by GAG is not observed in IL1RN-/- mice. These observations strengthen the 
hypothesis that the anti-inflammatory properties of GAG are dependent on IL-1Ra. 
 The anti-inflammatory properties of GAG were present at a concentration of 10 µg/mL, which is a 
relevant concentration in vivo, since Aspergillus can secrete GAG in a concentration of 50 µg/mL (data 
not shown). The finding that antibodies against GAG are present in human serum 8 suggests that 
there is an adequate exposure of GAG to trigger the immune system. In the present study we were 
also able to demonstrate that these antibodies do not inhibit the effect of GAG, since we observed 
significant effects of GAG on IL-1Ra induction and inhibition of IL-17 in the presence of human 
serum that contained measurable concentrations of antibodies against GAG (data not shown). The 
relevance of GAG is highlighted by its presence in the extracellular matrix in aspergilloma resected 
from patients and mice with aspergillosis 8. It is therefore expected that GAG plays a role in the 
immunological synapse between host immune cell and the mycelium, not only by inducing anti-
inflammatory responses through IL-1Ra but also by shielding β-glucan from recognition, which has 
been proposed previously 9. 
 It must be taken into account that in the setting of chronic inflammation in which neutrophils 
and increased Th17 responses are detrimental for the host, IL-1Ra plays a protective role, due to 
its significant capability to suppress the IL-1 signalling pathway. This hypothesis is in line with 
the observation that IL1RN-/- mice develop spontaneous destructive arthritis that is IL-1 and Th17 
dependent 31. The importance of IL-1Ra in controlling IL-1-mediated pro-inflammatory responses 
in humans is underlined by a disease called deficiency of IL-1Ra (DIRA). This disease is characterized 
by the absence of IL-1Ra and severe Th17-mediated responses with neutrophil influx in the skin 
and bones of these patients, subsequently resulting in severe skin inflammation and osteomyelitis 
32. Therefore, the timing of IL-1Ra induction is of utmost importance to protect the host from 
infection and overwhelming inflammation. Chronic allergic aspergillosis is associated with excessive 
inflammation, with increased production of IL-1 and IL-22 33. We have demonstrated in the present 
study that administration of GAG induces IL-1Ra and is able to decrease IL-22 production. Therefore 
we investigated the effect of GAG in a murine model of allergic bronchopulmonary aspergillosis 
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(ABPA). We observed that the administration of GAG reduces the amount of neutrophils, but not 
eosinophils in ABPA. Additionally, Th17 responses were downregulated, but not Th2 responses. It 
is therefore tempting to speculate that administration of GAG can be beneficial in the setting of 
chronic allergic inflammation that is associated with excessive neutrophil-driven inflammation by 
reducing Th17 dependent pathology by inhibiting the IL-1 pathway. In addition, GAG also protected 
CGD mice from experimental colitis. Therefore, we envisage a model in which GAG on the one hand 
might be detrimental for the host in the setting of an acute infection, and on the other hand could 
be beneficial for the host during chronic inflammation driven by IL-1. Next to the identification of 
GAG or IL-1Ra as a therapeutic target for invasive aspergillosis, it is the first time that a polysaccharide 
produced by a human pathogen has been identified as an inducer of IL-1Ra by cells of the innate 
immunity without inducing pro-inflammatory responses, and which has been demonstrated to have 
therapeutic capacity in IL-1-mediated disease. The search of the sensing and signal transduction 
cascade activated by this polysaccharide will now be the center of future research.
 The data presented here brings new questions into light and opens opportunities for future 
research. First, one of the most interesting observations is the complete protection of IL-1Ra 
knockout mice to invasive pulmonary aspergillosis. This opens new treatment strategies that target 
IL-1Ra in the setting of an acute invasive fungal infection. Second, the significant induction of IL-
1Ra by GAG makes GAG or a derivative structure of GAG a potential treatment compound for IL-1-
mediated diseases, such as joint, bone and muscle diseases and even very common inflammatory 
diseases such as diabetes and gout 34. Previously, we have shown that mitogenic stimulation of 
monocyte derived macrophages and lymphocytes by αCD3/αCD28 coated beads, or recombinant 
cytokine-induced IL-17 and IFNγ production is inhibited in the presence of live A. fumigatus 35. 
Although these changes in cytokine responses were attributed to changes in tryptophan and 
kynurenine, it is tempting to speculate that GAG secretion by live A. fumigatus could have attributed 
to the decreased IL-17 production. 
 In conclusion, our results demonstrate that GAG has potent anti-inflammatory effects in mice 
and humans that can be explained by the capability of GAG to induce IL-1Ra. These observations 
help to explain one of the immune-evasive mechanisms of A. fumigatus. Moreover, inhibition of 
GAG or IL-1Ra might prove beneficial in the treatment of acute invasive pulmonary aspergillosis, 
and GAG might be exploited for treatment of IL-1-mediated inflammatory diseases.
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Abstract
Background | Genetic polymorphisms have been associated with invasive mould infection (IMI)
among hematopoietic stem cell transplant recipients. To our knowledge, no study explored the role 
of such polymorphisms among solid organ transplant (SOT) recipients.
Experimental procedures | The STCS is a large, nationwide, prospective cohort including all SOT 
recipients followed at six transplant centers in Switzerland. DNA was isolated from patient samples 
and 24 single nucleotide polymorphisms (SNPs) were genotyped using a custom-made Illumina® 
Golden Gate assay. Association between SNPs and the endpoint were assessed by log-ranktest and 
Cox regression model after adjustment for all relevant covariates. In PBMCs from healthy donors 
carrying SNPs associated with IMI in SOT patients, cytokine production upon Aspergillus stimulation 
was measured by ELISA and correlated to the genotype.
Results | The study included 1101 Caucasian SOT recipients (715 kidneys, 190 liver, 102 lungs,79 
hearts, 15 other). Mould colonization (n=45) and IMI (n=26) were associated with polymorphisms 
in IL1B (interleukin-1β, rs16944; log rank test, colonization p=0.001 and IMI p=0.00005), IL1RN 
(interleukin-1 receptor antagonist; rs419598; p=0.01, and p=0.02) and DEFB1 (β-defensin 1, 
rs1800972; p=0.001, and p=0.0002, respectively). The associations with IL1B and DEFB1, remained 
independently significant with IMI in a multivariate stepwise regression model (IL1B rs16944 
p=0.0002, and DEFB1 rs1800972 p=0.005). Presence of two copies of the rare allele of rs16944 or 
rs419598 was associated with reduced Aspergillus-induced IL-1β and TNFα secretion by PBMCs.
Conclusions | Functional polymorphisms in IL1B and DEFB1 influence susceptibility to IMI in SOT 
recipients. This observation may contribute to individual risk stratification.
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Introduction
Over 100’000 solid organ transplants (SOT) are performed worldwide each year 1. Despite recent 
improvements in the management of SOT recipients, infectious complications after transplantation 
remain a challenging issue 2. In particular invasive aspergillosis can occur in up to 3% of SOT recipients 
and is associated with a mortality rates ranging 20-76% 3,4. Risk factors for the development of 
invasive aspergillosis include the type and level of immunosuppression, use of renal replacement 
therapy, older age, and CMV disease 3,5. However, not all patients with these risk factors develop 
invasive mould infections (IMI), while some patients without these risk factors do, making it difficult 
to predict the risk to develop IMI at the individual level.
 Over the last decade, a series of studies have identified common genetic polymorphisms that are 
associated with the development of invasive aspergillosis among hematopoietic stem cell transplant 
recipients and other onco-hematological patients 6,7. The identification of specific genetic variants 
may improve individual risk stratification and allow the development of personalized management 
strategies, as well as to use prophylaxis or specific surveillance in individuals at high risk to develop 
invasive aspergillosis 6. To date, no studies examined the role of such genetic polymorphisms on the 
susceptibility to fungal infections among SOT recipients. We explored for the first time the role of 
host genetics in susceptibility to IMI in a nationwide cohort of 1101 SOT recipients.
Experimental procedures
Patients and study design | The STCS is a large, nationwide, well documented prospective cohort 
including all SOT recipients followed at six Swiss University transplant centers (Basel, Bern, Geneva, 
Lausanne, St Gallen and Zurich) since May 2008 8. Patient data were systematically collected at 
enrollment, at six months and every 12 months after transplant on standardized case report forms. 
 Infectious complications were systematically evaluated by an infectious disease specialist based 
on clinical, histological, radiological and mycological evidence and reported on a separate case report 
form. Charts from patients reported to have fungal colonization or IMI were revised by an independent 
investigator (TL) 9. Proven or probable IMI, was defined based on standardized EORTC/MSG guidelines 
definitions 10 and adapted ISHLT guidelines definitions unique for lung transplant recipients such as 
anastomotic bronchial infections or tracheobronchitis 11. Colonization was defined by microscopic or 
culture detection of a mould from a specimen of a non-sterile site, including sputum, bronchoalveolar 
lavage, bronchial brush, sinus aspirate samples or urine in the absence of clinical signs/symptoms 
for infection. Patients who were diagnosed with mould colonization and/or IMI before transplant, 
and/or had received previous organ transplantation, were excluded. CMV infection was classified as 
asymptomatic replication, viral syndrome or probable and proven disease as previously reported 12.
 
Ethics statement | All patients provided written informed consent for participation to the STCS 
(including genetic analyses). The protocol was approved by the independent ethics Committees 
of each Swiss participating center (University Hospital of Lausanne (CHUV); University Hospitals 
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of Geneva (HUG); University Hospital Zürich (USZ); Cantonal Hospital St. Gallen (KSSG); Inselspital, 
Bern University Hospital; Clinica Luganese, Lugano; University Hospital of Basel). For functional 
assessment of polymorphisms, fresh venous blood was collected from healthy volunteers who 
provided written informed consent. The protocol was approved by the local ethics Committee 
(Radboud University Nijmegen Medical Center, The Netherlands).
PBMCs isolation and in vitro stimulation assays | Peripheral blood mononuclear cells (PBMCs) 
were isolated using Ficoll-Paque Plus (GE healthcare, Zeist, The Netherlands) density gradient 
centrifugation method as described previously 13. Cells were subsequently stimulated with 1x107/mL 
live or heat-inactivated Aspergillus fumigatus conidia for 24 hours or 7 days, respectively. Afterwards 
concentrations of the cytokines TNFα, IL-1β, IL-1Ra, IL-17, IL-22 (R&D systems, Minneapolis MN, USA) 
and IFNγ (Sanquin, Amsterdam, the Netherlands) were measured in cell supernatants by ELISA 
according to the manufacturer’s protocol.
Genotyping | A total of 24 SNPs in 21 genes were selected from the literature (Table 2) by performing a 
PubMed search until June 2012 using the keywords: candidemia, candidiasis, aspergillosis, SNP and/or 
previous reviews on fungal immunogenetics 6,7. Blood samples were obtained from all SOT recipients 
at the time of transplantation. Genomic DNAs was extracted from patients or healthy volunteer EDTA 
blood using the Gentra Puregene Blood Kit (Qiagen). Genotyping was performed using a customized 
GoldenGate Genotyping Assay on Veracode platform (Illumina, San Diego, CA, USA), unless otherwise 
indicated. Results were analyzed on a BeadXpress Reader according to standard protocols and quality 
controls. Additional SNPs were genotyped using Competitive Allele-Specific PCR (KASP) system (LGC 
Genomics, Herts, UK). For functional studies, IL1B rs16944 and IL1RN rs419598 variants were genotyped 
using pre-designed SNP assays on the ABI-Prism StepOne thermocycler (Applied Biosystems).
Statistical analysis | Statistical analyses were performed in Stata13 (StataCorp LP, College Station, 
Texas, USA), unless otherwise indicated. The cumulative incidence of mould colonization and IMI by 
genetic variants at 36 months after the first transplantation was assessed by the log-rank test, with 
censoring at the date of the last follow-up or death. Associated variants were selected based on the 
log-rank test and were further tested by uni- and multivariate Cox models. In order to estimate the 
independent contribution of each polymorphism to the endpoints, demographic and clinical factors 
previously associated with mould colonization and/or IMI (as described elsewhere 5,9), were entered 
into multivariate stepwise regression models (p<0.2) together with relevant genetic polymorphisms. 
Haplotypes were inferred using PHASE 2.1 (University of Washington, Seattle, WA, USA). Power 
calculation for Cox proportional hazard regression was done using an R implementation of the 
power and sample size calculation for survival analysis of epidemiological studies (powerSurvEpi 
R package 0.0.6) 14. The effect of presence of SNPs on the Aspergillus-induced cytokine levels was 
determined by the Mann-Whitney U test. The data are presented as mean ± standard error of the 
mean (SEM) and were analysed using Graphpad Prism v5.0 (San Diego, CA, USA).
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Results
Cohort Study
The study included 1101 Caucasian patients who received solid organ transplantation (670 kidneys, 
190 liver, 102 lungs, 79 hearts, 15 islets/pancreas and 45 combined organs) between May 2008 and 
December 2011 (Table 1). Mould colonization and IMI were diagnosed in 45 (4.1%) and 26 (2.4%) 
patients, respectively. Most IMI occurred >3 months after transplantation (n=17, 75%). The most 
frequent causative organism of IMI was Aspergillus spp. (n=21, 81%); only five IMIs were due to 
other fungi, including Fusarium spp. (n=2), Altenaria spp. (n=1), Zygomycetes spp. (n=1) and mixed 
pathogens (Zygomycetes and Fusarium spp., n=1). Factors significantly associated with IMI were 
identified and described elsewhere 9 and included in the multivariate analysis.
Variable n (%)
Recipient age (median years) 54 (19)
Donor age (median years) 1 53 (22)
Recipient sex M/F 730 / 371 (66 / 34 )
Donor sex M/F 2 573 / 523 (52 / 48)
Duration of cold ischemia (median) 5.6 (7.3)
Transplanted organ
Kidney 1 670 (61)
Liver 190 (17)
Lung 102 (9)
Heart 79 (7)
Pancreas and islets 15 (1)
Mixed 3 45 (4)
Donor type 4
Decreased 801 (73)
Living related/unrelated 299 (27)
Rejection type 5
Acute cellular rejection 342 (31)
Acute humoral rejection 35 (3)
CMV infection/disease 279/61
CMV serostatus (n=1186) 6
D+ R+ 350 (33)
D- R+ 256 (24)
D- R- 245 (24)
D+ R- 218 (20)
Induction therapy 7
Basiliximab (BAS) 641 (61)
Anti-thymocyte globulin +/- BAS 188 (18)
None 225 (21)
Maintenance regiment 8
Calcineurin inhibitors 817 (92)
Corticosteroids 910 (83)
MMF 721 (81)
AZA 31 (3)
mTOR inhibitors 54 (6)
Anti IMI prophylaxis (weeks 1-4) 74 (7)
1 Data were missing in 104 patients.
2 Data were missing in 5 patients
3 Including: 
kidney-pancreas   n=24
kidney-liver   n=10
kidney-kidney   n=5
kidney-islets   n=3
kidney-kidney-pancreas  n=2
kidney-lung   n=1 
4 Data were missing in 2 patients
5 Reported at any time of follow-up.
6 Data were missing in 32 patients.
7 Data were missing in 47 patients.
8 Reported at month 12.
Abbreviations: 
AZA: azathiopirine
BAS: Basiliximab
IMI: invasive mould infection
MMF: mycophenolate mofetil
Table 1 | Demographic characteristic of the solid organ transplant recipients
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Table 2 | Association of genetic variations with mould colonization or invasive mould infection
Gene Mould colonization (n=45)2 IMI (n=26)2
(nt|aa change)1 Rs number MAF HWE log-rank test p3 log-rank test p3
IL1B (-511 C/T) rs16944 0.33 0.160 0.001 * 0.00005 ***
DEFB1 (-44 C/G) rs1800972 0.18 1.000 0.001 * 0.0002 **
IL1RN (2018T/C) rs419598 0.25 0.320 0.01 0.02
TLR9 (-1237 C/T) rs5743836 0.13 0.060 0.2 0.04
INFG (874 T/A) rs2069705 0.33 0.086 0.05 0.06
PLG (D472N) rs4252125 0.30 0.340 0.4 0.1
CD209 (-139 A/G) rs2287886 0.36 0.610 0.2 0.2
IL10 (-1082 A/G) rs1800896 0.44 0.220 0.8 0.2
TLR6 (S249P) rs5743810 0.35 0.180 0.1 0.4
TNF (-308 G/A) rs1800629 0.14 0.010 0.2 0.4
SFTPA2 (A91P) rs17886395 0.14 0.900 0.004 0.5
CXCL10 (1642G/C) rs3921 0.41 0.280 0.6 0.5
MBL (G54D) rs1800450 0.15 0.099 0.8 0.4
IL10 (-819 C/T) rs1800871 0.27 0.820 0.8 0.6
TLR1 (R80T) rs5743611 0.07 0.500 0.6 0.7
TLR4 (D299G) rs4986790 0.05 0.540 0.8 0.8
IL1A (-889 C/T) rs1800587 0.29 0.620 0.6 0.8
MASP2 (D105G) rs72550870 0.02 0.150 0.8 0.8
CLEC7A (Y238X) rs16910526 0.08 0.340 0.7 0.8
TLR3 (L412F) rs3775291 0.29 1.000 0.9 0.9
IL23R (R381Q) rs11209026 0.07 0.811  0.7 0.7
Genetic risk factors for mould colonization and IMI in SOT patients
The minor allele frequency of the 21 SNPs are shown in Table 2. Three SNPs that deviated from Hardy-
Weinberg equilibrium were excluded from the analyses. The power to detect mould colonization 
and IMI was calculated for each SNP (Table 4).
 To assess the risk of fungal disease according to the different SNPs, we estimated the cumulative 
incidence of colonization and infection during the first 36 months after transplantation (Table 2). 
Mould colonization and IMI were both associated with SNPs in three different genes, including IL1B 
(rs16944 TT versus CT or CC; log-rank test p=0.001 and p=0.00005), β-defensin 1 (DEFB1, rs1800972 
CC versus GG or CG, p=0.001 and p=0.0002) and the interleukin-1 receptor antagonist (IL1RN, 
rs419598 CC versus CT or TT, p=0.0 and p=0.02, respectively Figure 1). In addition, we observed a 
significant association between a SNP in surfactant-associated protein 2 and mould colonization 
(SFTPA2, rs17886395 GG versus CC or CG, log-rank test p=0.004) but not infection (p=0.5). However, 
this association was due to a small number of individuals (Figure S4).
1 SNPs (TLR1 rs5743618, IL4 rs2243250 and CARD9 rs10870077) deviated from Hardy-Weinberg equilibrium were 
 excluded from the analyses.
2  Five patients who were colonized with mould before transplant, among whom two also developed IMI before 
 transplant, were removed from the analyses.
3  p-value was assessed by log-rank test, recessive mode (patients homozygous for the rare alleles are compared 
 to the other).
* Significant after correction for multiple testing (21 tests; p=0.02).
** Significant after correction for multiple testing (21 tests; p=0.004).
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 To determine whether the SNPs were independent risk factors for the mould colonization 
and IMI, we used multivariate Cox stepwise regression models, after adjustment for all relevant 
covariates (Table 3). The final model for colonization still included IL1B rs16944 (HR=2.52, CI 1.18-
5.36, p=0.02), DEFB1 rs1800972 (HR=6.11, CI 2.28-16.4, p=0.0003) and IL1RN rs419598 (HR=3.35, CI 
1.31-8.58, p=0.01). The final model for IMI still included IL1B rs16944 (HR=4.29, CI 1.71-10.8, p=0.002), 
DEFB1 rs1800972 (HR=4.73, CI 1.46-15.3, p=0.01), but not IL1RN rs419598. Associations were stronger 
when the SNPs were combined together (for IL1B rs16944 and DEFB1 rs1800972, HR=4.94; CI 2.06-
11.8; p=0.003; for IL1B rs16944 and IL1RN rs419598 HR=4.64, CI 1.92-11.2, p=0.0006; Supplementary 
Figure1). In order to account for a possible confounding role of antifungal prophylaxis, the analyses 
were repeated after removal of patients who received an anti-mould prophylaxis. The associations 
between the SNPs in IL1B, DEFB1 and IL1RN were still significant (not shown).
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Figure 1 | Cumulative incidence of mould colonisation and invasive mould infection
(A) Mould colonization (n=45) and (B) invasive mould infection (n=26) according to IL1B rs16944 (panel A, and B, 
respectively), β-defensin 1 rs1800972 (DEFB1, panel C and D, respectively) and interleukin-1 receptor antagonist 
rs419598 (IL1RN, panel E, and F, respectively) polymorphisms in solid organ transplant recipients. Patients who 
were colonized or infected with mould before engraftment were excluded from the analyses. p-values were 
calculated by log-rank test, recessive mode (patients homozygous for the rate alleles are compared to the other). 
For IL1B rs16944 and DEFB1 rs1800972 SNPs p-values remained significant after correction for multiple testing 
(21 tests; colonization for both polymorphisms p=0.02; infection p=0.001, and p=0.004, respectively).
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IL1B rs16944 and IL1RN rs419598 risk haplotype for mould colonization and IMI
IL1B and IL1RN genes are located within a ~400 kb region on chromosome 2q13-21, we therefore 
analyzed whether haplotypic combinations of IL1B rs16944 and IL1RN rs419598 SNPs further 
influenced mould colonization and IMI (Figure 2). Carriage of the rs16944-rs419598 C-T haplotype 
was associated with a decreased risk of both mould colonization and IMI (C-T haplotype vs. all other, 
HR=0.34, CI 0.18-0.63, p=0.0007 and HR=0.21, CI 0.10-0.45, p=0.00008, respectively). Reversely, 
carriage of the T-C haplotype was associated with an increased risk for both phenotypes (T-C 
haplotype vs. all other, HR=1.83, CI 1.02-3.29, p=0.04 and HR=2.09, CI 0.97-4.50, p=0.06, respectively).
Effect of IL1B rs16944 and IL1RN rs419598 polymorphisms on Aspergillus-induced cytokine release
In order to determine whether the SNPs associated with IMI and colonization had measurable biological 
effects, we analysed the production of different cytokines that are involved in antifungal host defence, 
including IL-1β, IL-1 receptor antagonist (IL-1Ra), TNFα, IL-17, IL-22and IFNγ in PBMCs from 73 healthy 
volunteers, after stimulation with live or heat-inactivated A.fumigatus conidia, respectively (Figure 
2). PBMCs from volunteers carrying the IL1B rs16944 TT genotype produced lower amounts of IL-1β 
(p=0.01), TNFα (p=0.03) and IL-22 (p=0.03) after stimulation with A. fumigatus, compared to PBMCs 
from volunteers carrying the TC and CC genotypes. However, the production of IL-1Ra, IL-17 and IFNγ 
Table 3 | Independent factors associated with mould colonization and infections in SOT recipients
Variable 
Mould colonization (n=42) 1 IMI (n=25) 1
HR (95%CI) p 2 HR (95%CI) p 2
IL1B rs16944 (TT vs CC/CT) 3 2.66 (1.25-5.64) 0.01 5.27 (2.19-12.7) 0.0002 **
DEFB1 rs1800972 (CC vs GG/GC) 3 7.09 (2.62-19.2) 0.0001 * 5.34 (1.67-17.0) 0.005
IL1RN rs419598 (CC vs TT/TC) 3 2.91 (1.13-7.47) 0.03 - -
Transplanted Lung or Heart 7.60 (3.71-15.6) <0.0001 3.45 (1.38-8.60) 0.008
MMF 0.31 (0.16-0.60) 0.0006 0.13 (0.06-0.30) <0.0001
Tacrolimus 0.49 (0.25-0.98) 0.04 0.49 (0.20-1.15) 0.1
Corticosteroids 2.47 (0.71-8.61) 0.2 3.74 (0.82-17.1) 0.09
CMV infection/disease - - 2.75 (1.14-6.64) 0.02
Living donor 0.33 (0.07-1.47) 0.2 - -
Recipient age (per year) 1.04 (1.01-1.06) 0.01 1.06 (1.02-1.10) 0.005
1  The total number of patient in the multivariate analysis (n=1047) was slightly lower than in univariate analysis  
 (n=1101) due to missing covariates. Five patients who were colonized with mould before transplant, among  
  whom two also developed IMI before transplant, were removed from the analyses.
2  Multivariate analysis assessed by stepwise regression. The variables included in the initial model were recipient 
 age and sex, CMV infection or disease, mycophenolate mofetil treatment, acute cellular rejection, transplant 
 from a living donor and type of transplanted organ.
3  Genetic associations are for recessive mode (patients homozygous for the rare alleles are compared to the   
 other).
*  Significant after correction for multiple testing (n=21, p=0.002).
**Significant after correction for multiple testing (n=21, p=0.004). 
Abbreviations: CI: confidence interval; CMV: cytomegalovirus; HR: hazard ratio; DEFB1: β-defensin 1; IL: 
interleukin; IL1RN: interleukin-1 receptor antagonist; IMI: invasive mould infection; MMF: mycophenolate mofetil.
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Figure 2 | Cumulative incidence of mould colonization and invasive infection in IL1B-IL1RN haplotypes 
(Panel A and B) and invasive mould infection (Panel C and D) according to rs16944-rs419598 C-T (Panel A and C) 
or T-C (Panel B and D) haplotype of IL1B and IL1RN polymorphisms in solid organ transplant recipients. P-values 
were calculated by the log-rank test by using the dominant mode of inheritance (patients carrying one or two 
copies of each haplotype are compared to the other). Patients who were colonized or infected with mould 
before engraftment were excluded from the analyses.
was not significantly influenced by IL1B rs16944. PBMCs from volunteers carrying the IL1RN rs419598 
CC genotype produced lower amounts of IL-1β (p=0.03) and TNFα (p=0.04) after stimulation with 
A. fumigatus, compared to PBMCs from volunteers carrying the TC and TT genotypes. However, the 
production of IL-1Ra itself as well as IL-22, IL-17 and IFNγ was not influenced by IL1RN rs419598.
Discussion
While a number of investigators have reported associations between genetic polymorphisms 
and susceptibility to invasive aspergillosis among onco-hematological patients 6,7, the role of 
such polymorphisms has not been studied among SOT recipients. We report for the first time an 
association between polymorphisms in IL1B, its antagonist IL1RN, and DEFB1, on susceptibility to 
IMI in this population.
 The IL1B gene encodes for the cytokine IL-1β that is essential in host defense against Aspergillus 
infection 15. IL-1β is a potent pro-inflammatory cytokine that recruits neutrophils to the lungs during 
infection, which are crucial for clearing Aspergillus 16. Resting Aspergillus conidia in the respiratory 
epithelium are detected by alveolar macrophages and/or dendritic cells (DCs). These cells express 
a wide variety of pattern recognition receptors (PRRs), 17 that detect molecular patterns from the 
fungal cell wall (e.g. o-linked mannan, galactomannan and β-(1-3)-glucan) 7. Whereas macrophages 
produce TNFα and IL-1β upon recognizing Aspergillus resulting in the recruitment of neutrophils and 
monocytes, activated DCs will migrate to lymph nodes to induce protective T-helper cell activity. IL-
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 Because of its potent inflammatory capacity, IL-1β responses need to be tightly controlled. This is 
underlined by the observation that patients with a mutation in IL-1Ra have severe inflammation of the 
skin and bones due to uncontrolled neutrophil influx and increased Th17 responses 18. Moreover IL-1Ra 
knockout mice were shown to be fully protected from developing invasive aspergillosis 19. Importantly 
galactosaminogalactan, an anti-inflammatory cell wall component of A. fumigatus, was able to 
induce IL-1Ra in vivo and consequently suppress the IL-1β pathway leading to increased susceptibility 
to invasive aspergillosis 19. IL-1β binds to the IL-1 receptor and this results in the recruitment of a 
second receptor (IL-1RacP) 20 that activates signalling transduction pathways thereby exerting potent 
inflammatory activities. IL-1Ra also binds to the IL-1 receptor, but prevents recruitment of the second 
receptor and thus does not activate signal transduction pathways 20. Therefore, the bioactivity of IL-1β 
is controlled by IL-1Ra 21.
 The polymorphisms associated with mould colonization and IMI in this study are located within 
the IL-1 cluster, located in chromosome 2, encompassing both IL1B and IL1RN. We found that the 
minor alleles of rs16944 and rs1143627 within IL1B were associated with an increased risk of mould 
colonization and IMI in SOT. Consistent with our observation, the minor allele of rs16944 tended to 
be associated with an increased risk of invasive pulmonary aspergillosis in a case-control study of 
Figure 3 |Effect of IL1B and IL1RN polymorphisms on Aspergillus-induced cytokine release
Levels of Aspergillus-induced TNFα, IL-1β, IL-1Ra, IL-17, IL-22, IFNγ release by PBMCs depending on presence or 
absence of two copies of IL1B rs16944 (A) or IL1RN rs419598 (B) SNPs. PBMCs from 73 healthy volunteers with 
different IL1B rs16944 or IL1RN rs419598 genotypes were stimulated either with live A. fumigatus conidia for 24 
hours (for TNFα, IL-1β, IL-1Ra) or heat inactivated A. fumigatus conidia for 7 days (for IL-17, IL-22, IFNγ). Cytokine 
levels were measured in cell culture supernatants and given in pg/mL. The effect of SNPs on cytokine levels were 
calculated by Mann-Whitney U test. The data are presented as mean ± standard error of the mean (SEM).
1β induces Th17 responses that are characterized by the production of IL-17, leading to an increased 
recruitment of neutrophils. Additionally, the activated T-helper cells induce IL-22 responses that will 
stimulate production of defensins by epithelial cells 7,13. Thus, IL-1β is a key player in the induction of 
protective innate and adaptive anti-Aspergillus host defense.
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110 neutropenic patients with hematological malignancies 22. The minor alleles of these SNPs were 
also associated with susceptibility to different bacterial and viral infections. Two studies showed 
an association between rs16944 and/or rs1143627 and mortality due to meningococcal disease 23. 
Studies among Chinese patients also showed an association between both SNPs and susceptibility to 
sepsis after major trauma 24 and H1N1 pandemic influenza A virus 25. 
 It has been previously shown that rs16944 located at position -511 corresponding to a putative AP-2 
binding site and rs1143627 located at position -31 within TATA box, are functional polymorphisms that 
could be responsible for alteration of promoter activity and thus being able to modulate expression and 
secretion of IL-1β in vitro 26. In our study, PBMCs from individuals carrying two copies of rare allele of 
IL1B rs16944 had diminished IL-1β release upon Aspergillus stimulation. In line with our data, human 
monocytes from individuals carrying minor allele of rs1143627 had moderated transcriptional activity 
of IL1B promoter in response to lipopolysaccharide (LPS) 26. Moreover carriers of minor alleles of rs16944 
or rs1143627 had significantly lower IL-1β levels in LPS-induced PBMCs 27. However, other studies have 
reported that the minor allele of rs16944 was correlated with increased transcriptional activity of the 
promoter in vitro upon LPS stimulation and high IL-1β secretion 28,29. There is no clear explanation for 
these discrepant observations, but they may be due, at least in part, to the use of different cells or 
tissues and/or stimuli, stimulating concentrations or durations, or failure to account for other, so far 
unknown, regulating factors. We found that the IL1B rs16944 polymorphism was not only associated 
with less IL-1β production, but also reduced TNFα production in response to Aspergillus. TNFα is 
another essential cytokine in antifungal host defense, and anti-TNF treatment has previously been 
associated with invasive aspergillosis 24,30.
 The IL1RN rs419598 SNP, which is in strong linkage disequilibrium with the IL1RN VNTR, has also 
been associated with mould colonization and IMI 31. Consistent with this finding, the minor allele of 
rs419598 was previously associated with severity of meningococcal disease and genital human 
papillomavirus (HPV) clearance 23,32. To our knowledge, the functional role of rs419598 has not been 
explored so far. In the present study, the minor allele of rs419598 did not influence IL-1Ra production in 
PBMCs from volunteers stimulated with A. fumigatus. However, rs419598 carriers had significantly lower 
levels of IL-1β and TNFα. This is consistent with a previous study, in which the VNTR*2 was associated with 
decreased IL-1β in the gastric mucosa as well as in PBMCs stimulated with LPS 28,33. Altogether, these data 
suggest that IL1RN participates to the regulation of Aspergillus-mediated cytokines production, and that 
IL1RN polymorphism may reduce the ability to clear the pathogen.
 DEFB1 encodes human β-defensin 1, a member of the defensins family. Defensins are encoded 
by polymorphic gene cluster located within a 450-kb region on chromosome 8p23 34. They exert 
antimicrobial activity against a broad spectrum of pathogens; they also exert a chemotactic activity on 
immune cell and are able to induce cytokine production 35,36. β-defensin 1 is constitutively expressed 
in lung epithelial cells and was shown to exert antimicrobial properties against C. albicans 37. To our 
knowledge, the antimicrobial properties of this β-defensin against other fungal pathogens have not 
been investigated so far.
 The minor allele of rs1800972 SNP in DEFB1 was associated with an increased risk of mould 
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colonization and IMI in SOT. In line with our findings, the same allele was previously associated 
with higher oral Candida carriage among diabetic and non-diabetic patients 38. The rs1800972 SNP 
is located at position -44 of 5’ untranslated region of DEFB1 and was predicted to alter a putative 
transcription factor binding site to this region of the gene 39,40. The minor allele of rs1800972 has been 
previously associated with lower β-defensin 1 expression in the skin with increased nasal carriage of 
Staphylococcus aureus 41. This allele may also decrease the expression of β-defensin 1 in the respiratory 
epithelium, with reduced ability to clear opportunistic pathogens such as mould under certain 
immunosuppressive conditions. Interestingly, the cytokine IL-22 is a potent inducer of defensins 
produced by epithelial cells 42,43. The IL1B rs16944 SNP was associated with a significant reduction in 
Aspergillus-induced IL-22 production in human PBMCs. Therefore, it can be proposed that this SNP may 
increase susceptibility not only because of the low production of essential innate cytokine such as IL-
1β and TNFα, but also because of a reduced induction of IL-22 that might result in defective induction 
of defensins.
 SFTPA2 encodes pulmonary surfactant-associated protein 2 (SP-A2), a member of collagen 
containing soluble CLRs (collectins). The SP-A2 was shown to play an important role in host response 
to Aspergillus, by its ability to bind A. fumigatus conidia and thus enhance phagocytosis by neutrophils 
and macrophages 44. Polymorphisms in collagen region of SFTPA2 (G1649C and/or A1660G) have been 
Table 4 | Power to detect association of genetic polymorphism with mould colonization or invasive 
infection in solid organ transplant recipients.
Gene 
(nt|aa change) 1 rs number MAF HWE
Colonization (Frequency 4.1%) IMI (Frequency 2.4%)
Power to detect 
colonization 
Observed 
values Power to detect IMI
Observed 
values
HR=3 HR=4 HR=5 HR Cox p2 HR=3 HR=4 HR=5 HR Cox p 2
IL10 (-1082 A/G) rs1800896 0.44 0.220 0.62 0.90 0.98 0.89 0.8 0.29 0.57 0.77 0.34 0.1
CXCL10 (1642G/C) rs3921 0.41 0.280 0.61 0.89 0.98 0.79 0.6 0.28 0.55 0.76 0.67 0.5
CD209 (-139 A/G) rs2287886 0.36 0.610 0.58 0.87 0.97 0.50 0.2 0.26 0.52 0.72 0.28 0.2
TLR6 (S249P) rs5743810 0.35 0.180 0.57 0.86 0.97 1.78 0.1 0.25 0.51 0.71 1.47 0.4
IL1B (-511 C/T) 4 rs16944 0.33 0.160 0.55 0.85 0.96 2.98 0.002 0.24 0.49 0.70 4.67 0.0002
INFG (874 T/A) rs2069705 0.33 0.086 0.55 0.85 0.96 0.17 0.08 0.24 0.49 0.70 0.00 1.0
PLG (D472N) rs4252125 0.30 0.340 0.51 0.82 0.95 1.45 0.4 0.22 0.46 0.66 2.24 0.1
IL1A (-889 C/T) rs1800587 0.29 0.620 0.50 0.81 0.94 1.24 0.6 0.21 0.45 0.65 0.81 0.8
TLR3 (L412F) rs3775291 0.29 1.000 0.50 0.81 0.94 1.10 0.8 0.21 0·45 0.65 0.94 0.9
IL10 (-819 C/T) rs1800871 0.27 0.820 0.47 0.78 0.93 1.02 1.0 0.20 0.42 0.62 0.56 0.6
IL1RN (2018T/C) rs419598 0.25 0.320 0.44 0.75 0.91 2.84 0.02 0.18 0.39 0.58 3.36 0.03
DEFB1 (-44 C/G) rs1800972 0.18 1.000 0.30 0.59 0.79 4.08 0.003 0.12 0.27 0.42 5.91 0.001
MBL (G54D) rs1800450 0.15 0.099 0.24 0.49 0.70 0.80 0.8 0.09 0.21 0.34 0.00 1.0
SFTPA2 (A91P) rs17886395 0.14 0.900 0.22 0.45 0.66 4.79 0.009 3 0.08 0.19 0.31 0.00 1.0
TNF (-308 G/A) rs1800629 0.14 0.010 0.22 0.45 0.66 0.00 1.0 0.08 0.19 0.31 0.00 1.0
TLR9 (-1237 C/T) rs5743836 0.13 0.060 0.19 0.41 0.61 2.27 0.3 0.07 0.17 0.28 4.13 0.054
CLEC7A (Y238X) rs16910526 0.08 0.340 0.09 0.21 0.34 0.00 1.0 0.03 0.08 0.13 0.00 1.0
TLR1 (R80T) rs5743611 0.07 0.500 0.07 0.17 0.28 0.00 1.0 0.03 0.06 0.11 0.00 1.0
IL23R (R381Q) rs11209026 0.07 0.811 0.07 0.17 0.28 0.00 1.0 0.03 0.06 0.11 0.00 1.0
TLR4 (D299G) rs4986790 0.05 0.540 0.04 0.09 0.16 0.00 1.0 0.02 0.04 0.06 0.00 1.0
MASP2 (D105G) rs72550870 0.02 0.150 0.01 0.02 0.03 0.00 1.0 0.005 0.009 0.01 0.00 1.0
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infection in solid organ transplant recipients.
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Colonization (Frequency 4.1%) IMI (Frequency 2.4%)
Power to detect 
colonization 
Observed 
values Power to detect IMI
Observed 
values
HR=3 HR=4 HR=5 HR Cox p2 HR=3 HR=4 HR=5 HR Cox p 2
IL10 (-1082 A/G) rs1800896 0.44 0.220 0.62 0.90 0.98 0.89 0.8 0.29 0.57 0.77 0.34 0.1
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CD209 (-139 A/G) rs2287886 0.36 0.610 0.58 0.87 0.97 0.50 0.2 0.26 0.52 0.72 0.28 0.2
TLR6 (S249P) rs5743810 0.35 0.180 0.57 0.86 0.97 1.78 0.1 0.25 0.51 0.71 1.47 0.4
IL1B (-511 C/T) 4 rs16944 0.33 0.160 0.55 0.85 0.96 2.98 0.002 0.24 0.49 0.70 4.67 0.0002
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PLG (D472N) rs4252125 0.30 0.340 0.51 0.82 0.95 1.45 0.4 0.22 0.46 0.66 2.24 0.1
IL1A (-889 C/T) rs1800587 0.29 0.620 0.50 0.81 0.94 1.24 0.6 0.21 0.45 0.65 0.81 0.8
TLR3 (L412F) rs3775291 0.29 1.000 0.50 0.81 0.94 1.10 0.8 0.21 0·45 0.65 0.94 0.9
IL10 (-819 C/T) rs1800871 0.27 0.820 0.47 0.78 0.93 1.02 1.0 0.20 0.42 0.62 0.56 0.6
IL1RN (2018T/C) rs419598 0.25 0.320 0.44 0.75 0.91 2.84 0.02 0.18 0.39 0.58 3.36 0.03
DEFB1 (-44 C/G) rs1800972 0.18 1.000 0.30 0.59 0.79 4.08 0.003 0.12 0.27 0.42 5.91 0.001
MBL (G54D) rs1800450 0.15 0.099 0.24 0.49 0.70 0.80 0.8 0.09 0.21 0.34 0.00 1.0
SFTPA2 (A91P) rs17886395 0.14 0.900 0.22 0.45 0.66 4.79 0.009 3 0.08 0.19 0.31 0.00 1.0
TNF (-308 G/A) rs1800629 0.14 0.010 0.22 0.45 0.66 0.00 1.0 0.08 0.19 0.31 0.00 1.0
TLR9 (-1237 C/T) rs5743836 0.13 0.060 0.19 0.41 0.61 2.27 0.3 0.07 0.17 0.28 4.13 0.054
CLEC7A (Y238X) rs16910526 0.08 0.340 0.09 0.21 0.34 0.00 1.0 0.03 0.08 0.13 0.00 1.0
TLR1 (R80T) rs5743611 0.07 0.500 0.07 0.17 0.28 0.00 1.0 0.03 0.06 0.11 0.00 1.0
IL23R (R381Q) rs11209026 0.07 0.811 0.07 0.17 0.28 0.00 1.0 0.03 0.06 0.11 0.00 1.0
TLR4 (D299G) rs4986790 0.05 0.540 0.04 0.09 0.16 0.00 1.0 0.02 0.04 0.06 0.00 1.0
MASP2 (D105G) rs72550870 0.02 0.150 0.01 0.02 0.03 0.00 1.0 0.005 0.009 0.01 0.00 1.0
Table 4 | continued)
1 Three SNPs that deviated from Hardy-Weinberg equilibrium  
 (TLR1 rs5743618, IL4 rs2243250 and CARD9 rs10870077) were  
 excluded from the analyses.
2 P value was assessed by Cox regression, recessive mode  
 (patients homozygous for the rare alleles are compared to  
 the other).
3 P value for the additive mode was 0.01, HR=1.91, CI 1.15- 
 3.17
4 In almost complete linkage disequilibrium (LD=0.99) with  
 the IL1B -31T/C rs1143627
Abbreviations: CARD9: caspase recruitment domain-9; CI: 
confidence interval; CLEC7A: C-type lectin domain 7; CXCL10: 
CXC-chemokine ligand-10; CD209: CD209 molecule; DEFB1: 
β-defensin 1; HR: hazard ratio; IL: interleukin; IL1RN: interleu-
kin-1 receptor antagonist; ; IL23R: interleukin 23 receptor; 
IMI: invasive mould infection; MBL: mannose banding lectin; 
MASP2: mannan-binding lectin serine peptidase 2; MAF: 
minor allele frequency; PLG: plasminogen; SFTPA2: surfactant 
protein A2; TLR: Toll-like receptor; TNF: tumour necrosis fac-
tor. 
associated with chronic cavitary pulmonary aspergillosis 45 and allergic bronchopulmonary aspergillosis 
in asthmatic patients 46. Here, we detected an association between the G1649C polymorphism and 
mould colonization, but not infection, in SOT recipients. The lack of association with infection may be 
due to insufficient statistical power due to the relatively small SNPs allele frequency and sample size.
 By using a list of 24 polymorphisms from 21 genes previously associated with susceptibility to fungal 
infections, we showed that SNPs from three genes (IL1B, IL1RN and DEFB1) were associated with mould 
colonization or IMI in Caucasian SOT recipients. Mould colonization may have been underestimated, as 
bronchoscopy is not routinely performed, especially in especially in non-thoracic SOT recipients. Yet, 
the polymorphisms associated with colonization were also associated with IMI, suggesting that these 
polymorphisms influence both phenotypes, with a continuum from colonization to invasive infection. 
We were not able to detect an association with polymorphisms in other genes, such as TLR4 or CLEC7A 
(encoding Dectin-1), that were previously reported to be associated with invasive aspergillosis by 
several investigators 6,7. This may be due to several reasons, such as the inclusion of different study 
populations, fungal pathogens and/or less invasive forms of infections. Importantly, the number of 
patients with mould colonization and/or IMI was small, leading to a limited statistical power, especially 
for infrequent SNPs, as detailed in Table 4. Larger studies and studies in patient from non-Caucasian 
ethnicities will be needed to replicate such associations.
Chapter 9  160 | 
 We report an association between polymorphisms in three genes and mould colonization and 
IMI in a nationwide cohort of SOT recipients. Theses associations were found to be independent from 
previously known risk factors, such as the recipient age, cytomegalovirus co-infection 3. The genes 
were formerly described as important components of immune defenses against fungal pathogens, 
and the associated polymorphisms were all shown to be functionally relevant. Altogether, these 
findings may contribute to a better understanding of the pathogenesis of IMI in SOT recipients and 
help in individual risk stratification in the future.
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Figure S1 | Cumulative incidence of mould colonization and infection with IL1B and DEFB1 genotype 
combinations 
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Figure S2 | Cumulative incidence of mould colonization and infection in thoracic solid organ transplant 
recipients
Cumulative incidence of mould colonization (n=25) and invasive mould infection (n=9) according to IL1B rs16944 
(panel A, and B, respectively), β-defensin 1 rs1800972 (DEFB1, panel C and D, respectively) and interleukin-1 
receptor antagonist rs419598 (IL1RN, panel E, and F, respectively) polymorphisms in thoracic solid organ 
transplant recipients. Patients who were colonized or infected with mould before engraftment were excluded 
from the analyses. P-values were calculated by log-rank test, recessive mode (patients homozygous for the rate 
alleles are compared to the other)
(Figure S1 continued) (A) Cumulative incidence of mould colonization and (B) invasive infection according to a 
combination of IL1B rs16944 with DEFB1 rs1800972 polymorphisms in solid organ transplant recipients. Patients 
who were colonized or infected with mould before engraftment were excluded from the analyses. p-values were 
calculated by the log-rank test by using recessive mode of inheritance (patients homozygous for the rare alleles 
are compared to the other). Only one patient colonized and/or infected with the mould was homozygous for 
both IL1B rs16944 and DEFB1 rs1800972 SNPs.
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 9 Figure S3 | Cumulative incidence of mould colonization and onfection in abdominal solid organ transplant 
recipients
Cumulative incidence of mould colonization (n=17) and invasive mould infection (n=16) according to IL1B 
rs16944 (panel A, and B, respectively), β-defensin 1 rs1800972 (DEFB1, panel C and D, respectively) and 
interleukin-1 receptor antagonist rs419598 (IL1RN, panel E, and F, respectively) polymorphisms in abdominal 
solid organ transplant recipients. Patients who were colonized or infected with mould before engraftment were 
excluded from the analyses. p-values were calculated by log-rank test, recessive mode (patients homozygous for 
the rate alleles are compared to the other).
Figure S4 | Cumulative incidence of mould colonization and infection associated to SFTPA2 genotype
Cumulative incidence of mould colonization (n=45) and invasive mould infection (n=26) according to SFTPA2 
rs17886395 (panel A, and B, respectively) polymorphism in solid organ transplant recipients. Patients who were 
colonized or infected with mould before engraftment were excluded from the analyses. p-values were calculated 
by log-rank test, recessive mode (patients homozygous for the rate alleles are compared to the other).
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Abstract
IL-36α, IL-36β, IL-36γ, and IL-36Ra, collectively called IL-36 cytokines, are part of the IL-1 family. IL-
36α, IL-36β, and IL-36γ are IL-36 receptor (IL-36R) agonists, while IL-36Ra is a receptor antagonist 
that blocks the activation of IL-36R signalling. IL-36 cytokines require processing in order to become 
fully active, however the protease(s) responsible for this are currently not known. The IL-36 receptor 
pathway activates dendritic cells and plays a role in polarizing T-helper responses. The skin is the 
predominant site where IL-36 cytokines are expressed and several reports have established that 
they play a significant role in the pathogenesis of skin diseases. In this review the discovery and 
biological function of the cytokines IL-36α, IL-36β, IL-36γ and IL-36Ra will be discussed, and their role 
in the pathogenesis of a wide variety of diseases.
Highlights
• IL-36 family cytokines share 20 to 52% homology with IL-1Ra.
• N-terminal processing is required for optimal bioactivity of IL-36 cytokines.
• IL-36 modulates immune responses by DC activation and T-helper subset polarization.
• IL-36 signalling plays a crucial role in skin homeostasis and inflammation.
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Introduction
A decade ago several new members of the IL-1 gene family were discovered 1-9. Two years after their 
discovery, these novel cytokines were renamed in order of their date of publication 10. With the 
elucidation of their biological function it was proposed in 2010 that these IL-1 family members should 
each be assigned an individual interleukin designation 11. The cytokines have been renamed: IL-36α, 
IL-36β, IL-36γ and IL-36 receptor antagonist (Ra), and are collectively called IL-36 cytokines (Table 1).
Discovery of the new members of the IL-1 gene family 
IL-36Ra is the first new IL-1 family member that has been reported after the discovery of IL-1β, IL-1α, 
IL-1Ra and IL-18. IL-36Ra shares 52% homology with IL-1Ra and is predominantly expressed in the 
skin 1. Shortly thereafter, another group reports that although IL-36Ra shares 47% homology with 
IL-1Ra, IL-36Ra does not have biological activity similar to IL-1Ra 2. In addition to this IL-1Ra like 
molecule, three other IL-1 family members are described that share less homology to IL-1Ra 3,4. One 
of these is IL-37, which will not be discussed in the present review. The other two, IL-36β and IL-36γ, 
share the core 12 fold, β-trefoil structure, and lack a signal peptide, classical features of IL-1 family 
members 3,4, but share 27 and 20% homology with IL-1Ra respectively 6,8. IL-36Ra is constitutively 
expressed in keratinocytes, whereas IL-36γ expression in keratinocytes is rapidly induced after 
stimulation with TNF or PMA 3. Smith et al., identified IL-36α next to IL-36Ra, IL-36β and IL-36γ, and 
described the predicted three-dimensional structure of IL-36α 6. Additional studies revealed that 
IL-36γ does not bind to the currently known IL-1 family receptors IL-1R, IL-18R or ST2 4,6 However, in 
2001 it was reported that IL-36γ can activate NFκB through IL-1Rrp2, and that IL-36Ra is able to block 
this activation, providing the first evidence that IL-36γ is an agonist and IL-36Ra is an antagonist 7. 
IL-38 is the sixth newly discovered cytokine of the IL-1 family and shares 41% homology with IL-36Ra 
and 37% homology with IL-1Ra 9. All six new IL-1 family member genes are located in a cluster on 
chromosome 2 and the gene order from centromere to telomere is IL-1A-IL-1B-IL-37-IL-36G-IL-36A-IL-
36B-IL-36RN-IL1F10-IL-1RN, and only IL-1A, IL-1B and IL-36B are transcribed towards the centromere 
8. These new genes all map to a small interval, and they probably arose from a common ancestral 
gene, which is most likely a primordial IL-1 receptor antagonist gene 5.
Processing of the IL-36 cytokines
A specific feature of the IL-1 family cytokines is that they require N-terminal cleavage to process 
them into full bioactive cytokines. Recently, it has been reported that IL-36 cytokines like IL-1 and 
IL-18 also need to be processed in order to gain full bioactivity 12. Truncation of IL-36α, IL-36β and 
IL-36γ results in a 1000-10.000 fold increased activity of these cytokines in comparison to their non-
truncated forms. Interestingly, only when the N-terminal methionine of IL-36Ra is removed, IL-36Ra 
gains full antagonistic activity, which probably explains why initial studies do not show consistent 
results on the antagonistic property of IL-36Ra 7,12,13. Proteases other than caspase-1 are likely to be 
responsible for cleaving these IL-36 cytokines, since the amino acids surrounding the truncation 
sites do not resemble a caspase-1 cleaving site 12. Moreover, no proteolytic cleavage of IL-36α can 
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be observed in LPS/ATP-stimulated bone marrow derived macrophages with confirmed caspase-1 
activity 14. The protease(s) responsible for cleaving IL-36 cytokines are currently unknown.
Agonists of the IL-36 receptor pathway
IL-36γ is able to induce NFκB activation in Jurkat cells transfected with the IL-1Rrp2 receptor (IL-
36R), and these observations provide the first line of evidence that these cytokines are agonists 
7. Furthermore, IL-36α, IL-36β and IL-36γ can all activate the MAPK, Erk1/2 and JNK through IL-36R/
IL-1RAcP, which targets the IL-8 promoter and results in IL-6 secretion 13. Additional studies have 
confirmed that IL-36α, IL-36β and IL-36γ all have agonistic characteristics and that they signal through 
the IL-36R 13,15,16. In contrast to the other IL-1family cytokines the IL-36 cytokines are expressed in a 
more restricted manner. They are mainly expressed in keratinocytes, bronchial epithelium, brain tissue, 
and monocytes/macrophages (Table 1). In addition, T-lymphocytes can express IL-36α and IL-36β 6,17,18, 
and peripheral blood lymphocytes are able to express IL-36γ in response to α-particles, which can 
be used for targeted cancer therapy 19. Interestingly, it has recently been shown that γδ T-cells can 
express IL-36β under specific conditions 20. Interestingly, IL-36β can induce expression of itself, and 
thus has an autocrine/paracrine loop similar to IL-1 21,22. IL-17 and TNF can induce expression of IL-
36α, IL-36β and IL-36γ in keratinocytes, which can be synergized by the cytokine IL-22 21. Furthermore, 
several reports indicate that epidermal growth factor signalling regulates the expression of IL-36α 
and IL-36β in the skin. Mice deficient in fibroblast growth factor receptors (FGFRs) have a defective 
Table 1 | overview of the IL-36 cytokines
New 
nomenclature
Alternative 
names Signalling
homology
Processing for optimal bioactivity expression Induction refs
 IL-1Ra IL-1β
IL-36Ra
IL-1F5, IL1HY1, 
IL-1L1, IL-1RP3, 
IL-1H3, FIL1delta
Binds IL-1Rrp2 
Blocks IL-1RAcP recruitment
Recruitment of SIGIRR
52%
47% 26%
Removal of N-terminal methionine
(V2)
Monocytes, B lymphocytes, 
DCs , Keratinocytes, skin, 
Uterus, Placenta, Heart, 
Braim, Kidney
1-7, 11, 13, 
15, 16,
63
IL-36α IL-1F6, FIL1epsilon
Binds IL-1Rrp2
Recuitment of IL-1RAcP
Activation of NFκB, MAPK, ERK1/2, JNK
24% 30%
Cleavage at 9 amino
acids N-terminal to a conserved 
A-X-Asp
(K6)
Monocytes, T/B-lymphocytes, 
Spleen, Bone-marrow, Tonsils, 
lymph nodes, Skin
IL-17, TNFα and IL-22
EGF
6, 7, 11, 
13, 15-18, 
21, 23
IL-36β IL-1F8, IL-1H2, FIL1eta 27% 31%
Cleavage at 9 amino
acids N-terminal to a conserved 
A-X-Asp
(R5)
Monocytes, T/B-lymphocytes, 
Bone-Marrow, Tonsils, Heart, 
Lung, Testis, Colon, neuron 
cells, glial cells
IL-36β
IL-17, TNFα and IL-22
EGF
IL-1β
LPS
4, 6, 11, 13, 
15-19, 21, 
23, 24, 26
IL-36γ IL-1F9, IL-1RP2, IL-1H1 20% 31%
Cleavage at 9 amino
acids N-terminal to a conserved 
A-X-Asp
(S18)
peripheral blood 
lymphocytes, Keratinocytes, 
Bronchial epithelial cells,
THP-1
IL-17, TNFα and IL-22
IL-1and TNFα
IL-17
TLR3
P. aeruginosa
E. coli LPS
P. gingivalis LPS
3, 4, 11, 13, 
15, 16, 19, 
21, 16, 27
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skin barrier that leads to activation of keratinocytes and γδ T-cells and significant expression of IL-36β 
in the epidermis 20. Downstream of FGFR2 is ADAM17 (a disintegrin and metalloproteinase 17), and 
ADAM17 deficient mice show a similar skin phenotype to FGFR deficient mice and have an increased 
expression of IL-36α in the skin compared to wild-type mice 23. These data point to an important role 
of the agonists IL-36α and IL-36β in skin homeostasis. Since the IL-36R is highly expressed in the brain, 
and more specifically on microglial cells and astrocytes, initial studies have investigated the role of 
these cytokines on brain inflammatory responses 24-26. Murine IL-36 is expressed in neuron cells and 
in glial cells, but cannot be upregulated by LPS or IL-1β stimulation 24,26. Furthermore, recombinant 
non-processed mouse IL-36β does not induce any of the classical IL-1 like responses in mixed glial 
cells in-vitro. Recombinant murine IL-36γ does not induce a response in mixed glial cells in vitro, 
and injection of IL-36 intra-cerebroventriclar does not result in fever or modification of food intake 
and body weight in mice 24. Notably, these studies have been performed with non-processed IL-36 
agonists, and therefore may not have revealed the genuine role of IL-36 cytokines in inflammatory 
responses in the brain. Bronchial epithelial cells express IL-36 cytokines, and stimulation of bronchial 
epithelial cells with pro-inflammatory cytokines such as IL-1+TNF, IL-17, Pseudomonas aeroginosa or 
TLR3 ligands results in significant expression of IL-36 16,27. In human lung fibroblasts, IL-36γ induces the 
chemokine IL-8 and the Th17 chemokine CCL20 16. These data suggest that IL-36 cytokines play a role 
in the host defence against viral and bacterial pulmonary infection and contribute to the regulation of 
neutrophil airway inflammation. Macrophages and monocytes express IL-36 6,28. Interestingly, THP-1 
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cells, a human monocyte cell line, specifically express IL-36γ, but not IL-36α or IL-36β, after stimulation 
with LPS derived from E. coli or P. gingivalis 28. Although monocytes and macrophages can thus be 
a source of IL-36 cytokines, the significance of this observation with respect to homeostasis and 
pathogenesis remains to be elucidated.
IL-36 receptor antagonist
Although IL-36Ra shares the most homology with IL-1Ra, it significantly differs in loop conformations 
from IL-1Ra, most likely explaining the inability of IL-36Ra to bind to the IL-1R1. It has even been 
proposed that IL-36Ra is an agonist, since residue 147 is an aspartic acid in both IL- 1β and IL-36Ra, 
but a lysine in IL-1Ra; changing the lysine of IL-1Ra to an aspartic acid results in a partial agonistic 
character of IL-1Ra 29. However, several reports have shown that IL-36Ra inhibits IL-36γ-induced NFκB 
activation 7,13. Moreover, IL-36Ra acts similar to IL-1Ra, by eliciting its antagonistic effects through 
binding of the IL-36R and blocking the recruitment of the second receptor IL-1RAcP 12. Although 
this suggests that IL-36Ra acts similar to IL-1Ra, several observations suggest otherwise. IL-36Ra 
needs to be processed in order to gain antagonistic properties 12. Unlike IL-1Ra which to date was 
not found to induce any cytokines, IL-36Ra itself can induce mRNA of IL-4 and protein expression in 
glia cells in-vitro, and this induction is blocked in the presence of anti-SIGIRR antibodies, and in-vivo 
experiments show that the anti-inflammatory action of IL-36Ra in the brain is dependent on IL-4 and 
SIGIRR 30. IL-36Ra reduces Th17 characteristic cytokines induced by C. albicans or Aspergillus, but not 
in a classical dose-dependent manner 31,32. These reports suggest IL-36Ra might be able to activate 
an anti-inflammatory signalling pathway or recruit anti-inflammatory IL-1 orphan receptors like 
SIGIRR, and thus under specific conditions does not act as the classical receptor antagonist IL-1Ra. 
IL-36 secretion
Because IL-36α, IL-36β and IL-36γ do not have a signal sequence they cannot be directed directly to 
the endoplasmatic reticulum, and thus require an alternative mechanisms that allows them to be 
secreted. The first study investigating the possible underlying mechanism of secretion of these IL-36 
cytokines has studied the secretion of IL-36α in bone marrow-derived macrophages that overexpress 
IL-36α (BMDMs) 14. IL-36α is secreted in these BMDMs upon stimulation with LPS/ATP, suggesting that 
IL-36α can be externalized in a stimulus-dependent manner comparable to IL-1β. Furthermore, they 
show that IL-36α has no caspase-1 cleavage consensus, and the release of IL-36α is not inhibited in 
the presence of a caspase-1 inhibitor 14. In contrast, a recent study proposes that the release of IL-36γ 
by keratinocytes is caspase-1 dependent, and describes that IL-36γ transcription is dependent on 
caspase-1 33. It remains to be defined what the underlying mechanism is for secreting IL-36 cytokines. 
The interplay of IL-36 cytokines with immune cells 
The IL-36 cytokines have a significant effect on dendritic cells (DCs) and T-cells 18,34. In murine DCs, 
IL-36 agonists upregulate CD80, CD86 and MHCII, markers of activation, and induce IL-6 and IL-
12 production that is completely dependent on IL-36R signalling 18. Although IL-36 cytokines do 
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not induce cytokine production in inactivated murine total splenic CD4+ T-cells, in the presence of 
mitogenic stimulation (aCD3/aCD28), IL-36 agonists enhance the capability of CD4 T-cells to produce 
and secrete IFNγ, IL-4 and IL-17 in a dose dependent manner. In a murine immunization model using 
intradermal BSA injections, IL-36β can act as an adjuvant that specifically enhances Th1 responses in-
vivo, and the adjuvanticity of IL-36β is completely dependent on IL-36R signalling 18. In humans the 
expression of the IL-36R within the human monocytic cell line is unique to DCs 34. Monocyte-derived 
DCs (MDDCs) and to a lesser extend plasmacytoid DCs express the IL-36R, while type 1 and type 2 DCs 
do not express IL-36R. Human MDDCs respond to IL-36β and IL-36γ by increasing their expression 
of HLA-DR and CD83. In addition, IL-36β induces the production of IL-12 and IL-18 in MDDCs, which 
subsequently results in the proliferation of IFNγ-producing T lymphocytes 34. Stimulation of CD11+ 
cells with IL-36α upregulates neutrophil chemokines CXCL1 and CXCL2, the cytokine TNFα and 
CD40 expression. Furthermore, these CD11c+ cells were found to induce CD4 T-cell proliferation 35. 
Although the IL-36R was initially found to be present on DCs, a recent study demonstrates that the 
IL-36R is also highly expressed on naïve T-cells 36. IL-36 cytokines stimulate proliferation of T-cells and 
induce IL-2 production by naïve T-cells. Furthermore, IL-36 plays a significant role in the development 
of Th1 responses 36. Human peripheral blood mononuclear cells that are stimulated with C. albicans, 
a potent inducer of the Th17 response in humans, produce less IL-17 and IL-22 in the presence of IL-
36Ra 31. The IL-36 receptor pathway also plays a role in regulating Th1 and Th17 responses induced 
by A. fumigatus, and neutralization of endogenous IL-36Ra could amplify the Th17 response to 
Aspergillus 32. Furthermore, IL-36 agonists in the absence of mitogenic stimulation do not induce 
characteristic T-helper cell cytokines in mice 18 and humans 32. Therefore, the data presented above 
suggest that IL-36 cytokines can modulate the immune system primarily through their effects on 
antigen-presenting cells, such as DCs and in this way can polarize T-helper responses. Furthermore, 
in the setting of activated T-helper cells, direct effects of IL-36 agonists have been observed and thus 
IL-36 cytokines can potentially play a role in fine-tuning T-helper responses during inflammation.
Role of IL-36 in disease
Since IL-36 cytokines are predominantly expressed in keratinocytes it is not surprising that specifically 
skin disorders have been explored for associations with these cytokines. Several reports show that 
psoriatic skin lesions express IL-36Ra and IL-36 agonists 7,37-39. The importance of the IL-36 cytokines 
in regulating skin inflammation is underscored by the observation that transgenic mice which 
overexpress the IL-36α gene in basal keratinocytes display acanthosis and hyperkeratosis of the 
skin, which are characteristics of psoriatic skin lesions 38. In addition, IL-36Ra deficiency exacerbated 
the skin lesions in IL-36α transgenic mice, suggesting an antagonistic effect of IL-36Ra in vivo for 
IL-36-mediated inflammation in the skin 38. Phorbol ester treatment of mouse skin overexpressing 
IL-36α results in an inflammatory condition with macroscopic and histological similarities to human 
psoriasis 40. In addition, the maintenance of characteristic inflammation of human psoriatic skin 
transplanted into immunodeficient mice is dependent on the IL-36R 40. Psoriasis is associated with 
cytokines such as TNFα, IL-22 and IL-17, and the observed interplay between these cytokines and 
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IL-36 cytokines suggest an important role for IL-36 cytokines in psoriasis 21. In line with this, anti-TNF 
treatment in patients with psoriasis results in decreased expression of the IL-36 agonists and IL-
36Ra, which was associated with improved clinical outcome 37. Although the expression of IL-36Ra 
by IL-17-stimulated keratinocytes derived from patients with psoriasis does not differ from healthy 
controls 41, increased expression of the IL-36 cytokines correlates with Th17 cytokines in human 
psoriatic skin lesions 21 and increased activation of MAPK and NFκB39.
 SNPs in a region in the IL-1 locus that includes the genes encoding IL-36β and IL-38 is associated 
with a higher susceptibility to psoriatic arthritis 42. Moreover it has recently been shown that 
mutations in IL-36RN can cause a rare life threatening disease called general pustular psoriasis (GPP) 
43-47. The currently found mutations in IL-36RN lead to introduction of a premature stop-codon, 
frameshift mutation, or an amino acid substitution which were found to result in a misfolded IL-
36Ra protein that is less stable and poorly expressed 43,45,46., and Moreover the misfolded IL-36Ra 
has less affinity with the IL-36R compared to the wild-type IL-36Ra protein, and therefore is not 
able to dampen IL-36R-mediated inflammation 43,45,46. These data indicate that IL-36Ra is a receptor 
antagonist, and that IL-36 signalling plays a significant role in regulating skin inflammation. Notably, 
mutations in the gene encoding IL-36Ra have not been found to date in Chinese patients with GPP, 
and only 2 out of 14 Japanese patients with GPP carried mutations in IL-36RN 46,48. 
 An early study reports that a polymorphism in IL-36Ra is associated with the development of 
alopecia areata, a disease characterized by patchy hair loss with T-cell infiltration in the hair follicles 
49. In contrast, a different SNP in IL-36Ra has been analysed in a large cohort of alopecia areata, which 
does not show an association. Another skin disorder where the IL-36R axis might play a significant 
role is Kindler syndrome, which is a rare syndrome characterized by skin blistering, increased 
photosensitivity of the skin, and progressive generalized poikiloderma 50. IL-36Ra expression is 
increased in keratinocytes isolated from patients with Kindler syndrome 50. Notably, these patients 
can also develop mucocutaneous fibrosis, such as stenosis of the esophagus and urethral stenosis. 
Additionally, psoriasiform dermatitis was found to be mediated by DC-keratinocyte cross talk 
independent on IL-1β, but dependent on IL-36 controlled IL-23, IL-17and IL-22 51. 
 IL-36Ra is significantly upregulated in an animal model where brain micromotion is simulated 
52. Although LPS does not induce expression of IL-36Ra in microglia cells and astrocytes, IL-36Ra 
expression is increased by a 1000-fold in astrocytes and a 230-fold in microglia cells that are 
subjected to low-magnitude cyclical strain. Furthermore, primary cortical neurons that are stretched 
in the presence or absence of IL-36Ra, show a 400-fold decrease of TNF superfamily member 
B11 (TNFRSF11b) in the presence of IL-36Ra 52. This decrease of TNFRSF11b is accompanied by a 
significant upregulation of pro-apototic genes, and suggests that IL-36Ra can regulate apoptotic 
pathways in low-magnitude strain induced brain tissue inflammation. 
 Preliminary data provide evidence that IL-36 cytokines might play a role in obesity. IL-36Ra is 
expressed in differentiated pre-adipocytes, and can be downregulated by the pro-inflammatory 
cytokine TNFα 53. In addition, IL-36α, but not IL-36γ expression is present in adipose tissue-resident 
macrophages and its expression is induced by LPS. IL-36α and IL-36β can induce inflammatory gene 
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expression in mature adipocytes 54. Furthermore, IL-1Ra plasma levels are associated with metabolic 
conditions and are under strong genetic control and interestingly; polymorphisms in IL-36β and 
IL-36Ra have been associated with plasma IL-1Ra levels in a cohort of 707 non-diabetic African 
Americans 55.
 IL-36 might also play a significant role in joint disease. Remarkably, IL-36β is expressed in mouse 
and human joints 15 and IL-36α was found to be upregulated in joints of patients with psoriatic and 
rheumatoid arthritis 56. IL-36β is constitutively expressed in human articular chondrocytes, and 
stimulation of both synovial fibroblasts and articular chondrocytes by recombinant IL-36β induces 
pro-inflammatory cytokine responses 15. IL-36β can be measured in the serum of healthy human 
volunteers, but when serum IL-36β concentrations of healthy volunteers are compared to serum 
concentrations in rheumatoid arthritis no significant differences have been found 15. In addition, 
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Figure 1 | The role of IL-36 cytokines in disease
Schematic overview of the organs and their specific diseases in which IL-36 cytokines have been found to play 
a role in disease pathogenesis.
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polymorphisms in IL-36β are associated with spondylitis ankylopoetica in a Caucasian cohort, but not 
in Asian cohorts 57,58. In contrast, recently it was demonstrated that in several experimental arthritis 
models IL-36γ, IL-36Ra and IL-36R were found to be expressed, but did not correlate with arthritis 
severity 59. Furthermore, treatment with neutralizing antibodies against IL-36R did not affect arthritis 
severity in collagen induced arthritis. 
 The gene encoding IL-36γ is located in an allergen induced bronchial hyperresponsiveness-1 
locus (Abhr1) in mice, and the expression of IL-36γ in the lung is increased in A/J mice (asthma 
susceptible) compared to C3H/HeJ mice (asthma resistant), suggesting that it might play a role in 
allergen-induced inflammation in the lung 60. Indeed, in mice that are challenged with house dust 
mite (HDM), IL-36γ expression in the lung is significantly increased compared to non-challenged 
mice. It must however be noted that this difference is not explained by differential expression of 
IL-36γ by bronchial epithelial cells, and it remains to be elucidated which cell is responsible for the 
observed increased IL-36γ expression in the lungs of mice challenged with HDM. Recombinant IL-36γ 
given intratracheally, in a dose of 10 µg, results in neutrophil influx, but not eosinophilic influx in the 
lungs of mice, suggesting that IL-36γ is involved in the regulation of neutrophilic airway inflammation 
61, which is in line with other studies 16. Recently, it was found that IL-36α can induce neutrophil influx 
in the airways. Intratracheal administration of IL-36α resulted in upregulation of the neutrophil 
chemokines CXCL1 and CXCL2 and expression of the IL-36R in the lungs of both wildtype and IL-
1αβ-/- mice. This supports the concept that IL-36 signalling can play a role in neutrophil recruitment 
independent of IL-1α or IL-1β 35. Furthermore, rhinovirus-infected primary bronchial epithelial cells 
from patients with asthma show a higher expression of IL-36γ compared to infected cells from healthy 
controls 62. A recent study that has investigated 507 inflammatory mediators in plasma from healthy 
volunteers, patients with COPD, and patients with COPD that have an acute exacerbation shows 
that 20 mediators are significantly different between these groups, of which IL-36α and IL-36Ra are 
significantly lower in patients with COPD that have an acute exacerbation 63. These data collectively 
provide evidence that IL-36 cytokines play a significant role in regulating airway inflammation.
 The role of IL-36 cytokines has also been studied in several other animal models of human disease. 
IL-36Ra is upregulated in a mouse model of biliary atresia 64. Local overexpression of IL-36α in the 
kidney is associated with tubulointerstitial lesions in mouse models of chronic glomerulonephritis, 
SLE, nephrotic syndrome and streptozocin-induced diabetes 65. However, the clinical significance of 
these finding remains to be elucidated.
IL-36 future issues
The IL-36R pathway shares features of the IL-1R1 pathway, however diseases such as deficiency 
of IL-1Ra (DIRA) and deficiency of IL-36Ra (DITRA) demonstrate that they each have unique non-
redundant properties 43,66. 
 Furthermore, mice that overexpress IL-36α in basal keratinocytes have skin abnormalities that 
are dependent on IL-36R but not IL-1R1 38. Notably, the IL-36 cytokines are expressed in a more tissue-
restricted way then IL-1. Therefore, IL-36 cytokines are not simple surrogates of IL-1; they are involved 
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in IL-1 independent inflammatory responses and they have most likely evolved to regulate tissue 
specific immune responses. However, the fact that a patients suffering from DITRA67 or generalized 
pustular psoriasis due to mutations in IL-36Ra 68 can be treated with anakinra (recombinant human 
IL-1Ra), suggests that the IL-36 are controlled by classical IL-1 family cytokines.
 To date, the IL-36 pathway has been associated with the pathogenesis of several inflammatory 
diseases. However, IL-36 pathway might also play a crucial role in antimicrobial host defence. For 
example, the host defence against fungi such as C. albicans and A. fumigatus can be modulated by 
the IL-36 receptor pathway 31,32. In addition, Th1 responses to BCG are dependent on IL-36 cytokine 
signalling 36. Yet the significance of the IL-36 pathway in antimicrobial host defence remains to be 
determined. With the current knowledge, it is tempting to speculate that IL-36 cytokines primarily 
play a role in skin and lung host defence. 
 An intriguing question that remains to be resolved is why IL-36Ra needs to be processed to 
gain fully antagonistic activity? Is it potentially dangerous to have IL-36Ra activity? Furthermore, 
what dramatic effects does the processing of the N-terminal methionine have on the molecule that 
it gains such increased activity? Moreover, which protease is responsible for this? The answers to 
these questions will probably further characterize IL-36Ra as an unique receptor antagonist that is 
different from the classical receptor antagonist IL-1Ra. 
 Another important issue is the presence of a unique mutation in the TIR domain of IL-36R (C445), 
which is only shared with the inhibitory IL-1 orphan receptor SIGIRR (C222) 69. Studies investigating 
IL-36 biology have demonstrated that it has no consequence for agonistic activity of IL-36 ligands 
when IL-1RAcP is recruited to IL-36R 12. This is elegantly proven by the fact that the chimera of the 
extracellular IL-1R1 with the intracellular IL-36R that has the mutated TIR domain does not result in 
an altered agonistic activity of IL-1 12. However, it is remarkable that this mutation exists in the TIR 
domain of IL-36R and it remains to be determined whether it has functional consequences in other 
specific conditions.
 In conclusion, over recent years much has been learned about the IL-36 cytokines and their role 
in inflammation. They predominantly play a role in regulating skin inflammation, and they might 
have important modulatory functions in inflammatory conditions of the lung and the brain. This 
knowledge provides a rationale to further explore immune-modulatory strategies that target the 
IL-36 signalling pathway in the inflammatory conditions described in this review.
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Abstract
IL-1 drives T-helper (Th) responses, particularly Th17, in host defense. Sharing the same co-receptor, 
the IL-1 family member IL-36 exhibits properties similar to those of IL-1. In the present study, we 
investigated the role of IL-36 in Aspergillus fumigatus-induced human T-helper cell responses. We 
observed that different morphological forms of A. fumigatus variably increase steady-state mRNA 
IL-36 subfamily members. Although, IL-36α is not significantly induced by any morphological form 
of Aspergillus, IL-36β and IL-36 receptor antagonist (IL-36Ra) are induced by heat-inactivated resting 
conidia. Most strikingly, IL-36γ was significantly induced by live A. fumigatus conidia and heat killed 
hyphae, whereas IL-36Ra was significantly induced by heat killed conidia and hyphae and live conida. 
We also observed that IL-36γ expression is dependent on the dectin-1/ spleen tyrosine kinase (Syk) 
and TLR4 signalling pathway. In contrast, TLR2 and CR3 inhibit IL-36γ expression. The biological 
relevance of IL-36 induction by Aspergillus is demonstrated by experiments showing that inhibition 
of the IL-36 receptor by IL-36Ra reduces Aspergillus-induced IL-17 and IFNγ. These data describe that 
IL-36-dependent signals are a novel cytokine pathway that regulates T-helper responses induced by 
A. fumigatus, and demonstrate a role for TLR4 and dectin-1 in the induction of IL-36γ.
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Introduction
The interleukin 1 family (IL-1F) consists of eleven members 1. The in silico discovery of IL-1 family 
members IL-1F5, IL-1F6, IL-1F8, and IL-1F9 have recently been renamed IL-36 receptor antagonist 
(IL-36Ra), IL-36α, IL-36β, and IL-36γ, respectively. Presently, there is a paucity of data on the biological 
properties and functional roles of the IL-36 subfamily in health and disease. The classic IL-1 family 
members IL-1α and IL-1β as well as IL-18 and IL-33 polarize T-helper (Th) responses 1. However, 
little is known about the role of the IL-36 subfamily (IL-36α, IL-36β, and IL-36γ) and the IL-36Ra in 
antimicrobial host defence. Each member of the IL-36 subfamily binds to IL-1Rrp2 (now renamed 
IL-36 receptor, IL-36R) and recruits the co-receptor for signal transduction, IL-1RAcP 2,3. The IL-36R is 
expressed on dendritic cells (DCs) 4,5 and T cells 5. Stimulation of T cells by IL-36R ligands results in 
the induction of IFNγ, IL-17 and IL-4 5, and DCs primed with IL-36 ligands are inducers of Th1 cells. 
Although the synthetic TLR3 ligand polyI:C induces IL-36γ secretion 6, nothing is known about the 
innate pattern recognition pathways that induce IL-36R ligands in the antimicrobial host defence.
 The opportunistic fungus Aspergillus fumigatus is ubiquitous; Aspergillus spores are inhaled 
daily by humans. Inhaled Aspergillus spores (conidia) are efficiently cleared in healthy individuals 7. 
However, in immunocompromised persons, or in patients with pre-existing lung injury, Aspergillus 
conidia germinate resulting in invasive infections associated with high mortality 8. T-helper responses 
are important in the host defence against invasive aspergillosis 9, and the major known cytokine 
pathways that are involved in the induction of Th1 and Th17 responses are IL-12/IL-18 and IL-1/
IL-23 respectively 9,10. Next to the induction of the specific Th-axis, there is also interplay between 
these cytokine pathways. IFNγ-induced IL-18 binding protein was found to downregulate the Th17 
response 11, and in several cases the induction of Th17 or IL-17 producing γδT cells was found to be 
dependent on IL-18 12,13
 In the present study, we have focused on gene expression of the IL-36 subfamily by different 
morphological phenotypes of A. fumigatus. In addition, we studied the IL-36R pathway in the 
induction of pro-inflammatory T-helper responses induced by A. fumigatus. Furthermore, we aimed 
to identify which pattern recognition pathways are involved in the induction of IL-36γ during 
Aspergillus-specific host defence. Here we demonstrate that the IL-36R pathway is involved in the 
regulation of Aspergillus-induced pro-inflammatory T-helper cytokine responses, and that the most 
important pathways for the induction of IL-36γ in Aspergillus host defence are represented by the 
dectin-1/ spleen tyrosine kinase (Syk) and TLR4 pathway.
Experimental procedures
Aspergillus fumigatus | A clinical isolate of Aspergillus fumigatus V05-27, which has been previously 
characterized 14, was used for all stimulations. Conidia and hyphae were prepared as described 
previously 15,the hyphae were quantified as the number of conidia used to grow the hyphae, and 
all hyphae were prepared in one batch to account for batch to batch variations. Aliquots from 
both the conidia and the hyphae were heat inactivated (HI) at 56°C for 1 hour and were checked 
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for viability in Sabouraud glucose broth. HI conidia, hyphae, and live conidia were stored at -80°C 
until use. A concentration of 1x107/mL was used in the experiments, unless otherwise indicated. To 
study germination of live A. fumigatus conidia, 1x107conidia/mL were plated in 12-wells plates. At 
0, 2, 4 and 8 hours, a 10 µL sample was taken and observed and photographed using a brightfield 
microscope at 1000x magnification (Leica DM 3000).
Cytokines | Recombinant, IL-1β, IL-18, IL-12 and IL-23, were purchased from R&D Systems 
(Minneapolis, MN). IL-36 cytokines were produced in E. coli by R&D Systems. After extraction, 
refolding and purification of IL-36 cytokines, the level of LPS was determined to be less that 1.0 EU/
microgram by the Limulus Amebocyte Lysate method. The molecular weight of recombinant IL-36Ra 
is 17,000 with an N-terminus at valine 2. On silver stained SDS-PAGE under reducing conditions, 
there is a single band and the purity is >95%.
PBMC isolation and stimulation | Venous blood from healthy subjects was drawn into 10 mL EDTA 
tubes after written informed consent was obtained. Blood sampling from healthy volunteers was 
approved by the ethical board of the Radboud University Nijmegen Medical Centre. Subsequently, 
PBMCs were isolated as described previously 16. Blood was diluted in phosphate buffered saline 
(PBS) (1:1) and fractions were separated by Ficoll (Ficoll-Paque Plus, GE Healthcare, Zeist, The 
Netherlands) density gradient centrifugation. Cells were washed twice with PBS and resuspended 
in RPMI-1640 culture medium supplemented with 10 µg/mL gentamicin, 10 mM L-glutamine and 
10 mM pyruvate (Gibco, Invitrogen, Breda, The Netherlands). The cells were counted using a particle 
counter (Beckmann Coulter, Woerden, The Netherlands) and the cell number was adjusted to 5x106/
mL. PBMCs were plated in 96-well round-bottom plates (Corning, NY, USA) at a final concentration of 
2,5x106/mL and were stimulated with medium, 1x107/mL HI A. fumigatus conidia, or live A. fumigatus 
conidia in a total volume of 200 µL. Cells were stimulated for 0 hours, 4 hours, 8 hours, 24 hours and 
7 days at 37°C and 5% CO2. After stimulation culture supernatants were collected and stored at -20°C 
and the cells were lysed in TRIzol reagent (Invitrogen) and stored at -20°C until RNA isolation was 
performed. Pattern recognition pathways were inhibited in PBMCs by pre-incubation for 1hour with 
a specific inhibitor. LPS derived from Bartonella quitana was used to block TLR4 17. Bartonella quitana 
LPS was extracted and purified as described previously 18. Mouse anti-humanTLR2 (eBioscience, 
Halle-Zoersel, Belgium) and control mouse IgG1 (eBioscience) were used at a final concentration of 
10 μg/mL. Anti-human integrin β2 (αCR3) and control goat IgG were purchased from R&D systems 
(Minneapolis, MN) and used in a final concentration of 10 μg/mL. Laminarin (Sigma, St Louis, MO) 
was used in a final concentration of 50 ng/mL to inhibit dectin-1. Syk inhibitor (3-(1-Methyl-1H-indol-
3-yl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) was purchased from Calbiochem 
(Merck, Darmstadt, Germany) and was used in a concentration of 50 nM to inhibit Syk signalling. 
This inhibitor is a cell-permeable oxindole compound that acts as a potent, reversible, and ATP-
competitive Syk inhibitor.
IL-36 and Aspergillus-induced Th-responses| 183
11
IL-36 and IL-36Ra expression | RNA was isolated according to the protocol supplied with the TRIzol 
reagent. Isolated mRNA (1 µg) was reverse transcribed into cDNA using the iScript cDNA synthesis kit 
(BIORAD, Hercules, CA). Quantitative real-time PCR (qPCR) was performed using power SYBR Green 
PCR master mix (Applied Biosystems, Carlsbad, CA) and Primers hIL-1F6-F 5’-TTG-CCT-TAA-TCT-CAT-
GCC-GAC-3’ and hIL-1F6-R 5’-CCG-ACT-TTA-GCA-CAC-ATC-AGG-3’ for amplification of IL-36α, hIL-
1F8-F 5’-AGA-AAT-TCA-GGG-CAA-GCC-TAC-3’ and hIL-1F8-R 5’-CAG-CCA-GGG-TAA-GAG-ACT-GAC-3’ 
for amplification of IL-36β, hIL-1F9-F 5’-GAA-ACC-CTT-CCT-TTT-CTA-CCG-TG-3’ and hIL-1F9-R 5’- GCT-
GGT-CTC-TCT-TGG-AGG-AG-3’ for amplification of IL-36γ, hIL1F5-FW 5’-ACT-CGG-CAT-TGA-AGG-TGC-
TTT-3’, hIL1F5-REV 5’-GGG-ACC-ACG-CTG-ATC-TCT-T-3’ for amplification of IL-36Ra, humIL-18 F 5’- 
TGT-CGC-AGG-AAT-AAA-GAT-GGC-T-3’ and humIL-18 R 5’-CCT-TGG-TCA-ATG-AAG-AGA-ACT-TGG-T-3’ 
for amplification of IL-18, IL-12p35 hum F 5’-CCT-TGC-ACT-TCT-GAA-GAG-ATT-GA-3’ and IL-12p35 
hum R 5’-ACA-GGG-CCA-TCA-TAA-AAG-AGG-T-3’ for amplification of human IL-12p35 and Beta2M 
hum F 5’-ATG-AGT-ATG-CCT-GCC-GTG-TG-3’ and Beta2M hum R 5’-CCA-AAT-GCG-GCA-TCT-TCA-
AAC-3’ for amplification of β2M. The PCR was performed using an Applied Biosystems 7300 real-time 
PCR system using PCR conditions 2 minutes 50°C, 10 minutes 95°C followed by 40 cycles at 95°C for 
15 sec and 60°C for 1 minute. The RNA levels of IL-36γ and IL-36Ra were corrected for differences in 
loading concentration using the signal of housekeeping protein β2M and RNA isolates from freshly 
isolated PBMCs (T=0) were set at 1.
IL-36 receptor blockade | PBMCs were plated in 96-well round-bottom plates (Corning) at a final 
concentration of 2.5x106/mL and were pre-incubated for 1 hour with medium or IL-36Ra at increasing 
concentrations. After pre-stimulation the PBMCs were stimulated for 24 hours or 7 days with medium, 
1x107/mL HI A. fumigatus conidia or hyphae (7 days) or live A. fumigatus conidia (24 hours) at 37°C and 
5% CO2. After stimulation, culture supernatants were collected and stored at -20°C until analysis.
IL-36Ra blockade | PBMCs were plated in 96-well round-bottom plates (Corning) at a final concentration 
of 2.5x106/mL and stimulated for 7 days with medium, 1x107/mL HI A. fumigatus conidia at in the 
presence of Goat IgG isotype control or Goat anti-human IL-36Ra (R&D Systems) at a concentration 
of 10 μg/mL. After stimulation, culture supernatants were collected and stored at -20°C until analysis.
RORγ and FoxP3 expression | Supernatant was removed from PBMCs that were stimulated for 7 
days with medium or 1x107/mL HI A. fumigatus conidia. The cells were re-stimulated for 4-6 hours 
with PMA (50 ng/mL) (Sigma-Aldrich), ionomycin (1 μg/mL) (Sigma-Aldrich) and Golgiplug (BD 
Biosciences, Breda, the Netherlands) according to the protocol supplied by the manufacturer. Cells 
were first stained extracellularly using PeCy7-conjugated anti-CD4 (BD Biosciences). Subsequently 
the cells were fixed and permeabilized with Cytofix/Cytoperm solution (eBioscience) according to 
the protocol supplied by the manufacturer. Following permeabilization the cells were intracellularly 
stained with FITC-conjugated anti-IL-17 (eBioscience) and allophycocyanin-conjugated anti-RORγ 
(eBioscience), or allophycocyanin-conjugated anti-FoxP3. The RORγ+ IL-17+ CD4+ cells and FoxP3+ 
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cells were detected on a FC500 flowcytometer (Beckman Coulter) and the data were analyzed using 
CXP analysis software v2.2 (Beckman Coulter).
Cytokine measurement | IL-1β, IL-1Ra, IL-4, IL-6, IL-10, IL-12P70, IL-13, IL-17, IL-22, IL-23, and IFNγ 
were measured using commercially available ELISAs (R&D Systems or Sanquin, Amsterdam, The 
Netherlands) according to the protocols supplied by the manufacturer. Detection limits are 39 pg/
mL, 780 pg/mL, 78 pg/mL, 15.6 pg/mL, 11.7 pg/mL, 39 pg/mL, 39 pg/mL, 78 pg/mL, 15.6 pg/mL and 
7.8 pg/mL respectively.
Receptor expression analysis | Supernatant was removed from PBMCs that were stimulated for 7 
days with medium or 1x107/mL HI A. fumigatus conidia. The cells were stained with PeCy7-conjugated 
anti-CD4, PE-conjugated anti-IL-12Rβ1, APC-conjugated anti-IL-1R1, and FITC-conjugated anti-IL-
18Rα. Cells were detected on a FC500 flowcytometer (Beckman Coulter) and the data were analyzed 
using CXP analysis software v2.2 (Beckman Coulter).
Statistical analysis | The differences between stimulations with control stimulation versus inhibitors or 
IL-36Ra were analyzed with the Wilcoxon signed rank test. A p-value of < 0.05 was considered statistically 
significant (*p<0.05, **p<0.01, and ***p<0.001). All experiments were performed at least twice and data 
represent results of all experiments performed. Data was analyzed using GraphPad Prism v5.0.
Figure 1 | A. fumigatus induces IL-17, IL-22, IL-13, IFNγ, Th17 cells and FoxP3+ cells 
(A) IL-17, IL-22, IL-13, and IFNγ concentrations in the culture supernatants of human PBMCs stimulated for 7 days 
with medium (med), heat-inactivated (HI) A. fumigatus conidia or hyphae were determined by ELISA. Data are 
presented as mean ± SEM of 10 donors. (B-E) After collection of culture supernatants PBMCs stimulated with 
medium or HI A. fumigatus conidia were used for intracellular (B) IL-17 and (C, D) RORγt or (E) FoxP3 staining. Data 
are shown as mean ± SEM of 7 (D) and 11 (E) donors and are representative of/pooled from 5 (A), 3 (D) and 5 (E) 
experiments performed. ***p<0.001, Means were compared uring the Wilcoxon signed rank test.
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Results
A. fumigatus induces the T-helper cell cytokines IL-17, IL-22, IFNγ and IL-13
To study the effect of IL-36 on pro-inflammatory T-cell responses induced by A. fumigatus, we first 
investigated the capacity of conidia and hyphae to induce in human PBMCs the production of the 
Th17 cytokines IL-17 and IL-22, and of the Th1 cytokine IFNγ, the Th2 cytokines IL-4 and IL-13 and the 
anti-inflammatory cytokine IL-10. Increasing numbers of heat-inactivated (HI) conidia were added 
to PBMC and after 7 days of incubation, IL-17, IL-22, IFNγ, IL-4, IL-13 and IL-10 levels were detemined 
in the culture supernatants. As shown in Figure 1A, 1x107/mL HI conidia or hyphae induced a IL-17, 
IL-22, and IFNγ response. IL-13 was induced by 1x107/mL conidia, but not by hyphae (Figure 1A), and 
production of IL-4 and IL-10 was undetectable after challenge with the fungus (data not shown). 
A. fumigatus-induced Th17 cells and FoxP3 cells
We investigated whether Aspergillus induced cells with a typical Th17 phenotype (IL-17+ RORγt+ CD4+ 
cells). We gated on CD4+ T cells and subsequently looked at the precence of intracellular IL-17 in 
PBMCs stimulated with medium or with HI Aspergillus conidia, which was increased after stimulation 
with Aspergillus (Figure 1B). Subsequently, we gated on the IL-17+ CD4+ cells and measured 
expression of RORγt (Figure 1C). Compared with medium-stimulated PBMCs, Aspergillus-stimulated 
cells demonstrate a significant increase of RORγt+ IL-17+ CD4+ cells (Figure 1D). Of the Aspergillus-
stimulated cells 83.4% (SD ±7.7) IL-17+ CD4+ cells were RORγ+, compared with non-stimulated cells 
32.8% (SD ±13.2). In addition to the RORγ+ Th17 cells, we investigated whether Aspergillus induced 
FoxP3+ cells. Compared with medium only, Aspergillus induced a significant expansion of the FoxP3+ 
population (Figure 1E). 
A. fumigatus increases steady state levels of IL-36α, IL-36β, IL-36γ, and IL-36Ra mRNA 
We next assessed whether A. fumigatus induces the IL-36 receptor ligands and IL-36Ra. The Aspergillus 
cell wall is highly dynamic and therefore will express different pathogen associated microbial patterns 
(PAMPs) at different stages of infection. Due to a hydrophobic (rodlet) protein layer that covers the 
resting conidia of A. fumigatus, few PAMPs will be exposed 19. When live conidia are incubated at 37°C 
in RPMI culture medium they initiate swelling after two to four hours, and form germtubes after six 
to eight hours (Figure 2A). During the swelling and germination phase, the hydrophobic rodlet layer 
is lost exposing PAMPs 19. To investigate the ability of different morphological forms of A. fumigatus 
to induce IL-36 family members, we compared resting conidia which are generaly considered to be 
poorly immunogenic, with live conidia that are allowed to germinate and expose numerous PAMPs 
in the process, and hyphae that are exposing numerous PAMPs. Human PBMCs were stimulated 
the morphological forms for 4 hours, 8 hours, and 24 hours. mRNA of IL-36α, IL-36β, IL-36γ and 
IL-36Ra by Aspergillus was induced by all different morphological forms of A. fumigatus, however 
the magnitute of expression of the IL-36 cytokines differed (Figure 2). IL-36α expression was only 
significantly induced by HI Aspergillus hyphae 4 hours after stimulation, conidia (live and HI) did not 
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Figure 2 | A. fumigatus induces transcription of IL-36α, IL-36β, IL-36γ and IL-36Ra
(A) Microscopic examination of germination of live A. fumigatus conidia over a time course of 8 hours at 1000× 
magnification. The bar represents 10 μm and is representative for each figure since the same magnification was 
used for all time points. (B) IL-36α, (C) IL-36β, (D) IL-36γ, and (E) IL-36Ra mRNA expression in human PBMCs that 
were stimulated with HI A. fumigatus conidia, live A. fumigatus conidia, or HI A. fumigatus hyphae was determined 
by quantitive RT-PCR. Baseline (0 hours) was set at 1 and the fold increase is expressed as mean ± SEM of 6 (HI 
conidia and hyphae) or 8 (live conidia) donors. Data shown are representative of/pooled from 3 (HI conidia and 
hyphae) and 4 (live conidia) experiments performed. *p<0.05, **p<0.01 Means were compared with baseline 
using the Wilcoxon signed rank test.
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significantly induce IL-36α expression (Figure 2B). IL-36β was only significantly induced by heat-killed 
A.fumigatus conidia (Figure 2C). Although stimulation with HI conidia did not result in a significant 
upregulation of IL-36γ expression, PBMCs stimulated with live conidia or with HI A. fumigatus hyphae 
resulted in a significant induction of IL-36γ transcription (Figure 2D). mRNA of IL-36Ra significantly 
induced by stimmulationw with all morphological forms of Aspergillus and ranged from 15-120 fold 
increase; dependent on the time of measurement and morphological form of Aspergillus. Overall, 
the expression of mRNA for the IL-36 cytokines was maximal at 8 hours after stimulation (Figure 2).
IL-36Ra inhibits Aspergillus-induced IL-17 and IFNγ responses
To elucidate the role of IL-36R in the induction of the Aspergillus-specific Th1 and Th17 T-cell 
responses, we added IL-36Ra to block the IL-36R pathway. Human PBMC were stimulated with A. 
fumigatus conidia and hyphae in the absence or presence of IL-36Ra at increasing concentrations 
from 0.1 ng to 100 ng/mL. We observed that IL-36Ra significantly inhibited Aspergillus-induced IL-17 
and IFNγ production, especially in the lower range of the dose response (100 pg/mL to 1 ng/mL) 
(Figure 3A and 3B). The production of IL-22 was only significantly affected at a concentration of 100 
pg/mL IL-36Ra (Figure 3A and 3B). IL-36Ra did not modulate IL-13 (Figure 3A) and proliferation of 
FoxP3+ cells (Figure 3C) induced by A. fumigatus conidia. 
Inhibition of endogenous IL-36Ra increases Aspergillus induced IL-17 and IL-22
Compared with other fungal pathogens Aspergillus is a relatively poor IL-17 inducer. Since, we 
observed that A. fumigatus conidia were potent inducers of IL-36Ra mRNA expression, we wondered 
whether this relatively low IL-17 induction might be due to high induction of endogenous IL-36Ra in 
the cultures. To investigate this, PBMCs were stimulated with A. fumigatus conidia and endogenous 
IL-36Ra was inhibited using an anti-human IL-36Ra blocking antibody. Aspergillus was able to induce 
significantly higher IL-17 and IFNγ levels in the stimulations where IL-36Ra was inhibited (Figure 3D). 
Inhibition of IL-36Ra in medium stimulated cells did not result in significant IL-17 induction. 
IL-36 ligands cannot act as surrogates for IL-1β or IL-18 
The IL-36R is expressed on CD4 T cells and stimulation with IL-36 ligands results in the induction of IL-
17, IFNγ, and IL-4 5. In addition IL-1 family members IL-1β and IL-18 can induce IL-17 or IFNγ respectively 
in the presence of STAT activators, such as IL-12 and IL-23 20. To investigate whether IL-36 ligands can 
directly induce T-helper cytokines we stimulated isolated CD4+ T cells with increasing concentrations 
of IL-36γ or IL-36β. We did not observe any detectable cytokine concentrations of IL-17 or IFNγ in the 
supernatants (Figure S1). When IL-36γ or IL-36β was combined with IL-12 or IL-23, we could not detect 
IL-17 or IFNγ production, in contrast to the combinations of IL-1/IL-23 and IL-18/Il-12 (Figure 4A).
 Furthermore, we investigated whether the observed differences in IL-17 and IFNγ production 
were due to downregulation of the receptors which sense IL-17 and IFNγ inducing cytokines. We 
stimulated PBMCs with Aspergillus fumigatus and subsequently stained the cells for the T-cell marker 
CD4 and the receptors: IL-1R1, IL-12Rβ1, and IL-18Rα. To determine the presence of the receptors we 
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gated for the CD4+ cells and dertemined the percentage of positive cells (Figure 4B). There were no 
significant differences in percentage of CD4+ cells expressing the receptors (Figure 4C) or the mean 
fluoresence intensity of receptor expression (Figure 4D) between Aspergillus-stimulated cells and 
cells stimulated with Aspergillus in the presence of addition of IL-36Ra in the range of 0.1 to 100 ng/
mL. There were no differences in the total expression of these receptors in CD4 negative cells, and 
PBMCs stimulated with medium did not show differences after the addition of IL-36Ra (Figure S2). 
IL-36Ra does not affect Aspergillus-induced IL-1β, IL-23, IL-18, IL-6, IL-1Ra, and IL-10
We next investigated whether IL-36Ra had an effect on the cytokines that are important for the 
induction of human Th1 and Th17 responses, such as IL-1β, IL-6, IL-1Ra, IL-23, IL-18 and IL-12p70 
production 9. As a anti-inflammatory cytokine we measured IL-10. Addition of IL-36Ra did not result 
reduce IL-1β, IL-6, IL-1Ra or IL-10 production induced by A. fumigatus. (Figure 4E) IL-12p70 and IL-23 
concentrations in the supernatants of PBMCs stimulated with Aspergillus were undetectable (data 
not shown), and no differences were found in mRNA levels of IL-12p35 and IL-18 (Figure S3).
Figure 3 | Inhibition of IL-17 and IFNγ responses by IL-36Ra
IL-17, IL-22, IL-13 and IFNγ concentrations in culture supernatants of human PBMCs that were stimulated for 
7 days with HI A. fumigatus (A) conidia or (B) hyphae in the presence or absence of IL-36Ra (concentration 
ranging from 0.1 to 100 ng/mL) were determined by ELISA. The change in IL-17, IL-22, IL-13, and IFNγ is shown as 
percentage change from control; data are presented as mean ± SEM of 8 (A) or 6 (B) donors. (C) The percentage 
of FoxP3+ CD4+ cells after stimulation with A. fumigatus conidia in presence or absence of IL-36Ra (concentration 
ranging from 0.1 to 100 ng/mL) was determined by flow cytometry. Data are shown as mean ± SEM of 6 donors. 
(D) The IL-17, IL-22, and IFNγ concentrations (mean±SEM) in culture supernatants of human PBMCs stimulated 
with medium or HI A. fumigatus conidia in the presence of anti-IL-36Ra or isotype control were determined by 
ELISA. Data are shown as mean ± SEM of 7 donors. All data shown are representative of/pooled from 4 (A) 3 (B, 
C, D) experiments performed. *p<0.05 **p<0.01, Means were compared using the Wilcoxon signed rank test.
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Figure 4 | IL-36 ligands cannot act as surrogates for IL-1β or IL-18
(A) The IL-17, IL-22, and IFNγ concentrations in culture supernatants of PBMCs stimulated with IL-23 or IL-12 
alone or in combination with IL-1β (IL-23 only), IL-18 (IL-12 only), IL-36β or IL-36γ were determined by ELISA. (B-D) 
IL-12Rβ1, IL-1R1, and IL-18Rα expression on CD4+ T cells stimulated for 7 days with A. fumigatus in the presence 
or absence of IL-36Ra (concentration ranging from 0.1 to 100 ng/mL) are shown. Whole PBMCs were stained 
with anti-CD4, anti-IL-12Rβ1, anti-IL-1R1, and anti-IL-18Rα for flow cytometry. The CD4+ population was gated 
and (C) the % of positive cells for each of the receptors was determined as well as (D) the mean fluorescence 
intensity of the signal. mean±SEM. (E) IL-1β, IL-6, IL-1Ra and IL-10 concentrations in culture supernatants of 
human PBMCs that were stimulated for 24 hours with HI A. fumigatus conidia in the presence or absence of 
IL-36Ra (concentration ranging from 0.1 ng/mL to 100 ng/mL) was determined by ELISA. All data are shown as 
mean ± SEM of 4 donors and are representative of/pooled from 2 experiments performed.
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Induction of IL-36γ by A. fumigatus is dependent on dectin-1 Syk signalling and TLR4
The Toll-like receptors (TLRs) TLR2 and TLR4 were previously reported to recognize A. fumigatus 21-
25. In addition, the β-glucan receptor dectin-1 and its downstream signalling kinase Syk are also 
involved in the recognition of A. fumigatus 26-29. To identify whether TLR2, TLR4, CR3, dectin-1 or 
Syk are required for the induction of IL-36γ by A. fumigatus, we stimulated PBMCs in the absence or 
presence of specific blockers of pattern recognition receptors that have been associated with the 
recognition of A. fumigatus. PBMCs were stimulated with live A. fumigatus for 8 hours, since at this 
time point we observed the highest level of mRNA of IL-36γ (Figure 2B). Inhibition of dectin-1 or Syk 
resulted in significant reduction of Aspergillus-induced IL-36γ transcription (Figure 5A). Blockade 
of TLR4 also resulted in decreased IL-36γ transcription (Figure 5B). In contrast, when complement 
receptor 3 (CR3) or TLR2 were blocked, we observed that IL-36γ transcription increased (Figure 5B,C). 
Taken together these data demonstrate that the dectin-1/Syk and TLR4 pathway are involved in the 
induction of IL-36γ, whereas TLR2 and CR3 induce signalling that negatively regulates the induction 
of IL-36γ by Aspergillus (Figure 5D).
Discussion
In the present study, we investigated the role of the IL-36R pathway in the induction of Aspergillus-
specific pro-inflammatory T-helper responses. In addition, we identified the pattern recognition 
pathways responsible for the induction of IL-36γ by A. fumigatus. We demonstrate that A. fumigatus 
induces Th1 and Th17 responses in human PBMCs and that these responses are dependent on the 
IL-36R pathway. The induction of IL-36γ by A. fumigatus is mediated through the dectin-1/Syk and 
TLR4 pathway, while for unknown reasons, triggering TLR2 and CR3 suppresses the induction of 
IL-36γ. These data describe a novel cytokine pathway that regulates T-helper responses induced by 
A. fumigatus and describes for the first time the recognition pathways that regulate IL-36 responses 
in host defence.
 Invasive aspergillosis is a devastating disease in the immunocompromised patient and is 
associated with a high mortality 8. Adjunctive therapeutic strategies are needed to overcome this 
significant disease burden in immunocompromised patients. Furthermore, invasive pulmonary 
aspergillosis is increasingly recognized in non-neutropenic intensive care unit patients that are 
treated with corticosteroids 30,31. Knowledge of the host defence against A. fumigatus is essential 
to understand the susceptibility to invasive aspergillosis and to develop new treatment strategies. 
T-helper responses play an important role in the host defence against A. fumigatus 9. IL-1 family 
members drive the induction and polarization of T-helper responses 1, and the IL-36 subfamily (IL-
36α, β, and γ) induce IFNγ and IL-17 in mouse splenocytes during mitogenic stimulation 5. 
 Here, we show that the IL-36 receptor pathway plays a role in the A. fumigatus-induced Th1 and 
Th17 responses in human cells, since blockade of the IL-36R with the addition of exogenous IL-36Ra 
inhibits IL-17 and IFNγ production induced by A. fumigatus. Moreover, blocking the endogenous IL-
36Ra results in a significant increase in IL-17 and IFN, providing additional evidence that the IL-36R 
pathway is involved. It is tempting to speculate that the relatively low IL-17 production induced by 
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Figure 5 | Induction of IL-36γ by is dependent on TLR4 and dectin-1/Syk 
signalling 
IL-36γ mRNA expression in human PBMCs that were pre-incubated 
with RPMI or isotype control (Co), (A) mouse anti-human TLR2 (TLR2) 
or B. quintana LPS (TLR4), (B) laminarin (dectin-1) or Syk inhibitor (SYK) 
or (C) anti-human CR3 (CR3), and subsequently stimulated with live A. 
fumigatus conidia, was determined by quantitive RT-PCR. (D) A model of 
IL-36γ induction by A. fumigatus. Data are shown as mean ± SEM of 7 
donors and are representative of/pooled from 3 experiments performed. 
*p<0.05, means were compared using the Wilcoxon signed rank test.
Aspergillus compared with other pathogens is due to the capacity of Aspergillus to induce IL-36Ra. 
We observed that low concentrations of IL-36Ra were more efficient in inhibiting T-helper cytokine 
production than higher concentrations, this effect is still unexplained and needs further investigation. 
Moreover, we also demonstrate that the different IL-36 family members are induced by different 
morphological forms of A. fumigatus. Interestingly, we observed that heat-inactivated resting 
conidia, which are generally thought to have a low stimulatory capacity due to their hydrophobic 
protein layer, are potent inducers of both IL-36 ligands (IL-36β and IL-36γ) and the antagonist IL-
36Ra, while hyphae, which are associated with invasive fungal growth, are potent inducers of IL-36γ 
expression, but induce the antagonist IL-36Ra to a lesser extent. This could indicate that when hyphae 
are formed during invasive fungal growth, the balance between receptor agonist and antagonist is 
shifted, however it remains to be determined whether this is detrimental or beneficial for the host. 
  An important issue that remains to be resolved is whether the effect of IL-36 cytokines on 
Aspergillus-induced T-helper responses is due to an effect of IL-36 cytokines on T cells or dendritic 
cells (DCs) or both. IL-36 cytokines act directly on murine DCs and murine CD4 T cells. In humans, 
dendritic cells express high levels of IL-36R and DCs primed with ligands for this receptor are very 
potent inducers of Th1-cell proliferation 4. We observed that isolated CD4 T cells stimulated with IL-
36 cytokines do not produce IL-17 or IFNγ production. Furthermore, we found that IL-36 cytokines 
cannot serve as a surrogate for the IL-1 family members IL-1β or IL-18 in inducing Th polarization. 
Collectively, these data suggest that the primary effects of IL-36 cytokines on T-helper responses 
is probably through antigen presenting cells, and that IL-36 cytokines might be able to modulate 
T-helper responses, but only in the setting of activated T-helper cells. 
 The IL-36R agonist IL-36γ is expressed in the lung and is responsible for neutrophil influx in 
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a model of house dust mite-induced inflammation in the lung 32. In human bronchial epithelial 
cells, IL-36γ induces the chemokines IL-8 and CCL20, which is an important Th17 chemokine 33. 
This suggests that IL-36γ can directly recruit neutrophils through the induction of IL-8 and that it 
is important for CCL20-dependent recruitment of Th17 cells, which in turn will result in additional 
neutrophil recruitment to the site of infection. Although the TLR3 ligand poly I:C induces secretion 
of IL-36γ 6,33, other cell surface recetors that induce IL-36R ligands by pathogenic microorganisms 
have not yet been assessed. We demonstrate that the induction of IL-36γ by A. fumigatus is 
dependent on the TLR4 and dectin-1 pathways, whereas the TLR2 and CR3 pathway reduce the 
induction of IL-36γ. These pathways are each important for anti-Aspergillus host defence 34. Both 
TLR4 and dectin-1 polymorphisms have been linked to susceptibility to invasive aspergillosis 35-37, 
and TLR4 and dectin-1 play a role in the protective anti-Aspergillus host defence during a murine 
model of A. fumigatus keratitis 38. Furthermore, dectin-1 deficiency results in defective IL-17 and 
IL-22 responses in the lungs of mice challenged intratracheally with A. fumigatus 27. In this model 
of invasive pulmonary aspergillosis, IL-22 deficient and IL-17 deficient mice show an impaired 
recruitment of neutrophils in the lungs and increased fungal burden 27. It was found that monocyte 
derived macrophages from healthy individuals express IL-1β and IL-1α and later make a switch to 
IL-36β expression after stimulation with Aspergillus fumigatus. While cells of patients with chronic 
cavitary pulmonary aspergillosis did not show such a switch 39.
 Posttranslational processing by the enzyme caspase-1 facilitates the secretion of IL-1 family 
members IL-1β and IL-18, which play important roles for the induction of protective Th1 and Th17 
responses in antifungal host defence 40,41. Interestingly, IL-36 receptor ligands also require post-
translational processing for full agonist or antagonist activity 3. Although it has been suggested that 
the release of active IL-36γ from the cell is dependent on caspase-1 6, the amino-acid sequences 
surrounding the truncation sites of IL-36γ do not resemble a caspase-1 site 3. It is therefore possible 
that other proteases are responsible for posttranslational processing of IL-36γ, and it remains to be 
elucidated whether the pathways that we identified in the regulation of IL-36γ transcription are 
involved in the release and activation of IL-36 and IL-36Ra.
 The IL-36 receptor pathway has recently gained a lot of interest, since it plays a crucial role 
in the pathogenesis of psoriasis. Overexpression of IL-36γ in mice results in psoriatic skin lesions 
and these lesions are exacerbated when IL-36γ was overexpressed in mice that are knock-out for 
IL-36Ra 42. Moreover, IL-36 and IL-36Ra are expressed in human psoriatic skin lesions and IL-36Ra 
polymorphisms lead to familial pustular psoriasis 42-44. Therefore, the IL-36R pathway represents an 
attractive therapeutic target for treating psoriasis. Considering this, it is relevant to know the effects 
of blocking the IL-36R pathway on the host defence against pathogenic microorganisms. 
 Although further research is required to investigate the role of IL-36 in the immune responses 
to other pathogens, we have observed that IL-36Ra can also inhibit Candida albicans-induced IL-17 
and IL-22 production 45. Furthermore, the IL-36 cytokines do not only regulate the expression and 
enhance the function of Th17 cytokines, but are also regulated by IL-17 and IL-22 46. This suggests 
a feedback loop between the IL-36 and Th17 cytokines, which makes the IL-36R pathway a central 
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player in Th17-related mucosal host defence, and the role of this feedback in host defence against 
fungal pathogens is currently under investigation.
 In conclusion, we demonstrate that IL-36R signalling modulates the production of A. fumigatus-
induced T-helper cytokines IL-17 and IFNγ, and that A. fumigatus induces IL-36γ in a TLR4 and 
dectin-1/Syk-dependent manner. These findings describe for the first time the innate recognition 
pathways involved in the induction of IL-36R ligands by a microorganism, and describe a novel 
pathway involved in the induction of T-helper responses by A. fumigatus. The future development 
of therapeutic strategies that will target the IL-36R pathway, and the high mortality associated with 
invasive aspergillosis, warrants further exploration on the importance of the IL-36R pathway in the 
host defence against Aspergillus.
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Figure S1 | 
IL-17, IL-22, and IFNγ concentrations in culture supernatants of CD4 cells (5x105) stimulated for 7 days with 
medium, IL-36β or IL-36γ. Concentrations of IL-36 cytokines range from 1 to 100 ng/mL.
Figure S2 | 
IL-12Rβ1, IL-1R1, and IL-18Rα expression on CD4 T-cells and total PBMCs (n=4 donors) stimulated for 7 days with 
A. fumigatus in the presence or absence of IL-36Ra (concentration ranging from 0.1 ng/mL to 100 ng/mL). Whole 
PBMCs were stained with anti-CD4, anti-IL-12Rβ1, anti-IL-1R1, and anti-IL-18Rα. CD4 positive population was 
gated and subsequently the % of positive cells for each of the receptors was determined.
Figure S3 | 
IL-18 and IL-12p35 mRNA expression in PBMCs stimulated for 24h with 1x107/mL Aspergillus conidia or hyphae in 
the presence or absence or IL-36Ra in concentrations ranging from 1 to 100 ng/mL.
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Abstract
Background | Invasive fungal infections are very severe infections associated with high mortality 
rates, despite the availability of new classes of antifungal agents. Based on pathophysiological 
mechanisms and limited pre-clinical and clinical data, adjunctive immune-stimulatory therapy with 
interferon-gamma (IFNγ) may represent a promising candidate to improve outcome of invasive 
fungal infections by enhancing host defence mechanisms. 
Experimental procedures | In this open-label, prospective case series, we describe eight patients 
with invasive Candida and/or Aspergillus infections who were treated with recombinant IFNγ (rIFNγ, 
100 μg s.c., thrice a week) for 2 weeks in addition to standard antifungal therapy. 
Results | Recombinant IFNγ treatment in patients with invasive Candida and/or Aspergillus 
infections partially restored immune function, as characterized by an increased HLA-DR expression 
in those patients with a baseline expression below 50%, and an enhanced capacity of leukocytes 
from treated patients to produce pro-inflammatory cytokines involved in antifungal defence. 
Conclusions | The present study provides evidence that adjunctive immunotherapy with IFNγ can 
restore immune function in fungal sepsis patients, warranting future clinical studies to assess its 
potential clinical benefit. 
Trial registration | ClinicalTrials.gov - NCT01270490
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Introduction
The incidence of fungal infections is steadily increasing in the last years due to invasive medical 
diagnosis and immunosuppressive treatment modalities. Despite development of new classes 
of antifungal agents 1, the invasive fungal infections remain associated with unacceptable high 
mortality rates and represent a major cause of death worldwide 2-7. The emergence of significant 
resistance to the currently available antifungal therapies emphasizes the need for novel approaches 
to treat invasive fungal infections 8,9. Invasive fungal infection are most commonly observed in 
individuals with immune defects or a compromised immune system, and the number of these 
patients is steadily increasing 10. Therefore, adjunctive immunotherapy to improve host defence is 
an attractive strategy to improve the outcome of patients with disseminated fungal infections.
 In the past decade, major progress in the understanding of antifungal host responses has 
enabled the development of a number of novel molecular and cell-based immunotherapeutic 
approaches for invasive fungal infections 11. Although invasive candidiasis and aspergillosis are 
rather different in their pathogenesis, the major protective host response against both fungi is the 
effective induction of T-helper(Th)1 and IFNγ responses 12-16. The Th1 cytokine response activates of 
effector phagocytic cells that kill the fungus 17. Interestingly, Th1 immunity against A. fumigatus was 
demonstrated to be cross-protective against C. albicans 18. 
 Interferon-gamma (IFNγ), the prototype Th1 cytokine, promotes Th1 differentiation and skews 
the immune response towards a protective Th1 phenotype 19. As such, it has been implicated as 
a treatment option in (invasive) fungal infections 20,21. Moreover, limited evidence suggests that 
recombinant IFNγ (rIFNγ) has a beneficial effect on the outcome of fungal infections in patients with 
chronic granulomatous disease (CGD) 22, HIV 23-25, leukaemia 26,27, and in patients receiving organ 
transplants 28. However, it has not been investigated whether rIFNγ actually enhances the immune 
response in these patients to explain these beneficial clinical effects. 
 In this report we describe a series of patients with invasive Candida and/or Aspergillus infections 
in whom we investigated the effects of treatment with rIFNγ on the host innate and adaptive 
immune responses.
Experimental procedures
Patients and treatment | To assess the feasibility and preliminary efficacy of IFNγ in combination 
with anidulafungin for the treatment of candidemia, a single-centre, prospective, randomized 
open-label pilot (Phase IIIb) study was conducted. This study was registered at ClinicalTrials.gov 
(NCT01270490) and approved by the local ethics committee of the Radboud University Medical 
Center. Due to slower than anticipated enrolment rates (from August 2010 until March 2013, only 
12 patients could be screened, of which 6 were eligible and provided informed consent [Figure 
1]), the study was terminated early. However, during this period, several other patients presented 
with invasive fungal infections which had an insufficient response to standard antifungal therapy. 
Although these patients did not meet the inclusion criteria (i.e. presenting with one or more positive 
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cultures of blood or normally sterile tissue growing Candida spp.), they were deemed to benefit from 
adjunctive immunotherapy as “therapy of last resort” as decided by the attending physician. Within 
the parameters of standard clinical care these patients were treated according to the same protocol as 
the patients enrolled in the study, and were therefore included in the present case series. All patients 
with a history of documented epileptic seizures, pre-existent severe renal impairment (creatinin 
clearance <30/mL/min) or severe liver failure (defined as a spontaneously increased prothrombin 
time) were excluded. After obtaining informed consent, eight patients (3 study patients, 5 last 
resort patients) were treated with rIFNγ (Immukine, Boehringer Ingelheim, 50 μg/m2 body surface, 
subcutaneously, three times a week) in addition to standard antifungal therapy as recommended by 
national and international treatment guidelines 29,30. Three patients who were included in the Phase 
IIIb Candida pilot-study were assigned to the control group and did not receive rIFNγ. 
Blood sampling | Plasma, serum and whole blood specimens were collected at baseline (BL) and 
serially after the start of antifungal therapy (days 1, 2, 3, 7, 14 and 28). Blood cultures were performed 
as part of routine care.
Figure 1 | Screening, Randomization, and Follow-up of the Study Patients
The principal investigator was immediately notified when Candida spp. were cultured in blood. With at least 
one systemic inflammatory response syndrome (SIRS) symptom present in the 24 hours prior to blood culture 
withdrawal, and administration of systemic antifungal therapy < 72 hours, patients were deemed eligible for the 
‘IFNγ as an adjunctive treatment for candidemia’ pilot-study. In addition, 5 patients not meeting inclusion criteria 
but who were also treated with rIFNγ as a therapy of last resort, were included in analysis.
 
 
12 patients were assessed for eligibility
7 patients met one or more exclusion criteria, 
or did not provide informed consent
6 patients were randomized
3 patients were assigned
to receive IFN-γ
3 patients were assigned
to receive placebo
3 patients were included
in the analysis at day 28
3 patients were included
in the analysis at day 28
5 patients who did not meet the 
inclusion criteria were treated with
IFN-γ as “therapy of last resort”
In total, 11 patients were analyzed : 
3 study patients and  5 “last resort” 
patients received IFN-γ
5 patients were included
in the analysis at day 28
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Leukocyte populations and surface HLA-DR expression | Heparin anticoagulated blood was 
stored at 4°C immediately after withdrawal and analysed by flow cytometry. To determine the 
extent of immune suppression, HLA-DR expression was determined by calculating % HLA-DR-
positive cells and HLA-DR mean fluorescence intensity (MFI) within CD14+ cells and various 
lymphocyte subsets within CD45+ leukocytes+ (see supplementary material for details and a 
representative flow diagram). Lymphocyte subsets were defined as: T-cells (CD45+CD3+), T-helper 
cells (Th, CD45+CD3+CD4+), cytotoxic T-cells (Tc, CD45+CD3+CD8+), B-cells (CD45+CD19+), and NK-
cells (CD45+CD3-CD56+). Subset counts were calculated by multiplying the percentage of gated cells 
by the total lymphocyte count. Patients with <50% HLA-DR positive monocytes at baseline were 
considered to exhibit immune paralysis. This threshold of 50% is well below the lower bound of the 
99% confidence interval obtained in healthy volunteers in an earlier study of our group using the 
same methodology in the same laboratory 31. Therefore mHLA-DR expression levels below 50% are 
likely to represent immunoparalysis.
Cytokine assays | Venous blood was drawn into 10 mL EDTA tubes, after which peripheral blood 
mononuclear cells (PBMCs) were isolated as described previously 32. In short, blood was diluted in 
phosphate buffered saline (PBS) (1:1) and fractions were separated by Ficoll (Ficoll-Paque Plus, GE 
healthcare, Zeist, The Netherlands) density gradient centrifugation. Cells were washed twice with 
PBS and resuspended in RPMI-1640+ (RPMI-1640 Dutch modification supplemented with 10µg/mL 
gentamicin, 10mM L-glutamine, and 10mM pyruvate) (Gibco, Invitrogen, Breda, The Netherlands). The 
PBMCs were counted using a particle counter (Beckmann Coulter, Woerden, The Netherlands) and 
were plated in 96 well round-bottom plates (Corning, NY, USA) at a final concentration of 2,5x106/mL, 
in a total volume of 200 µL. The PBMCs were stimulated for 24 hours, 48 hours, and 7 days with medium 
alone, or medium containing E. coli lipopolysaccharide (LPS; 10 ng/mL), phytohaemaglutinnin (PHA; 
10μg/mL), heat-inactivated Candida albicans blastoconidia (1x106/mL) or heat-inactivated Candida 
albicans hyphae (derived from 1x106/mL conidia). After stimulation, cell culture supernatant was 
collected and stored at -20°C. When all samples were collected, cytokines were measured using 
commercially available ELISAs (R&D Systems, MN, USA and Sanquin, Amsterdam, The Netherlands) 
according to the protocols supplied by the manufacturer. Ex-vivo production of cytokines was 
assessed at timepoints at which their production has been shown to peak 33. Monocyte derived 
cytokines such as Interleukin (IL)-1β and tumour necrosis factor (TNF)α were measured in culture 
supernatants of 24 hour cultures, IL-10 was measured in culture supernatants of 48 hour cultures. 
T-cell derived cytokines IL-17 and IL-22 were measured in culture supernatants of 7 day cultures.
Statistical analysis | In view of the small sample size, normality of distribution was not assumed. 
Comparisons of baseline with follow up time points were made using Wilcoxons signed rank test 
(within-group comparisons, 2 groups). A p-value of <0.05 was considered statistically significant. 
Data are expressed as means ± standard error of the mean. Calculations and statistical analyses were 
performed using GraphPad Prism v 5.0 (GraphPad Software, San Diego, CA, USA).
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Table 1 | Summary of clinical characteristics of all patients with invasive fungal infections
Results
Patient characteristics
The patients treated with rIFNγ (5 men, 3 women) had a median age of 49.5 (IQR 28.5-68.8) years. 
The three female patients in the control group were 36, 51 and 73 years old. Clinical characteristics 
of the participants are listed in Table 1. Of the 6 patients included in the pilot study, three patients 
had a positive blood culture for C. albicans, two patients for C. glabrata, and one patient for C. 
tropicalis. During randomization, the three patients with C. albicans cultures were assigned to 
rIFNγ treatment, whereas the two patients with C. glabrata and one with C. tropicalis cultures were 
assigned to the control group. However, no pathophysiological evidence currently exists to suggest 
that rIFNγ therapy would have a different effect on the immune system in case of albicans vs. non-
albicans Candida infections. Of the other 5 patients treated with rIFNγ as therapy of last resort, three 
patients had positive cultures for A. fumigatus in bronchoalveolar lavage (BAL) fluid, and had proven 
invasive aspergillosis according to the EORTC/MSG criteria 34. One patient had a positive blood 
culture for C. tropicalis associated with osteomyelitis. This patient developed new suspected lesions 
IFNγ treated patients
Age Pathogens n= Site of infection n= Antifungal therapy n= Underlying ilness n= Outcome n=
49.6
±SD19.8 C. albicans 3 Candidaemia 2 Anidulafungin 1 Stem cell transplantation for AML 1
Cured without further infectious 
complications 2
BMI Candida spp 2 CandidaemiaEndicarditis 1 Fluconazole 1 Sarcoidosis treated with prednisone and azathioprin 1
Lost to follow up after discharge from 
hospital 1
22.9
±SD6.9 A. fumigatus 2
Pulmonary
aspergilllosis 3 L-AMB + Voriconazole 1 First remission induction chemotherapy for AML 1 Slight reduction hepatic lesions 1
Gender C. tropicalis 1 Osteomeyelitis 1 Voriconazole + Anidulafungin 1 ICD, Streptococcus sanguis endocarditis, aorta valve replacement with bioprosthesis 1
Cured but complicated with mycotic 
cerebral aneurysms 1
F: 5
M: 3
A. fumigatus
+
M. genavese
1 Hepatic abcess 1 Itraconasole, L-AMB, Voriconazole 1
persistent pulmonary cavity after radiotherapy for a 
T1N0M0 lungcarcinoma 1
Cured from candidemia episode, 
4 months later unrelated bacterial 
sepsis episode
1
Anidulafungin and step down to 
fluconazol 3
Total parenteral nutrition via Hickmann catheter 
because of slow transit bowel, intestinal pseudo 
obstruction, or gastroparesis
3
Died due to infectious complications 
71 or 15 days after initiation of IFN-γ 
therapy
2
Placebo treated patients
Age Pathogens n= Site of infection n= Antifungal therapy n= Underlying ilness n= Outcome n=
53.0
±SD19.1 C. glabrata 2 Candidaemia 3 Anidulafungin 2
Total parenteral nutrition via Hickmann catheter 
because of slow transit bowel 1
Cured without further infectious 
complications 3
BMI C. tropicalis 1 Anidulafungin + amphotericin B 1 HIV with porth-a-cath for venous access 1
18.5
±SD4.0
construction of ileal conduit urinary diversion (Bricker 
deviation) because of pT4N2M1 bladder cancer. 1
Gender
F, female; M, male; ICD, implantable cardioverter-defribillator; HIV, human immunodeficiency virus; L-AMB, 
liposomal amphotericin B; BAL, bronchoalveolar lavage; AML, acute myeloid leukemia;F: 3
M: 0
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on positron emission tomography-computed tomography (PET-CT) while receiving antifungal 
treatment. In another patient, CT-scan revealed progression of suspected hepatic Candida lesions 
during antifungal treatment. All patients included suffered some degree of immunosuppression: 
the 6 patients with positive blood cultures for Candida spp. had impaired physical barriers due to the 
presence of indwelling venous catheters (for the need of recurrent blood sampling or total parental 
nutrition), or an implantable cardioverter-defribillator (ICD) lead. The patient with progression of 
suspected hepatic Candida lesions on the CT-scan, and one patient with multiple pulmonary cavities 
and A. fumigatus in BAL fluid were immunocompromised because of (therapy for) acute myeloid 
leukaemia. Another patient with acute invasive aspergillosis received immunosuppressive therapy 
(prednisone and azathioprin) for sarcoidosis and suffered from a co-infection with Mycobacterium 
genavense localised in the bone marrow. A third patient with proven A. fumigatus in BAL fluid had 
a persistent pulmonary cavity after radiotherapy for a T1N0M0 lung carcinoma and developed a 
chronic aspergillosis. Only two patients, both with acute proven aspergillosis represented by A. 
fumigatus in the BAL fluid, were admitted to the Intensive Care Unit to receive organ supportive 
therapy (mechanical ventilation and hemodynamic support).
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BMI Candida spp 2 CandidaemiaEndicarditis 1 Fluconazole 1 Sarcoidosis treated with prednisone and azathioprin 1
Lost to follow up after discharge from 
hospital 1
22.9
±SD6.9 A. fumigatus 2
Pulmonary
aspergilllosis 3 L-AMB + Voriconazole 1 First remission induction chemotherapy for AML 1 Slight reduction hepatic lesions 1
Gender C. tropicalis 1 Osteomeyelitis 1 Voriconazole + Anidulafungin 1 ICD, Streptococcus sanguis endocarditis, aorta valve replacement with bioprosthesis 1
Cured but complicated with mycotic 
cerebral aneurysms 1
F: 5
M: 3
A. fumigatus
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M. genavese
1 Hepatic abcess 1 Itraconasole, L-AMB, Voriconazole 1
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T1N0M0 lungcarcinoma 1
Cured from candidemia episode, 
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1
Anidulafungin and step down to 
fluconazol 3
Total parenteral nutrition via Hickmann catheter 
because of slow transit bowel, intestinal pseudo 
obstruction, or gastroparesis
3
Died due to infectious complications 
71 or 15 days after initiation of IFN-γ 
therapy
2
Placebo treated patients
Age Pathogens n= Site of infection n= Antifungal therapy n= Underlying ilness n= Outcome n=
53.0
±SD19.1 C. glabrata 2 Candidaemia 3 Anidulafungin 2
Total parenteral nutrition via Hickmann catheter 
because of slow transit bowel 1
Cured without further infectious 
complications 3
BMI C. tropicalis 1 Anidulafungin + amphotericin B 1 HIV with porth-a-cath for venous access 1
18.5
±SD4.0
construction of ileal conduit urinary diversion (Bricker 
deviation) because of pT4N2M1 bladder cancer. 1
Gender
F, female; M, male; ICD, implantable cardioverter-defribillator; HIV, human immunodeficiency virus; L-AMB, 
liposomal amphotericin B; BAL, bronchoalveolar lavage; AML, acute myeloid leukemia;F: 3
M: 0
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Clinical outcome 
The three patients in the control group and five out of eight patients treated with rIFNγ recovered 
uneventfully from the fungal infection (Table 1). Two patients with invasive aspergillosis that were 
already admitted to the ICU at the time of treatment died due to infectious complications of severe 
pulmonary aspergillosis, despite rIFNγ treatment. The patient with a Candida endocarditis, who 
despite rIFNγ treatment developed intracerebral mycotic aneurysm, could be discharged from the 
hospital 93 days after onset of invasive candidiasis. 
 In all patients treated, rIFNγ was well tolerated. Five patients reported moderate fever upon 
administration of rIFNγ, which responded well to acetaminophen. Two patients developed liver 
enzyme abnormalities for which tuberculostatic antibiotics and voriconazol were temporarily 
discontinued, resulting in recovery of the liver enzyme abnormalities while rIFNγ treatment was 
continued. No other significant adverse events were observed.
Effect of rIFNγ on ex-vivo IL-1β and TNFα production
To assess the effect of rIFNγ on the capacity of PBMCs to produce pro-inflammatory cytokines, cells 
were isolated and stimulated before, during, and after treatment. We monitored the fold change in 
cytokine production compared with baseline (before start of treatment). IL-1β and TNFα are pro-
inflammatory cytokines of the innate immune system crucial in the induction and maintenance 
of the antifungal immune response 35-40. Before IFNγ treatment, inter-patient variability in cytokine 
production was high (e.g. TNFα median [IQR] concentration after stimulation with LPS was 792 pg/
mL [314-2005]). Nevertheless, in all patients an increase in the capacity to induce different cytokines 
was observed in the first two days after initiation of IFNγ treatment, independent of their baseline 
values (group data shown in figure 2), at subsequent time points only a trend towards increased 
could be observed. In contrast, the placebo-treated patients IL-1β and TNFα responses over time 
remained similar to baseline. The response against hyphae of C. albicans was highly variable between 
patients. Some rIFNγ-treated patients demonstrated a profound increase of TNFα production after 
treatment (up to 70 fold), whereas other patients showed no relevant change in TNFα production. 
Cytokine production remained similar in patients in the control group.
Effect of rIFNγ on ex-vivo IL-17 and IL-22 production
Both IL-17 and IL-22 are cytokines that are thought to be protective in the host defence against 
invasive fungal infections 35,41-45. PHA-induced IL-17 and IL-22 production was increased 1 day 
after initiation of rIFNγ treatment (figure 3). However, at subsequent time points a trend towards 
increased IL-17 and IL-22 production was observed, which reverted to baseline levels at day 28. 
Production of IL-17 and IL-22 upon stimulation with Candida blastoconidia was elevated after rIFNγ 
treatment in 6 of 8 patients. Hyphae induced IL-17 and IL-22 production was increased in 4 of 8 and 
5 of 8 patients respectively. Patients who received placebo therapy did not display a trend towards 
increased IL-17 or IL-22 production during the course of treatment (group data shown in figure 3). 
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Figure 2 | Effect of rIFNγ on ex vivo IL-1β and TNFα production 
PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after rIFNγ administration. Isolated PBMCs 
were stimulated for 24 hours with LPS, PHA, C. albicans blastoconidia, or C. albicans hyphae. (A) IL-1β and (B) 
TNFα concentrations were measured in culture supernatants. Baseline concentrations were used as control and 
set at 1; subsequent measurements are plotted as the mean relative fold change ± SEM. Significant change from 
baseline was determined by subjecting the data to Wilcoxons signed rank test. (*=p<0,05; **=p<0,01).
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Effect of rIFNγ on ex vivo IL-10 production
In addition to pro-inflammatory cytokines, the capacity to produce anti-inflammatory cytokines 
can also influence disease outcome. In particular the anti-inflammatory cytokine IL-10 has been 
associated with protection against immunopathology during severe infections. IL-10 production in 
response to stimulation with LPS, PHA and Candida was highly variable between patients and did 
not show a distinct pattern following rIFNγ treatment (figure 4). No relevant differences compared 
to the placebo-treated patients were observed. 
Figure 3 | Effect of rIFNγ on ex vivo IL-17 and IL-22 production 
PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after rIFNγ administration. Isolated PBMCs 
were stimulated for 7 days with PHA, C. albicans blastoconidia, or C. albicans hyphae. (A) IL-17 and (B) IL-22 
concentrations were measured in culture supernatants. Baseline concentrations were used as control and set 
at 1; subsequent measurements are plotted as the mean relative fold change ± SEM. Significant change from 
baseline was determined by subjecting the data to Wilcoxons signed rank test. (*=p<0,05).
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HLA-DR expression
The numbers of HLA-DR-positive monocytes, a marker of immunosuppression, varied substantially 
between patients at baseline (39.05 % [27.5-61.6] vs. 90.6 [88.7-92.5] in IFNγ-treated patients and 
placebo-treated patients, respectively). Five out of eight IFNγ treated patients exhibited HLA-DR 
positive monocyte levels below the “immunoparalysis threshold” of 50% and in these patients, an 
increase of HLA-DR-positive monocytes after IFNγ treatment between 10% and 44% was observed 
which persisted throughout the study period (Figure 5). Patients with a baseline HLA-DR expression 
higher than 50% did not show a change in expression. The patient with a HLA-DR-expression <50% 
who did not show increased levels of HLA-DR positive monocyte numbers at any time point, was one 
of the two patients who died due to infectious complications. No correlation was found between the 
level of mHLA-DR expression and TNFα production of LPS-stimulated PBMCs. An inverse correlation 
of baseline mHLA-DR levels with severity of underlying illness and tissue involvement was found 
(with higher mHLA-DR levels in patients with only impaired physical barriers, e.g. due to indwelling 
catheters, compared to patients with impaired immune responses, e.g. due to chemotherapy, 
immune suppressive agents, bone marrow disease,; data not shown because this compromises 
patients anonymity).
Figure 4 | Effect of rIFNγ on ex vivo IL-10 production 
PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after rIFNγ administration. Isolated PBMCs 
were stimulated for 48 hours with LPS, PHA, C. albicans blastoconidia, or C. albicans hyphae. IL-10 concentrations 
were measured in culture supernatants. Baseline concentrations were used as control and set at 1; subsequent 
measurements are plotted as the mean relative fold change ± SEM.
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Cell populations
There were no significant changes in the total leukocyte and granulocyte numbers in rIFNγ-treated 
patients (Figure S2A). Monocyte counts significantly increased one week after initiation of rIFNγ 
therapy (Figure S2C) and lymphocyte numbers significantly increased at 2 and 7 days after initiation 
of rIFNγ therapy (Figure S2D), which could be attributed to slight changes in CD4 lymphocytes 
(Figure S2E), B-lymphocyte (Figure S2F) and NK-cell numbers (Figure S2G) and a significant increase 
of CD8 lymphocytes (Figure S2H). No clear changes in leukocyte (subset) counts were observed in 
placebo-treated patients.
Figure 5. mHLA-DR expression
(A) mHLA-DR expression in rIFNγ treated patients (solid dots) 
and in patients in the control group (open squares). (B) mHLA-DR 
expression in rIFNγ treated patients, divided into immunoparalyzed 
patients with baseline HLA-DR expression below 50 % (solid dots), 
and without HLA-DR defined immunoparalysis (open dots). Data 
are expressed as median (IQR).
Discussion
While several small clinical trials illustrated the beneficial clinical effects of adjuvant treatment with 
IFN-y, the proposed immunostimulating effect of IFNγ as the mechanism of action has not been 
investigated. In this case series we demonstrate for the first time that adjunctive immunotherapy 
with rIFNγ improves the leukocyte immune responses in patients with severe invasive fungal 
infections. This was primarily reflected by increased ex-vivo pro-inflammatory cytokine responses 
of the innate immune system such as IL-1β or TNFα, as well as an increased production of the T-cell 
cytokines IL-17 and IL-22, which are known to play an important role in the antifungal host defence 
35,41-45, and by an increase in HLA-DR expression in mHLA-DR expression in those patients with a low 
cellular expression as a measure of their immune suppression.
 In addition to enhanced ex-vivo responses, subtle changes in the leukocyte differentiation were 
observed following IFNγ treatment. Although there were no significant differences in total leukocyte 
numbers after treatment with rIFNγ, shifts in leukocyte subpopulations such as increased monocyte 
and lymphocyte counts were apparent. While lymphocyte numbers increased after rIFNγ therapy, 
it could not directly be attributed to a specific subset as all of them showed increased values. The 
most significant increase was that of CD8 cells one week after initiation of rIFNγ therapy. Monocytes 
and lymphocytes are known to be crucial cells in the host defence against fungal infections. 
However, the increase of monocytes and lymphocytes during rIFNγ therapy was accompanied 
by slightly decreased circulating granulocyte numbers. It is not known whether this reduction is 
due to activation and migration into the infected tissue, or whether a true decrease in granulocyte 
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generation was induced by the treatment. Although the decrease in granulocyte numbers was 
slight, the fact that granulocytes, and especially neutrophils, are crucial in the antifungal host 
defence warrant careful monitoring of granulocyte numbers during IFNγ treatment. 
 Several clinical studies and case reports have previously demonstrated beneficial effects of rIFNγ 
in combination with antifungal therapy on outcome of fungal infections (for example in patients 
with CGD (n=130) 22,46,47, HIV (n=173) 23-25, leukaemia (n=5) 26,27, and transplant patients (n=7) 28, in a 
patient with S. aureus liver abscess and invasive C. albicans infection 48, in a patient with intracerebral 
aspergillosis 49, in two patients with progressive chronic pulmonary aspergillosis 50, and in two 
patients with idiopathic CD4 lymphopenia and cryptococcal meningitis 51). However, in contrast 
to our study, ex-vivo immune responses in these patients were not investigated. Due to the limited 
number of patients and the very heterogeneous population, we could not assess clinical endpoints, 
although a mean mortality of 25% in the IFNγ treated patients lies below the mean 40% estimated 
in patients with invasive fungal infections 10,52. 
 To the best of our knowledge, we are the first to describe mHLA-DR expression, a widely 
used marker of immunosuppression in (bacterial) sepsis patients 53, in patients with invasive 
fungal infections. In all IFNγ treated patients who showed baseline mHLA-DR levels below the 
immunoparalysis threshold of 50% and survived, IFNγ-mediated upregulation of mHLA-DR 
expression was observed. In agreement with the data presented in this case series, rIFNγ has been 
shown to significantly increase numbers of HLA-DR-positive monocytes both in a human preclinical 
bacterial sepsis model and in septic patients 31,54. Reduced production of TNFα by leukocytes ex-vivo 
stimulated with LPS has also been shown to be marker of immunoparalysis in sepsis patients. In 
contrast to our study, mHLA-DR expression and ex-vivo TNFα production were found to be highly 
correlated in bacterial sepsis patients 54,55. A possible explanation for this discrepancy is that, in 
contrast with the emerging consensus that immunoparalysis renders patients more vulnerable to 
opportunistic infections in general 53, different defects in immune defences may be responsible for 
enhanced susceptibility towards different pathogens. 
 Based on the apparent inverse correlation of baseline mHLA-DR levels with severity of 
underlying illness and tissue involvement, mHLA-DR levels seem to reflect disease severity and 
general immune status, and not specific immune defects per se. Hence, patients with invasive 
fungal infections and associated impaired antifungal immune responses will probably benefit more 
from immunostimulatory treatment compared to patients with only impaired physical barriers, 
e.g. due to indwelling catheters and apparent intact antifungal immune responses. Biomarkers 
reflecting the capacity of specific antifungal immune defences are required to identify patients who 
suffer from invasive fungal infections due to impaired cell-mediated immunity. It is important to 
identify such patients and attempt a tailored immunotherapeutic approach guided by the actual 
level and type of immunoparalysis of that specific patient. A blood based assay has been described 
that demonstrates a failure to induce IFNγ expression in renal transplant patients and differences in 
IL-10 and TNFα expression 56, which could be promising biomarkers to identify patients who could 
benefit from adjunctive immunotherapy.
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 The intracellular mechanism(s) through which the beneficial effects of IFNγ are mediated remain 
to be elucidated. Recently it was proposed that IFNγ exerts its effects at the transcription level 57, 
while others have demonstrated that IFNγ reverses tolerance-associated epigenetic modifications 
58. Another possible mechanism involved in the IFNγ-mediated reversal of immunoparalysis is the 
downregulation of negative TLR regulators such as IRAK-M, a protein that negatively regulates LPS-
induced inflammatory responses and contributes to the development of immunoparalysis 59. 
 Administration of rIFNγ was tolerated well. Several patients developed a mild fever upon 
administration, which responded well to acetaminophen treatment. No other side effects were 
observed. The most important limitation of the present study is the limited number of patients 
studied. Because the control group consisted of only three patients, no statistical analysis between 
the treatment and control groups could be performed. However, despite the small sample size, 
the increase in HLA-DR expression in patients with mHLA-DR expression levels below 50% and 
the increased ex-vivo response of several cytokines that are crucial in antifungal host defence is 
a promising observation that underlines the potential of immunotherapy. The slow enrolment of 
patients presenting with candidemia was the main factor contributing to the decision to terminate 
the phase IIIb Candida pilot-study early. With a reported incidence of 2.5-11 per 100.000 persons 
in Europe 60, and based on previous epidemiological data in our hospital this low enrolment was 
not expected at the time of the initiation of the study. The much lower incidence of candidemia 
in the last two years in our hospital is most likely due to a new antibiotic stewardship introduced 
recently in our hospital, which has reduced the incidence of opportunistic infections. The cut-
off value of mHLA-DR expression levels of 50% to distinguish between immunoparalyzed and 
immunocompetent patients is another limitation of this study, as this is an arbitrary value chosen. 
We chose this value because it is well below the 99% CI of mHLA-DR values in healthy volunteers 
31. Therefore, patients with mHLA-DR below 50% do have an impaired antigen presenting capacity 
of their monocytes which we show to be enhanced by IFNγ therapy. Whether this cut-off value 
truly represents immunoparalysis, reflected by enhanced susceptibility to secondary infections or 
reduced capacity to clear opportunistic infections, remains to be investigated. Furthermore, the 
use of a standardized analysis technique to quantify mHLA-DR, such as the Quantibrite method, is 
preferable, because it facilitates an objective comparison of mHLA-DR expression levels between 
studies and aids in the definitive establishment of a cut-off value to identify immunoparalyzed 
patients. Larger studies are required to confirm the data obtained here. To do so, multicentre studies 
should be facilitated in order to fully explore the potential of IFNγ immunotherapy. 
 Our data indicate that adjunctive immunotherapy with rIFN-γ in patients with invasive fungal 
infections partially restores cell-mediated immunity. This suggests that IFNγ treatment enhances 
antifungal immunity and larger studies are warranted to validate the findings reported here and 
to assess the impact of IFNγ treatment on clinical outcome. Biomarkers of impaired antifungal 
immunity should be further investigated in order to identify patients who will benefit most from 
immunostimulatory therapy. 
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Supplementary material
Flow cytometric analysis of mHLA-DR expression and lymphocyte subset counts | To ascertain 
that expression levels did not change due to a delay between withdrawal and analysis, we performed 
separate experiments on 5 different blood samples. Expression was determined immediately after 
withdrawal and after 24 hours storage at 4°C. When samples were immediately stored at 4°C after 
withdrawal and analyzed within 24 hours, we did not observe significant differences in % or MFI 
compared with samples that were immediately analyzed after withdrawal. Therefore, analysis was 
performed within 24 hours after immediate storage at 4°C. After withdrawal, 100 µL blood was 
incubated with the following fluorochrome-conjugated monoclonal antibodies, for 15 minutes 
protected from light at 4°C. After erythrocyte lysis (NH4CL: 180 mL + 20 mL lysis stock dilution 
[BD Pharm-Lyse, BectonDickinson]), cells were washed three times in PBS and monocytes and 
lymphocytes were identified in a 8-color immunophenotyping (NAVIOS flow cytometer, Beckman 
Coulter, Miami). Monocytes and lymphocytes were identified by forward and side scatter and by cell-
specific binding. The following monoclonal antibodies were used for monocyte HLA-DR analysis: 
HLA-DR-PE  (Immu-357), CD14-ECD (RMO52), CD45-KO (J33).  Lymphocyte subpopulations were 
identified by gating on the lymphocyte population in the CD45/SS plot followed by a gating on CD3-
APC (UCHT1),  CD4-PECy5.5 (13B8.2),  CD8-APCAlexa700 (B9.11), CD19-APCAlexa750 (HD37)  and 
CD56-PECy7 (N901) to determine the helper T cells, cytotoxic T cells, B cells and NK cells within the 
lymphocyte gate (all MoAbs were obtained from Beckman Coulter, Marseille, France). 
A B C D E
Figure S1 | Representative flow diagram of monocyte HLA-DR measurements
(A) Heparin blood was first analysed on forward- and side scatter to exclude cell debris and erythrocytes. (B)
Subsequently, CD45+ cells were selected and (C) within the CD45+ fraction was gated for CD14+ cells. (D) The 
CD45+ CD14+ cells (E) were analysed for the percentage of HLA-DR positivity.
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Figure S2 | Changes in immune cell populations
(A) Total leukocyte numbers and (B) numbers of granulocytes, (C) monocytes and (D) lymphocytes measured 
in peripheral blood. (E) Numbers of CD4 lymphocytes, (F) B-lymphocytes, (G) CD8 lymphocytes and (H) NK cells 
within the lymphocyte population were quantified using flowcytytometry.
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General discussion and future perspectives
Chapter 13
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General discussion 
The research within this thesis aimed to explore the recognition and cytokine signalling pathways that 
play a role in the host defence against Aspergillus fumigatus. Here we studied the pattern recognition 
receptors (PRRs) involved in the host defence against A. fumigatus and elucidated that the dectin-1/ 
spleen tyrosine kinase (Syk) pathway is an important regulator of LC3-associated phagocytosis. 
Furthermore, we dissected which PRRs were involved in the induction of the T-helper(Th)1, Th17, 
Th22 and Th2 subsets in response to A. fumigatus. We found that a deficiency in the intracellular 
receptor NOD1 protects immunocompromised mice against invasive aspergillosis. In the second 
part of the thesis our studies explored cytokine signalling in the host defence against A. fumigatus. 
We discussed the relevance of the interleukin(IL)-1 pathway in aspergillosis and were able to show 
that common genetic variants in IL-1 family genes predispose solid organ transplant patients for 
invasive aspergillosis. We demonstrated that the molecule galactosaminogalactan of the Aspergillus 
cell wall selectively interferes with IL-1 signalling. In addition, we discovered that the novel IL-1 family 
cytokines, the IL-36 cytokines, play an important role in regulating Aspergillus-induced Th1 and Th17 
responses. Furthermore, we explored the potential of adjunctive immunotherapy with recombinant 
IFNγ in a case series of patients with invasive fungal infections. Collectively, these studies contribute 
to the rapid developing research field of antifungal host defence mechanisms against A. fumigatus. 
Knowledge from these host defence mechanisms are important in order to be able to identify and 
design novel treatment strategies.
Several key findings in this thesis have the potential to have an impact on the treatment of invasive 
aspergillosis, and they need to be explored in more detail:
• How crucial is LC3-associated phagocytosis in the host defence against A. fumigatus?
• Is NOD1 a potential target for immunotherapy?
• What is the importance of the IL-1 pathway in aspergillosis?
• What should be the aim of immunotherapy for aspergillosis? 
 to modulate or to stimulate the host response?
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How crucial is LC3-associated phagocytosis in the host defence against A. fumigatus?
Autophagy is an ancient mechanism where the cell “eats itself” to remove unwanted or non-required 
cellular components 1. It is considered to be a primary response to stressful situations where recycling 
of cellular components can be used as a source for energy and trace molecules. However, autophagy 
proteins can also localise to a phagosome when Toll-like receptors are activated 2. This non-canonical 
form of autophagy has recently been termed as LC3-associated phagocytosis (LAP). Interestingly, 
recruitment of autophagy proteins to the phagosome is crucial for killing phagocytosed pathogens 
3 and plays an important role in regulating antigen presentation 4.
 We investigated in chapter 3, the induction of LAP by A. fumigatus, and found that the β-glucan 
activating the dectin-1/Syk pathway plays a major role in inducing LAP. For years dectin-1 has been 
associated as a crucial molecule for an adequate host defence against A. fumigatus 5,6, and was found 
to promote MHCII antigen presentation through LAP 7. In our studies we not only confirmed the role of 
dectin-1 and Syk in inducing LAP, but we were able to identify that corticosteroids interfere with LC3-
associated phagocytosis of Aspergillus. Corticosteroid treatment has been associated as an important 
risk factor for aspergillosis 8, due to blocking tyrosine kinase phosphorylation in T- and B-cells 9-11, 
and block reactive oxygen species (ROS) production in macrophages during fungal infection 12. It 
is tempting to speculate that the interference of corticosteroids with LAP is another mechanism 
why corticosteroids contribute to this increased risk of developing invasive aspergillosis. Moreover, 
patients with chronic granulomatous disease are incapable of generating NADPH dependent 
ROS and are uniquely susceptible to Aspergillus. In chapter 3 we identified that CGD patients are 
deficient in LAP, which was supported by another study 13. Furthermore, we were able to show that 
anakinra (blocking the IL-1 receptor) was able to restore LAP in CGD mice which protected them from 
aspergillosis 13. This suggests that the defect in LAP in CGD contributes to their high susceptibility to 
invasive mould infection and that the IL-1 pathway could have an important role in controlling LAP.
 Since corticosteroids inhibit crucial host defence mechanisms against A. fumigatus, one could 
argue that treatment of immunopathology associated with chronic pulmonary aspergillosis or 
allergic pulmonary aspergillosis (ABPA) with corticosteroids might not be the best treatment option, 
and that more targeted treatment strategies are needed. Nevertheless, corticosteroids are widely 
used for severe exacerbations of ABPA. In chapter 5 we demonstrate that treatment of cells isolated 
from ABPA patients with IFNγ can reverse the Th2 bias that is associated with the pathogenesis of 
ABPA. Clinical studies are therefore required to investigate whether treatment with IFNγ could be 
used to reduce or even replace corticosteroid therapy in this patient group.
Is NOD1 a potential target for immunotherapy?
NOD receptors recognise bacterial peptidoglycan 14,15, but recent reports suggest that NOD receptors 
could be involved in the recognition of Aspergillus as well 16-19, despite the fact that Aspergillus does 
not express peptidoglycans. In our studies in chapter 6 we found that NOD1 deficient mice were 
protected against aspergillosis, despite receiving cyclophosphamide-induced immunosuppression 
that results in wild-type mice being extremely susceptible to invasive aspergillosis 20. Only one report 
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has shown an interaction between Aspergillus and the NOD1 receptor in corneal epithelial cells 19, but 
we could not have anticipated that NOD1 deficiency could be protective and enhance fungal killing. 
To our knowledge this is the first report that demonstrates that the absence of NOD1 signalling is 
beneficial for survival and killing of a (opportunistic)pathogen, as NOD1 was previously demonstrated 
to be required for killing of Helicobacter pylori 21 and plays an important role in the pulmonary host 
defence against Mycobacterium tuberculosis 22 and Pseurdomonas aeruginosa 23. We observed that the 
absence of NOD1, but not NOD2, improved fungal killing and resulted in increased release of reactive 
oxygen species. These results could be very important, especially when bearing in mind that ROS 
production is crucial for protection against invasive aspergillosis 24. In addition, we found that NOD2 
deficient mice had an increased survival, but demonstrated severe symptoms of illness. Moreover, 
cytokine responses were found to be decreased in NOD2 deficient cells of both humans and 
animals, while ROS production and fungal killing was not enhanced in NOD2 deficient cells. Follow 
up studies are need to dissect the protective effect of NOD1 and comparing it with the effects of 
NOD2 deficiency. Moreover, both NOD receptors share the same downstream signalling kinase RICK, 
and it is therefore surprising that deficiency of either receptor results in a different phenotype. Such 
differential regulation by the NOD receptors has been previously observed in murine arthritis model 
25. We therefore suggest that our current data warrants further investigation of the NOD1 receptor 
as a potential target for immunotherapy of invasive aspergillosis in immunocompromised patients.
What is the importance of the IL-1 pathway in aspergillosis?
Cytokines of the interleukin-1 (IL-1) family play an essential role in the host defence during infection, 
but are also associated with detrimental acute and chronic inflammation. The IL-1 family consists 
of 11 members and the most well studied cytokines of the IL-1 subfamily are: IL-1α, IL-1β and IL-
1Receptor antagonist (Ra)26. To illustrate the importance of this IL-1 subfamily, we demonstrated 
in chapter 9 that common genetic variants in IL1B and IL1RN are associated with invasive fungal 
infection in solid organ transplant patients. This is in line with previous studies that demonstrated that 
polymorphisms in IL-1 genes can predict the risk for invasive aspergillosis following hematopoietic 
stem cell transplantion 27, and that IL-1 polymorphisms were associated with chronic cavitary 
pulmonary aspergillosis 28. Interleukin-1 plays a crucial role in early neutrophil recruitment via direct 
effects 29,30, but also regulates recruitment of neutrophils during later stages of infection through 
induction of the T-helper 17 subset 31. We were able to identify In chapter 4 that IL-1 signalling is 
crucial for the induction of the Th17 cytokines IL-17 and IL-22 by Aspergillus, however we found IL-1 
also to be crucial for induction of the Th1 cytokine IFNγ. In chapter 5 we demonstrated that IL-1 
neutralization abolishes Aspergillus-induced Th2 responses. These data suggest that IL-1 is a general 
regulator of T-helper subsets and not only the Th17 subset, as was described earlier. Furthermore, 
we identified in chapter 8 that galactosaminogalactan from the cell wall of A. fumigatus can 
interfere with IL-1 signalling by specifically inducing IL-1Ra thereby reducing Th17 responses 
and making mice more susceptible to aspergillosis. An attractive strategy would be to target this 
molecule in order to relieve the inhibition of the IL-1 pathway. However, in allergic aspergillosis or 
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chronic aspergillosis immunopathology driven by IL-1, and IL-1 itself could be a potential target for 
immunotherapy. Moreover, the detrimental hyperinflammatory response in CGD is driven by IL-1 
32. Despite the fact that ROS was found to get Aspergillus-induced inflammasome activation 33, in 
CGD patients ROS independent activation of the inflammasome was observed 34,35. In these patients 
blocking of IL-1 reduced this detrimental inflammatory response resulting in increased survival of 
CGD mice with aspergillosis 13. Thus IL-1 plays a prominent during aspergillosis, however whether 
IL-1 signalling is beneficial or detrimental for the outcome of aspergillosis depends on the timing, 
type of infection, and the underlying defects that result in aspergillosis.
 In addition to the IL-1 subfamily, we found in chapter 11 that the novel IL-1 family members IL-
36α, β, γ and IL-36Ra regulate the induction of T-helper responses by Aspergillus. IL-36 cytokines are 
primarily associated with skin disorders such as psoriasis 36-39 and reports suggest that these cytokines 
can play an important role in the pulmonary host defence by modulating pulmonary neutrophil 
recruitment 40. These observations suggest that IL-36 cytokines could play a role during pulmonary 
aspergillosis, but future studies are required to confirm a role for IL-36 in vivo. However, the description 
of a novel cytokine pathway that regulates Th1 and Th17 responses against Aspergillus opens up new 
strategies for potential targets for immunotherapy and warrants future studies to investigate whether 
common genetic variations in the IL-36 genes also influence susceptibility against aspergillosis. 
 Furthermore, another cytokine of the IL-1 family that could potentially be of importance in the 
host defence against Aspergillus fumigatus is IL-37. IL-37 is a potent anti-innflammatory cytokine that 
suppresses the immune response through IL-1R8 (SIGIRR) and subsequently SMAD3 41. Of specific 
interest, this cytokine was found to diminish airway inflammation in mice 42. Both IL-1R8 43,44 as well as 
IL-37 43 itself have been found to play a role in the host response against A. fumigatus by suppressing 
immunopathology. However, in the host defence against the opportunistic pathogen Candida albicans 
IL-37 was found to decrease the capacity to recruit neutrophils and mount cytokine responses 45, 
antifungal host responses that are also important for the host defence against A. fumigatus. Therefore, 
in an experimental model for Aspergillus where immunopathology plays a less significant role IL-37 
could potentially also be detrimental by impairing innate antifungal host defence mechanisms. 
 Collectively, a prominent role of IL-1 cytokine family in the host defence against A. fumigatus 
is illustrated. However, this is a role with two sides: pro-inflammatory immune responses are 
required for an efficient clearance of Aspergillus conidia, yet activation of pro-inflammatory immune 
responses could also lead to massive neutrophil recruitment which is associated with detrimental 
immunopathology. Still, since the cytokines of the IL-1 family seem to play a key role in host defence 
against Aspergillus they should be considered potentially promising targets for immunotherapy. In 
addition, polymorphisms in the IL-1 family could be potential markers for susceptibility screening.
What should be the aim of immunotherapy in aspergillosis: 
to modulate or to stimulate the host response?
The treatment of aspergillosis poses a serious challenge for clinicians worldwide. Patients often 
have a complicated immune status that predisposes them to develop invasive, chronic or allergic 
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aspergillosis. Furthermore, resistance to antimycotic therapy is being increasingly reported 46,47, 
even the use of agricultural azoles is being associated with antimycotic resistance of clinical isolates 
48,49. Patients that suffer from aspergillosis rarely have a normally functioning immune response, 
they are either immunosuppressed, have non-resolving inflammation or mount hyperinflammatory 
responses against the fungus. Therefore, modulation of the host response in these patients could be 
an attractive adjunctive treatment strategy. 
 In chapter 12 we investigated whether adjunctive treatment with IFNγ benefits patients with 
invasive fungal infections, and found that IFNγ boosted the patient’s ability to mount a cytokine 
response against C. albicans. However, patients that received hematopoietic stem cell transplantation 
go through a period where the immune system is absent, and are not likely to benefit from 
immunostimulatory therapy. In such patients infusion of ex vivo differentiated Aspergillus-specific 
T-cells is being suggested as a potentially promising immunotherapy 50, and studies have already 
demonstrated that the generation of “clinical grade” Aspergillus-specific T-cells is possible 51 and that 
infusion of such T-cells can help to prevent Aspergillus infections in HSCT patients 52.However, it is 
questionable whether such immunostimulatory therapy is beneficial for all patients. Inflammatory 
responses during aspergillosis has two sides, one side where the host response is required to 
clear the infection and another side where the host response is causing collateral damage to the 
host. The hyperinflammatory Th2 response plays a distinct role in the pathogenesis of ABPA 53 and 
excessive pro-inflammatory responses contribute to the pathology during CPA 54. Therefore, random 
immunostimulatory therapy could potentially worsen outcome of infection in these patient groups. 
In chapter 5 we investigated several biologicals that could suppress detrimental Th2 responses. 
Blockade of IL-1 or TNF suppressed Th2 responses. However, protective Th1 responses that are 
important for an effective clearance of Aspergillus were also suppressed 55-57. We therefore suggest that 
treatment with IFNγ could be beneficial by suppressing detrimental inflammation driven by Th2 and 
restoring protective host defence by supplementing the decreased IFNγ production observed in these 
patients. However, alternative approaches that act on the Th2 axis are being investigated, Vitamin D for 
example was found to attenuate Th2 responses in CF and ABPA patients 58. The targeting of regulatory 
T-cells in ABPA might be another potential immunotherapy due to their capacity to suppress potentially 
detrimental Th2 and Th17 responses in the lung 59. This hypothesis is further supported by studies that 
have demonstrated that regulatory T-cells can attenuate asthma 60,61, and that regulatory T-cells are 
found to play an important role in preventing detrimental immunopathology in aspergillosis 62-64. 
 Due to the various options for immunotherapy, screening the patient’s host response prior 
to therapy could be a possible strategy to decide which immunomodulatory approach might be 
useful as adjunctive therapy to antifungals. For example, a patient that fails to mount a Th1 response 
against Aspergillus in vitro might benefit from recombinant IFNγ therapy. However, when a patient 
is already capable of mounting a Th1 response, he/she might benefit more from an alternative 
approach. Because, the clinical presentation of aspergillosis varies among patients, and patients 
have a wide variety of co-morbidities it is important to stratify patients according to their immune 
status in order to design personalized treatment strategies for adjunctive immunotherapy.
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Future perspectives
Although we tried to provide in these studies additional insight to our understanding of the 
interaction between the host response and A. fumigatus, our current knowledge of the host-
Aspergillus interaction is far from complete and still many challenges remain that require future 
attention. For example, which PAMPs of A. fumigatus trigger the pattern recognition receptors CR3, 
TLR2, TLR4, NOD1, and NOD2? In addition, what are the receptors that recognize Aspergillus cell 
wall components such as chitin and galactosaminogalactan? For immunotherapeutic strategies it 
still remains difficult to predict whether promoting pro-inflammatory immune responses is needed 
in order to more efficiently clear the fungus, or suppression is needed to prevent detrimental 
inflammatory pathology during the infection. Continuing our efforts to understand the complexity 
of the immune system and its interaction with A. fumigatus will help us to answer these questions and 
further elucidate novel cytokine and recognition pathways that are of importance for developing 
novel treatments and (genetic) susceptibility screening.
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Summary
The immune system plays a key role during infections with Aspergillus fumigatus, and can be 
beneficial as well as detrimental for the host. A compromised status of the immune system or a 
hypersensitive immune system can make patients susceptible for invasive or allergic aspergillosis 
respectively. An efficient clearance of the fungus by the immune system is crucial for preventing and 
inhibiting fungal outgrowth in invasive aspergillosis (IA). However, the host response can also induce 
damaging immunopathology that can contribute to the pathogenesis of allergic bronchopulmonary 
aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). Within this thesis several studies are 
described that shed new light on the pathways that regulate the recognition of A. fumigatus and on 
the cytokine networks that govern antifungal host defence against A. fumigatus.
Pattern recognition receptors in the host defence against Aspergillus fumigatus
Recognition of conserved pathogen associated molecular patterns (PAMPs) by the pattern 
recognition receptors (PRRs) is the first step in mounting an immune response against a pathogen. 
Recognition of PAMPs on the Aspergillus cell wall is crucial for inducing host defence mechanisms. 
In chapter 2 we present an overview of the current knowledge on the PRRs that are involved in 
initiating host defence mechanisms in response to Aspergillus infection. We describe that nearly 
all classes of PRRs, except RIG-I helicases, are involved in recognition of PAMPs on the A. fumigatus 
cell wall. In addition, we reviewed the role of PRRs in activation of specific immune responses such 
as neutrophil recruitment, opsonisation, phagocytosis, killing, NETtosis and induction of adaptive 
immune responses. Although this review illustrates the broad knowledge on PRR signalling in host 
defence in aspergillosis, many of the PAMPs that activate these receptors remain unknown, and 
for many of these receptors it remains to be determined how they regulate antifungal immune 
mechanisms. 
 One of the mechanisms induced by PRRs is phagocytosis. In immune-competent individuals, 
phagocytic cells efficiently eliminate A. fumigatus spores, thus preventing germination and invasive 
fungal growth. However, little is known on the molecular mechanisms regulating intracellular 
killing of A. fumigatus by human phagocytes. In chapter 3, we describe that swelling of conidia 
during A. fumigatus infection within human monocytes triggers an early and selective induction 
of the autophagy pathway. It was previously described that conidial swelling results in exposure of 
PAMPs 1, including β-1,3-glucan 2. We found that the formation of LC3 positive (auto)phagosomes 
containing A. fumigatus germinating spores was also tightly regulated by β-glucan surface 
exposure following conidial swelling and germination. Dectin-1 is the pattern recognition receptor 
on monocytes that recognizes β-glucan, and was previously found to be important for effective 
antifungal in host defence 3-8. By using specific inhibitors and cells of patients that are deficient 
for dectin-1 we were able to show its role in mediating LC3-associated phagocytosis induced by 
β-glucan. In addition, immunosuppressive therapy with high doses corticosteroids is a major risk 
factor for the development of aspergillosis 9. Within this chapter we additionally demonstrated that 
corticosteroids can interfere with Aspergillus-induced LC3-associated phagocytosis by selectively 
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inhibiting the dectin-1/ spleen tyrosine kinase (Syk) pathway needed for efficient LC3-associated 
phagocytosis. 
 Although PRRs initially regulate innate immune cell activation and cytokine release, they create 
a cytokine environment that regulates the induction of adaptive immune responses such as T-helper 
cell polarization. Little is known about the T-helper responses induced by Aspergillus in humans, and 
in particular the IL-22 response induced by these cells. Moreover, the IL-22 response to Aspergillus 
recently gained interest because of its protective role in a murine model of invasive aspergillosis 6, 
and its detrimental role in a model for ABPA 10. In chapter 4, we elucidated the PRR and cytokine 
pathways that regulate the induction of human Aspergillus-induced T-helper responses. We found 
that IL-17 and IL-22 induction was inhibited by blockade of TLR4 and complement receptor 3, while 
TLR2 blockade boosted these responses, revealing a potential inhibitory role for TLR2. IFNγ induction 
in this study was only influenced by blockade of complement receptor 3. In contrast to previous 
reports 3,6,10, we found that dectin-1 blockade did not affect human Aspergillus-induced T-helper 
responses, and we were able to confirm this with cells isolated from dectin-1 deficient patients. In 
addition to the PRRs regulating the induction of these T-helper cytokines we demonstrated that the 
IL-17, IL-22 and IFNγ responses induced by A. fumigatus in human PBMCs were almost exclusively 
T-cell dependent. Furthermore, we characterized the human T-cell subsets that produce IL-22, IL-17, 
and IFNγ induced by A. fumigatus. Of specific interest, we found that the production of IL-22 is not 
restricted to a specific T-helper subset but is co-expressed in IL-17, and IFNγ positive cells. We further 
characterized Aspergillus-induced IL-22+ CD4+ T-cells and showed that these cells co-express TNFα, 
a hallmark of the recently described Th22 subset 11. Moreover, we demonstrate that the induction 
of this subset is dependent on both IL-1 and TNFα. These last observations point to a role for Th22 
cells in the Aspergillus-induced T-cell responses which would be interesting to investigate because 
of their described beneficial role in invasive aspergillosis 6 and detrimental role in ABPA 10. 
 Many patients with severe asthma demonstrate sensitization to fungal allergens. The allergic 
phenotype in these patients is primarily caused by the Th2 response which also plays an important 
role in the progression of fungal sensitization to the more severe form of fungal asthma namely 
ABPA12,13. Moreover the Th2 pathway plays an important role in dampening the protective Th1 
responses during invasive aspergillosis 14,15, thereby impairing fungal clearance and decreasing 
survival. In chapter 5 we explored the PRRs that regulate the Aspergillus-induced Th2 response. 
We found that A. fumigatus conidia were in particular capable of inducing Th2 cytokine responses 
whereas hyphae and other pathogens such as Candida albicans and Staphylococcus aureus induced 
IL-5 and IL-13 to a lesser extent. Similar to the findings in the previous chapter we found that CR3 plays 
an important role in the induction of Th2 responses while TLR2, TLR4 and dectin-1 neutralization 
did not significantly influence the Th2 response. Interestingly, we were able to demonstrate that, 
compared to non-allergic controls, ABPA patients have a significantly increased Th2/Th1 response 
ratio when their PBMCs are exposed to Aspergillus ex vivo. Since it is thought that a distorted balance 
between Th2 and Th1 responses is responsible for the detrimental immunopathology and impaired 
fungal clearance in ABPA, we attempted to reverse this ratio by exploring immunomodulatory drugs 
| 231
14 
Summary
in vitro. Neutralization of IL-1 signalling by anakinra (recombinant IL-1 receptor antagonist) or TNFα 
by soluble TNF receptor resulted in decreased Th2 responses, but unfortunately also decreased Th1 
responses. However, recombinant IFNγ (immukine) that is used in clinical practice could dampen 
Aspergillus-induced Th2 responses, while leaving Th1 responses unaffected, and even supplement 
IFNγ deficiency.
 The NACHT-LRR receptors (NLRs) NOD1 and NOD2 are intracellular pattern recognition receptors 
that play a major role in the recognition of bacterial peptidoglycan derivates by innate immune cells 
16-20. Unexpectedly, accumulating evidence indicated a role for NOD2 in the host response against A. 
fumigatus 21,22. In chapter 6 we investigated the role of NOD1 and NOD2 in the immune response 
to Aspergillus and susceptibility to invasive aspergillosis. By using cells of patients with Crohn’s 
disease, that carry a NOD2 mutation, we observed that NOD2 is required for mounting an efficient 
innate and T-cell cytokine response against A. fumigatus. We additionally explored the role of NOD1 
and NOD2 in susceptibility to invasive aspergillosis in an in vivo mouse model, and observed that 
these receptors differentially regulate the host response against A. fumigatus. Both NOD1 and NOD2 
deficiency protects immunosuppressed mice during invasive aspergillosis. NOD2 deficient mice 
develop inflammation and severe symptoms, but survive the infection, whereas NOD1 deficient 
mice very rapidly clear the infection. In vitro experiments with splenocytes demonstrate that NOD1 
deficient cells are more efficient than wild-type and NOD2 deficient cells in generating a cytokine 
response against Aspergillus. In addition we demonstrate that bone marrow derived macrophages 
from NOD1 deficient mice are more efficient in generating reactive oxygen species, which was 
associated with an increased fungal killing capacity compared to wild-type mice. Collectively, the 
data in this chapter demonstrates that NOD1 has a detrimental inhibitory effect on the antifungal 
host defence against A. fumigatus. 
Cytokine networks in the host defence against Aspergillus fumigatus
Intercellular communication is crucial for mounting an effective immune response, for example 
for effective communication between the innate and adaptive immune system. In particular 
the cytokine Interleukin-1 has a prominent role in the immune response. It plays a crucial role in 
regulating the recruitment of neutrophils, either directly or through inducing T-helper responses 
23,24. In chapter 7 an overview of the literature is presented on the role of the IL-1 cytokine family 
and in particular the classical members of the IL-1 family, IL-1β, and IL-1α, and their role in the host 
defence against A. fumigatus.
 A. fumigatus employs various strategies to evade immune recognition. Rodlets and melanin, 
that are present on the conidial surface, shield PAMPs that elicit pro-inflammatory host 
responses 1,25,26. Galactosaminogalactan (GAG), a cell wall component of A. fumigatus can act as a 
virulence factor 27. This polysaccharide that is shed into the host environment during Aspergillus 
vegetative growth induces immunosuppressive effects and diminishes neutrophil recruitment 
favouring A. fumigatus infection in mice 27. However, the mechanism through which GAG induces 
immunosuppressive effects as well as its effects on the human immune response were unknown. 
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In chapter 8 we demonstrate that GAG is not only immunosuppressive in mice, but can also 
inhibit human pro-inflammatory T-helper responses such as Th17 responses in human PBMCs. We 
identified that the potent anti-inflammatory properties of GAG were dependent on the capacity of 
GAG to induce interleukin-1 receptor antagonist (IL-1Ra), a potent anti-inflammatory cytokine that 
blocks IL-1 signalling. In addition, we observed that IL-1Ra deficient mice are protected against the 
immunosuppresive effects of GAG in invasive pulmonary aspergillosis. Moreover, the observation 
that GAG similar to IL-1Ra can protect mice from DSS-induced colitis identifies GAG or a derivative 
structure of GAG as a potential therapy for IL-1-mediated diseases such as joint, bone and muscle 
diseases and even very common inflammatory diseases, such as diabetes and gout.
 Due to the important role of Interleukin-1 in host defence and in particular the host defence 
against Aspergillus, it can be anticipated that common genetic variations that influence IL-1 activity 
can have impact on the susceptibility to and the outcome of invasive aspergillosis. In chapter 9 
we describe that common genetic variations in IL1B and IL1RN result in altered Aspergillus-induced 
cytokine signalling in PBMCs isolated from healthy volunteers. Moreover, in a cohort of solid organ 
transplant patients these genetic variations and a polymorphism in the BDEF1 gene encoding for 
β-defensin, a potent antimicrobial peptide, were highly associated with fungal colonization and 
invasive aspergillosis. This association highlights the importance of the IL-1 axis and antimicrobial 
peptides in the defence against fungi in transplant patients. 
 The IL-1 family does not only consist of IL-1α, IL-1β, and IL-1Ra, but also includes other members 
such as IL-18 that regulates Th1 responses and IL-33 that regulates Th2 responses. Some members 
have recently been renamed IL-36α (IL-1F6), IL-36β (IL-1F8), IL-36γ (IL-1F9) and IL-36Ra (IL-1F5) due 
to new insight in their biological function 28. These IL-36 cytokines elicit their effects through the 
IL-36 receptor (IL-36R) pathway and received a lot of interest recently, since they have been found 
to play a major role in the pathogenesis of psoriasis 29-31. In chapter 10 we present a general 
overview of the current knowledge on the IL-36 cytokine family by reviewing the biology of the 
IL-36 cytokines and their role in disease. This review describes the discovery of the new members 
of the IL-1 family, followed by the known biological functions of the IL-36 cytokines. The processing 
and secretion of the IL-36 antagonists and agonists, and the general role of IL-36 signalling in the 
immune response is described. Furthermore, we discuss the literature on the role of IL-36 in a wide 
variety of inflammatory diseases, and give future perspectives about research on the role of IL-36 
cytokines.
 Although the IL-36 cytokines seem to play a prominent role in the skin they have also been 
found to be important for the recruitment of neutrophils to the airways 32. The IL-36R is primarily 
expressed on naive CD4 T-cells, and the IL-36R pathway is involved in the activation of T-cells 33. For 
these reaseons we investigated, in chapter 11, the role for the IL-36R pathway in the host response 
against Aspergillus. We found that Aspergillus induced expression of both the IL-36 cytokines and their 
antagonist IL-36Ra, and that the IL-36 receptor pathway plays an important role in the regulation of 
Th1 and Th17 responses. However, inhibition of the IL-36 pathway did not affect Aspergillus-induced 
Th2 and regulatory T-cell responses. We provided additional evidence for the biological importance 
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of the IL-36 pathway by blocking endogenous IL-36Ra, which resulted in the increase of Aspergillus-
induced IL-17 and IFNγ responses. Furthermore, in this chapter we also decipher for the first time the 
innate recognition pathways, namely TLR4 and dectin-1/Syk, which are involved in the induction of 
IL-36γ by A. fumigatus.
 In chapter 12 we present a case series consisting of patients included in a clinical trial who 
received adjunctive immunotherapy with recombinant IFNγ and several patients for whom the 
treatment was given as “last resort therapy”. The data in this chapter provides proof-of principle 
that IFNγ is capable of increasing the capacity of PBMCs from these patients to produce higher 
levels of pro-inflammatory cytokines upon stimulation ex vivo. These data support the rationale for 
IFNγ treatment in patients with severe invasive fungal infections that have a decreased inefficient 
immune response, and provide an important argument that further studies including larger numbers 
of patients are warranted to confirm the clinical usefulness of (IFNγ) adjuvant immunotherapy in 
invasive fungal infection.
General conclusion
The fact that aspergillosis is rarely found in individuals with an unaffected immune system tells 
us that the human immune system has adequately evolved to prevent aspergillosis. Meaning that 
in patients with a suppressed immune system key components of the host response that prevent 
infection with Aspergillus are neutralized. By investigating how Aspergillus is recognised by the host 
and which cytokine signalling networks that regulate immune responses to Aspergillus fumigatus, 
we can identify these key components that, if defective or working suboptimal, render patients 
more susceptible to aspergillosis. However, the inflammatory response that is induced to counter 
Aspergillus infection can become detrimental or skewed towards an allergic phenotype, which is an 
important aspect in the pathogenesis of fungal asthma. These two faces of the host response against 
Aspergillus are important to keep in mind when identifying eligible targets for the development 
of novel immunomodulatory therapies that can be given in combination with currently available 
antimycotic therapy.
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Samenvatting
Het immuunsysteem speelt een fundamentele rol tijdens infecties met de schimmel Aspergillus 
fumigatus, en heeft zowel heilzame als nadelige gevolgen voor de gastheer. Patiënten met een 
gecompromitteerde immuun status zijn gevoelig voor het ontwikkelen van aspergillose, en 
individuen die een overgevoelige afweerrespons tegen Aspergillus opwekken lopen risico om een 
allergische aspergillose te ontwikkelen. Het efficiënt opruimen van ingeademde schimmelsporen 
door het immuunsysteem is cruciaal voor het voorkomen van uitgroei van schimmels in de longen. 
Het immuunsysteem kan echter ook nevenschade veroorzaken in de vorm van immunopathologie, 
hetgeen bijdraagt aan de ontwikkeling van allergische bronchopulmonale aspergillose (ABPA) 
en chronische pulmonale aspergillose (CPA). In dit proefschrift worden verschillende studies 
beschreven die nieuw licht werpen op hoe het immuunsysteem de schimmel A. fumigatus herkent 
en welke cytokine netwerken een rol spelen in de afweer tegen A. fumigatus.
Pathogeen herkenning receptoren in de afweer tegen Aspergillus fumigatus
De herkenning van pathogeen specifiek moleculaire patronen (PAMPs) door gespecialiseerde 
pathogeen herkenningsreceptoren (PRRs) op afweercellen, is de eerste stap in de afweer tegen een 
binnengedrongen pathogeen. Herkenning van PAMPs op de celwand van Aspergillus is cruciaal voor 
het activeren van afweermechanismen. In hoofdstuk 2 wordt een overzicht gepresenteerd van de 
huidige kennis op het gebied van herkenning van Aspergillus door het immuunsysteem en wordt 
beschreven hoe de gespecialiseerde PRRs specifieke afweermechanismen activeren. We constateren 
dat haast alle bekende PRRs, behalve RIG-I helicase, een rol spelen in de herkenning van PAMPs op 
de celwand van A. fumigatus. Daarnaast wordt een overzicht gegeven van de wijze waarop deze 
immuunreceptoren specifieke afweermechanismen zoals: fagocytose, cytokine signalen en de 
adaptieve afweerrespons activeren. Alhoewel in het overzicht de brede kennis op het gebied van 
herkenning van Aspergillus in de afweerreactie wordt beschreven is het onbekend welke moleculaire 
patronen op de celwand van Aspergillus herkend worden, en bij veel immuunreceptoren is het 
onbekend hoe zij de antischimmel afweerreactie in gang zetten.
 Fagocytose is één van de belangrijkste mechanismen die door PRRs gereguleerd wordt. In 
individuen met een goed functionerend immuunsysteem ruimen de fagocyterende immuuncellen 
de ingeademde schimmelsporen efficiënt op. Tot op heden is weinig bekend over de regulerende 
mechanismen in afweercellen die de gefagocyteerde Aspergillus sporen doden. In hoofdstuk 3 
wordt beschreven dat het ontkiemen (opzwellen) van Aspergillus sporen in monocyten resulteert in 
een selectieve inductie van autofagie. Het opzwellen van sporen leidt tot blootstelling van PAMPs, 
zoals β-1,3-glucan 2, die door de PRRs op afweercellen 1 herkend kunnen worden. We vonden dat 
de vorming van LC3 positieve (auto)fagosomen, met daarin ontkiemende A. fumigatus sporen, 
gereguleerd worden door de oppervlakte expressie van β-glucan. Dectine-1 is de receptor op 
monocyten die β-glucan herkent, en van deze receptor is eerder beschreven dat deze cruciaal is 
voor een doeltreffende afweer tegen schimmels 3-8. Met behulp van specifieke dectine-1 remmers 
en cellen van patiënten, die deficiënt zijn voor dectine-1, hebben we aangetoond dat herkenning 
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van β-glucan door dectine-1 van fagocytose met associatie van LC3 reguleert. Immunosuppressieve 
behandeling met hoge doseringen van corticosteroïden is een belangrijke risicofactor voor de 
ontwikkeling van aspergillose 9. In dit hoofdstuk hebben we aangetoond dat corticosteroïden 
interfereren met LC3 geassocieerde fagocytose van Aspergillus door selectief de herkenning van 
β-glucan door dectine-1 te remmen. Men zou daarom kunnen aannemen dat corticosteroïden 
bijdragen aan de gevoeligheid voor aspergillose doordat de LC3 fagocytose, die nodig is voor het 
opruimen van Aspergillus, specifiek door corticosteroïden worden geremd.
 Hoewel PRRs aanvankelijk cel activatie en cel-cel communicatie door middel van cytokines in 
het aangeboren immuunsysteem reguleren, zorgen zij er indirect voor dat er een cytokine milieu 
gecreëerd wordt dat de inductie van adaptieve immuunrespons reguleert. Er is nog weinig bekend 
over de adaptieve T-helper immuunrespons tegen Aspergillus in mensen, en in het bijzonder de 
Interleukine(IL)-22 respons door T-helper cellen. Deze IL-22 respons is recentelijk onder de aandacht 
gekomen doordat verschillende studies hebben aangetoond dat deze cytokine respons belangrijk 
is voor de bescherming van de gastheer tegen invasieve aspergillose 6. Deze cytokine kan echter 
een schadelijke rol spelen in allergische aspergillose 10. In hoofdstuk 4 hebben we onderzocht hoe 
PRRs en verschillende cytokines van het aangeboren immuunsysteem de inductie van de T-helper 
respons tegen Aspergillus reguleren. We vonden enerzijds dat inductie van de T-helper cytokines 
IL-17 en IL-22 geremd werd door blokkade van Toll-like receptor (TLR)4 en complement receptor 
(CR)3, terwijl anderzijds blokkade van TLR2 deze reacties versterkte. De inductie van de T-helper 
cytokine Interferon(IFN)γ werd alleen beïnvloed door blokkade van complement receptor 3. In 
tegenstelling tot eerdere studies die uitgevoerd zijn in muizen 3,6,10, vonden we met behulp van 
dectine-1 blokkade, dat dectine-1 slechts een beperkte rol speelt in de humane T-helper response 
geïnduceerd door Aspergillus. We konden deze bevinding bevestigen met cellen afkomstig van 
dectine-1 deficiënte patiënten. Naast de regulatie van de T – helper respons door pathogeen 
herkenningsreceptoren hebben we aangetoond dat de IL-17, IL-22 en IFNγ respons op Aspergillus 
uitsluitend T-cel afhankelijk is. Vervolgens hebben we de T-cel subsets die deze cytokines produceren 
verder gekarakteriseerd. We vonden in het bijzonder dat de productie van de cytokine IL-22 niet 
beperkt is tot een specifieke T-helper subset, maar geproduceerd kan worden door T-cellen die ook 
IL-17 en IFNγ tot expressie brengen. De subset T-cellen die uitsluitend IL-22 produceren hebben we 
verder gekarakteriseerd, en we vonden dat deze cellen naast IL-22 ook tumour necrose factor(TNF)
α tot expressie brengen, een kenmerk van de recent beschreven Th22 subset 11. Verder hebben we 
aangetoond dat de inductie van deze subgroep afhankelijk is van zowel IL-1 en TNFα . Deze data 
wijzen op een rol voor de recentelijk beschreven Th22 cellen in de afweer tegen Aspergillus, wat 
interessant is om verder te onderzoeken door de eerder beschreven gunstige effecten van IL-22 in 
invasieve aspergillose 6 en de nadelige effecten in allergische aspergillose 10.
 Patiënten met ernstige vormen van astma hebben vaak positief testresultaat tegen allergenen 
afkomstig van schimmels. De allergische reactie wordt in deze patiënten gedreven door de 
T-helper 2 respons, die ook een belangrijke rol speelt in de progressie van overgevoeligheid 
voor schimmelallergenen als ziektebeeld van allergische bronchopulmonale aspergillose (ABPA) 
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12,13. Daarnaast is de Th2 respons in staat om de protectieve Th1 response tegen Aspergillus te 
onderdrukken 14,15, waardoor het uitgroeien van Aspergillus sporen minder goed onderdrukt wordt, 
hetgeen uiteindelijk leidt tot een verhoogde schade in de longen en een hogere mortaliteit. In 
hoofdstuk 5 hebben we onderzocht welke PRRs de inductie van de Th2 respons door Aspergillus 
reguleren. We vonden dat uitsluitend de sporen van Aspergillus een allergische Th2 respons 
opwekken, terwijl hyfen van Aspergillus en andere pathogenen de Th2 respons niet sterk induceren. 
Zoals in het vorige hoofdstuk beschreven vonden we dat CR3 wederom een belangrijke rol speelt in 
de inductie van de Th2 response door Aspergillus. We constateerden dat de receptoren TLR2, TLR4 
en dectine-1 geen rol speelden in de inductie van de Th2 respons door Aspergillus. Een interessante 
observatie in deze studie was dat cellen van ABPA patiënten een verhoogde Th2/Th1 ratio 
hebben, wanneer de respons wordt vergeleken met niet allergische individuen. In de wetenschap 
wordt er van uitgegaan dat een verstoorde Th2/Th1 ratio ten grondslag ligt aan de schadelijke 
immunopathologie in ABPA. Derhalve hebben we geprobeerd de verstoorde Th2/Th1 ratio met 
immunomodulatoire medicijnen te herstellen. Neutralisatie van IL-1 door anakinra (recombinant 
IL-1 receptor antagonist) of TNFα door etanercept (recombinant TNFα receptor II) resulteerde 
in een verlaging van de Th2 respons op Aspergillus, maar neutraliseerde ook de inductie van de 
Th1 respons. Recombinant IFNγ (immukine) werd gebruikt om de Th2 respons te neutraliseren en 
interfereerde daarbij niet met de Th1 respons. Deze observaties laten zien dat behandeling met 
recombinant IFNγ een mogelijke immunomodulatoire therapie is voor ABPA door het remmen van 
de Th2 as en het ondersteunen van de Th1 respons tegen Aspergillus.
 De NACHT-LRR receptoren (NLRs) NOD1 en NOD2 zijn intracellulaire PRRs die een cruciale 
rol spelen in de herkenning van bacterieel peptidoglycaan door cellen van het aangeboren 
immuunsysteem 16-22. Tegen verwachting in is er bewijs dat de NOD2 receptor mogelijk een 
rol speelt in de afweer tegen A. fumigatus 21,22. In hoofdstuk 6 hebben we de rol van NOD1 en 
NOD2 onderzocht in de afweer tegen Aspergillus en de gevoeligheid voor het ontwikkelen van 
aspergillose. Door cellen te gebruiken van patiënten met de ziekte van Crohn, bij wie de NOD2 
receptor niet functioneel is, hebben we aangetoond dat NOD2 nodig is voor het opwekken van een 
immuun respons tegen Aspergillus door zowel het aangeboren immuunsysteem als het adaptieve 
immuunsysteem. Daarnaast hebben we de rol van NOD1 en NOD2 onderzocht in een muismodel 
voor invasieve aspergillose. We vonden dat muizen die deficiënt zijn in ofwel NOD1 dan wel NOD2 
beschermd zijn tegen een dodelijke infectie met Aspergillus. NOD2 deficiënte muizen ontwikkelden 
echter nog ernstige symptomen van de ziekte. Aan de andere kant lieten de NOD1 deficiënte muizen 
weinig symptomen van de infectie zien en zij herstelden zich snel na de infectie. Door cellen van 
deze muizen in vitro te gebruiken hebben we aangetoond dat NOD1 deficiënte cellen efficiënter 
zijn in het opwekken van een cytokinerespons tegen Aspergillus dan cellen van wild-type of NOD2 
deficiënte muizen. Daarnaast hebben we aangetoond dat macrofagen die NOD1 missen beter in 
staat zijn een oxidatieve burst te genereren, en daarbij beter in staat zijn om sporen van Aspergillus 
te doden. De resultaten in dit hoofdstuk tonen aan dat NOD1 een slechte invloed heeft op de 
afweer tegen Aspergillus, omdat deficiëntie van NOD1 geassocieerd wordt met bescherming tegen 
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dodelijke Aspergillus infectie en een verhoogde capaciteit om een effectieve immuunrespons tegen 
de schimmel op te wekken. Om deze redenen wordt gesteld dat NOD1 mogelijk een toekomstig 
doelwit is voor nieuwe immunotherapie om de afweer tegen Aspergillus te verbeteren gedurende 
een periode waarin het immuunsysteem gecompromitteerd is.
Cytokine netwerken in de afweer tegen Aspergillus fumigatus
De mate waarin verschillende immuuncellen met elkaar communiceren is essentieel voor het 
opwekken van een efficiënte immuunrespons. Een effectieve communicatie tussen het aangeboren 
afweersysteem en het adaptieve immuunsysteem door cytokines speelt een belangrijke rol in 
het polariseren van de adaptieve immuunrespons. Wanneer dit echter niet efficiënt gebeurt kan 
de adaptieve afweerreactie de aangeboren afweer niet versterken. De cytokine IL-1 speelt een 
prominente rol in de immuunrespons. Deze cytokine speelt een cruciale rol in het rekruteren van 
neutrofiele granulocyten, zowel direct, alsmede door indirect eerst T-helper responsen te induceren 
die vervolgens granulocyten rekrutering activeren 23,24. In hoofdstuk 7 focust de samenvatting van 
de literatuurstudie op de rol van de IL-1 cytokine familie in de afweer tegen A. fumigatus, en met name 
de klassieke leden van de IL-1 familie: IL-1β en IL-1α. Ook wordt de potentie van de IL-1 pathway als een 
potentieel doelwit voor immunotherapie in aspergillose geëvalueerd. IL-1 is een zeer potente activator 
van de proinflammatoire immuun respons. Juist om deze reden zou het blokkeren van L-1 gebruikt 
kunnen worden om Aspergillus geassocieerde immunopathologie te voorkomen die beschreven is in 
de ziektebeelden ABPA, CPA en chronische granulomateuze ziekte (CGD). Echter het versterken van 
de IL-1 as zou op zijn beurt een potentiële therapie kunnen zijn voor immuungecompromitteerde 
patiënten, die een verbetering van schimmel klaring kan bewerkstelligen. In dit hoofdstuk is ook 
ingegaan op de wijze waarop polymorfismen in genen van de IL-1 pathway genetische markers zijn 
om gevoeligheid voor aspergillose te voorspellen en risicopatiënten te identificeren die baat kunnen 
hebben bij intensieve zorg en profylactische antimycotische therapie.
 A. fumigatus gebruikt verschillende strategieën waardoor het voorkomt door het immuunsysteem 
herkend te worden. Rodlets en melanine zijn aanwezig op het oppervlak van de sporen en 
schermen PAMPs af die de immuunrespons kunnen activeren 1,25,26. Galactosaminogalactan (GAG), 
een molecuul in de celwand van A. fumigatus, kan zich voordoen als een virulentie factor 27. Deze 
suiker wordt uitgescheiden tijdens de groei van Aspergillus en remt het rekruteren van neutrofiele 
granulocyten, hetgeen ten gunste van de schimmel is 27. Het was onbekend hoe GAG deze immuun 
onderdrukkende effecten induceerde, daarom hebben we deze effecten in hoofdstuk 8 nader 
onderzocht. In dit hoofdstuk wordt bewezen dat GAG het menselijk immuunsysteem onderdrukt. 
Deze polysacharide is in staat om de Th17 respons in humane immuuncellen te remmen. De 
immunosuppressieve effecten van GAG zijn onderzocht en aangetoond is dat GAG IL-1 receptor 
antagonist (IL-1Ra) een potente anti-inflammatoire cytokine induceert. Daarnaast hebben we 
geconstateerd dat muizen die voor IL-1Ra deficiënt zijn beschermd tegen de immunosuppressieve 
effecten van GAG. Dit creëert mogelijkheden voor nieuwe behandelingen tegen acute invasieve 
aspergillose gericht op IL-1Ra. Ook hebben we geconstateerd dat therapie met GAG muizen 
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beschermt tegen inflammatoire ziekten zoals colitis ulcerosa en allergische aspergillose. Deze 
observatie uit het onderzoek kan er toe leiden dat GAG, of een afgeleide structuur van GAG, 
gebruikt zou kunnen worden voor behandeling van IL-1 gedreven inflammatoire ziekten zoals 
colitis, gewricht- en spierziekten, diabetes en jicht.
 Door de belangrijke rol van IL-1 in de afweer, en in het bijzonder de afweer tegen Aspergillus, is 
het aannemelijk dat genetische variaties die de activiteit van IL-1 beïnvloeden een rol spelen in de 
gevoeligheid voor aspergillose en het klinisch verloop van aspergillose. In hoofdstuk 9 beschrijven 
we dat veel voorkomende genetische variaties in IL1B en IL1RN (de genen voor IL-1β en IL-1Ra) 
de cytokine respons tegen Aspergillus door afweercellen van gezonde vrijwilligers beïnvloeden. 
Ook is in een groep patiënten die orgaantransplantatie ondergingen deze genetische variaties, 
en een variatie in het DEFB1 gen dat codeert voor de potente antimicrobiele peptide β-defensin, 
geassocieerd met een verhoogde gevoeligheid voor invasieve schimmelinfecties. Deze associatie 
benadrukt hoe belangrijk de IL-1 as en β-defensin zijn in de afweer tegen schimmelinfecties bij 
patiënten met een orgaantransplantatie. De onderzochte genetische variaties kunnen in de 
toekomst gebruikt worden om risicoanalyses te maken. Hierdoor krijgen transplantatiepatiënten een 
gepersonaliseerde profylactische antimycotische therapie en worden zij intensiever diagnostisch 
gescreend. 
 De IL-1 cytokine familie bestaat niet alleen uit: IL-1α, IL-1β, en IL-1Ra, maar ook uit andere leden 
zoals IL-18 dat de Th1 respons reguleert en uit IL-33 dat op zijn beurt de Th2 respons reguleert. 
Sommige IL-1 familieleden zijn door nieuwe inzichten in hun biologische functie28 recentelijk 
herbenoemd, namelijk: IL-36α (IL-1F6), IL-36β (IL-1F8), IL-36γ (IL-1F9) en IL-36Ra (IL-1F5). De IL-36 
cytokines oefenen hun biologische functie uit door de IL-36 receptor te binden en te activeren, en 
krijgen de laatste tijd steeds meer aandacht vanwege hun rol in de pathogenese van psoriasis 29-31. 
In hoofdstuk 10 wordt een overzicht gegeven van de huidige kennis over de IL-36 cytokine familie, 
met een focus op de biologie van deze cytokines in verschillende ziektes. Dit overzichtsartikel 
beschrijft hoe de nieuwe IL-1 familieleden ontdekt zijn en beschrijft de biologische functies 
van deze cytokines. Ook is in dit hoofdstuk beschreven hoe de IL-36 agonisten en antagonisten 
geproduceerd worden, en hun algemene rol in het immuunsysteem. Tenslotte wordt op basis van de 
wetenschappelijke literatuur de rol van de IL-36 cyokines in een breed spectrum van inflammatoire 
ziektes beschreven en wordt gespeculeerd over de mogelijke toekomstperspectieven van IL-36 
cytokines voor de medische wetenschap.
 Naast het feit dat de IL-36 cytokines een belangrijke rol spelen in homeostase van de huid, 
zijn deze cytokines ook belangrijke signaalmoleculen voor het rekruteren van granulocyten naar 
de luchtwegen 32. De IL-36 receptor zit op het oppervlak van naïeve CD4 T-cellen en speelt een 
belangrijke rol in de activatie van deze cellen 33. Derhalve is in hoofdstuk 11 de rol van IL-36 in 
de afweer tegen Aspergillus onderzocht. We vonden dat Aspergillus mRNA expressie van de IL-36 
cytokines en hun antagonist IL-36Ra kon induceren. Daarnaast vonden we dat de IL-36 cytokines 
de inductie van de Th1 en Th17 respons door Aspergillus reguleerden. Deze regulatie is vervolgens 
bevestigd door endogeen IL-36Ra met antilichamen weg te vangen wat resulteerde in een 
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versterking van de Th1 en Th17 inductie door Aspergillus. Verder is in het onderzoek aangetoond 
dat de PRRs TLR4 en dectine-1 de inductie van IL-36γ door Aspergillus reguleren. De bevinding dat 
een nieuwe cytokine familie de Th1 en Th17 inductie door Aspergillus reguleert, zorgt voor nieuwe 
mogelijke doelen voor de ontwikkeling van een immunotherapie voor aspergillose. De screening 
van genetische variaties in deze cytokines zou kunnen helpen om een verhoogde gevoeligheid 
voor aspergillose te voorspellen.
 Door vaker voorkomende resistentie van A. fumigatus voor anti-mycotica is er een vraag 
naar alternatieve behandelingsstrategieën. Modulatie van de afweerreactie wordt geprezen 
als een veelbelovende therapie die in combinatie met de standaardtherapie de mortaliteit van 
invasieve schimmelinfecties kan terugbrengen. In hoofdstuk 12 worden casussen beschreven 
van patiënten met invasieve candidiasis. De patiënten zijn geïncludeerd in een klinische trial en 
ontvingen naast de standaard zorg additionele immunotherapie behandeld met recombinant 
IFNγ. Ook zijn verschillende patiënten beschreven met invasieve schimmelinfecties die als “laatste 
redmiddel” immunotherapie met IFNγ kregen. De resultaten van dit onderzoek geven een eerste 
bewijs dat immunotherapie met IFNγ de capaciteit van immuuncellen om pro-inflammatoire 
cytokines te produceren kan versterken. Deze data ondersteunen de gedachte dat patiënten met 
ernstige invasieve schimmelinfecties baat zouden hebben bij immunotherapie met IFNγ. Daarnaast 
vormen ze de basis voor het ontwikkelen van nieuwe studies met grotere groepen patiënten om 
klinische toepassing van immunotherapie (met INFγ) in invasieve schimmelinfecties diepgaand te 
onderzoeken. 
Conclusies en toekomstperspectieven
Het feit dat aspergillose zelden voor komt in individuen met een intact immuunsysteem zegt 
ons dat het menselijk immuunsysteem adequaat is geëvolueerd om infecties met Aspergillus 
te voorkomen. Hetgeen betekend dat in patiënten met een gecompromitteerd imuunsysteem 
bepaalde immunologische herkennings- en signaalmechanismen, die een rol spelen in de afweer 
tegen Aspergillus, niet goed functioneren. Door de wetenschappelijke kennis van deze mechanismen 
toe te passen worden cruciale componenten geïdentificeerd die, indien defect, patiënten gevoelig 
maken om aspergillose te ontwikkelen. De immuunrespons die geïnduceerd wordt om Aspergillus 
te klaren kan echter ook nadelige gevolgen hebben door zich bijvoorbeeld te ontwikkelen tot een 
allergisch fenotype of schade te berokkenen aan de gastheer. Deze twee keerzijden van de afweer 
tegen Aspergillus zijn belangrijk om in gedachten te houden bij het identificeren van potentiële 
nieuwe targets voor immunotherapie die gebruikt zouden kunnen worden in combinatie met de 
huidig beschikbare anti-mycotische therapieën. 
 Het onderzoek in dit proefschrift wil een bijdrage leveren aan het snel ontwikkelende 
onderzoeksveld dat de afweer tegen Aspergillus onderzoekt. Door de pathogeen herkennings- en 
cytokine signaalwegen te onderzoeken die de afweerreactie tegen Aspergillus reguleren worden 
in dit proefschrift nieuwe perspectieven gethematiseerd van de verschillende aspecten die de 
complexe interactie tussen Aspergillus en het immuunsysteem van de mens beschrijven.
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 De studies in dit proefschrift hebben bijgedragen aan de optimalisatie van onze kennis 
van deze interacties. Echter de huidige kennis van de interactie tussen Aspergillus en gastheer 
is verre van compleet en veel wetenschappelijke uitdagingen vragen om verder onderzoek. 
Toekomstige studies moeten uitwijzen welke PAMPs van Aspergillus de PRRs CR3, TLR2, TLR4, 
NOD1, en NOD2 activeren. Ook is onbekend welke afweerreceptoren de celwandmoleculen chitine 
en galactosaminogalactan herkennen. Voor immunomodulatoire therapieën is het moeilijk te 
concluderen of de proinflamatoire afweerreactie versterkt moet worden om efficiëntere klaring 
van de infectie te krijgen, dan wel moet worden afgeremd om schadelijke immunopathologie te 
voorkomen. Om de complexiteit van het immuunsysteem te ontrafelen en te begrijpen moet het 
immuunsysteem Aspergillus verder onderzocht worden zodat de eerder geformuleerde vragen in 
de toekomst beantwoord worden. Tenslotte zal het toekomstig onderzoek naar nieuwe cytokine 
en herkenningsmechanismen ons helpen om voor patiënten nieuwe therapieën en screening van 
risicomarkers voor aspergillose te ontwikkelen.
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betrekt bij nieuwe (inter)nationale collaboraties vind ik erg bijzonder. Dit heeft mij de gelegenheid 
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